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To be, or not to be, — that is the question: —
Whether ’tis nobler in the mind to suffer
The slings and arrows of outrageous fortune,
Or to take arms against a sea of troubles,
And by opposing end them? — To die, to sleep, —
No more; and by a sleep to say we end
The heart-ache, and the thousand natural shocks
That flesh is heir to, — ’tis a consummation
Devoutly to be wish’d. To die, to sleep; —
To sleep, perchance to dream: — ay, there’s the rub;
For in that sleep of death what dreams may come,
When we have shuffled off this mortal coil,
Must give us pause: there’s the respect
That makes calamity of so long life;
For who would bear the whips and scorns of time,
The oppressor’s wrong, the proud man’s contumely,
The pangs of despis’d love, the law’s delay,
The insolence of office, and the spurns
That patient merit of the unworthy takes,
When he himself might his quietus make
With a bare bodkin? who would these fardels bear,
To grunt and sweat under a weary life,
But that the dread of something after death, —
The undiscover’d country, from whose bourn
No traveller returns, — puzzles the will,
And makes us rather bear those ills we have
Than fly to others that we know naught of?
Thus conscience does make cowards of us all;
And thus the native hue of resolution
Is sicklied o’er with the pale cast of thought;
And enterprises of great pith and moment,
With this regard, their currents turn awry,
And lose the name of action.
Hamlet, Act III, scene i
ABSTRACT
The use of amniotic membrane (AM) as a dressing for ocular surface
injuries has attracted the interest of the military ophthalmological commu-
nity. First applied in the 1930s, the tissue is widely used today, although
clinical indications for treatment are incompletely defined. While AM is
most commonly stored frozen and thawed before use, dried AM is preferred
for logistical reasons. Optimal preservation of the tissue is necessary to
preserve its quality. The effect of drying on the physical and biological prop-
erties of the tissue are unknown.
A systematic review of the evidence of AM treatment of acute chemi-
cal injuries was conducted. A framework was proposed for optimising the
dried tissue through thermal, moisture sorption and surface analytical tech-
niques. The physical properties of AM preparations were compared by me-
chanical testing and mathematical modelling, and an attempt was made
to cross-link the AM collagen. Inflammatory aspects of the tissue were as-
sessed by immunological techniques, zymography and macrophage assays.
There is a lack of high quality evidence to support the clinical application
of AM for acute burns. Complex interactions were demonstrated between
the dried tissue, its excipients and moisture, suggesting novel ways of op-
timising the product. The mechanical properties of the dried membrane
indicated that the process adversely affected the tissue, and artificial cross-
linking could not be achieved. While the presence of antimicrobial peptides
was not clearly established, the elution of collagenolytic enzymes was shown
in therapeutic preparations of AM. The production of tumour necrosis factor
by macrophages, which adhere to the spongy layer of AM, was suppressed.
This project makes original contributions relevant to the use of dried AM
as a biomaterial in ophthalmic surgery. Further refinements of this work,
animal model experimentation and clinical trials may support its future
acceptance as a clinical application.
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GLOSSARY OF SPECIALISED TERMS1
Enthalpy (H): A thermodynamic quantity used to express energy change,
enthalpy is the energy required to heat a material to a given temperature.
Tensile stress (σv): The failure strength of a material is measured in New-
tons (N) and can be described as the ultimate tensile strength (UTS). Nom-
inal tensile stress measure of the force pulling a material divided by the
cross-sectional area, expressed as
σvN =
F
A0
=
F
w0t0
(1)
where F is force, and A0 is the initial area (initial width, w0, multiplied by
initial thickness, t0). Stress is measured in Pascals (Pa, equal to Nm−2).
The ultimate stress, σvf , represents the stress at failure. For measurements
of true stress, σvT , the instantaneous cross-sectional area A must be known.
In the special case of incompressible materials, σvT is calculated as
σvT = λ1σv
N (2)
where λ1 is the ratio of final length to original length. Thus, A0 measure-
ments can be used to convert force-distance curves into true stress-strain
curves.
Tensile strain (ε): ε is a measure of the amount of lengthening of a material
(ΔL) in response to tensile stress divided by its original length, L
ε =
△L
L
= λ1 − 1 (3)
As a ratio, ε does not take a unit, and it may be expressed as a percent-
age. Failure strain, εf , represents the limit of deformation. The area under
the true stress-strain curve can be integrated to give a value of toughness,
1Adapted from Ashby and Jones, 2012, Gabbott, 2008 and Adams, 2007.
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measured in Joules (J) mm−3.
Poisson’s ratio (υ): When a compliant material is stressed longitudinally,
it gets thinner. The amount by which it narrows is defined by Poisson’s
ratio, the negative of the ratio of lateral strain to tensile strain. Perfectly
incompressible elastic materials have a nominal υ of 0.5.
Shearmodulus (G*): This defines amaterial’s response to shearing strains.
It is defined as the ratio of shearing stress to shearing strain. G∗ consists of
the storage modulus, G′, related to the elastic part of the response, and the
loss modulus, G′′, which corresponds to viscous behaviour.
Elastic modulus (E): The application of tensile force to a unit area (stress,
σv) of a material results in a degree of deformation (strain, ε). The resistance
encountered is an inherent feature of the material known as its modulus.
For a purely elastic substance, σv is in phase with ε. E (stress divided by
strain) takes the same unit as the numerator and is derived by measuring
the gradient of a stress-strain curve. A higher E equates with increased
stiffness. Elastic moduli for linearly elastic materials are defined through
Hooke’s law, which states that strain is proportional to stress:
σv = Eε (4)
or, at any given time point, t, the instantaneous derivative is represented by
E =
dσv
dε
∣∣
ε,t (5)
where E is known as Young’s modulus, measured in Pa, and ε is strain. In a
perfect, Hookean relationship between stress and strain, E does not change,
and is related to G and υ by the equation
E = 2G(1 + υ) (6)
or, for an incompressible material,
E = 3G (7)
The modulus of an elastic polymer (elastomer) such as rubber is between
107 and 108 Pa. Polycarbonate has a modulus of 2.6 × 109 Pa, whereas ice
(H2O) has a modulus of 9.1 × 109 Pa.
Viscoelasticity: Viscoelastic materials exhibit hysteresis, a dissipation of
energy which manifests in varying degrees under cyclic loading at different
deformation rates. Strain increases as a constant stress is applied (creep).
Stress decreases as a constant strain is applied (stress relaxation). For a
viscoelastic material, there is a phase lag between σv and ε. The in-phase
tensile storage modulus, E´, represents the sample elasticity, whereas the
out-of-phase loss modulus, E´´ , represents the viscous portion. The phase
lag between σv and ε is expressed as a phase angle, defined by the equation
tan δ =
E ´´
E´
(8)
Tan δ is a measure of damping.
Glass transition (Tg): Tg, is a complex event that occurs over a range of
temperatures and depends on many factors, e.g, the method of measure-
ment. The vitrified (glassy) state is a characteristic of amorphous materials
(having no crystalline structure, or long-range molecular order). In this
state, molecules in amorphous materials (or in the amorphous portion of
semi-crystalline materials) are disordered and immobile, and the material
can be rigid and brittle. At the Tg temperature , the molecular relaxation
time shortens. In amorphous and semi-crystalline polymers, this is mani-
fest as an increase in malleability, and is known as a rubbery state. Other
amorphous materials, such as sugars, may undergo a Tg from a highly vis-
cous, immobilised state to a less viscous state. Plasticisation can occur as a
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result of moisture absorption, resulting in reduction of the Tg temperature.
In addition to the Tg, smaller thermal transitions characteristically occur in
relation to events such as covalent cross-linking of molecules.
Water activity (Aw): Aw describes the extent to which water is available
in a sample at equilibrium, and is dependent on temperature. The Aw of a
sample can be described by the equation
Aw =
p
p0
(9)
where p is the vapor pressure of water in the sample, and p0 is the vapor
pressure of pure water at the same temperature, and it therefore has a value
of between 0 and 1. When temperature equilibrium is observed between a
sample and ambient air, the Aw equilibrates with ambient RH. Thus, the
RH of a sample at equilibrium can be calculated simply by expressing Aw as
a percentage:
RH = Aw × 100% (10)
Aw directly influences organism growth and chemical reactions in the sam-
ple, thus affecting quality indicators such as physical appearance and shelf
life. Most moulds normally require an Aw of at least 0.80 to grow.
Triple point: At subatmospheric pressures, the three states of water (ice,
liquid and vapour) can co-exist at a certain temperature known as the triple
point. Below this point, ice becomes converted directly into a gaseous state,
a process called sublimation. For pure water, the triple point occurs at ex-
actly 273.16 K (0.01°C) and a partial vapour pressure of 6.1173 millibars.
However, the addition of sodium chloride results in a mixture that depresses
the freezing point. This is known as a eutectic system, the eutectic point of
a saturated solution of sodium chloride in water being -21.12°C.
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Chapter 1
INTRODUCTION
1.1 Introduction
Human amniotic membrane (AM) is widely used in modern ophthalmic
surgery. Although it is most commonly used in chronic eye conditions, it also
has a place in the treatment of certain acute eye injuries, including burns.
In military conflicts, eye injuries can be very serious, frequently resulting
in the repatriation of combat troops. For logistical reasons of transport and
storage, dried AM is more suitable for field use than frozen AM, which is
the current standard in modern hospital settings. While treatment with
AM may be useful, the parameters of treatment are incompletely defined.
In addition, there are no clear guidelines for the preparation of dried AM for
therapeutic use. If it is to be accepted by the surgical community, the qual-
ity of dried AM must be comparable with that of the more widely available
frozen version, the biological properties of which are not fully understood.
1.1.1 Purpose and objectives
The purpose of this study is to investigate the potential of dried AM in the
treatment of acute eye injuries in a military setting. The project objectives
are as follows:
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1. To conduct a systematic review of studies of the treatment of acute oc-
ular surface burns with AM and to examine the quality of the evidence
supporting its use.
2. To construct a framework for optimising dried AM with excipients, us-
ing moisture sorption, thermal, dynamic mechanical and surface ana-
lytical techniques.
3. To conduct a comparative study of the mechanical properties of thera-
peutic AM and to cross-link the collagenous matrix.
4. To investigate biological aspects of AM, including its antimicrobial
properties and its effects on inflammation.
1.2 Literature review
1.2.1 Ocular surface injuries
Ocular surface injuries form a disparate group of injuries ranging from mild
to severe.
1.2.1.1 Epidemiology of ocular surface trauma
In 1998, ocular surface injuries were estimated to be responsible for ap-
proximately 1.6 million cases of blindness, 2.3 million cases of bilateral low
vision and 19 million cases of unilateral blindness or low vision worldwide
(Négrel and Thylefors, 1998). The global annual incidence of monocular
blindness, as a result of trauma and corneal ulceration, has been calculated
to reach approximately two million (Whitcher et al., 2001). In a survey from
rural India, the majority of victims of ocular trauma were young and male
(Sinha, 2008).
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1.2.1.2 Cost of ocular surface injuries
Visual impairment from any cause has profound psychological, economic
and social consequences for patients (Wong et al., 2008), and the steep costs
of avoidable visual loss makes it a highly important public health concern
worldwide (Chiang et al., 2006). The burden of severe eye injuries is highest
in developing countries, where chemical assaults give rise to least one third
of all cases of ocular burns (Merle et al., 2008) and hospitals are ill-equipped
to treat them (Adepoju et al., 2007). Even in developed countries, the eco-
nomic burden of visual impairment is comparable to that of cancer, arthritis
and dementia (Frick et al., 2007; Keeffe et al., 2009). Treatment can make
a difference in the quantity and quality of vision, and can influence future
quality of life and dependence on care services (Vu et al., 2005).
1.2.1.3 Ocular surface injuries in military conflict
In the case of military personnel, ocular surface burns are significant con-
cerns for their employers and society at large. The frequency of battlefield
ocular injuries is out of proportion to the surface area of the eye, and is com-
mon even in modern conflicts despite mandatory eye protection (Blanch and
Scott, 2009). Anterior segment closed-globe injuries accounted for 103 out
of 523 cases of globe and adnexal trauma sustained in combat by American
troops during Operations Iraqi and Enduring Freedom between March 2003
and October 2006 (Weichel et al., 2008). Between July 2004 and May 2008,
of 630 British soldiers surviving major trauma in hostile operations, 48 had
significant eye injuries, including a number of blast injuries and burns to the
ocular surface (Blanch et al., 2011). Moreover, corneal injuries are the com-
monest non-battle ocular injuries in recent conflicts in Iraq and Afghanistan
(Ari, 2006), although most are treated in the theatre of operations and only
infrequently require repatriation (Psolka et al., 2007).
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1.2.1.4 Chemical warfare
Mustard agents, which cause cell death by alkylation of DNA, remain a
threat to armed forces and civilians. Out of over 5000 soldiers and civilians
treated for exposure to 2,2’-dichlorethyl sulphide (mustard gas) during the
eight-year war between Iran and Iraq, 10% suffered ocular surface damage
including persistent epithelial defects (Safarinejad et al., 2001). Two per
cent progressed to corneal ulceration, neovascularisation, scarring and vi-
sual loss. The clinical picture of late complications from exposure to vesicant
agents is identical to the presentation of limbal stem cell deficiency caused
by chemical burns (Kadar et al., 2009).
1.2.1.5 Ballistic and blast injuries
Two distinct patterns of ocular injury occur in conflict, including direct bal-
listic trauma and burns. In military action, the gross effects of both these
mechanisms can be observed in blast injuries from explosions (Abbotts et
al., 2007). During an explosive blast, a primary pressure wave is followed
by secondary fragmentation, tertiary physical displacement and quaternary
thermal effects, leading to multiple injuries (Champion et al., 2009). The im-
provised explosive device (IED), seen in roadside mines and suicide bomb-
ings, was the main threat to troops in recent operations in Afghanistan (Ra-
masamy et al., 2009). IEDs cause high-pressure, superheated gaseous det-
onation products to eject at supersonic speed, together with fragments and
ejecta from soil and clothing. Examples of IED injuries to the face and eyes
are shown in figure 1.1. Fragmentation effects cause the majority of se-
vere eye injuries (Morley et al., 2010). These are frequently bilateral, and
may have a thermal component and may cause foreign material to be re-
tained in the ocular surface (Weichel et al., 2008). Although superheated
metallic fragments are sterile, the clothing and soil ejecta which frequently
accompany blasts are not. In recent warfare in Afghanistan and Iraq, the
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Figure 1.1: Blast injury to face and eyes
Images of blast injury patients from the conflict in Afghanistan (2001 - present) are shown.
The injuries resulted from nearby detonation of an improvised explosive device. Gross effects
of complex thermal and mechanical damage are visible in image A. The left eye has been
sliced open by a projectile fragment in a second patient (image B). Image C shows a spiral
computer-assisted tomography scan demonstrating multiple fragmentation injuries through
bones of skull and orbits (courtesy of Lieutenant Colonel Neil McKenzie RAMC).
proportion of evacuated US personnel with significant ocular injuries was
13%, of whom 79% suffered blast injury with fragmentary munitions (We-
ichel and Colyer, 2008). The most common cause of severe ocular injury
among troops during the Iraq Insurgency was the IED, occasionally aug-
mented with gasoline jelly, producing complex trauma and thermal damage
to the ocular surface (Mader et al., 2006).
1.2.1.6 Classification of ocular surface injuries
Assessing complex eye trauma produced by secondary blast injuries requires
an understanding of the different mechanisms involved, including both me-
chanical and thermal components. These disparate mechanisms of wound-
ing have different classifications. The Birmingham Eye Trauma Terminol-
ogy (BETT) system, developed by Kuhn et al. (2002), is used to classify me-
chanical globe injuries (figure 1.2). The ocular trauma score (OTS) works
in synchrony with this system to prognosticate visual outcome (Kuhn et al.,
2002). In complex injuries in which the ocular surface is burned, this clas-
sification may be used in conjunction with a burns classification, discussed
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Figure 1.2: Birmingham Eye Trauma Terminology
The Birmingham Eye Trauma Terminology (BETT) system is used to classify mechanical
globe injuries. IOFB, intra-ocular foreign body. Reproduced from Kuhn et al., 2002 with
kind permission.
in detail in Chapter 2. Acute ocular injuries, including burns, mechanical
trauma and mixed injuries are a complex group of pathologies without a
single, unifying course of treatment.
1.2.2 Corneal wound healing
Corneal healing mechanisms are a useful platform from which to assess
the therapeutic potential of AM. Regardless of the aetiology, corneal in-
juries have common motifs potentially amenable to manipulation by adju-
vant treatments. An immediate tissue response occurs following ocular sur-
face injuries, mediated by local signalling mechanisms (Lim et al., 2003) and
systemic signals which attract bone marrow-derived cells to the cornea, at
least in animal models (Nakamura et al., 2005). Multiple pathways are ac-
tivated, leading to a complex healing response which may result in further
tissue destruction, fibrotic repair, or, potentially, regeneration of healthy
corneal tissue (Fini, 1999).
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1.2.2.1 Epithelial healing
Corneal epithelial healing is a highly regulated process requiring the co-
ordination of multiple humoral and neural signalling pathways, involving
lacrimal gland cells, keratocytes, epithelium and extracellular matrix (ECM)
(Lu et al., 2001). Superficial cells initially slide towards the denuded sur-
face. Presumed stem cell-derived cells in the central and peripheral cornea
proliferate and migrate towards the injury, differentiating into stratified
squamous epithelial layers until integrity is restored (Chang et al., 2008).
Mammalian corneal epithelial cells (CECs) are thought to originate from
slowly-dividing epithelial stem cells resident in specialised crypts at the
corneal limbus (Dua et al., 2005), and possibly from cells retaining stem-
like qualities (‘stemness’) in the limbal basal epithelium and distributed
throughout the mammalian ocular surface (Majo et al., 2008).
1.2.2.2 Stromal healing
Renewed attention to the pathways governing fibrotic repair, remodelling
and regeneration and has come from the refractive surgery community (Sa-
lomao and Wilson, 2009). The healing response involves communication
between the epithelium and the stroma, a process in which interleukin (IL)
1α is a key player (Wilson et al., 1999). If the injury is limited to the epithe-
lial layer, without damage to the underlying BM, apoptosis of the underlying
stromal cells occurs following autocrine production of the Fas ligand (Wilson
et al., 2003). This may be an evolutionary response protecting the cornea
from inflammation and scarring (West-Mays and Dwivedi, 2006).
Evidence from wound-healing studies suggests that the stromal scarring
response is switched on by injury to the basement membrane (BM) and
driven by epithelial factors, of which the transforming growth factor (TGF)
β isoform appears to be pivotal. In an animal model, blockage of TGF-β
was shown to abrogate the myofibroblast response, reducing stromal fibro-
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Figure 1.3: Corneal repair mechanisms
A schema of corneal repair mechanisms is shown. An injury that breaches the basement
membrane stimulates fibrotic repair. After the initial response, remodelling is mediated by
matrix metalloprotease enzymes. A regenerative response may also occur. Smad3, small
mothers against decapentaplegic homolog 3; NF-κB, nuclear factor κ B; Pax 6, paired box
protein 6; IL-1, interleukin-1; TGF-β2, transforming growth factor β2.
sis (Moller-Pedersen et al., 1998). The extent of the response depends on
the size and irregularity of the injury. If the BM is breached, the epithelial
cells communicate with stromal cells via cytokines and growth factors to
trigger multiple pathways (Fini and Stramer, 2005). Some of these interac-
tions are summarised in figure 1.3. A subpopulation of stromal keratocytes
becomes activated following interaction with epithelial cell-derived TGF-β2
(in a murine model), transforming into myofibroblasts via activation of the
so-called small mothers against decapentaplegic homolog (Smad) 3 intracel-
lular pathway (Fini and Stramer, 2005). Myofibroblast activation is charac-
terised by expression of the α isoform of smooth muscle actin stress fibres,
as well as suppression of cluster of designation molecule (CD) 34, proteogly-
cans and MMPs (Barbaro et al., 2006). Myofibroblast induction may require
synergistic platelet-derived growth factor (PDGF) and fibronectin/integrin
signalling (Jester et al., 2002).
Following the initial fibrotic response, there is a gradual shift towards
remodelling. Animal gene targeting and knock-out models have shown that
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keratocytes interact with ECM proteoglycans such as lumican and kera-
tocan activating intracellular signalling pathways (Kao, 2006). Autocrine
secretion of IL-1αmay occur in keratocyte-derived fibroblasts, a mechanism
that appears to involve transcription factor nuclear factor κ B (NF-κB) (Fini
and Stramer, 2005). This is a central transcription factor that regulates
numerous biological processes on the ocular surface, including wound heal-
ing and angiogenesis (Lan et al., 2012). This up-regulates MMPs, which
participate in remodelling the cornea after the BM has undergone repair
(West-Mays et al., 1995).
Stromal cells expressing stem cell markers may retain stem cell charac-
teristics capable of activating regenerative gene expression pathways (Du et
al., 2005, 2007, 2009). Keratocyte progenitors are thought to express mes-
enchymal markers such as the paired box protein (Pax) 6 gene, and could
contribute to stromal regeneration by secreting organised collagen and ECM
(Funderburgh et al., 2005). Moreover, cultured keratocytes can express
markers of relatively undifferentiated putative haematopoietic stem cells
(Perrella et al., 2007). In a rabbit model, a rapid bone marrow reaction
occurs after a corneal alkali injury, releasing progenitor cells into the cir-
culation (Ye et al., 2008). This suggests that corneal wound-healing is the
product of a co-ordinated system which simultaneously elicits repair, remod-
elling and regeneration.
1.2.3 The amniotic membrane
The precise role of AM in the complex process of corneal wound healing is
unclear. In attempting to address the question of how AM might interact
with with the ocular surface, it is necessary first to understand the basic
development, structure and function of AM.
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1.2.3.1 Embryological origins
AM is the avascular internal lining of the amniotic sac in which foetal
growth occurs. Its embryological origins are reflected in its mature struc-
ture and function, since AM is genetically foetal tissue consisting of layers
derived from both ectoderm (epithelium) and mesoderm (mesenchyme or
stroma) (Bryant-Greenwood, 1998). The membrane origins lie in the for-
mation of the blastocyst, an embryonic collection of cells which cavitates
internally to form a space, the blastocoel, on the 5th day after fertilisation
in primates (Enders et al., 1986). A mass of cells inside the blastocyst forms
the bilaminar disc of primary ectoderm and endoderm, the precursors of the
amniotic sac and the yolk sac (the developmental circulatory system) re-
spectively. The external blastocyst layer differentiates into the trophoblast,
the precursor of foetally-derived chorion and placenta. The bilaminar disc
acquires an intermediate third layer, the mesoderm, by day 12. Mesoderm
migrates to invest every structure in the blastocoel, including the yolk sac,
the amniotic sac and the internal wall of the trophoblast, by day 18. Thus,
the ectodermally-derived epithelial layer of AM becomes fused with a stro-
mal layer of mesodermal origin. By day 23, the amniotic sac begins to en-
wrap the formative foetus, which, in turn, internalises the yolk sac. The
ectoderm of the fluid-filled amniotic sac is contiguous with the foetal skin
and the future umbilical cord. The mesodermal outer layer of the amniotic
sac eventually fuses with the mesodermal layer lining the trophoblast, oblit-
erating the blastocoel. The obliterated blastocoel is filled with the spongy
layer (see below).
1.2.3.2 Anatomy
Basic AM structures can be visualised by light and electron microscopy. It is
composed of 5 layers, the innermost of which is composed of a single layer of
cuboidal to columnar amniotic epithelial cells (AEC) (Bourne, 1960). Figure
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Figure 1.4: Human amnion and chorion
A diagram of a section through amnion and chorion is shown, highlighting the various
layers. Reproduced from Bourne, 1960 by kind permission.
1.4 shows the general organisation of the multilayered amnion and chorion.
The epithelial cells secrete collagen (Types III and IV) and non-collagenous
proteins (laminin, entactin and proteoglycans) forming the basement mem-
brane (BM) (Parry and Strauss, 1998). The BM overlies a compact and
mechanically resistant reticular third layer containing interstitial collagens
(types I and III), small amounts of minor fibrillar collagens (V, VI and VII)
(Malak et al., 1993) and non-collagenous proteins including laminin, elastin,
fibronectin, plasminogen and others. The third layer varies in thickness and
provides the bulk of tensile strength (Bryant-Greenwood, 1998), and is se-
creted by mesenchymal cells (fibroblasts). These reside in a fourth layer of
loose connective tissue (Parry and Strauss, 1998). AEC and stromal fibrob-
lasts have different profiles of gene expression and protein translation, each
contributing to the overall AM structure (Bryant-Greenwood, 1998). The
final layer is the spongy layer (SL), which consists of jelly-like hyaluronan-
rich mucopolysaccharide (Meinert et al., 2001) and permits a sliding move-
ment between the AM and the chorion (Fawthrop and Ockleford, 1994). AM
varies in thickness from 20 or so microns in the apical zone to a few hundred
microns in the zone overlying the placenta, and contains no blood vessels. It
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comprises a mechanically strong and biologically complex collagenous and
elastin-rich interstitium designed to accommodate growth and eventually
rupture.
1.2.3.3 Physiology
AM is an aneural membrane whose functions include homeostasis of the
amniotic fluid (see review by Dua et al., 2004). It obtains nutrients from
the surrounding fluid and the maternal decidua via a complex intercellu-
lar canalicular network (Bourne, 1966). A wide array of enzymes, such as
prostaglandin synthase (Smieja et al., 1993), growth factors such as epi-
dermal growth factor (EGF) and TGF-β2 (Koizumi et al., 2000b), and cy-
tokines such as IL-6 and IL-8 (Keelan et al., 1997) are associated with the
membrane. Human AEC and mesenchymal cells both appear to release
prostaglandins (Whittle et al., 2000), an occurrence associated with apopto-
sis prior to membrane rupture (Moore et al., 2003). The amniotic ECM is
a complex biological medium, hosting a variety of autocrine and paracrine
cascades (Bryant-Greenwood, 1998). These include the activation of MMPs
and their inhibitors, which are thought have a critical function in the even-
tual rupture of the membrane (Arechavaleta-Velasco et al., 2002). Antimi-
crobial peptide mRNA has been found in AEC (King et al., 2007b; Stock
et al., 2007), suggesting that the membrane can mediate an antimicrobial
response. Amnion-derived mesenchymal cells may have progenitor charac-
teristics, although it is not clear at present why this should be the case in a
tissue predisposed eventually to be discarded (Dobreva et al., 2010).
1.2.3.4 Structural composition
As a complex biological material, AM is a composite of structural, matriceal
and biological components, and has a high water content (table 1.1). The
composition of dry amnion from healthy donors has been calculated by var-
12
Table 1.1: Composition of human AM
Component Composition Reference
Total collagen 382 μg/mg (SD 23) Meinert et al. (2001)
Total collagen 419 μg/mg (SD 73) Prévost (2006)
Total collagen 357 μg/mg (SD 68) MacDermott and Landon
(2000)
Glycosaminoglycans 213 μg/mg (SD 31) Prévost (2006)
Small proteoglycans Approx. 2% Meinert et al. (2001)
Hyaluronic acid Approx. 2% Meinert et al. (2001)
Elastin Approx. 10 - 20% Jabareen et al. (2009)
Glycoproteins < 1% Bhatia et al. (2007)
Water 86% Prévost (2006)
Water 87.5% (SD 2.6) Halaburt et al. (1989)
Water 87% (SD 4.2) Prévost (2006)
SD, standard deviation. Composition given as dry weight.
ious authors. The total collagen content in the studies cited was calculated
using the hydroxyproline assay described by Stegeman and Stalder (1967),
which stipulates the hydroxyproline to collagen ratio to be 7.64:1. The extra-
cellular matrix consists (in dry weight) of approximately 35-45% collagen,
10-20% sulphated glycosaminoglycans such as dermatan and chondroitin
sulphate, 10-20% elastin, and smaller quantities of small proteoglycans
(biglycan, decorin), hyaluronic acid, large proteoglycans and glycoproteins
such as fibronectin. 10-15% of the dry weight is accounted for by bound wa-
ter. There is less collagen but more elastin than other collagen-rich tissues
such as skin (Park and Lakes, 1992).
1.2.4 Therapeutic application
1.2.4.1 Historical background
The idea of using AM therapeutically emerged nearly a century ago. The
amniotic sac lining was first grafted to the skin by a pioneering plastic sur-
geon at the Johns Hopkins Hospital in Baltimore following a suggestion
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from a medical student, but it had limited success (Davis, 1910). Two re-
ports emerged in 1913 highlighting the potential of AM as a skin graft for
burns (Sabella, 1913; Stern, 1913). The first documented use of foetal mem-
branes in ophthalmic surgery was in 1938 by de Rötth, of Budapest, who
used amnion still attached to chorion as a conjunctival substitute to treat 5
cases of symblepharon (de Rötth, 1940). Of these cases, one was deemed a
partial success.
Wider applications for AM were found in diverse surgical specialities
(Trelford and Trelford-Sauder, 1979). In neurosurgery, AM separated from
chorion and stored in 70% ethanol, termed ‘amnioplastin’, was used to fill in
defects of the dura mater (Chao et al., 1940). Reports of a case of lime burn
(Lavery, 1946) and of a series of 56 chemical and 2 firework injuries (Sorsby
and Symons, 1946; Sorsby et al., 1947) treated with amnioplastin patch-
ing within one or two days of injury suggested favourable outcomes. The
tissue, prepared in salt solutions rather than ethanol, appeared to func-
tion as a splint for proliferating tissue. It was recognised that AM might
be a suitable biomaterial for treating ophthalmic injuries on the battlefield
(Dansey-Browning, 1949), and it was thought to improve comfort and pre-
vent symblepharon (Shafto, 1950).
For unclear reasons, the documented use of AM in ophthalmic surgery
almost completely disappeared from English language scientific literature
for a period of almost forty-five years thereafter. A study on the treatment
of corneal ulcers with AM emerged from India during this period (Shukla,
1962). In contrast to the dearth of reports in English after 1950, a num-
ber of publications on the ophthalmological applications of AM appeared in
Eastern bloc countries (Zankiewicz, 1960; Wolsztyn, 1951; Stoenchev, 1953;
Makeeva, 1983).
Samples of this ‘allotransplant’ were obtained by Dr Horacio Serrano fol-
lowing a visit to Russia, and used in Venezuela in 1988 without knowledge
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of its true biological identity (Dua et al., 2004). Following its histological
identification, AM was again promoted as a conjunctival substitute (Batlle
and Perdomo, 1993), and its use in ophthalmic surgery was further concep-
tualised by Scheffer Tseng and his colleagues at the Bascom Palmer Eye
Institute in Miami. Following experiments on rabbit eyes, it was suggested
that AM had a possible role in promoting transformation of conjunctival
epithelium to a corneal phenotype, thus significantly enhancing ocular sur-
face reconstruction (OSR) and preventing neovascularisation of the stem
cell-deficient ocular surface (Kim and Tseng, 1995b,a). Soon afterwards, re-
ports emerged of the treatment of corneal PEDs and pterygium with AM
(Lee and Tseng, 1997; Prabhasawat et al., 1997). Over the next few years,
AM became more and more accepted into mainstream ophthalmic surgical
practice.
1.2.4.2 AM in modern ophthalmic surgery
Since its re-introduction into modern ophthalmic surgery, the number of
therapeutic indications for AM treatment has risen steadily (Dua et al.,
2004). Its versatility is perhaps best illustrated by an example of its po-
tential use over the course of an ocular burn. In the acute and early phases
of a burn, AM can be sutured over the entire ocular surface as a surgical
dressing (Meller et al., 2000). Alternatively, it can be wrapped around a
conformer and inserted between inflamed forniceal tissues. In later phases,
the scarred and contracted conjunctival fornices can be managed by trans-
planting AM to restore the gross anatomy (Solomon et al., 2003). How-
ever, mucous membrane, buccal and basal turbinate mucosae are consid-
ered more robust (De Sousa et al., 2009). Multilayered AMT can be per-
formed for refractory corneal melts and deep ulcers in danger of imminent
perforation (Kruse et al., 1999; Hanada et al., 2001), and small perforations
can be managed with AMT in conjunction with cyanoacrylate (Su and Lin,
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2000) and fibrin glues (Hick et al., 2005). The AM scaffold becomes incorpo-
rated into the host tissue, adding bulk to the stroma and supporting fibrotic
change (Nubile et al., 2011). Furthermore, AM can be used to augment the
treatment of bacterial keratitis, an effect of prolonging the action of topi-
cally applied antibiotics (Gicquel et al., 2007). Inflammatory cells stick to
the stromal aspect of AM, which may promote anti-inflammatory activity
(Shimmura et al., 2001). The size of the AM transplant can be customised
according to need. Thus, it can be applied as a limited corneal inlay graft - 1
or 2 mm in diameter - to treat a persistent epithelial defect (PED), or as a 5
cm diameter dressing for the entire ocular surface. Several different modal-
ities of AM treatment can be applied simultaneously (Letko et al., 2001).
Besides being widely used to treat the human ocular surface, AM has an
established role in the treatment of veterinary eye injuries (e.g., Kim et al.,
2009).
The evolution of AM use in ophthalmic surgery is illustrated by the 12
applications listed in chronological order in table 1.2. It can be seen that
the majority of these applications make use of the physical properties of
AM, and do not require additional biological functions. Biological factors
are invoked in the treatment of acute burns, but this is speculative. A sur-
vey of the first 233 cases of AMT in the United Kingdom, carried out be-
tween June 1998 and December 2002, showed that the most common indica-
tions for treatment were PEDs (37.8%) followed by OSR (28.8%), treatment
of painful bullous keratopathy (18.0%) and acute chemical injuries (18.0%)
(Saw et al., 2007). These functions rely primarily on the properties of AM
as a membrane, with any additional biological functions being suggested
rather than demonstrated.
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Table 1.2: Applications of AM in ophthalmic surgery
Function Surgical
application
Examples of
pathology
Primary reference
Substitute for conjunctiva Conjunctival graft Conjunctival defect de Rötth (1940)
Surgical dressing Ocular surface patch
(stroma down)
Acute burn Sorsby and Symons
(1946)
Spacer to prevent
symblepharon
Forniceal patch Acute burn Sorsby and Symons
(1946)
Corneal patch Multilayered overlay Corneal ulcer Shukla (1962)
Substrate for
epithelial growth
Corneal inlay PED Lee and Tseng (1997)
Scaffold for stromal
matrix growth
Multilayered graft Reconstruction of
ulcers
Kruse et al. (1999)
Patch to prevent leak Scleral patch Leaking bleb Budenz et al. (2000)
Substrate for stem
cell expansion
Ocular surface
reconstruction
Diffuse LSCD Tsai et al. (2000)
Plug for corneal
perforations
Corneal underlay Acute perforation Su and Lin (2000)
Source of soluble
factors
Ocular surface patch
(stroma up)
Acute burn Meller et al. (2000)
Trap for inflammatory
cells
Bilayered patch
(stroma up)
Inflammation Shimmura et al.
(2001)
Reservoir for topical
antibiotics
Multilayered corneal
inlay
Infectious keratitis Gicquel et al. (2007)
PED, persistent epithelial defect; LSCD, limbal stem cell deficiency.
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1.2.4.3 AMT in stem cell deficiency
AM is commonly used as an adjunct in the rehabilitation of eyes with limbal
stem cell deficiency (LSCD) (Cauchi et al., 2008). In partial LSCD, AM can
be applied as an inlay within a PED (Anderson et al., 2001). When applied
with the epithelial side up, it facilitates the migration and adhesion of ep-
ithelial cells (Lee and Tseng, 1997). In many cases, however, it is difficult
to identify a treatment effect because the extent of LSC loss at the outset
may be unclear (Shimmura and Tsubota, 2008). In total LSCD, AM can be
applied as a protective patch overlying limbal tissue grafts (Tsubota et al.,
1996). Alternatively, autologous LSCs can be expanded directly onto AM
prior to transplantation (Tsai et al., 2000). AM can be denuded to facilitate
the expansion of ex vivo LSC colonies (Koizumi et al., 2000b), producing a
stratified corneal epithelium Koizumi et al. (2001a). Cultivated autologous
oral mucosal epithelial sheets on denuded AM substrates are a more recent
development (Nakamura and Kinoshita, 2003; Kinoshita and Nakamura,
2004; Inatomi et al., 2006). Patients with ocular surface disorders such as
Stevens-Johnson syndrome (SJS) and chemical injuries have been treated
with epithelial sheets cultivated on AM both from corneal LSCs (Koizumi et
al., 2001b; Shimazaki et al., 2002) and autologous oral mucosal stem cells
(Nakamura et al., 2004; Ma et al., 2009). AM is not an obligatory carrier,
and methods of expanding LSC on fibrin have been developed (Rama et al.,
2010).
1.2.4.4 Mechanism of action of AMT
The putative mechanisms of action of AM on the ocular surface broadly fall
into two categories: those that can be explained by directly observable phys-
ical interactions between the membrane and the eye, and those that are
implied by presumed biological properties of AM. In the first of these cat-
egories, AM functions as a biocompatible membrane with empirically ob-
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servable benefits, such as sealing a perforation (Duchesne et al., 2001) or
preventing a leak from a surgical procedure (Budenz et al., 2000). In the
second category, a biological property is attributed to AM over and above its
self-evident value as a biomaterial, such as promotion of epithelial healing
and suppression of inflammation (Tseng et al., 2004).
Many of the useful effects of AM are due to its gross physical properties
as a thin membrane. Placing an AM bandage on denuded cornea appears to
reduce pain (Dua et al., 2004). This effect may occur by reducing eyelid fric-
tion over the injured surface whilst allowing oxygen transfer to take place
(Baum, 2002).
In addition, AM may function as a physical barrier to inflammatory cells
and as a source of anti-inflammatory and pro-epithelial mediators, such as
fibronectin and epidermal growth factor. These constitute the properties of
a ‘biological dressing’ (Talmi et al., 1990; Tseng et al., 2004). AM is known
to express biological factors, such as anti-inflammatory and anti-angiogenic
proteins (Hao et al., 2000). Preserved AM contains mRNA for numerous
growth factors (e.g., EGF, TGF-α and -β isoforms) and their protein products
in both the stroma and the epithelium (Koizumi et al., 2000b). Soluble AM-
derived factors appear to be capable of suppressing the immune response in
vitro (Li et al., 2005). Conditioned supernatants from AM cultures suppress
alloreactive T lymphocytes in mice, an action attributed to soluble inhibitory
factors (Ueta et al., 2002).
However, the putative role of biological factors in therapeutic AM is con-
troversial. Since AM epithelial and stromal cells are not considered viable
following preparation (Dua et al., 2004), the contribution of biological fac-
tors is limited to those produced before preservation. AEC undergo a process
of programmed cell death before the onset of labour, suggesting that these
cells may be declining by the time of harvesting of AM for therapeutic ap-
plication (Lei et al., 1996). Some of the factors have opposing effects, not
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all of which can be expected to be positive (Dua et al., 2004). For example,
regulatory proteins retained in therapeutic AM include TGF-β1 (Hopkinson
et al., 2006b), which may cause scarring. Similarly, anti-angiogenic factors
such as TIMP-1 (Hao et al., 2000) may promote ischaemia. Furthermore,
the concentration of biological factors in therapeutic AM is variable, both
due to its heterogeneity (Gicquel et al., 2009) and as a result of processing
(Hopkinson et al., 2006b). The lack of evidence surrounding the pharmaceu-
tical use of AM indicates that the benefits of AMT in some conditions are as
yet unproven, and suggest an important need for clinical research into this
treatment to continue. Since the promotion of AMT may be driven by com-
mercial interests, it is particularly important to clarify its true potential.
1.2.4.5 Animal models
Experimental animal models have been used to explore the potential of AM
as a dressing for a range of ocular injuries with diverse causes. These have
produced variable results. A study of alcohol-induced epithelial injuries in
a canine model reported faster healing in eyes treated with AMT (Kim et
al., 2009), while there was no difference in the healing rate of mechani-
cal corneal wounds in rabbit eyes treated with AM (Libera et al., 2008).
In another study, ex vivo rabbit corneas were placed in an air-interface
organ culture and treated with 20 μl of amniotic fluid every eight hours,
showed significantly faster rates of re-epithelialisation compared to controls
(Castro-Combs et al., 2008). Conditioned culture medium from human AEC
suppressed corneal neovascularisation in experimental mice (Kamiya et al.,
2005). In a rabbit model of alkali corneal burns, AMT produced faster ep-
ithelial healing (Kim et al., 2000). In addition, AM acted as a barrier to neu-
trophils, reducing levels of proteinase activity. In similar experiments, AMT
was more effective at promoting epithelialisation than autologous serum or
preservative-free artificial tears (Shahriari et al., 2008). Another study doc-
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umented fewer α-SMA cells and reduced expression of MMPs 14 days after
an alkali burn in rabbit eyes treated with AMT (Takahashi et al., 2007).
Laser-induced corneal wound models have been helpful in understanding
the effects of AM on stromal injuries. In a rabbit model, AM patching for
48 hours after excimer laser to the corneas resulted in significantly reduced
numbers of keratocytes infiltrating the anterior stroma (Choi et al., 1998).
Similar studies reported significantly faster epithelial healing (Woo et al.,
2001) and reduced corneal haze (Wang et al., 2001). In one series, rab-
bit eyes with induced total LSCD recovered a corneal epithelial phenotype
following treatment with AMT, suggesting LSC recovery (Kim and Tseng,
1995a,b). In contrast, in similar experiments by Koizumi et al. (2000b), all
the rabbit eyes had persistent total epithelial defects. While many of these
studies suggest a benefit of AMT, the risk of bias is sometimes ignored.
1.2.4.6 Surgical application
There are different methods of applying AM to the ocular surface, whether
as a temporary patch or as a graft. As a temporary patch, AM is frequently
sutured onto the ocular surface, although it can also be applied wrapped
around a symblepharon ring conformer. There are reports of difficulty in
keeping AM fixated to the ocular surface (Gris et al., 2002), which has led to
the use of adhesives such as fibrin glue (Sekiyama et al., 2007; Kheirkhah et
al., 2008), chemical bioadhesives (Takaoka et al., 2008) and medical grade
glues such 2-octyl-cyanoacrylate (Kitagawa et al., 2009) to keep it in place.
AM coated with 2-octyl-cyanoacrylate has been used effectively as a primary
treatment for corneal perforations up to 3 mm in diameter (Kitagawa et al.,
2011). When AM is applied as a graft, the corneal epithelium grows over the
AM, which slowly disintegrates, obviating the need for an additional proce-
dure to remove sutures. The integration of an AM allograft into corneal
tissue is an active process which results in the formation of adhesion struc-
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tures, desmosomes and hemidesmosomes (Resch et al., 2006). Besides pro-
moting CEC migration, AM appears to have an important effect on corneal
stromal cells, providing them with a collagenous AM scaffold into which
they migrate and proliferate (Said et al., 2009). This may have important
implications for repair of stromal damage.
1.2.4.7 Clinical use of dried AM
A dried AM product, known as ‘hyper-dry-amnion’ was developed for clini-
cal use in Japan as a non-immunogenic alternative to frozen AM (Toda et
al., 2007). It had the advantage of being easy to handle by ophthalmic sur-
geons, and could be stored indefinitely at room temperature. It was applied
clinically as a conjunctival replacement. Since then, clinical publications on
the application of dried AM have been few, restricted to reports of corneal
perforations and wound leaks (e.g., Kitagawa et al., 2009, 2011). Other cen-
tres have considered the potential of dried AM as an ocular biomaterial
through the in vitro studies and animal models (e.g., Sekiyama et al., 2007;
Nakamura et al., 2008; Libera et al., 2008). Lyophilised AM has also been
used as a biological dressing in the treatment of skin burns, with apparently
favourable results (Gajiwala and Gajiwala, 2004).
1.2.4.8 Limitations of treatment
While there are now numerous common indications for AM treatment, AM
has been used in excess of its true potential Dua et al. (2004). Because of its
early promise, the usefulness of AM has sometimes been overstated in the
search for novel applications, often without evidence of benefit and despite
the lack of RCTs (Bouchard and John, 2004). Even for its most common in-
dications, AM treatment by no means guarantees success. When stringent
outcome criteria were applied to a large series of cases, the success rate of
AM treatments was less favourable than had been previously reported, with
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many cases of treatment failure (Saw et al., 2007). Similarly, Maharajan et
al. (2007) analysed 74 AMT procedures retrospectively, clearly defining ob-
jectives for AM treatment. High failure rates were found, especially where
there was associated stem cell deficiency.
Significant heterogeneity between AM samples in terms of both physical
attributes such as thickness and transparency (von Versen-Höynck et al.,
2004; Connon et al., 2007; von Versen-Hoeynck et al., 2008; Connon et al.,
2010) and biochemical components such as growth factors (Hopkinson et
al., 2006b; Gicquel et al., 2009). These differences exist between donors
and also between therapeutic samples obtained from a single donor, and the
preparation process itself results in the depletion of factors. Although AM is
widely used, there is no standard method of preparation and storage (Dua
et al., 2010). The variability in AM, its preservation and its application
constitute significant limitations of AM treatment.
The clinical use of AM has to be weighed against its potential risks and
limitations (Rahman et al., 2009). With proper testing, the risk of donor
transmission of infectious disease is negligible, but cannot be discounted
entirely. Fungal and other corneal infections can occur after AMT, and must
therefore be considered as a risk factor (Das et al., 2009). AM has the advan-
tage of low immunogenicity (Wang et al., 2006), but the host can become sen-
sitised to the donor AM epitheliummajor histocompatibility complex (MHC)
class I antigens and reject future transplants (Hori et al., 2006). The pos-
sibility of sensitisation is indicated by a report of a steroid-responsive hy-
popyon in a patient who received sequential AM grafts from the same donor
(Gabler and Lohmann, 2000). Serious adverse outcome of AM treatment
have included corneal melting (Schechter et al., 2005).
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1.2.5 AM procurement and preparation
1.2.5.1 Procurement
The use of AM is not risk-free, and carries an important risk of maternal
disease transmission Rahman et al. (2009). To minimise this risk, potential
AM donors undergo a formal consenting process in which social risk factors
for communicable diseases are identified, and these patients are usually ex-
cluded from donation. Mandatory screening is carried out for a number of
contagious diseases, including HIV, Hepatitis B and C and syphilis. Infec-
tion screening can be done by serological testing. This requires repeat test-
ing after six months’ quarantine to exclude the transmission of recently ac-
quired, undiagnosed infections in seronegative mothers (Adds et al., 2001b).
An alternative method is by polymerase chain reaction (PCR) of the donor
tissue, along with tissue culture, which yields results within two weeks of
birth. In developing countries in particular, this risk assessment is not as
strict, and unpreserved tissue has been used to reconstruct the ocular sur-
face (Mejía et al., 2000) and to treat acute burns (Uçakhan et al., 2002).
1.2.5.2 Preparation
After harvesting, therapeutic AM must be sterilised and preserved. The
risk of bacterial contamination of donor AM is present in samples obtained
by Caesarean section, and is increased in membranes obtained by vagi-
nal delivery (Adds et al., 2001a). In most countries, donor AM is normally
harvested in strict aseptic conditions after a caesarean section (Dua et al.,
2004). Once it has been separated from the chorion and placenta, AM is
typically washed several times in saline solution containing a cocktail of
broad-spectrum antibiotics and antimycotics, and is then ready to be pro-
cessed by freezing or drying for clinical use.
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1.2.5.3 To denude or not to denude?
Cell viability is not considered necessary for AM to function as a bioma-
terial. In order to circumvent any allogeneic effects, researchers have de-
veloped cell-free AM matrices for tissue engineering purposes (Wilshaw et
al., 2006; Portmann-Lanz et al., 2007). They used detergents to ensure the
complete removal of cellular material from AM. Human AEC are rendered
non-viable by glycerol preservation, by washing in water, by freezing and
lyophilisation and by γ-irradiation (Hennerbichler et al., 2007). A number
of leaders in the field of ocular surface reconstruction routinely remove the
amniotic epithelium (Nakamura et al., 2003; Sangwan et al., 2003). Epithe-
lial cell attachment and stratification may occur preferentially on denuded
membrane, the cells forming significantly more desmosomes and junctional
attachments than those cultured on intact AM (Koizumi et al., 2007). Lim-
bal epithelial stem cell progeny may lose their stemness and become differ-
entiated early on denuded AM, evidenced by the expression of markers of
corneal basal epithelium (Grueterich and Tseng, 2002). Conversely, the lim-
bal phenotype may persist longer on intact AM, giving rise to the conceptu-
alisation of intact membrane as a ‘surrogate niche’ for stem cells (Grueterich
et al., 2003; Li et al., 2006b; Dietrich-Ntoukas et al., 2012). Nonetheless, cell
outgrowths of limbal explants cultured on intact membrane appear to lose
staining for putative stem cell markers ABCG2 and ΔNp63 (Kolli et al.,
2008). Shortt et al. (2009) did not find any difference in the expression of
putative stem cell markers between cells cultured on intact and denuded
membrane. Currently, the weight of evidence suggests that the clinical dif-
ferences between intact and denuded AM are not significant, and therefore
the debate concerning the retention of biological factors of AM is less rel-
evant than is commonly supposed. AM epithelium can be removed using
a variety of methods involving trypsin, dispase, ethylenediaminetetraacetic
acid (EDTA), urea or ethanol in combination with mechanical scraping (see
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review by Riau et al., 2010). One method uses thermolysin, which cleaves
the epithelium away from the BM at the level of hemidesmosome complexes
(Hopkinson et al., 2008).
1.2.5.4 Preservation by freezing
At present, the most common method of preserving AM is by freezing. The
freezing of tissue for long-term storage - cryopreservation - is an area of
expertise in the domain of mammalian reproductive technology, where ga-
metes and embryos can be frozen in the presence of cryoprotectants and
stored at -196°C (reviewed by Woods et al., 2004). Cryoprotectants are low-
toxicity, highly soluble compounds that cause a profound drop in the in-
tracellular freezing temperature, and include glycerol, dimethyl sulfoxide
(DMSO), ethanediol and propanediol (Pegg, 2007). Each cell type requires
a carefully optimised protocol of cryoprotectant selection and concentration,
as well as cooling, freezing and thawing rates to maintain cell viability. Hu-
man ovarian tissue preservation, for example, is made possible either by
staging programmed reductions of temperature, allowing water to diffuse
out of the cell without ice crystallisation, or by a process known as vitrifica-
tion, in which freezing is prevented by appropriate cryoprotectants (Keros
et al., 2009). Without adequate cryoprotection, freezing of tissues results in
irreversible cell damage. During chilling, cell membrane micro-domains ag-
gregate together, leading to inappropriate signalling and ion leakage and
rendering the cells non-viable (Crowe et al., 2003). As the temperature
drops to below 0°C, uncontrolled freezing causes major damage to the cells
due to the formation of ice crystals and the harmful concentration of solutes.
AM does not require vascular support for its function, making it an excel-
lent candidate for cryobiological preservation. It is typically frozen in a 1:1
Dulbecco’s Modified Eagle Medium (DMEM)/glycerol mixture at -80°C and
thawed immediately before surgical application, although it can be refrig-
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erated at 4°C for shorter periods (Hennerbichler et al., 2007). Glycerol does
not protect the epithelium or prevent osmotic damage to the AM-derived
cells (Woods et al., 2004). In contrast to reproductive cells, therefore, the
cells do not usually retain any viability after cryopreservation in glycerol,
and mitochondrial activity is abolished (Hennerbichler et al., 2007; Kruse
et al., 2000). Under electron microscopy, the devitalised AEC have grossly
altered morphology, detach from the BM and form vacuoles (Rejzek et al.,
2001). Glycerol preservation may adversely affect the ability of AM to serve
as a substrate for limbal stem cell expansion (Shortt et al., 2009). Nonethe-
less, useful factors may be retained within the damaged cell membrane,
eventually becoming released on the ocular surface (Kruse et al., 2000).
In keeping with Lee and Tseng’s original method of cryopreservation (Lee
and Tseng, 1997), both experimental and commercial methods of cryopre-
serving AM have continued to use 50% glycerol (Grueterich et al., 2002;
Tsai et al., 2000). The most widely available commercial preparations of
glycerol-cryopreserved AM include AmnioGraft® and ProKera®, both from
Bio-Tissue, Inc. (Miami, USA), founded by Tseng in 1997. In the United
Kingdom, AM is cryopreserved in tissue banks in a similar way, and sup-
plied to the National Health Service following a period of quarantine.
DMSO is an alternative cryoprotectant used by some researchers and
clinicians (e.g., Shimazaki et al., 1997). The viability of AEC following cry-
opreservation in DMSO has been estimated at 13-18% (Hennerbichler et
al., 2007), 21.9 ± 23.3% (Wolbank et al., 2009), 40% (Rama et al., 2001)
and over 50% (Kubo et al., 2001). DMSO-preserved AM was found to se-
crete significant quantities of factors such as IL-8, whereas factor release
from glycerol-preserved AM was negligible (Wolbank et al., 2009). Although
DMSO-preserved AM is often used to treated ocular surface conditions (Azuara-
Blanco et al., 1999; Daya et al., 2005; Shimazaki et al., 2002), the clinical
effects of DMSO in comparison to glycerol are not fully understood, and it
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may have toxic side effects. Thus, whether glycerol or DMSO can improve
clinical aspects of AM is unknown. For most purposes, simple freezing of
the intact AM in buffered saline at -80°C may be adequate for clinical use.
1.2.6 Dry preservation
Although therapeutic AM is most commonly frozen, dried preparations have
distinct advantages, eliminating the need for a cold chain and permitting
storage at room temperature (RT), thus reducing transportation and stor-
age costs. In contrast to frozen tissue, dried AM can be deployed for field
use. However, experience with this preparation is limited, and the impact
of drying on the properties of AM is unclear. While dried AM can be recon-
stituted for use, rehydration is not mandatory, as the tissue can also be used
in its dry form. Whether undertaken in the laboratory or on a commercial
level, the principles of preservation are the same. Preserved biological tis-
sues undergo degradation as a result of endogenous enzyme activation and
exposure to exogenous (microbial or host) enzymes. These processes can be
slowed by exposure to temperatures below the standard physiological range
(freezing), or by removing the water medium in which enzymatic reactions
take place (drying).
1.2.6.1 Commercial preparations
As a thin film, AM presents a large surface area for evaporation and can
be dried quickly and efficiently by a variety of methods. Commercial prepa-
rations of dried AM include heat-dried products such as Acelagraft™ from
Celgene Cellular Therapeutics (Cedar Knolls, NJ, USA), and AmbioDry™
(formerly made by Okto-Ophtho, Costa Mesa, California, US) (Chuck et
al., 2004). Others include AmniSite-Cornea® (Bioland, Korea), which is
reported to be lyophilised (Koh et al., 2007). One method of preparation
makes use of far-infrared rays and microwaves to produce a hyper-dry tis-
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sue (Kitagawa et al., 2009), whereas laboratory-based preparations of AM
are typically air-dried (Singh et al., 2003; von Versen-Hoeynck et al., 2008).
1.2.6.2 Sterilisation
Dried preparations can be sterilised by exposure to 25 kGy of γ-irradiation,
which gives the tissue a high sterility assurance level (Singh et al., 2007b).
There is evidence that γ-irradiation can weaken the collagen fibres in AM
(Fujisato et al., 1999), although this may not be functionally significant
(Nakamura et al., 2004; Singh et al., 2007). Low-dose electron beam irradia-
tion can also be used, but may significantly weaken the tissue (Chuck et al.,
2004). Irradiation can be performed after vacuum-packaging the product.
An alternative method of sterilisation involves pre-soaking the membrane
in peracetic acid (PAA)/ethanol solution (Wilshaw et al., 2006).
1.2.7 Biosynthetic alternatives
Although AM has proven to be a useful surgical biomaterial, it has clear
disadvantages, such as variability and imperfect transparency. A number of
biosynthetic alternatives to AMT have recently emerged, offering improve-
ments in hygiene and consistency (Yiu et al., 2007). These have included a
thermosensitive hydrogel bandage developed from polyethylene glycol and
polylactic co-glycolic acid (PEG/PLGA) (Pratoomsoot et al., 2008). Stored
cold, it undergoes gelation upon contact with the ocular surface. Hydro-
gels and collagen shields have been used to treat surgically induced wounds
following cataract surgery (Dell et al., 2011). Recombinant human collagen-
phosphorylcholine hydrogels implanted onto rabbit eyes that had received
severe alkali burns two months earlier were found to promote nerve and cell
regeneration and to delay neovascularisation (Hackett et al., 2011).
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Chapter 2
AMNIOTIC MEMBRANE TREATMENT OF ACUTE
OCULAR BURNS
2.1 Introduction
Ocular surface burns can constitute true ophthalmic emergencies involv-
ing the eyelids and both external and internal ocular structures. They can
be devastating injuries causing permanent visual loss, blindness and cos-
metic deformity, and include injuries caused most commonly by chemical
agents, but also by thermal insults, munitions and explosive blasts. The
common feature is compromised regeneration of the ocular surface, leading
to unwanted sequelae. The acute stage of the injury represents a window
of opportunity in which treatment can maximise recovery and prevent com-
plications. Although AM has found widespread use in ophthalmic surgery,
the specific parameters of treatment for acute ocular surface burns remain
undefined. Questions remain about which grade of burn to treat, the timing
and dose of treatment, the recommended surgical method and the expected
outcome. The enthusiasm of a number of retrospective studies have not
translated into reliable evidence for AM treatment of burns. A Cochrane
systematic review was performed.
30
2.2 Literature review
2.2.1 Epidemiology of ocular burns
Between 11.5% (Wong et al., 2000) and 22.1% (Loon et al., 2009) of trau-
matic eye injuries are caused by chemical burns. The commonest causes
of exposure to alkali or acid are from occupational hazards in industry and
agriculture, domestic accidents and assault (Wagoner, 1997). The most se-
vere ocular surface injuries typically result from alkali burns. Chemicals
used in agriculture, chemical engineering and other industries are most
commonly implicated (Wagoner, 1997). These include alkalis like ammo-
nia (NH3), used in fertilisers, refrigerants and cleaning agents, and lime
(Ca(OH)2), used in plaster, cement and whitewash. Common acids causing
ocular burns include sulphuric acid (H2SO4), found in battery acid and in-
dustrial cleaners. Some chemicals, like magnesium hydroxide (Mg(OH)2),
which is present in fireworks, produce marked thermal damage to the eye.
Industrial accidents involving alkalis such as ammonia remains a serious
consideration(Bhattacharya et al., 2007). The prevalence of facial attacks
with acids or alkalis can be marked in developing nations, especially the
Middle East (Afghanistan and Pakistan), South East Asia (Cambodia), West
Africa and the Caribbean (Merle et al., 2008). Industrial accidents may
cause ocular surface burns on a mass scale, a notable example being the
Bhopal disaster of 1984, when methyl isocyanate was released into the at-
mosphere causing thousands of eye injuries (Dwivedi et al., 1985). Thermal
burns are usually prevented by the protective reflex of the eyelids and are
comparatively rare (Malhotra et al., 2009). In civilian ophthalmic practice,
munitions injuries are commonly seen in firework accidents, which com-
bine heat and mechanical trauma (Knox et al., 2008). Damage ranges from
minor and self-limiting, involving the most superficial layers, to severe, in-
volving the stem cell population and leading to sight loss if left untreated
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(Shimazaki et al., 2006). Thermal eye injuries can result from a variety of
agents including hot liquids in homes (Vajpayee et al., 1991), molten metals
in industrial workplaces (Schrage et al., 2000) and direct contact with an
open flame (Boone et al., 1998). Infrequent causes of corneal burns include
steam and molten metals (Schrage et al., 2000). Radiation and electrical
burns also occur rarely (Borderie, 2004).
2.2.2 Pathogenesis of ocular surface burns
The depth of penetration, duration of exposure and area of involvement de-
termine the severity of an ocular burn (Wagoner, 1997). In the case of chem-
ical injuries, the relative toxicity of the substance is another determinant of
severity. Alkalis cause saponification of cell membrane fatty acids, rapidly
penetrating the anterior chamber of the eye to cause extensive cell and tis-
sue damage. Acids tend to cause protein coagulation, thus limiting penetra-
tion. Hydrofluoric acid is an exception, the free fluoride ions being able to
produce deep penetration and severe toxic effects (McCulley et al., 1983). It
may not be possible to distinguish alkali from acid burns by clinical exam-
ination. The immediate effects of a burn can include irreversible damage
to multiple ocular tissues, including the cornea and conjunctiva. The ep-
ithelial layers are denuded, and protein denaturation occurs. In the cornea,
destruction of Bowman’s layer exposes the stroma, where orthogonally ar-
ranged collagen bundles become subject to enzymatic degradation (Fini et
al., 1998). Particulate matter may become lodged in the stroma, perpetuat-
ing severe damage (Schrage et al., 1990). Occlusion of blood vessels causes
ischaemia to the corneal limbus, the presumed source of limbal stem cells
(LSC) necessary for regeneration of the ocular surface epithelium. Limbal
ischaemia stimulates inflammation and new vessel formation, leading to
long-term complications and visual loss. In severe cases, deep ischaemia
leads to necrosis (Pfister and Koski, 1982). Deep corneal structures, such as
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the endothelium, and intraocular structures such as the lens and trabecular
meshwork are damaged by severe burn injuries, causing corneal opacifica-
tion, cataract and a rise in intraocular pressure. This, in turn, leads to
glaucoma.
2.2.2.1 Limbal stem cell failure and stromal ulceration
For all kinds of ocular burn injuries, the extent of limbal involvement is of
special significance, as it can be used to estimate the likelihood of failure of
re-epithelialisation (Dua et al., 2001). This is a critical determinant of fu-
ture complications, as there is evidence that human corneal epithelial stem
cells originate in crypts located in the subconjunctival space adjacent to the
limbus (Dua et al., 2005). Extensive damage to the conjunctiva causes con-
junctival stem cell loss in the fornices, and the loss of goblet cells and acces-
sory lacrimal glands, essential for surface wetting. The compromised ocular
surface is vulnerable to sight-threatening infections. In the absence of an
intact epithelium, stromal proteoglycans and collagens become exposed to
hydrolysis, a process mediated by latent collagenases such as MMPs (Fini
et al., 1998). Immunoregulatory cells are recruited from the tear film and
the blood vessels contributing to the inflammatory reaction. Polymorphonu-
clear cells degrade exposed collagen fibres via enzymes and reactive oxygen
species (Hayashi et al., 1997). There is loss of keratocytes and endothe-
lial cells, resulting in impairment of collagen regeneration and water reg-
ulation (Pfister and Koski, 1982). Ascorbate levels in the eye become de-
pleted, compromising vitamin C-dependent collagen synthesis (Levinson et
al., 1976). Stromal ulceration stops once epithelialisation is complete, which
explains the primacy of directing treatment towards epithelial regeneration.
Viable conjunctiva grows over corneal zones with insufficient limbal stem
cell reserves, and fibrosis of the damaged structures occurs over weeks and
months.
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2.2.3 The natural history of ocular surface burns
The clinical course of chemical injuries was divided into four distinct phases
by McCulley (1987): immediate, acute (day 0-7), early repair (day 7-21) and
late repair (after day 21) phases. This classification may also apply to non-
chemical burns. The eye rapidly becomes inflamed in the acute phase. For
mild injuries, there is a rapid recovery of the epithelial surface. In the case
of severe chemical injuries, delayed epithelialisation becomes apparent in
the early repair phase. At this point, the initial clinical suspicion of the
grading of the injury may be confirmed, and corneal ulceration can begin.
The late repair phase, lasting many months, is characterised by marked
scarring, including between the ocular surface and eyelids (symblepharon).
Progressive conjunctival fibrovascular tissue (‘pannus’) may have extended
across the denuded cornea, protecting it against further melting. This has
been called a Type III healing pattern, resulting in a tectonically stable,
but optically compromised, eye (Wagoner, 1997). In contrast, Type I and II
healing patterns are associated with total or sub-total recovery of the ocular
surface. In severe injuries, if the cornea remains denuded of either corneal
or conjunctival epithelium, corneal melting will develop in the weeks after
the burn injury (Type IV healing), leading to perforation unless the appro-
priate surgical intervention is performed. In these eyes, the entire anterior
segment may be severely damaged, including intraocular structures. The
outcome in the long term depends on the severity of the initial injury, stem
cell survival and the healing response (Shimmura and Tsubota, 2008). Se-
vere burns carry an extremely poor prognosis (Kuckelkorn et al., 1995b).
2.2.4 Classification of ocular burns
The extent of damage at initial assessment can help to predict the final
visual outcome (prognosis) of chemical injuries. The 1965 Roper-Hall classi-
fication of ocular burns (Roper-Hall, 1965) concentrated on corneal involve-
34
Table 2.1: Roper-Hall classification
Grade Prognosis Cornea Conjunctiva
I Good Corneal epithelial damage No limbal ischaemia
II Good Corneal haze, iris details visible < 33% limbal ischaemia
III Guarded Total epithelial loss, stromal haze, iris details
obscured
33% to 50% limbal
ischaemia
IV Poor Cornea opaque, iris and pupil obscured > 50% limbal ischaemia
Table 2.2: Dua classification
Grade Prognosis Limbal involvement Conjunctival
involvement
Analogue scale
I Very good 0 clock hours 0% 0/0%
II Good < 3 clock hours < 30% 0.1–3/1 to 29.9%
III Good 3 to 6 clock hours > 30% to 50% 3.1–6/31 to 50%
IV Good/ guarded 6 to 9 clock hours > 50% to 75% 6.1–9/51 to 75%
V Guarded/ poor 9 to <12 clock hours > 75% to < 100% 9.1–11.9/75.1 to 99.9%
VI Very poor 12 clock hours 100% 12/100%
ment and limbal ischaemia to predict the anatomical and visual outcomes
from the initial clinical presentation (table 2.1). Burns were graded from
I (mild) to IV (severe). This benchmark classification for chemical burns
takes into account the degree of corneal opacity, limbal ischaemia (a marker
of presumed stem cell loss) and epithelial involvement at presentation. The
Roper-Hall (1965) classification was a modified version of earlier systems of
classification by Ballen (1964) and by Hughes (1946), who recognised the
relationship between the initial appearance and the final visual outcome.
A modern understanding of ocular surface stem cell distribution and ocu-
lar surface surgery underscores the Dua classification of thermal and chem-
ical ocular burns, which further subdivides Roper-Hall grade IV burns into
grades IV, V and VI (Dua et al., 2001). The Dua classification is based on
an estimate of limbal involvement (in clock hours) and the percentage of
conjunctival damage (table 2.2). The prognosis is considered in the light of
recent advances in the surgical rehabilitation of burned eyes, which have
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greatly improved outcomes. The Dua classification has been found to be su-
perior to the Roper-Hall classification in predicting the outcome of an ocular
burn (Gupta et al., 2011). However, the initial clinical appearance can be
misleading, and can result in the misclassification of clinical injuries, lead-
ing to unexpected outcomes (Shimmura and Tsubota, 2008).
Another classification, from the International Life Sciences Institute, in-
cludes two clinical parameters requiring specialised equipment for diagno-
sis (Bagley et al., 2006). These parameters are the depth of corneal injury,
which can be assessed by confocal microscopy, and the extent of corneal en-
dothelial cell loss, which can be assessed by specular microscopy. Classifica-
tions of ocular surface burns have not been validated in animal models or in
prospective human trials. They do not allow the prognosis to be modified on
account of the causative agent or the extent (depth) of exposure, but are a
useful clinical guide to the healing potential of the damaged ocular surface.
The prognosis of ocular surface burns is affected by damage to associated
adnexal structures (Malhotra et al., 2009). If the external environment of
the ocular surface is compromised by damage to the eyelids, healing will be
delayed or impossible.
2.2.5 Management of ocular acute surface burns
The immediate management of burns is directed at removing any noxious
agent from the ocular surface. In the case of chemical injury, this may in-
clude irrigation for several hours until pH returns to normal. In the case of
firework, munition and blast injuries, debris is carefully removed under a
microscope and penetrating injuries are managed surgically. A careful as-
sessment of the injury will reveal the extent of the burn and the likelihood
of further complications. Subsequent medical and surgical treatment mea-
sures are directed at promoting epithelialisation, augmenting corneal repair
and controlling inflammation (Wagoner, 1997). Aggressive treatment in the
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acute phase is necessary to prevent a type IV healing pattern. The sur-
vival of conjunctival and corneal stem cells is critical to a recovery with few
complications. Treatment goals in the acute phase include pain relief. Pro-
motion of epithelialisation, prevention of infection and dampening of inflam-
mation constitute early phase goals. Long-term aims include prevention of
conjunctivalisation, of neovascularisation and of fibrotic sequelae including
symblepharon.
2.2.5.1 Medical management
Acute ocular surface burns are conventionally treated with emergency ir-
rigation and removal of particulate matter within minutes of presentation.
Irrigation is carried out with phosphate-free solutions to limit calcification
(Daly et al., 2005). Medical therapy is instilled as soon as possible in the 7-
10 day ‘window of opportunity’ to limit damage (Wagoner, 1997). Treatment
is directed at assisting re-epithelialisation and preventing ulceration, for
which the reduction of inflammation is a priority. Tear substitutes and an-
tibiotic eye drops are administered to prevent infection. Ocular surface in-
flammation is maximally controlled by topical corticosteroids in the first 10-
14 days after the injury. However, one of the unwanted effects of the steroids
is to inhibit keratocyte migration and collagen synthesis, precipitating melt-
ing. Thus, steroids are used minimally in cases where the epithelium has
not healed after 14-21 days. Further measures are directed at reducing
the risk of corneal melting and perforation by promoting collagen regener-
ation. Corneal repair is helped by orally administered doxycycline, which
appears to inhibit the induction of corneal MMP-9 by TGF-β1 (Kim et al.,
2005). It also inhibits the activity of MMP-2 in the cornea by chelating es-
sential metal ions (Smith and Cook, 2004). Topical and orally-administered
ascorbate may assist healing by replenishing vitamin C supplies essential
for collagen synthesis (Levinson et al., 1976). Topical sodium citrate drops
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are given to chelate calcium required by inflammatory polymorphonuclear
cells (PMN), which release harmful MMPs. Citrate therapy may reduce the
incidence of corneal ulceration (Pfister et al., 1997). Control of eye pressure
may require topical and/or systemic medications. Pain control can be helped
with cycloplegic eye drops, and adequate lubrication is given for comfort.
2.2.5.2 Surgical management
Surgical treatment during the acute phase is rarely necessary as long-term
measures, which include LSC transplants, are usually only successful once
the eye inflammation has subsided (Tsai and Tseng, 1995). If lid closure
is not possible, a bandage contact lens may be placed on the eye (Tuft and
Shortt, 2009) or surgical appositioning of the lids (tarsorrhaphy) may be
performed (Malhotra et al., 2009). In severe alkaline injuries, fluid para-
centesis of the anterior chamber can help reduce the pH. Acute measures
are directed at providing a vascular supply to ischaemic tissues and an ep-
ithelial covering to prevent corneal melting (Wagoner, 1997). All necrotic
tissue is excised. Following excision of necrotic tissue, healthy conjunctiva
and the subconjunctival Tenon’s layer may be advanced over the burned
tissue to the limbus (Tenon-plasty), allowing the conjunctiva to grow onto
the cornea to provide temporary protection and nourishment (Reim et al.,
1992). Tenon-plasty can only be carried out if there is sufficient residual
vascularised tissue. Alternatively, a conjunctival autograft from the unin-
jured fellow eye may be placed directly onto the burned areas of the ocu-
lar surface (Thoft, 1977). Autologous conjunctival grafting requires healthy
residual conjunctiva and an adequate blood supply to the damaged ocular
surface. Oral and nasal mucosal transplants are possible alternatives, and
are carried out in some centres (Kuckelkorn et al., 1996). Conjunctival and
mucosal grafts may fail to vascularise and become necrotic, limiting their
use (Kuckelkorn et al., 1995). In contrast to autologous conjunctiva and
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mucosa, AM is avascular and generally easily available, and has acquired a
more widely accepted role in the treatment of acute ocular burns.
2.2.6 AM patching of acute ocular surface burns
2.2.6.1 Historical background
Before the First World War, ocular burns were treated with autologous oral
mucous membrane (Denig, 1912). The procedure Denig advocated was the
excision of necrotic conjunctiva and its replacement with the membrane. An
alternative dressing was subsequently proposed in the form of rabbit peri-
toneum (Brown, 1941). Rather than applying the membrane over excised
tissue, Brown invested the entire ocular surface, anchoring the membrane
in the forniceal recesses with external bolsters and reflecting the membrane
to the lid margin. Rabbit peritoneum, however, was not well tolerated. A
few years after the de Rötth (1940) series on AMT as a conjunctival re-
placement, AMT was used as a patch for the whole ocular surface to treat
acute burns (Sorsby and Symons, 1946; Sorsby et al., 1947; Lavery, 1946;
Shafto, 1950). These early studies affirmed that AMT relieved pain, pro-
moted healing and prevented symblepharon. AM treatment for burns soon
became widespread, and a method of suturing AM into the inferior fornix
was described as a means of preventing symblepharon after chemical in-
juries (Shafto, 1950). Alternatives, such as egg membrane, were proposed
around this time (Croll and Croll, 1952). Roper-Hall’s 1965 address to the
Ophthalmological Society of the United Kingdom cited AM as one of a num-
ber of membranes used in the immediate surgical management of ocular
burns, along with mucous membrane, cadaveric conjunctiva, egg membrane
and peritoneum (Roper-Hall, 1965). At the same meeting, the use of a stain-
less steel ring wrapped in AM was advocated to prevent symblepharon and
pain by keeping the inflamed bulbar and tarsal surfaces apart. AM was also
in use in Eastern bloc countries as a treatment for ocular burns (Uglova and
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Goleminova, 1957; Alberth and Kettesy, 1971; Batmanov et al., 1990).
2.2.6.2 Current practice
In recent years, attention has turned back to AMT as a treatment for burns
during the acute and early repair phases. Since the introduction of cryopre-
served AM by Scheffer Tseng, of the Ocular Surface Center in Miami, it has
again been suggested that AMT applied therapeutically during the acute
phase of a burn could promote healing (Meller et al., 2000). Tseng and co-
authors have claimed that AMT can dampen inflammation, promote epithe-
lialisation and prevent scarring and neovascularisation through a variety of
biological factors (Tseng et al., 2004). In keeping with this concept, autolo-
gous serum drops and umbilical cord serum have recently been tried as ther-
apeutic modalities in acute ocular surface chemical injuries (Sharma et al.,
2011), with some degree of success reported. Moreover, patching with AMT
has been tried for a subset of inflammatory eye diseases that are similar
to acute burns. These are acute Stevens-Johnson syndrome (SJS) (Gregory,
2008) and toxic epidermal necrolysis (TEN) (Shay et al., 2010), which are
commonly regarded as being part of the same disease of hypersensitivity. In
common with acute burns, the syndromes cause acute epithelial loss, even-
tually leading to neovascularisation, chronic inflammation and conjunctival
ingrowth. Conclusive evidence of the benefits of AMT in these conditions
has not been established in clinical trials, yet the treatment is not risk-free.
Although there are no common adverse effects reported from using AM, rare
reports of serious complications of AMT can be found in the literature in-
cluding fungal keratitis (Das et al., 2009), uveitis (Srinivasan et al., 2007)
and corneal melt (Schechter et al., 2005). A steroid-responsive hypopyon (a
collection of inflammatory cells in the eye) may appear after repeated ex-
posure to AM from the same donor, suggesting sensitisation (Gabler and
Lohmann, 2000).
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2.2.7 Standardisation of treatment
The application of AM for burns is not standardised (Dua et al., 2010). The
tissue is heterogeneous, with both biochemical (Hopkinson et al., 2006b; Gic-
quel et al., 2009) and physical (von Versen-Höynck et al., 2004; Connon et
al., 2007; von Versen-Hoeynck et al., 2008; Connon et al., 2010) variations
between donors and even between areas of one donor membrane. These
variations may be increased by tissue handling during processing. Variabil-
ity may be accentuated by different methods of preserving AM. The timing,
surgical application and extent of treatment vary. AM can be applied from
a few hours (Kobayashi et al., 2003) to weeks (Sridhar et al., 2000) after an
ocular surface burn. AM is usually placed with the stromal side in direct
contact with the ocular surface, but it may be placed epithelial side down
(Meller et al., 2000). Suturing of AM patches to the lids can be performed
with interrupted sutures or with running sutures for easy removal (Arora et
al., 2005; Kobayashi et al., 2003). Alternative methods of application include
fitting a purpose-made plastic ring conformer (symblepharon ring) wrapped
in AM (Arora et al., 2005; Kheirkhah et al., 2008; Tamhane et al., 2005) and
gluing with fibrin-based adhesives (Sekiyama et al., 2007). Although AM is
typically applied as a removable patch (Kobayashi et al., 2003; Kheirkhah et
al., 2008), the tissue can be grafted onto the damaged ocular surface and left
until it degrades (Meller et al., 2000). The burns treated have ranged from
mild (Kheirkhah et al., 2008) to severe (da Silva Ricardo et al., 2009; Joseph
et al., 2001; Sridhar et al., 2000). Together with unclearly defined criteria
for success and failure, this has led to confusion regarding the purpose and
objectives of treatment (Maharajan et al., 2007).
Because of its early promise, AM has been used in spite of a lack of RCTs
(Bouchard and John, 2004). On one hand, it has been argued that AM has
been used in excess of its true potential (Dua et al., 2004). Conversely, AM
may be underused, with only 35% of American Burn Association facilities
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admitting to using it for acute ocular burns in a recent survey (Son et al.,
2011). Ophthalmic surgeons need to know which grades of burns to treat
and when, which products and techniques to use and what outcomes may
be expected (Panda et al., 2002). High quality evidence of the benefits of
this treatment has thus far been lacking, suggesting a pressing need for a
systematic review to highlight which characteristics are needed for future
RCTs. This in turn will encourage high quality trials to be conducted. Sys-
tematic reviews are becoming increasingly powerful tools for assessing the
quality of evidence, since studies may lack methodological quality and con-
tain multiple sources of bias (Jüni et al., 2001).
2.3 Materials and Methods
2.3.1 Eligibility criteria
The objectives of this systematic review were to assess RCTs of amniotic
membrane patching of moderate and severe ocular burns in the acute phase
(day 0 to 7).1 The minimum length of patient follow-up was 6 months. Par-
ticipants of all ages were eligible and included those presenting for emer-
gency eye care with chemical ocular surface burns of grade II or worse or
ocular surface thermal injuries of similar severity. Exclusion criteria in-
cluded pre-existing ocular surface disease or visual loss. Participants who
received AM treatment after day 7 and those who received secondary pro-
cedures such as limbal transplants were not considered eligible. Two sub-
group populations were considered:
• moderate burns - patients who had ocular burns of grade II and III
(Roper-Hall and Dua classifications).
• severe burns - patients who had ocular burns of grade IV (Roper-Hall)/
1This systematic review was undertaken in collaboration with Dr Catey Bunce, statisti-
cian, Dr Hanif Suleman and Professor Harminder Dua, content expert.
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grades IV to VI (Dua).
RCTs were included in which amniotic membrane patching of whole or part
of the ocular surface (including the fornices but not the external lids) was
performed within seven days of injury, combined with all types of medical
therapy together. Studies in which AM extracts or suspensions were ap-
plied as drops were not eligible. As Tenon-plasty and autologous conjunc-
tival patching are not commonly reported, a comparison between surgical
treatments could not be performed. The control patients received all types
of medical therapy together, with no surgical intervention other than man-
ual lysis of mechanical adhesions between the eyelids and the globe during
the repair phases. The medical therapy used was defined for each included
study. Relevant studies that were excluded from the analysis were tabu-
lated with details of study characteristics and comments from the study
conclusions.
2.3.2 Outcome measures
Outcome measures included primary and secondary outcomes for each in-
cluded RCT. An explanation of the significance of each outcome to the study
is provided with each outcome measure. These included dichotomous, con-
tinuous, time-to-event and ordinal measures.
2.3.2.1 Primary outcomes
1. The proportion of eyes with complete corneal epithelialisation 21 days
after the burn injury. A persistent epithelial defect (PED) after 21 days
of an ocular surface burn carries an increased risk of corneal stromal
melting, and is therefore clinically meaningful.
2. Visual outcomes at final follow-up.
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2.3.2.2 Secondary outcomes
1. The proportion of eyes with symblepharon. Symblepharon limits nor-
mal movement, is an index of severity.
2. The proportion of eyes with new vessels in the cornea (corneal neovas-
cularisation). The extent of new vessels is an index of oxygen depri-
vation to the tissues. The number of quadrants of neovascularisation
was expressed as an ordinal outcome from 0 to 4.
3. The proportion of eyes with adverse events, including rare incidences
of corneal infections and immune reactions to AM.
4. The time-to-complete corneal epithelialisation.
5. The proportion of eyes with vascularised scarring on the cornea (fi-
brovascular pannus), a cause of disfigurement and visual loss.
6. The proportion of patients who report pain reduction after AMT.
2.3.2.3 Follow-up
For the primary outcome of epithelial healing, the critical point for follow-up
was 21 days after the injury, because in the absence of an intact epithelium
at the end of the early repair phase, the chances of requiring later ocular
surface reconstruction are significant. Therefore, any difference between
treatment and control groups at this stage can be considered to be clini-
cally significant, and it is more likely to reflect a difference in treatment in
the acute phase than would be the case after several more weeks. By 21
days, attrition rates of follow-up appointments would not be high, and sec-
ondary surgeries would not yet have been performed. For most secondary
outcomes (except pain reduction, which would be immediate), measurement
time points reflected the healing process during the late repair phase. The
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exact time points were less critical, and could be multiple (e.g., 6 and 12
months), depending on outcome reporting.
2.3.3 Data extraction
Multiple sources were used to conduct a comprehensive review, including
electronic databases and reference lists. Starting with the highest yield
source, the Cochrane Central Register of Controlled Trials (CENTRAL, con-
taining the Cochrane Eyes and Vision Group Trials Register) (The Cochrane
Library, Issue 8, 2011), MEDLINE (January 1966 to August 2011), EM-
BASE (January 1980 to August 2011), Latin American and Caribbean Health
Sciences Literature Database (LILACS), themetaRegister of Controlled Tri-
als (mRCT) (www.controlled-trials.com) and the www.clinicaltrials.gov web-
site were searched electronically. There were no date or language restric-
tions in the electronic searches for trials. Medical subject headings were
finalised after review by the Cochrane Eye and Vision Group. Details of
search strategies are available in Appendix A. References cited in studies
identified as relevant were also assessed, and the authors of included stud-
ies were contacted to find out about ongoing trials.
The search results were screened to assess relevant titles and abstracts.
These were categorized as included, excluded or unclear. Published arti-
cles were retrieved to identify and link multiple publications from the same
study and to review the study characteristics of all included and unclear
studies. A screening form containing eligibility criteria was used to justify
inclusion or otherwise. This included details on study type, grade of burn,
intervention and control characteristics and outcome reporting.
Data from included studies was then entered into a data extraction form
to obtain details of methodology and outcomes. General information en-
tered included demographic details of the participants and trial character-
istics. The diagnostic criteria, grades and causative agents of the injuries,
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timing and method of application of AMT and primary and secondary out-
come data of interest were also recorded. The form was used to confirm
eligibility for review. In the event of missing data, the trial authors were
contacted for more details. The data was entered into RevMan software
(version 5.1), which is standard software for preparing Cochrane reviews.
For dichotomous and stratified ordinal data, the proportion of patients in
each intervention arm having the outcomes of interest was recorded. Con-
tinuous data were recorded with relevant statistical data. Time-to-event
data was processed separately in GraphPad Prism statistical software (La
Jolla, California). The curves were attached as additional figures.
2.3.4 Risk of bias assessment
A domain-based evaluation of the risk of bias was conducted within each in-
cluded study, using an assessment tool provided in the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins and Green, 2011). The
following domains were considered:
• Specification of sequence generation method
• Implementation of allocation concealment
• Masking of participants and personnel
• Masking of outcome assessment
• Completeness of outcome data
• Selective outcome reporting
• Other biases related to particular clinical setting
The risk of bias in each domain was assessed as low, serious or very serious.
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2.3.5 Measures of treatment effect
The relative risk (RR) of incomplete epithelialisation was calculated by di-
viding the number of incompletely epithelialised eyes (treatment failures)
by the total number of eyes (successes and failures) in each group, and then
dividing the risk of failure in the experimental group by the risk of failure
in the control group. This was reported with the 95% confidence interval
(CI) and the p value. The number-needed-to treat (NNT) for one additional
patient to benefit (NNTB) or suffer harm (NNTH) was calculated with its
95% CI using the Newcombe-Wilson hybrid score without a continuity cor-
rection (Newcombe, 1998). In cases of non-significance (i.e., where the CI
of the difference between the control event rate and the experimental event
rate does not exclude 0), the estimated confidence intervals for NNT were
quoted using the method described by Altman (1998). Visual acuity mea-
surements were converted to a logarithmic scale to calculate the difference
in the mean visual acuities between the experimental and control groups.
Treatment effects on dichotomous outcomes were evaluated by calculating
RR. The number of quadrants of neovascularisation was expressed as an or-
dinal outcome from 0 to 4 and then dichotomised at a clinically meaningful
cut-off point (0 versus 1-2 or 0 versus 3-4), allowing the calculation of a clin-
ically informative RR. Time-to-complete epithelialisation data were anal-
ysed with survival curves to express the findings as a hazard ratio (HR).
Additional sensitivity analyses could not be conducted at different cut-off
points because of the small sample size.
2.3.6 Data synthesis
The primary outcomes were eye-related rather than patient-related. Anal-
yses based on a single eye per individual conveniently allow standard sta-
tistical methods to be employed, although information for the fellow eye is
lost (Murdoch et al., 1998). If one eye was chosen for bilateral patients,
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the method of selection was documented. Studies which included bilateral
injuries were not excluded, as long as treatment to one eye in no way de-
termined treatment to the second eye. In the event of fellow eyes having
different treatments, the treatment to one eye might determine treatment
to the other eye, introducing a bias. On the other hand, if both eyes were
treated similarly the likely correlation between fellow eyes might induce a
cluster effect. These issues would be assessed for each study individually.
The heterogeneity of outcomes was analysed by considering the grades of
burns severity (i.e., moderate versus severe) as separate subgroups, as these
have different natural histories. In the absence of evidence of a different
treatment effect of AM on burns caused by different causative agents, these
were considered as single categories rather than subgroups.
Guidelines developed by the GRADEWorking Group were used to assess
the quality of the evidence (GRADEWorking Group, 2004) with GRADEpro-
filer software (GRADEpro). The GRADEprofiler software allowed a down-
grading of the quality of the evidence based on the risk of bias, inconsistency,
indirectness, imprecision and publication bias. These were identified as ab-
sent, serious or very serious, which resulted in a grading of the quality of
evidence for each outcome from high to very low. Tables summarising the
findings of the included study were constructed with reference to two out-
comes of interest: the proportion of eyes with complete epithelial closure by
the 21st day after the injury and visual acuity at final follow-up (table 2.7).
Moderate and severe burns were addressed separately.
2.4 Results
2.4.1 Results of the search
The studies identified by the original electronic search included patients
of a wide range of ages with alkaline, acid and thermal injuries. Besides
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Figure 2.1: Study selection
An electronic search for studies on the treatment of acute ocular burns with AMT produced
a subset of eligible participants from one RCT.
RCTs, retrospective and uncontrolled or non-randomised prospective stud-
ies, review articles, animal models and studies which did not directly deal
with AMT or acute ocular burns were found by this strategy. A number
of historical and non-English language studies were identified by extensive
cross-referencing of known recent studies and more general articles about
AM, and not by the electronic search. There were 88 citations identified in
total (2.1). Seventy-eight studies were excluded after reading the title or
abstract. Of these, 10 were recent retrospective case series of ocular burns
Chen et al. (2000); Sridhar et al. (2000); Joseph et al. (2001); Uçakhan et
al. (2002); Kobayashi et al. (2003); Zhou et al. (2004); Tejwani et al. (2007);
Prabhasawat et al. (2007); Kheirkhah et al. (2008); da Silva Ricardo et al.
(2009). One citation (Baradaran-Raffiee, 2008) concerned a clinical trial of
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AMT for acute chemical burns for which no results have yet been published.
Repeated efforts to contact the principal investigator proved unsuccessful,
which led to a classification of the study as ongoing. Five citations concerned
non-randomised prospective studies (Arora et al., 2005; López-García et al.,
2006, 2007; Meller et al., 2000; Muraine et al., 2001). These were defini-
tively excluded after checking the full report against the eligibility criteria
(full-text assessment). Four citations concerned two relevant RCTs carried
out by the same group in New Delhi, India ((Tamhane et al., 2005; Tandon et
al., 2011; Gupta et al., 2011; Chew, 2011)). Of these, two were excluded af-
ter reading the abstract (Chew, 2011; Gupta et al., 2011). Of the two RCTs,
one was excluded after contacting the authors for further details (Tamhane
et al., 2005). One RCT contained a subset of participants that fulfilled the
inclusion criteria for this review (Tandon et al., 2011).
2.4.2 Excluded studies
The studies on AMT for ocular burns that were excluded from the analysis
are shown in tables 2.4 and 2.3. These fall into four main groups shown be-
low. Additional study characteristics and reasons for exclusion are provided.
A number of case series comment on the limitations of AMT in severe burns,
and a small number of series have dealt exclusively with AMT for severe oc-
ular burns (Joseph et al., 2001; Sridhar et al., 2000; da Silva Ricardo et al.,
2009).
1. Non-randomised prospective case series (table 2.3): The non-randomised
prospective studies either lacked controls (Meller et al., 2000; Arora et
al., 2005) or reported outcomes that were not directly clinically rele-
vant, such as histological findings (López-García et al., 2006) and im-
pression cytology (López-García et al., 2007).
2. Retrospective case series (table 2.4): Similarly lacking in controls, most
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Table 2.3: Prospective studies/RCTs
Reference n Grade Controls Timing (days) Comments
Meller et al.
(2000)
13 II-IV (R-H) - Mean 9.4 (SD
4.5)
‘AMT alone rapidly restores
both corneal and conjunctival
surfaces’
Muraine et
al. (2001)
9 Severe - 1 month to 5
years
‘preferable to conjunctival
advancement’
Arora et al.
(2005)
15 II-IV (R-H) - Mean 9.9 (SD
3.8)
‘AMT increases patient
comfort and reduces
inflammation’
López-García
et al. (2006)
12 Moderate 12 4-6 ‘Corneal epithelialisation
occurred earlier in patients
treated with AMT’
(Impression cytology study)
López-García
et al. (2007)
5 III-IV (Dua) 4 4-6 ‘AMT improved limbal stromal
and epithelial regeneration’
(Histopathological study)
Tamhane et
al. (2005)
20 II-IV (R-H) 24 Range 1 to 14 ‘Reduces pain and promotes
epithelialisation’
R-H: Roper-Hall classification, n: number of treatment eyes
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Table 2.4: Retrospective series
Reference n Grade Controls Timing (days) Comments
Chen et al.
(2000)
6 - - - ‘...can effectively reduce
neovascularization, fibrosis
and inflammation’
Uçakhan et
al. (2002)
5 II-IV (R-H) - M 14.2 (SD
12.3)
‘...decreased the extent and
severity of vascularization’
Kobayashi et
al. (2003)
5 II-III (R-H) - Md 4 (0 to 6) ‘...facilitating rapid
epithelialisation and pain
relief ’
Zhou et al.
(2004)
20 III - - ‘...can prevent corneal ulcer’
Tejwani et al.
(2007)
24 II-IV (Dua) - Md 2 (1 to 20) ‘...partially restores limbal
stem cell function’
Prabhasawat
et al. (2007)
13 II-IV (R-H) 8 1-10 ‘...promoted rapid epithelial
healing and reduced corneal
complication’
Kheirkhah et
al. (2008)
5 I-III (R-H) - M 3.7 ± 3.1 ‘...may help preserve
remaining limbal stem cells’
Sridhar et al.
(2000)
2 Severe - ‘Within weeks’ ‘Long-term studies are
warranted’
Joseph et al.
(2001)
4 Severe - 14 - 21 ‘..AMT did not help to restore
ocular surface’
da
Silva Ricardo
et al. (2009)
5 Severe - 10 - 30 ‘...not possible to avoid the
limbic deficiency’
R-H: Roper-Hall classification, n: number of treatment eyes; Md, Median, M, Mean.
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retrospective studies had fewer than 10 participants (Chen et al., 2000;
Kheirkhah et al., 2008; Kobayashi et al., 2003; Uçakhan et al., 2002).
Two uncontrolled studies of more than 20 participants have been re-
ported (Tejwani et al., 2007; Zhou et al., 2004). One retrospective se-
ries from Thailand compared the treatment group to a set of matched
controls (Prabhasawat et al., 2007).
3. Non-comparative case series of severe ocular burns (tables 2.4 and
2.3): For these, AMT was performed during the early to late reparative
phases (table 2.4).
4. RCTs (table 2.3): The RCT conducted by Tamhane et al. (2005) did not
present sufficient evidence of adequate randomisation, and patients
were treated outside the 7-day period. The authors were contacted and
could not supply the necessary data to stratify the treatment. There-
fore, the Tamhane et al. (2005) RCT was excluded from the systematic
review.
2.4.3 Included studies
One RCT (Tandon et al., 2011) contained a subset of patients that met the
inclusion criteria for this review, and additional data were provided by the
authors. AMT was carried out within two days of presentation by drap-
ing the stromal side over the entire ocular surface up to the lid margins
and securing it in place with vicryl sutures. As there was no stratification
of treatment into acute versus early repair phases, the authors were con-
tacted for further information. The original data reported outcomes for 100
patients. Of the original 100 participants, 68 were treated in the first 7
days and have been included in this review (figure 2.1). In the event of bi-
lateral injuries, only the right eye was entered into the study. The length of
follow-up of the included patients was 6 to 24 months. The 68 participants
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100#eyes#with#acute#
ocular#burns
68#eyes#treated#within#7#
days#of#injury#(included)
32#eyes#treated#at#>7#
days#of#injury#(excluded)
35#moderate#burns#(Dua#
II"#"III)
33#severe#burns#(Dua#IV#E#
VI)
16#AMT 19#control 17#AMT 15#control
Figure 2.2: Included patients
Flow chart showing the subset of patients selected from an RCT by Tandon et al. (2011) for
analysis as part of a systematic review.
included 36 with moderate and 32 with severe ocular burns. In the moder-
ate burns group, there were 34 males and two females, with a mean age of
22.3 years (SD 10.1). The burns were cause by alkali in 22 cases, acid in 10
and direct heat in four. The severe category consisted of 24 males and 8 fe-
males with ocular burns, 23 caused by alkali, seven by acid and two by heat.
The mean age was 19.3 years (SD 15.8). All patients were randomised to re-
ceive AMT and medical therapy or medical therapy alone. This consisted of
topical prednisolone acetate (1%) every six hours, ofloxacin (0.3%) every six
hours, sodium ascorbate (10%) every four hours, sodium citrate (10%) every
four hours, preservative-free tear substitutes every two hours, homatropine
drops (2%) twice daily and oral vitamin C (500 mg) every six hours for two
to four weeks. Anti-glaucoma therapy included timolol maleate drops (0.5%)
and/or oral acetazolamide if required.
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Table 2.5: Risk of bias summary figure
Domain Risk
Random sequence generation Low
Allocation concealment Low
Masking of participants and personnel High
Masking of outcome assessors High
Incomplete outcome data Low
Selective reporting Low
Other bias High
2.4.4 Risk of bias in included RCT
A summary of the Cochrane Collaboration’s tool for assessing the risk of
bias of the included study (Tandon et al., 2011) is shown in figure 2.5. The
risk of bias is summarised across domains for both study-level entries, such
as allocation, and outcome-specific entries such as masking. The patients
were randomised to a treatment assignment list prepared from a random
numbers table. Serial numbers were given to the cases, and the randomly
allocated treatment decision was concealed by using sealed envelopes. This
suggests that adequate measures were taken to prevent foresight of treat-
ment at the point of enrolment. The overall risk of allocation (selection) bias
was therefore classified as low. For practical reasons, it was not possible
to mask study participants and personnel from knowing which treatment
was received, indicating a high risk of performance bias. Although digital
photographs were used for assessment of outcomes by masked observers,
the outcome assessors would have known whether AMT had been allocated
since the AM persists for several weeks. This indicates a high risk of de-
tection bias (Higgins and Green, 2011). Since no patients in the study were
lost to follow-up, the overall risk of attrition bias was classified as low. The
possibility of a selective reporting bias in the study was considered to be low,
i.e. the outcomes reported are not a subset of those included in the protocol
and they have not been chosen because they were significant.
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2.4.4.1 Other causes of bias
The risk of bias from other causes in the included study was considered to be
high. Several potential sources of bias are identified below. For each reason,
the risk of bias is shown in brackets. Cases in which the direction of bias
favoured a treatment effect were graded as having a high risk of bias.
1. The data presented concerns a subset of the patients recruited in the
included RCT. This may have introduced a bias, since the patients
treated within 7 days of injury may have have had different charac-
teristics to the remaining patients (unclear).
2. Of the 68 patients included in the study, 24 went on to have secondary
procedures, such as limbal transplantation, in the months following
the initial injury. The confounding effects of the secondary procedures
on the measured outcomes (e.g., vision) are not clear. These eyes are
likely to have suffered more serious injuries, and any treatment effect
of AM is therefore likely to be smaller (unclear).
3. There was a significant difference in baseline visual acuity between
treatment and control groups in the moderate burns category. The
mean LogMAR visual acuity at presentation was 0.45 in the treatment
group (SD 0.29) and 0.92 in the controls (SD 0.88) (independent sam-
ples t test, p = .047, equal variances assumed). This could have skewed
the final visual outcomes in favour of a treatment effect (high).
4. Although final visual acuities were better in the AMT group (0.06, SD
0.10 versus 0.38, SD 0.52), the mean difference (MD) in visual acuity
before and after treatment was greater in the control eyes (AMT -0.39,
95% CI -0.23 to -0.55, p = .001 vs controls -0.54, 95% CI -0.08 to -1.00, p
< .001). The implication that final visual acuity was improved by AMT
is therefore misleading (high).
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5. The poor outcomes in the control eyes are not fully explained. In the
moderate category, three control eyes had a time-to-epithelial closure
of 90 days, while in the treatment group only one eye took longer than
18 days for the epithelium to heal. Five control eyes had a final vi-
sual acuity of less than 0.50. In contrast, no participant in the AMT
treatment group had a final visual acuity of less than 0.30. While a
treatment effect cannot be excluded, moderately burned eyes typically
have a good prognosis. This raises the possibility that some injuries in
the control group were misclassified at presentation. The randomisa-
tion process would not normally result in differential misclassification,
which raises the possibility of a flawed process (high).
6. There was a significantly longer follow-up for treated eyes (Md 14.5
months, range 10 to 24 versus Md 12 months, range 6 to 24; Mann-
Whitney U = 94, z = -2.31, p = .021). Since there was no common time-
point for reporting visual acuity, this constitutes a potential source of
bias. In the severe group, length of follow-up (12 months) was not
significantly different between the groups (unclear).
7. The methodology of measurement of epithelial healing may be a source
of bias. The study authors state that in some AMT cases, the mar-
gins of the epithelial defect could not be made out beneath the am-
niotic membrane. There is no indication that any data were miss-
ing or excluded, yet it is not explained in the report how the prob-
lem was circumvented. The unit of measurement of the healing rate
(mm2/day) implies that the eyes were seen every day until complete
healing, which was not the case. This suggests that the precise tim-
ing of epithelial closure was a best guess between appointments or the
appointment day itself. This may have led to imputation of data (un-
clear).
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Table 2.6: AMT versus medical therapy
Outcome/subgroup AMT Controls Stat. Method Effect Estimate p
value
PED at 21 days
Moderate burns 1/16 7/20 RR (95% CI) 0.18 [0.02, 1.31] .09
NNTB 3.5 [NNTB 2 to 104.5]
Severe burns 16/17 14/15 RR (95% CI) 1.01 [0.84, 1.21] .93
NNTH 127.5 [NNTH 4 to∞
to NNTB 5]
Corneal nv
Moderate burns (1-2
quadrants)
4/16 8/20 RR (95% CI) 0.63 [0.23, 1.71] .36
Moderate burns (3-4
quadrants)
0/16 1/20 RR (95% CI) 0.41 [0.02, 9.48] .58
Severe burns (1-2
quadrants)
4/17 4/15 RR (95% CI) 0.88 [0.27, 2.93] .84
Severe burns (3-4
quadrants)
12/17 10/15 RR (95% CI) 1.06 [0.66, 1.70] .81
Symblepharon
Moderate burns 0/16 0/20 - - -
Severe burns 2/17 2/15 RR (95% CI) 0.88 [0.14, 5.52] .89
Mean final VA (SD)
Moderate burns 0.06 (0.10) 0.38 (0.52) MD (95% CI) -0.32 [-0.09, -0.55] .007
Severe burns 1.77 (1.31) 1.64 (1.48) MD (95% CI) 0.13 [-0.84, 1.10] .79
RR, risk ratio; MD, mean difference; CI, confidence interval; nv, new vessels.
2.4.5 Effects of interventions
The median follow-up of both moderate and severe burns in the included
study was 12 months (range 6 to 24). A summary of the treatment effects is
shown in table 2.6. All treatment effects are represented as a RR with the
exception of final LogMAR visual acuities, which were calculated as means
at final follow-up. For failure of epithelialisation, the treatment effect is also
shown as the NNTB/NNTH. 95% CI were used throughout. No information
was available about the effects on pain or the presence of fibrovascular pan-
nus. The study reported that no complications were encountered during the
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Figure 2.3: Survival analysis of epithelial defects
Survival curves of epithelial defects of moderate (A) and severe (B) ocular burns treated
with AMT and medical therapy versus medical therapy alone.
study period. Survival curves representing the time-to-epithelialisation for
the treatment and control arms of the moderate and severe burns groups
are shown (figure 2.3 A and B respectively). Since the lines cross, the pro-
portional hazards assumption and a HR are not valid with these data.
2.4.5.1 Quality of the evidence
Summaries of the findings of the systematic review are shown in tables 2.7
and 2.8 for moderate and severe burns respectively.
Based on the GRADE assessment, the quality of the evidence is shown to
be low or very low for two outcomes (the relative risk of failure of epitheliali-
sation and visual acuity) in both subgroups. The quality of the evidence was
downgraded due to the risk of bias (assessed to be serious) and to impreci-
sion in outcome reporting (assessed to be serious). In the moderate category,
the risk of bias assessment reflected the imbalance between the control and
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Table 2.7: Summary of findings, moderate burns
Outcomes
Illustrative comparative risks* (95% CI)
Relative effect
(95% CI)
No of
participants
Quality of
the evidence
Assumed risk
(control)
Corresponding risk (AMT)
Epithelial non-healing (Day 21) 350 per 1000 63 per 1000 (7 to 458)
RR 0.18 (0.02 to
1.31)
36 Low 1
Mean visual acuity (final follow-up) 0.38** MD -0.32 (0.09 lower to 0.55 higher) 36
Very low
2, 3, 4
Patient or population: patients with acute ocular burns (moderate severity). Settings: ophthalmology secondary care for emergencies.
Intervention: amniotic membrane transplantation.
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its
95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio; AMT: Amniotic membrane transplant. **LogMAR visual acuity range 0 -3 (lower is better).
GRADE Working Group grades of evidence High quality: Further research is very unlikely to change our confidence in the estimate
of effect. Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may
change the estimate. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect
and is likely to change the estimate. Very low quality: We are very uncertain about the estimate.
1Epithelial defect assessed on day of clinic review, not daily. Defect was assessed under partially opaque membrane. This suggests possible imputation of data; 2High risk of performance and
detection biases, as not possible to mask personnel and outcome assessors; 3Mean visual acuity in control eyes significantly worse than treatment eyes at presentation. Improvement in visual
acuity was greater in control group. Follow-up was significantly longer in treatment group. In a number of control eyes, outcome was very poor, suggesting possible misclassification. These
factors could have skewed findings in favour of treatment; 4Visual acuity measured at final follow-up rather than at a fixed interval;
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Table 2.8: Summary of findings, severe burns
Outcomes
Illustrative comparative risks* (95% CI)
Relative effect
(95% CI)
No of
participants
Quality of
evidence
Assumed risk
(control)
Corresponding risk (AMT)
Epithelial non-healing (Day 21) 933 per 1000 943 per 1000 (784 to 1000)
RR 1.01 (0.84 to
1.21)
32 Low 1, 2
Mean visual acuity (final follow-up) 1.64** MD 0.13 (0.84 lower to 1.10 higher) 32 Low 1, 3
Patient or population: patients with acute ocular burns (moderate severity). Settings: ophthalmology secondary care for emergencies.
Intervention: amniotic membrane transplantation.
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its
95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio; AMT: Amniotic membrane transplant. **LogMAR visual acuity range 0 -3 (lower is better).
GRADE Working Group grades of evidence High quality: Further research is very unlikely to change our confidence in the estimate
of effect. Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may
change the estimate. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect
and is likely to change the estimate. Very low quality: We are very uncertain about the estimate.
1High risk of detection and performance biases related to difficulties in masking personnel and outcome assessors; 2Possible imputation of data due to non-daily clinic attendance of patients
and assessment of defect under partially opaque membrane; 3Visual acuity measured at final follow-up rather than at a fixed interval
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treatment groups, as well as the performance and detection biases. The im-
precision of outcome reporting related to data gathering for both epithelial
healing (measured in mm2/day despite there being no daily reviews) and
visual outcomes (measured to final follow-up rather than a fixed interval).
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2.5 Discussion
Systemic reviews and meta-analyses are an integral part of evidence-based
medicine, and recent years have seen a vast increase in their publication
for ophthalmic interventions (Chen and Jhanji, 2012). The value of this
systematic review will be to highlight the lack of evidence supporting the
use of AMT in acute ocular burns and to provide a protocol for future RCTs
(Clare et al., 2011).
Several non-randomised, uncontrolled studies have affirmed that AMT
accelerates corneal epithelialisation and suppresses inflammation, neovas-
cularisation and scarring (tables 2.3 and 2.4). According to these stud-
ies, AM prevents symblepharon (Meller et al., 2000), scarring (Chen et al.,
2000), perforation (Zhou et al., 2004) and melting (Arora et al., 2005). In
addition, impression cytological and histopathological studies of the corneal
limbus of eyes with moderate burns have indicated that epithelial and stro-
mal regeneration are more complete in eyes treated with AMT than in
eyes treated with medical therapy alone (López-García et al., 2006, 2007).
Intact AM has been postulated to act as a microenvironmental niche for
stem cells (Grueterich and Tseng, 2002), and some researchers have sug-
gested that this reduces the need for a limbal stem cell transplant in burned
eyes (Kheirkhah et al., 2008; da Silva Ricardo et al., 2009). However, the
strength of the claims is limited by the study designs. The burns treated
were of varying severity and aetiology, and the timing of application of AM
ranged from a few hours (Kobayashi et al., 2003) to several days (Tejwani et
al., 2007) after the initial injury. These limitations reduce confidence in the
study conclusions, since different grades of burn carry different prognoses,
and the variability in the timing and duration of AMT further obfuscates
any treatment benefits. Many non-comparative studies fail to define the
purpose and objectives of AM treatment and criteria for treatment success
and failure (Maharajan et al., 2007). The outcome measures are often un-
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clear, with inadequate grading systems of the outcomes. In this context, the
need for an RCT had been pressing.
Two RCTs from the same centre have addressed AMT patching for acute
burns (Tamhane et al., 2005; Tandon et al., 2011). In the first RCT (Tamhane
et al., 2005), 20 eyes with ocular burns were treated with AMT, with 24
controls. Participants with grades II-IV (Roper-Hall classification) were in-
cluded, and treatment was carried out between one and fourteen days after
the injury. The study found that AMT reduced pain and promoted early
epithelialisation. The latter finding was determined by comparing the loga-
rithm of the mean percentage reduction of the epithelial defect size at var-
ious time points. Although the study found some statistically significant
difference in the healing rates, the treatment and control groups did not
differ in clinical parameters such as final visual outcome. There was also
a high participant dropout rate, further weakening the study. Moreover,
there was significant baseline imbalance, with the treatment group hav-
ing more severe injuries, and this was attributed to the small sample size
and the randomisation strategy. This was reported as a ‘fallacy’ in a subse-
quent RCT, conducted to redress this bias by increasing the sample size and
improving the randomisation process (Tandon et al., 2011). A total of 100
participants were recruited. The authors found epithelial healing to be sig-
nificantly faster in the treatment arm of the moderate burns group. While
the later study addressed come of the limitations of the former, it has been
considered underpowered (Chew, 2011).
Both RCTs (Tamhane et al., 2005; Tandon et al., 2011) considered the
rate of corneal epithelial healing as a primary outcome measure. While
the speed of epithelial healing is important, it is not considered a ‘patient-
centred’ outcome. Outcomes that are important to patients can be investi-
gated through direct interview with eye-injured patients, and include qual-
ity of life measures and a return to normal function (Pager et al., 2004).
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Moreover, the rate of epithelial healing may reflect variables other than a
treatment effect, including timing of presentation, size of epithelial defect,
severity of injury and patient factors. Besides being technically difficult to
achieve, accurate and precise measurements of the rate of corneal epithelial
healing following burns are limited by the number of time-points of patient
attendance and by treatment with semi-opaque AM patches. For these rea-
sons, the first of two primary outcome measures addressed in the current
systematic review was not the epithelial healing rate, but the proportion
of eyes with a PED at the end of the early reparative phase as designated
by (McCulley, 1987). A further primary outcome measure was final visual
acuity. In patients with moderate burns treated with AMT within the first
7 days of injury in the Tandon et al. (2011) study, there was a RR of a PED
at day 21 of 0.18 compared to controls, which was non-significant. Although
visual outcomes were better in the treatment group (M 0.06 versus 0.38),
there was a high risk of bias from a baseline imbalance. As a result, the
quality of the evidence of the two main outcomes was found to be low, indi-
cating a need for further research.
2.6 Conclusion
The systematic review demonstrates the lack of conclusive evidence sup-
porting the use of AMT in acute ocular burns, and reveals the lack of clarity
that surrounds the use of AMT. Nonetheless, AM remains a useful biomate-
rial in ophthalmic surgery. Its biocompatibility and versatility enable it to
be used empirically when the benefits of its application outweigh the risks.
For military use, dried versions of the product may be a useful substitute
for frozen or unpreserved tissue, and may in fact be advantageous in some
clinical scenarios. Technical considerations of drying AM for therapeutic
use are far from straightforward, yet are critical to its optimisation, and are
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explored in the next chapter.
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Chapter 3
OPTIMISATION OF DRIED AM
3.1 Introduction
The preservation of a biological material, whether by drying or any by other
method, has as its primary goal the retention of maximal product quality
for as long as possible. Excipients, such as trehalose, can be used to achieve
this. For AM that is dried for therapeutic use, quality attributes include a
long shelf life and sterility. These are determined by two related concepts:
water activity (Aw) and glass transition (Tg). The determination of these
variables falls within the related domains of moisture sorption and ther-
mal analysis. The lines of investigation available for optimisation include
dynamic vapour sorption (DVS), which can be used to correlate moisture
content to Aw for a particular material. The Tg temperature can be localised
by thermal methods, such as differential scanning calorimetry (DSC) and
mechanical methods, such as dynamic mechanical analysis (DMA). In addi-
tion, thermogravimetric analysis (TGA) can be used to determine end mois-
ture content. Surface analytical techniques, which include X-ray diffrac-
tion (XRD), attenuated total reflectance-Fourier transform infrared spec-
troscopy (ATR-FTIR) and time-of-flight secondary ion mass spectrometry
(ToF-SIMS), can provide useful supplementary information about the inter-
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actions between the excipient and the product. The objective of this chapter
was to employ these techniques to create a framework for the optimisation
of therapeutic dried AM, with trehalose as an excipient. The Aw and the Tg
temperature both of trehalose-treated and untreated AM were investigated.
3.2 Literature review
3.2.1 Lyophilisation
Lyophilisation, or freeze-drying, is a complex and specialised drying tech-
nique and is the preferred method of drying biological tissues (Adams, 2007).
The initial step in freeze-drying is freezing. Freezing complex biological ma-
terials below a critical point produces a mixture of crystallised solutes and
an amorphous matrix associated with unfrozen moisture. The frozen tissue
can then be placed on a temperature-controlled shelf in a sealed vacuum
chamber. As pressure in the chamber falls (to a few millibars), a vapour
pressure gradient is set up between the tissue and an ice condenser, which is
typically programmed to reach at a temperature of ~ -55°C. At temperatures
below the triple point, frozen water undergoes sublimation into vapour. Si-
multaneously, moisture from the amorphous matrix evaporates. The result-
ing water vapour freezes onto the ice condenser. Together, sublimation and
evaporation constitute a primary drying phase, which can proceed for sev-
eral days. A secondary phase, in which the pressure is lowered further (to
the level of microbars), then removes residual unfrozen moisture by desorp-
tion. The vacuum may be broken by an inert gas, and the product sealed
within the chamber to avoid equilibration with ambient humidity. Lyophili-
sation minimises tissue shrinkage, deformation, solute concentration effects
and thermal inactivation of proteins and enzymes that occur during drying
by alternative heat-based methods. Because it operates within a closed sys-
tem, particulate contamination is minimised. Lyophilisation can achieve
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very low levels of moisture, typically between 1 to 4%. However, if the ini-
tial freezing step is uncontrolled, cellular structures can be damaged by the
formation of ice crystals (Fuller and Paynter, 2007). Avoiding ice crystal
formation during cryopreservation is a complex task, requiring controlled
cooling and cryoprotectants. The extent to which this process is controlled
will ultimately depend on the cost to benefit ratio.
The initial freezing step is omitted in drying protocols of certain bio-
logical tissues, a process more correctly referred to as vacuum-drying (Tin-
dall, 2007). This may occur in freeze-drying systems without temperature-
controlled shelves. It is not clear from the published protocols whether AM
has been lyophilised or vacuum-dried in a freeze-drier (Nakamura et al.,
2004; Libera et al., 2008). As a thin film, frozen AM may thaw during the
process of freeze-drying, invalidating the benefits of the initial freezing step.
Vacuum-drying can protect proteins against the effects of thermal inactiva-
tion, but not from harmful solute concentration effects. While AEC become
devitalised during both drying and conventional cryopreservation (Henner-
bichler et al., 2007), cellular damage can be reduced by preserving the tis-
sue in isotonic media such as phosphate buffered saline (PBS) (Acker et al.,
2002) and by adding lyoprotectant excipients such as trehalose, a naturally
occurring osmolyte widely used in the food and pharmaceutical industries
(reviewed by Kaushik and Bhat, 2003).
3.2.2 Stabilisation of biological materials
Preservation invariably causes quality modifications to tissues, manifest as
phenomena such as shrinkage and discolouration (Quirijns, 2006). The Tg is
a key determinant of the quality of amorphous (non-crystalline) materials,
such as foods and pharmaceuticals (MacNaughtan and Farhat, 2008; Saun-
ders, 2008). This is a thermal transition between long and short molecular
relaxation times. Amorphous polymers undergo a Tg from a glassy, or vitri-
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fied, state to a more malleable, rubbery state. Amorphous sugars, such as
trehalose, undergo a Tg from a highly viscous to a less viscous state. Below
the Tg temperature, the molecules of biological materials and pharmaceuti-
cals are immobilised, which directly influences their shelf life and stability
(Patist and Zoerb, 2005). Increasing the moisture content directly lowers
the Tg temperature, an effect known as plasticisation. The moisture content
also determines the Aw. This is an index of the water available for biological
processes to take place. Aw determines the susceptibility of the tissue to
contamination by micro-organisms (Adams, 1995) and to enzymatic degra-
dation (Huis in ’t Veld, 1996). Aw is equivalent to sample relative humidity
(RH), which is expressed as a percentage. Excipients such as trehalose are
widely used in the pharmaceutical and food industries to preserve quality,
and have a useful role in the preservation of biomaterials (Crowe et al.,
1996). Moisture content in excipients is a key determinant of protein stabil-
ity, and can affect the stability and mechanical behaviour of pharmaceutical
products (Khankari and Grant, 1995). Trehalose can exist in a variety of
conformational states, including amorphous and crystalline forms, depend-
ing on the preparation method (Surana et al., 2004b). Some, but not all, of
the crystalline forms are protective during drying. The preserved material
and trehalose-PBS are immiscible, forming a heterogeneous mixture with
distinct thermodynamic profiles. Therefore, it is important that both the
material and the excipient are stored in glassy phases.
3.2.3 Thermal properties of collagen
As a collagen and elastin-rich tissue with abundant ECM, AM can be con-
ceived of as a composite polymer consisting of crystalline and amorphous
fractions (Li, 2000). Individual collagenmolecules consist of ordered polyproline-
like triple-helical chains with regularly arranged amino acid motifs rich in
glycine (Gly), proline (Pro) and hydroxyproline (Hyp) (most commonly Gly-
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Pro-X and Gly-Hyp-X). The chains form weak associations as a result of
Van der Waal’s forces and hydrogen bonds, which may cause viscoelasticity
(Sasaki and Odajima, 1996). Peptide-bound aldehyde groups form covalent
cross-links between the molecules, giving rise to polymeric fibrils (Eyre et
al., 2008). Type I and III collagen molecules form heterotypic fibrils, inter-
acting with other fibrils, proteoglycans and water to provide the bulk of me-
chanical strength (Cameron et al., 2002). The long-range crystalline order
of the helical ultrastructure of the fibrils is suggested from X-ray diffrac-
tion patterns (Cameron et al., 2002). The polypeptides consist of ordered
chains flanked by disordered fringes, analogous to semi-crystalline polymers
(Morawetz, 1985). Collagenous tissue exhibits a Tg at about 40°C and a de-
naturation of the crystalline collagen fibrils at about 56°C (Li, 2000). This
is contingent upon moisture content, which lowers the stiffness of purified
collagen (Ntim et al., 2006). Bound water molecules are intrinsic to the
collagen structure, forming an extensive network of bridges within and be-
tween the collagen molecules and fibrils (Zhang et al., 2011). When collagen
is dehydrated, neighbouring peptides develop weak associations, causing
stiffness to increase (Pashley et al., 2003). The collagen fibres are enmeshed
in an amorphous matrix consisting of non-collagenous glycosaminoglycans,
glycoproteins and elastin (Kaplan et al., 1987). The mechanical behaviour
of elastin is similar to that of an amorphous polymer (Lillie and Gosline,
1990).
DSC is the most widely used thermal analytical technique, providing a
wealth of information about the thermal properties of a material (Gabbott,
2008). It is especially effective in the analysis of semicrystalline polymers,
where it can be used to determine events such as melting and crystalli-
sation, to characterise Tg and to quantify corresponding enthalpy changes
(Schick, 2009). In one study, DSC was used together with TGA to investigate
the thermodynamic properties of air-dried AM-derived collagen membranes
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cross-linked with chitosan (Kumar et al., 2003). The authors showed a sin-
gle DSC plot for AM-derived collagen, identifying endotherms at 86.21°C
and 218.90°C as being due to water loss and melting respectively. The ini-
tial weight loss tapered off at around 100°C, and was followed by a grad-
ual thermal decomposition at temperatures upwards of 175°C. The cross-
linked membrane decomposed more gradually than a non-cross-linked con-
trol, which was taken as evidence of improved thermal stability. The study
failed to identify a Tg temperature. DMA is an even more sensitive method
of investigating thermal transitions than DSC, and is especially useful in
characterising the viscoelastic properties of amorphous and semi-crystalline
polymers (Duncan, 2008), including purified collagen (Ntim et al., 2006) and
elastin (Lillie and Gosline, 1990).
3.2.4 Moisture sorption
An understanding of a biomaterial’s moisture sorption characteristics is
fundamental to its characterisation (Gabbott, 2008), since a high Aw in-
creases the risk of spoilage (Adams, 1995). In many foods, the Aw above
which fungal growth can occur is approximately 0.65 (Abdullah et al., 2000).
In common with foodstuffs, biological soft tissues are at risk of contami-
nation from psychrotrophic bacteria, yeasts and moulds. Vacuum-packing,
sterilisation and a low Aw extend the shelf-life (Gould, 1996). The non-linear
relationship between equilibrium moisture content and Aw is given by the
moisture sorption isotherm, which must be determined experimentally by
DVS. Moisture can either be adsorbed onto the surface of type I collagen or
absorbed into the bulk of the tissue (Zhang et al., 2011), and the same may
be true for AM. Adsorption can occur as a monolayer, by interaction with
polar groups on the surface, or as a multilayer, through hydrogen bonding.
The data from DVS analysis can be used in mathematical models to distin-
guish between the different types of adsorption and absorption (Young and
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Nelson, 1967). The equilibrium moisture content can be obtained by TGA,
which measures weight changes as a function of temperature in a controlled
atmosphere (Bottom, 2008).
3.2.5 Trehalose lyoprotection
In nature, the accumulation of trehalose by certain organisms enables them
to survive drying (see Møbjerg et al., 2011). This discovery led to its use
as a cryoprotectant for eukaryotic cells (Wolkers et al., 2002). Trehalose is
a non-reducing disaccharide with a hydrolysis-resistant glycosidic bond be-
tween two α-glucose units (α-D-glucopyranosyl-(1→1)-α-D-glucopyranoside).
It does not cause non-enzymatic discolouration of organic materials, caused
by the reaction between amino acids and reducing sugars (Maillard reac-
tion), making it particularly suitable as an excipient for biomaterials (Sche-
bor et al., 1999). Trehalose can enable mammalian platelets to survive
freeze-drying (Wolkers et al., 2001) and can preserve the function of mam-
malian pancreatic cells after long-term storage (Beattie et al., 1997). It
is widely thought to be an exceptional stabiliser of proteins and enzymes
(Crowe et al., 1998). The molecular mechanisms by which trehalose sta-
bilises cellular proteins are not fully understood (see review by Jain and
Roy, 2009). Crowe et al. (1998) have suggested that it achieves this effect
both by vitrification and by direct interactions with proteins. When amor-
phous trehalose undergoes vitrification (Tg), it encases cell membranes and
proteins in a protective glassy matrix, stabilising cell membrane integrity
(Chen et al., 2001). By maintaining the separation of micro-domains, it
keeps the lipid bilayer in its liquid crystalline phase as it becomes dehy-
drated (Wolkers et al., 2010). Moreover, trehalose can have intracellular
effects. In solution, trehalose can cross the cell membranes of platelets and
red blood cells by endocytosis (Crowe et al., 2003). Intracellular vitrifica-
tion prevents the fusion of organelles and the formation of large ice crystals.
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Trehalose may also protect proteins from unfolding during drying by entrap-
ping water at the interface with the molecule (Crowe, 2007). By disrupting
the tetrahedral hydrogen bond network of water, it reduces the amount of
water available for freezing (Patist and Zoerb, 2005). This mechanism has
been termed water sequestration. In addition, it interacts directly with po-
lar residues via hydrogen bonding, replacing water molecules (Crowe et al.,
1984). Known as water replacement, this is thought by some researchers to
be necessary for lyoprotection (Christensen et al., 2008). However, this does
not fully explain its functions, which are related to its structural polymor-
phism (Nagase et al., 2002).
3.2.5.1 Conformational states of trehalose
Trehalose exists in various polymorphic structural conformations that dif-
fer in their molecular interactions and hygroscopic properties (Gil et al.,
1996). The forms are summarised in figure 3.1. They include ordered crys-
talline and amorphous forms. Other conformations are also possible (e.g.,
liquid). The most common form is the dihydrate crystal, which is formed
from solution in water (Sussich et al., 2001). Gil et al. (1996) identified an
anhydrous form with unique properties. Formed by evaporation of moisture
from the dihydrate crystal, anhydrous trehalose is able to readily absorb
moisture (Sussich et al., 2001). ‘Fast’ evaporation from the dihydrate crys-
tal molecule gives rise to an amorphous form in preference to the crystalline
alternatives (Sussich et al., 2001). At least two other crystalline forms (e.g.,
anhydrate) can be formed from the dihydrate and the amorphous sugar.
As these do not easily interact with moisture and do not vitrify, they are
not protective (Hancock and Zografi, 1997). The crystallisation of trehalose
from dihydrate, amorphous and glassy forms releases water to the mate-
rial, which profoundly reduces its performance as a protectant (Costantino
et al., 1998a; Hunter et al., 2010). The ability of trehalose to bind water
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Figure 3.1: Trehalose forms
Schema of trehalose conformational states, adapted from Sussich et al. (2001). The dihy-
drate crystal, formed from solution in water, can reversibly release moisture to produce an
anhydrous form which can act as a desiccant. Under certain conditions, amorphous tre-
halose can be produced, which can undergo vitrification. The dihydrate and the amorphous
form can also produce two other crystalline forms which are not protective. Only relevant
transitions have been included.
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is determined by the torsional angles around the C-O-C glycosidic linkage
(Akao et al., 2001). The anhydrous form is characterised as having an ‘open’
conformation, and can bind water stoichiometrically. Conversely, the non-
protective anhydrate form is densely packed. The causes of crystallisation
of trehalose on preserved products are incompletely understood. In experi-
mental conditions, crystallisation can be induced by altering the humidity
and temperature of the dihydrate and amorphous forms for periods of time
lasting several hours (Akao et al., 2001; Surana et al., 2004b).
3.2.5.2 Vitrification of trehalose
Amorphous and anhydrous conformations can be formed simultaneously
(Nagase et al., 2002). The anhydrous crystal acts as a desiccant, prevent-
ing devitrification and recrystallisation of the amorphous sugar (Akao et
al., 2001). This effectively enables the sugar to remain glassy despite the
sorption of moisture. When completely dry, amorphous trehalose possesses
a Tg temperature of 120°C (Chen et al., 2000). Moisture acts as a plasticiser,
reducing the Tg temperature down to even less than -100°C. As the Tg tem-
perature approaches ambient temperature, crystallisation of the amorphous
sugar causes its protective effect to be lost (Costantino et al., 1998b). This
occurs at a RH of approximately 50%, suggesting that, in order to maintain
the protective effects of trehalose, the Aw should be kept below at least 0.5
(Costantino et al., 1998b). Sitaula and Bhowmick (2006) have reported that
a dry basis trehalose-PBS ratio of 10:1 provides the optimal trehalose con-
centration for the storage of cells as long as Aw is kept below 0.23 to main-
tain the glassy state. The trehalose effect is complicated by the addition
of other excipients. While the Tg may be decreased by increasing the mass
fraction of buffered saline in the medium (Sitaula and Bhowmick, 2006),
certain divalent cations are reported to act synergistically with amorphous
sugars to stabilise proteins by inhibiting crystallisation (Carpenter et al.,
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1992).
3.2.6 Trehalose-AM interactions
Despite the interactions of trehalose and cell membranes, the disaccharide
is excluded from the lipid bilayer of most intact cells (Satpathy et al., 2004),
yet may have important effects on the whole tissue. It has been suggested
that trehalose can preserve the ultrastructure of lyophilised, denuded AM
(Nakamura et al., 2008). As different methods of drying strongly influence
the pharmaceutically relevant forms and properties of trehalose (Surana
et al., 2004b), they can substantially alter the preservation of AM. Drying
methods that produce more amorphous and anhydrous forms of trehalose
would favour its role in preserving both the gross physical properties of AM
and its more subtle properties such as cell morphology and protein content.
The precise interactions between AM, moisture and excipients are un-
known, and can be explored by ancillary techniques commonly used in ther-
mal analysis, including XRD, ATR-FTIR and ToF-SIMS/PCA. These tech-
niques have the advantage of being able to sample biological tissues without
much further preparation, providing information on molecular changes at
or near the surface.
The extent to which substances can be characterised as amorphous or
crystalline can be estimated from XRD spectra by a method described by
Hermans and Weidinger (1948). XRD is performed by irradiating a sample
through a range of angles at a known wavelength. The angle of deflection
(angle 2θ) corresponds to the characteristic spacings of planes within crystal
structures (d-spacings). This produces a series of diffraction peaks, which
can be identified by comparing the data to tabulated PDFs, available from
the International Centre for Diffraction Data®. The various polymorphic
crystalline forms of trehalose have XRD profiles with characteristic peaks
Nagase et al. (2002). Trehalose dihydrate can be identified from a character-
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istic diffraction peak with an angle 2θ of 23.9°, whereas the anhydrous form
has a characteristic peak at 16.1°. These are absent in the non-protective
crystalline forms, while the amorphous phase is smooth and featureless.
The principal parameter that can be obtained from FTIR spectra is the
band position of molecular group vibrations (Movasaghi et al., 2008). As
a collagenous material, AM demonstrates characteristic amide absorption
bands at 1655 cm-1 (C O stretching, amide I), 1551 cm-1 (N H bending,
amide II) and 1239 cm-1 (N H bending, amide III) (Singh et al., 2007). Ma
et al. (2010) found additional peaks at 3315 cm-1 (N H stretching) and 2929
cm-1 (C H stretching). The FTIR spectra of trehalose polymorphs were ini-
tially reported by Gil et al. (1996). The dihydrate crystal exhibits a char-
acteristic sharp peak at 3500 cm-1, corresponding to the stretch vibration
of two crystal water molecules (O H stretching), and another at 1680 cm-1
(H O H bending). Additional FTIR peaks occurring at 994 and 954 cm-1 cor-
respond to asymmetric and symmetric stretching of the trehalose α-(1↔1)-
glycosidic bond. The sharp peak at 3500 cm-1 disappears in the anhydrous
and amorphous forms, while altered conformation of the glycosidic linkage
causes the 994 and 954 cm-1peaks to shift in a characteristic way that is
specific for the various forms (Akao et al., 2001). The spectrum of amor-
phous trehalose is similar to that in solution and markedly different from
the crystalline form, suggesting that hydrogen bonding in the dried state is
comparable to the dissolved state (Wolkers et al., 2004). Hydrogen bonding
between the trehalose hydroxyl groups and surface polar groups shifts the
FTIR bands to frequencies typical of hydrated proteins (Crowe et al., 1984).
As a result, the surface proteins of freeze-dried platelets retain a similarity
to proteins in fresh platelets when treated with trehalose (Wolkers et al.,
2001). Conversely, the addition of large amounts of PBS to trehalose has
been shown to reduce the hydrogen bonding capacity of trehalose (Sitaula
and Bhowmick, 2006). FTIR studies have demonstrated that at high RH,
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trehalose undergoes crystallisation, losing its protective ability (Costantino
et al., 1998b).
The investigative technique of ToF-SIMS uses a primary ion beam is
used to generate secondary ions from the uppermost surface monolayer of
a material (a depth of approximately 10 Å). This highly energetic process
fragments the molecules into smaller ions which can be analysed by their
time-of-flight to produce a mass spectrum (Gross, 2004). This can generate
a vast repository of information, so multivariate analysis (MVA) is usually
necessary to extract the information required from the ToF-SIMS spectral
data in a meaningful way (Wagner et al., 2004). Principal component anal-
ysis (PCA) is a powerful method of MVA of spectra from different samples,
providing statistically robust transformations of large data sets into more
manageable ones (Yang et al., 2005). A thorough understanding of PCA
assumes a knowledge of vector and matrix algebra. A comprehensive ex-
planation is given by Lee and Gilmore (2009). Since the spectral peaks of
the amino acid fragment ions are known, ToF-SIMS/PCA can used to char-
acterise adsorbed protein films on biomaterial surfaces (Wagner and Cast-
ner, 2001). Using ToF-SIMS and PCA, Xia et al. (2002) found that proteins
treated with trehalose retained hydrophilic or polar amino acids, analogous
to their state in aqueous solution, whereas untreated proteins had high con-
centrations of hydrophobic amino acids typically found in the interior of the
protein molecule.
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3.3 Materials and methods
3.3.1 Tissue procurement and processing
3.3.1.1 Harvesting of AM
AM was obtained from healthy volunteers following ethics committee ap-
proval of this project. A formal consenting procedure was observed requir-
ing the patient’s signature. Women with a history of intravenous drug abuse
and multiple sexual partners were not invited to participate. The medical
notes were checked for infectious diseases, such as Hepatitis B and C, HIV,
syphilis and tuberculosis. Gestational diabetes was considered a contra-
indication, as were other rarer medical conditions. Tissue was only pro-
cured if the healthy pregnant mother understood the explanation and was
satisfied. A maternal age over 40 was considered a bar to donation. The
operating theatres were informed of all mothers wishing to participate. The
midwives who were responsible for checking the placenta were asked to iso-
late the placenta in a sterile plastic bag with the umbilical cord clamped
at its two ends. It was collected immediately after birth had occurred and
transported to the laboratory for processing.
3.3.1.2 AM preparation
Processing was carried out in a fume hood, following departmental proto-
cols described by Hopkinson et al. (2006b). The mid-zone and apical AM
was cut with scissors to leave a 2 cm skirt of tissue around the placenta
(figure 3.2 A). The tissue was immediately placed in normal saline solution.
The AM was separated from the chorion by peeling (B) and placed into a
flask containing 300 mL of cold normal saline. It was washed by placing
the flask on a rocker and replacing the saline every 30 mins × 3. After the
final 30 min wash, the hydrated spongy layer was then peeled off by push-
ing it away in a single layer with the back of a surgical blade (C), and any
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Figure 3.2: Preparation of AM
This sequence shows cutting of amniochorion from placenta (A), peeling of chorion from AM
(black arrow, B) and removal of spongy layer (black arrows, C)
areas of blood contamination were removed before a further quick wash.
The AM was carefully checked for blood and then cut into sections. This
was initially carried out with a surgical blade. To achieve a more consistent
size and shape, stainless steel templates were designed for the purpose.
The templates were round, to allow circular cutting movements, and were
available in 2.5 cm or 5.0 cm diameter sizes. Fresh AM was placed in a so-
lution of modified, sterile-filtered 1 × Dulbecco’s PBS without magnesium
chloride (Sigma-Aldrich, UK) and kept at 4°C. For freezing, the AM pieces
were placed in polypropylene universal tubes (Sarstedt, Germany) contain-
ing PBS. These were labelled and placed in a freezer at -80°C. Alternatively,
AM pieces were vacuum-dried. AM preserved by freezing and then thawed
for experimentation is referred to as ‘freeze-thawed’, abbreviated to ‘f-t AM’.
3.3.1.3 Thermolysin denuding
When required, the thermolysin method was used to denude the epithe-
lium as described by Hopkinson et al. (2008) and modified by Gicquel et al.
(2009). The bacterial protease thermolysin (from Bacillus thermoproteolyti-
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cus rokko) was obtained from Sigma-Aldrich (St. Louis, MO, USA). Sections
of fresh AM (5 cm × 5 cm) were placed flasks containing a solution of ther-
molysin in 1 × PBS (125 μg/mL). The flasks were agitated for 9 mins at 37°C
or for 20 mins at room temperature. The thermolysin-treated membranes
were then washed in PBS in a flask until it turned cloudy, and then washed
twice more until the cloudiness disappeared. Next, the AM sections were
washed on a rocker for 20 mins in PBS.
3.3.1.4 Trehalose pre-treatment
When required, AM was pre-treated in trehalose solution in PBS. A 5% or
10% weight to volume solution of trehalose dihydrate (FW = 378.34) was
prepared by dissolving the desired weight of trehalose in 1 × PBS. For a
10% solution, 4 g of trehalose dihydrate powder (molar mass 378.33 g mol-1)
was dissolved in 40 mL 1 × PBS, containing 0.32 g NaCl, 0.008 g potas-
sium phosphate (monobasic), 0.046 g sodium phosphate (dibasic) and 0.008
g potassium chloride. Sections of AM were incubated in 0%, 5% or 10% tre-
halose solution and agitated in an orbital shaker at 37°C for 2 hrs prior to
vacuum-drying. This produced AM pieces covered with a mixture of tre-
halose and PBS with an approximate dry weight ratio of sugar to salt of
10.5:1 (100 g sugar per 9.55 g salt).
3.3.1.5 Vacuum-drying
As a thin film, AM could be dried very rapidly without pre-freezing. In or-
der to minimise processing steps, the cut AM discs were placed stromal side
down into open smooth thermoplastic pouches (Orved SpA, Musile di Pi-
ave, Italy), made of a transparent polyamide air-impenetrable exterior and
a polyethylene interior, before vacuum-drying. These were placed into a
vacuum drying chamber (ALPHA 1-4 LSC Advanced Freeze Dryer, Christ®,
Osterode, Germany). The time and pressure settings during main and final
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drying were programmed manually. The main drying phase settings used
included a time of 2 hrs, ice condenser temperature of -55°C and chamber
pressure of 1.030 mbar. The final drying phase was 60 mins, with a pressure
of 0.0010 mbar. This was sufficient to produce a dry tissue which could be re-
hydrated in a few drops of sterile water. Once the vacuum-drying cycle was
completed, the thermoplastic pockets containing the samples were vacuum-
sealed in a VM12 vacuum chamber (Orved SpA). Samples were stored at
room temperature. Vacuum-dried AM was tested either as a dry tissue or
in its reconstituted state. Vacuum-dried AM is referred to as ‘v-d AM’. The
samples which were incubated in PBS with no trehalose are referred to as
‘0% v-d AM’ or ‘untreated v-d AM’. The addition of 5% or 10% w/v trehalose
is referred to as 5% or 10% trehalose treatment, and the samples are re-
ferred to as ‘5% v-d AM’ or ‘10% v-d AM’.
3.3.2 Moisture sorption analysis
3.3.2.1 Dynamic vapour sorption1
DVS was performed on three pairs of 0% and 10% v-d AM samples. Two
pairs (A and B) were prepared with 2 hrs main drying time and 1 hr final
drying. One pair (C) was prepared with 1 hr main drying and 30 mins fi-
nal drying. The 10% v-d AM sample from this pair was given a final wash
in PBS prior to drying. The 0% v-d AM sample was exposed to the atmo-
sphere for 7 days prior to testing. AM samples were chopped into 5 mm
squares with a blade. These were weighed and placed in a glass basket in
a temperature-controlled chamber in the DVS instrument (model DVS-1,
Surface Measurement Systems Ltd, Wembley, UK) (figure 3.3). The glass
basket was cleaned with ethanol prior to to use and dryness assured by re-
peat gravimetric checking. The DVS phases consisted of a drying phase,
lasting 500 mins, and a sorption-desorption phase lasting 167 hrs.
1The DVS was operated by Dr Bill MacNaughtan at the School of Pharmacy.
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Figure 3.3: DVS instrument
The DVS-1 instrument is shown in A, with a chopped AM sample (arrow) in a glass basket
in the temperature-controlled chamber before closure (B).
Drying phase In preparation for the sorption isotherms, drying curves
were obtained for the three pairs of v-d AM samples (A, B and C). During
the drying phase, the samples were exposed to a dry stream of N2 gas at
a constant temperature for 500 mins. The temperature was kept at 20.3°C
throughout. The percentage mass lost due to drying was calculated from an
initial normalised mass of 100%. The slopes of the final 10% of the drying
curves were calculated by using simple linear regression analysis software
(Sigmaplot® for Windows, Systat Software, Inc., CA, USA). The data was fit
to the following polynomial linear equation:
y = y0 + ax
where x is time, y is mass and a is the returned value for the slope.
Sorption isotherms At the end of the drying phase, the dry weight was
set at 100%. The samples were exposed to a series of step changes in target
RH, while the change in mass was monitored continuously. This instrument
was programmed to allow the dry gas to mix with gas of a known water
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vapour saturation, producing the desired target RH. This was increased
from 0% to 95% in nine steps lasting 500 mins: 10%, 20%, 30%, 40%, 50%,
60%, 70%, 80% and 95%. The sample RH was measured continuously by an
electronic humidity probe in the chamber. At the end of the last step, the
target RH was decreased back to 0% in equal steps. A number of plots were
produced from the data:
1. Target RH and equilibrium RH were plotted against time, comparing
the equilibration of 0% and 10% v-d AM.
2. Water vapour sorption kinetic graphs were plotted. This plots the
change in percent dry mass (moisture content) alongside the measured
sample RH (Aw) and is useful for comparing the sorption characteris-
tics of 0% and 10% v-d AM. These variables were tabulated at a series
of RH values (10%, 60%, 70%, 80% and 95%) to compare v-d AM sam-
ples.
3. Moisture content (change in mass) was plotted against the Aw of the
0% and 10% v-d AM samples to produce isotherm graphs. The two
components of each isotherm include a sorption phase (increasing hu-
midity) and a desorption phase (decreasing humidity). The hysteresis
was calculated as the maximum difference in mass between the sorp-
tion and desorption phases at any one target RH. From these curves,
the Aw was extrapolated from moisture contents of 10% and 20% as
examples. Conversely, the moisture content was extrapolated from the
target RH at 70%.
4. The DVS software automatically generated Young and Nelson plots.
These fit the sorption and desorption data to a mathematical equation
which estimates differences in the monolayer and multilayer adsorp-
tion and bulk absorption of 0% and 10% v-d AM. The Young and Nelson
parameters are generated as positive changes in mass for adsorption
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and negative changes for internal absorption by the software.
Statistical comparisons between samples of 0% and 10% v-d AM (A and B)
were made using the paired t test.
3.3.3 Thermal analysis
3.3.3.1 Thermogravimetric analysis
TGA was performed by open and closed pan methods to compare their suit-
ability for measurement of thermal events in v-d AM. Baseline adjustment
experiments were performed for both methods by conducting TGA runs on
empty pans. The change in pan mass over the course of the experiment was
then subtracted from the sample runs to determine the actual gravimetric
change in sample mass.
Open panmethod TGAwas initially performed in open platinum pans to
determine the moisture content of four sets of 0%, 5% and 10% v-d AM sam-
ples. A Q600 SDT simultaneous thermogravimetric analyser/differential
scanning calorimeter (TA Instruments, Delaware, USA) was used. Vacuum-
sealed AM samples were cut into squares of approximately 10 mm × 10
mm immediately prior to testing and weighed. The platinum pans used as
sample holders were heated with a small blowtorch to burn off any residual
organic material. AM samples approximately identical in weight (2 - 3 mg)
were placed inside open platinum pans. Trehalose dihydrate powder was
analysed for comparison. The pans were placed side by side on transducers.
These were then sealed in a chamber which was filled with N2 gas. The
instrument was started at room temperature, and heating was ramped up
by either 5°C or 10°C min-1. At the end of each cycle, the instrument was
air-cooled to a temperature close to room temperature in preparation for
a further sample. Trace of mass versus temperature were recorded by TA
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Universal Analysis software. The data were analysed at a cut-off start tem-
perature in order to zero the TGA curves from the different runs. Two sets of
0%, 5% and 10% v-d AM samples was analysed with a cut-off temperature
of 25.2°C and a heating rate of 10°C min-1. For two further sets, the cut-
off temperature was 19.5°C and the heating rate was 5°C min-1. The TGA
curves obtained were analysed using Universal Analysis 2000 software (TA
Instruments) and by plotting first derivative curves (below). The decompo-
sition gradients were measured from the TGA curves and expressed as %
mass loss per °C.
First derivatives The first derivatives of the TGA curves were plotted,
enabling key points of flux to be identified. This useful function is available
as a macro within Sigmaplot® software. The point at which total evap-
oration occurred and decomposition started was identified as the point at
which the initial slope of water loss became completely flat (complete evap-
oration of bound water). The maximal rate of decomposition was identified
as a point on the decomposition gradient at which a reversal in the first
derivative curve occurred. The gradient of decomposition and moisture con-
tent were obtained for each sample. The moisture content was obtained by
subtracting the sample weight at the point of maximal water loss from the
mass at the cut-off temperature. The curves were normalised by express
mass as a percentage. A locally weighted smoothing function (loess algo-
rithm), available in Sigmaplot®, was applied to the first derivative curves
with a sampling proportion of data of 0.1 and a polynomial degree of 1.
Alternative drying methods To assess the effectiveness of vacuum dry-
ing AM, samples were dried by alternative methods. AM samples were laid
on PTFE sheets and placed in a standard laboratory drying cupboard heated
to 70°C for 24 and 48 hrs. Further samples were placed in glass vials in a
vacuum oven (Heraeus® Vacutherm® Oven, Fisher Scientific UK, Ltd) at
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50°C and 50 mbar for 48 hrs. For comparison, TGA was performed on single
samples dried by each method (three in total). The moisture content was
measured by subtracting the mass at the point of maximum water loss from
the mass at the cut-off temperature (25.2°C).
Closed pan method Further TGA experiments were performed in her-
metically sealed aluminium pans to determine the moisture content of qua-
druplicate 0%, 5% and 10% v-d AM samples. The SDTA 851e (Mettler
Toledo, Leicester, UK) was used for the closed pan experiments. This in-
strument uses a TSO801RO sample robot to pierce the pans a few millisecs
before heating starts. Thermogravimetric data is fed to a STARe software
interface for analysis. Whole dried discs of AM were cut from the same tem-
plate to a diameter of 5 cm and placed into the sealable aluminium pans,
which were then capped shut and placed in the instrument. In this set of
experiments, the cut-off temperature was 25.0°C and the heating rate was
5°C min-1. Moisture content calculations were performed from the curves.
This method enabled the identification of the maximal rate of water loss
(‘peak loss’) as an additional variable. This was calculated along with evap-
oration and decomposition.
3.3.3.2 Differential scanning calorimetry
DSC was initially conducted by increasing the temperature at a constant
rate until a desired end point is reached (ramp mode). This, however, did
not permit visualisation of any thermal transitions that may occur beneath
the main endotherms. An alternative method was employed by ramping the
temperature up to an intermediate, reversible level and then repeating the
cycle (cyclic DSC). Cyclic DSC permits the unmasking of hidden reversible
changes, for example by those masked by water, as the flatter curves reveal
additional hidden transitions. The main property that DSC measures is
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heat flow in watts (W). Thermal transitions are characterised by changes in
heat flow, known as endotherms (or exotherms if the direction of heat flow is
outward). Tg temperature can be localised as an endothermic step on a DSC
trace. By subtracting a baseline from the heat flow curve, the specific heat
capacity (Cp) of a material may be determined. Enthalpy is then calculated
by integrating the area under the Cp curve.
Ramp mode DSC was performed in triplicate on 0% v-d AM samples and
in duplicate on 10% v-d AM samples from different donors. A DSC Q2000
(TA Instruments, Delaware, USA) was used in ramp mode at a heating rate
of 5°C min-1from -40°C to 300°C. V-d AM samples were carefully weighed
and loaded into aluminium pans which were also weighed and then sealed
with a crimper. A separate pan was weighed as a reference for the sample
pans. The samples were loaded by a robot arm, and the pre-set heating rate
was applied at 5°C min-1as a single ramp. The data was recorded in Univer-
sal Analysis 2000 (TA Instruments) software files. Baseline measurements
were subtracted.
Cyclic DSC Cyclic DSC runs were performed on the TGA/SDTA851 in-
strument (Mettler-Toledo). Whole v-d AM discs were weighed and placed in
stainless steel pans which were then hermetically sealed and loaded in the
automated instrument. Duplicate samples of 0%, 5% and 10% v-d AM were
analysed. A sample of vacuum-dried 10% w/v trehalose dihydrate powder in
PBS was analysed alongside the v-d AM samples. This was prepared under
the same conditions as 10% v-d AM to keep the same fractions. For all the
samples, the cycle temperature ranged from -50°C to 180°C, rising at a rate
of 10°C min-1. The onset, peak and end points of the endotherms and the
enthalpies of the curves were obtained by automated STARe software. Base-
line measurements were subtracted automatically. For Tg temperatures, the
inflection point of the sigmoidal step was calculated by extrapolating the
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tangents of the curves and finding the midpoint of a line joining the tan-
gents. The onset and end point of the transition were obtained from the
crossing points of the extrapolated tangents.
3.3.4 Dynamic mechanical analysis2
DMA testing of vacuum-dried AMwas carried out using a Triton Technology
Dynamic Mechanical Analyser (PerkinElmer, Inc., MA, USA) equipped with
humidity and temperature control. The instrument applies a sinusoidal
displacement (strain) to samples under tension and measures the material
response (stress) with a linear variable differential transducer. In auto-
matic tension mode, it adjusts the static displacement via a feedback mech-
anism, attempting to maintain the static force at a set percentage above
the dynamic force required to drive the sample. As the sample slackens or
tightens, the static displacement is automatically adjusted to keep the sam-
ple under tension and maintain the oscillatory amplitude. The oscillatory
amplitude is typically within the linear viscoelastic region of the material
(Turi, 1997). Parameters generated by DMA include the storage modulus
E´, the loss modulus E´´ and the ratio between the loss and storage moduli,
tan δ. These undergo characteristic changes at the Tg, which occurs over a
temperature range. The instrument has a E´ resolution of 0.0001 Pa and a
force resolution of 0.0025 N. Only once the sum influences of the static and
dynamic forces are correct will the initial E´ measurements appear credible.
The Tg of an amorphous viscoelastic polymer is illustrated by an exam-
ple of a DMA trace obtained from data for a strip of PMMA of geographic
dimensions of 12.44 mm × 7.10 mm × 2.36 mm (figure 3.4).3 Frequencies
of 1 and 10 Hz and an oscillatory amplitude of 0.5% were used to obtain
the trace. As the material undergoes a transition between its glassy and
2This was performed with the help of Dr Jeffrey Glyn van de Velde, formerly of Triton
Technology.
3Data kindly provided by Dr Bill MacNaughtan
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Figure 3.4: Multifrequency moduli and tan δ of PMMA
An example of a DMA trace obtained for PMMA is shown. The storage modulus E´ begins
to decrease more steeply above ~100°C, whereas both E´´ and tan δ exhibit peaks. Tg is
frequency dependent, occurring at higher temperatures with higher oscillatory frequencies
(A; 1 Hz and 10 Hz). The measurement of Tg from a DMA trace can include different
methods (B), including the onset of the steep decrease in E´ (black arrow), the inflection
point of E´ (gray arrow) and the maximum values of E´´ and tan δ (1 Hz).
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Figure 3.5: DMA of v-d AM sample
A 10 mm wide multiplex strip of AM (white arrow) is clamped for DMA. The free length is
10 mm.
rubbery states, E´ begins to fall, while E´´ and tan δ exhibit peaks. The
Tg values undergo shifts in temperature at different oscillatory frequencies,
demonstrating strain-rate dependency. A number of measurements are pos-
sible, including the onset of the fall in E´ , the peak of E´´ and the peak of tan
δ at each frequency. The inflection point of E´ has been obtained from the
first derivative of the data, and represents the maximum flux of the slope.
ISO 6721-11 part 11 stipulates that this measurement should be quoted as
the Tg temperature of plastics. Measurements can be complicated by over-
lapping processes, such as smaller thermal relaxations and the effects of
moisture and excipients, which can be variable and broad. Accurate and
precise measurement of the sample geometry is essential in obtaining cred-
ible data.
V-d AM specimens (mid-zone of AM, random orientation) were cut into
longitudinal strips 10 mm wide and 30 mm long (figure 3.5). The geome-
try of the strips was measured by using a digital micrometer and a digital
caliper (Mitutoyo UK, Andover). The strips were mounted lengthways in
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tension clamps, with a free length of 1 mm, 5 mm or 10 mm between the
clamps. The dimensions of the sample were entered into the instrument
software. Exploratory frequency sweep DMA runs were conducted across
a variety of ranges of humidity and temperature. These were performed
with automatic tension mode off. The longitudinal oscillatory displacement
amplitude was set at 0.05% of the free length of the sample. An additional
static force of between 0.01 and 0.5 N was then applied. Applying a small
force ensured that residual slack from the clamping procedure was taken
up, placing the sample under tension.
Following the initial frequency sweep tests, temperature sweep and hu-
midity sweep modes were used to obtain information on the Tg temperature
and the effects of moisture. The ratio of static to dynamic force was con-
trolled by applying an automatic tension setting of 150% for the humidity
and temperature sweep modes. A DMA run was considered successful if
the static force remained higher than the dynamic force during the glassy
phase. To increase the amount of tensile force applied to the sample, DMA
runs were also conducted with multiple layers of v-d AM sandwiched to-
gether. On checking the data, a decision was made to proceed or halt the
experiment. DMA runs were abandoned if the sample broke or if the dy-
namic force exceeded the static force in the initial part of the run, giving
lower than expected values of E´ . The ratio of sample to total stiffness (in-
strument + sample) was used as an additional guide. Typically, this ratio is
high (above ~80%) in the glassy phase of the run. An unusually low ratio
suggested slackness of the sample. Runs that ended in sample breakage
were halted and repeated until successful traces were obtained if possible.
3.3.4.1 Frequency sweep
DMA measurements were performed on 12 strips of 0% v-d AM and six
strips of 10% v-d AM in ambient temperature. The DMA was started in
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frequency sweep mode to determine the kinetic parameters at which the
moduli E´ and E´´ and tan δ could be measured. The exposed area of AM
between the clamps was 10 mm × 10 mm. A positive total applied static
force of 0.02 N was applied, and the displacement amplitude was set at 50
μm. DMA runs were performed in triplicate at 15 intervals of increasing
frequency ranging from 0.10 to 100 Hz. The frequencies were set at incre-
ments of between 0.1 and 100 Hz. E´, E´´ and tan δ were plotted against the
oscillatory frequency of the DM analyser for a representative strip of 0% v-d
AM.
3.3.4.2 Humidity sweep
Humidity sweep DMA runs were carried out in triplicate on strips of 0%, 5%
and 10% v-d AM. V-d AM strips of different dimensions (10 mm and 1 mm)
were used to assess the influence of RH on Tg. The oscillatory frequencies
were set at 1 and 10 Hz. A moisture control system was attached to a seal-
able chamber on the DMA instrument. The samples were enclosed within
the chamber before testing. The system was capable of varying the RH be-
tween 10% and 90%. The humidity sweep tests were conducted at room
temperature or at a constant temperature. RH was increased either as a
series of stages or in a single ramp. E´, E´´ and tan δ were plotted against
RH to localise the Tg.
3.3.4.3 Temperature sweep
Temperature sweep DMA runs were performed at ambient RH on triplicate
samples of 0% and 10% v-d AM samples. Samples with free lengths of 10
mm, 5 mm and 1 mm were tested to assess the relationship between tem-
perature and Tg. The oscillatory frequencies were set at 1 and 10 Hz. A
liquid nitrogen-based cryogenic cooling system and a radiant oven were at-
tached to a sealable chamber that enclosed the DMA clamps. Each sample
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Figure 3.6: XRD instrument
The Bruker-AXS D5005 XRD diffractometer is shown (A), with a close-up view of the AM
sample (B, arrow).
was carefully mounted before the temperature-control chamber was placed
on the instrument. The heating ramp rate was 2 - 4°C min-1. The moduli
E´, E´´ and tan δ were plotted with RH to localise the Tg. The temperature
sweep tests were performed at ambient humidity, which was not recorded.
3.3.5 Surface analysis
3.3.5.1 Wide-angle X-ray diffraction
The X-ray patterns of duplicate 0% and 10% v-d AM samples were obtained
using a Bruker-AXS D5005 diffractometer (Siemens, Erlanger, Germany).
AM samples were folded twice into a strip, which was mounted horizontally
on a stainless steel sample holder and secured with tape. The steel holder
was placed in the X-ray diffractometer (figure 3.6). An X-ray beam was
shone from a 2.2 kW sealed copper anode (K-alpha emission wavelength λ
1.5418 Å) at a current of 40 mA and a voltage of 40 kV. The scanning region
of the diffraction angle (θ) ranged from 2˚ to 45˚ with a step size of 0.05˚ and
a time per step of 1.5 secs. The sample rotation speed was 60 rpm. The in-
tensity of the peaks was plotted against the angle of deflection, 2θ. The AM
traces were aligned and normalised to a peak from the sample holder that
was common to all traces. Background emission from the empty steel holder
was then subtracted from the AM traces. The proportion of crystallinity of
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the samples was estimated visually by dividing the area under the peaks
only (crystalline regions) by the area under the entire diffraction pattern
(crystalline plus amorphous regions).
3.3.5.2 Infrared spectroscopy
For ATR-FTIR, a beam of infrared light is passed into a crystal with a tissue
sample apposed to the optically denser crystal surface. The light is reflected,
although a small amount of light also penetrates the sample to a depth of
a few μm. The vibrating molecular bonds within the sample absorb spe-
cific infrared frequencies, attenuating the propagating wave. A mathemati-
cal algorithm (Fourier transform) then converts the attenuated wave into a
spectrum. The sample absorbance can be plotted against the wavelengths
(wavenumbers, measured in cm-1) to give characteristic patterns relating
to specific chemical bond vibrations, such as carboxyl stretching or amide
bending.
Initial ATR-FTIR runs were carried out on 0%, 5% and 10% v-d AM
samples using a Bio-Rad FTS-6000 spectrometer (now made by Digilab)
equipped with a thallium bromoiodide crystal (KRS-5). The penetration
depth of a sample with a refractive index of 1.4 at 1,000 cm-1is 1-2 μm, de-
pending on the angle of incident infrared light. The instrument was cali-
brated by running a background scan with no sample. This was then set as
a baseline for subsequent samples. Εach sample was pressed directly onto
the crystal to maximize optical contact. The incident light was set at an
angle of 45˚. The AM samples were folded in two or three layers in order to
allow the instrument to obtain a reading. Trehalose dihydrate powder was
examined by covering the crystal with powder and pressing it down. The
AM spectra were normalised with respect to the peak absorbance of C O
stretching, a characteristic absorption band which formed a prominent peak
at 1652 cm-1 in v-d AM, but which was negligible in trehalose dihydrate and
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of equal wavenumber across treated and untreated samples. The various
spectral bands were identified from studies on AM by Ma et al. (2010) and
on trehalose by Akao et al. (2001). The spectra were annotated for compari-
son.
ATR-FTIR was then conducted on triplicate 0% and 10% v-d AM sam-
ples on a Bruker TENSOR™ 27 FT-IR spectrometer (Bruker Optik GmbH,
Ettlingen, Germany), which is equipped with a diamond crystal. A back-
ground scan was performed prior to sample testing. The spectra were nor-
malised automatically by OPUS 5.5 spectroscopic software. In contrast to
the previous method, this involved automated vector normalisation of the
entire FTIR spectra. The spectra were not compared quantitatively. The
fingerprint regions of trehalose were examined to identify the polymorphs
present.
3.3.5.3 Mass spectrometry
Samples of 0%, 5% and 10% AMwere prepared and cut in two to assess both
surfaces, designated a and b, separately. Each sample was secured onto a
sample holder for loading into the spectrometer and placed in an airlock
overnight which was pumped down to ultra-high vacuum conditions. The
samples were placed in the main chamber of the mass spectrometer for anal-
ysis. ToF-SIMS analysis of the samples was conducted using a TOF-SIMS
IV time-of-flight secondary ion mass spectrometer (ION-TOF GmbH, Mün-
ster, Germany) using a 25 KeV Bi3+ primary ion source and a single-stage
reflectron analyser. Positive and negative secondary ion ToF-SIMS spectra
were acquired from a mass-to-charge ratio of 0 to 800 m/z over a rastered
area of 100 μm × 100 μm at a resolution of 256 × 256 pixels, while maintain-
ing a primary ion dose less than 1012 ions/cm2 to ensure static conditions.
The data was integrated by the instrumentation software and exported as
for further pre-processing. The area selected was as flat as possible, since
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topographical variation could give rise to small changes in recorded data.
Each sample was analysed in two different areas for both positive and neg-
ative spectra. A pulsed low-energy electron flood gun was used for charge
neutralization for all the samples used in this study. Positive and negative
ion ToF-SIMS spectra were calibrated prior to further analysis.
3.3.5.4 Data analysis4
The ToF-SIMS data were initially analysed using SurfaceLab 6 (ION-TOF
GmbH) software. The peak intensities were corrected by the software to
account for differences in dead time, which arises from the detection of only
one secondary ion count per primary ion pulse, regardless of the number of
secondary ions arriving at the detector at any time interval. A data set was
designed as a spreadsheet matrix, consisting of 12 column for each of both
sides of three duplicate v-d AM preparations (0%, 5% and 10%) and n rows
for each spectral peak. The corrected peak intensities for each secondary
ion were normalised to the total intensity produced by each sample. This
corrected for the differences in total secondary ion yield between spectra
that can result from instrumental drift. The data was mean-centred by
subtracting the mean intensity in each column from the samples, generating
a new data set with the data mean at the origin.
The ToF-SIMS data sets were then analysed by PCA using PLS_Toolbox
(version 5.2, eigenvector Research, Manson, WA) for MATLAB (Mathsworks,
Inc., Natick, MA). For PCA, each peak intensity value in a mass spectrum
is considered as a unique variable in a multidimensional coordinate sys-
tem. Each sample produces a mass spectrumwith different intensity values,
recorded as a data set. The data set is used to generate a covariance matrix
that measures the extent to which the data points vary from the mean with
respect to each other. Thus, the maximal variation across the various spec-
4Performed with the kind help of Dr David Scurr.
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tra can be captured and plotted on a new axis, known as a principal com-
ponent (PC). Each PC is ranked so that the axis that captures the largest
fraction of the variation is denoted PC1. PC2, which must be uncorrelated
to PC1, captures the next largest variation, and so on for the remaining
PCs. The dimensionality of each new axis in the multidimensional space is
termed eigenvector. Each eigenvector is associated with a numerical value
that represents the amount of variance it contains, termed an eigenvalue
(PC1 has the largest eigenvalue). The individual numbers in an eigenvec-
tor are called ‘loadings’. Linear combinations of the original variables and
their loadings generate new data values called ‘scores’ for each sample on
each PC, producing a scores matrix (T). The correlation between the original
variables and the PC axes is calculated as a loadings matrix (P). The scores
enable discrimination between the samples, whereas loadings plots identify
the positive and negative peaks exhibiting most variation. An analytical
model is used to reduce the data matrix X to the sum of a cross-product of a
transposed loadings matrix (P´ ) and the scores matrix T , with a residual
matrix, E, representing ‘noise’:
X = TP ´ + E
TP´ is a reproduced data matrix, representing the bulk of the original vari-
ance in X. Thus, PCs are linear, uncorrelated combinations of the original
data sets. Transformation of data into uncorrelated eigenvalues and eigen-
vectors is a straightforward procedure with appropriate software. A small
number of PCs is required to capture the salient information in a partic-
ular data set, making the detection of patterns in the differences between
samples relatively straightforward.
PCA was performed by software algorithm to determine the eigenval-
ues and eigenvectors of the covariance matrix of the data set. Hotelling’s
T2 statistic, a multivariate generalisation of the student’s t distribution,
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was used to detect outliers. The scores of respective PCs (e.g., PC1 and
PC2) were plotted against each other to identify variations between sam-
ples. Loadings plots were used to identify the individual chemical species
exhibiting the most variance by their mass-to-charge (m/z) ratio. The m/z
ratios were matched to their chemical species. The average normalised cor-
rected peak intensities of the chemical species identified were then plotted
against the different v-d AM preparations.
3.4 Results
3.4.1 Moisture analysis
Moisture analysis was performed on a total of six v-d AM samples. Two
pairs of samples (A and B) were prepared by drying for a 2 hr main phase
and a 1 hr final phase. One pair of samples (C) had a main drying phase of
1 hr and a final drying phase of 30 mins. 10% v-d AM sample C was given a
final wash in PBS before vacuum drying. 0% sample C was left exposed to
the atmosphere for 7 days prior to DVS.
3.4.1.1 Drying curves
The drying curves are recorded as mass versus time plots and normalised
by expressing the sample mass as a percentage (figure 3.7). The results
are shown in table 3.1. The mean percentage loss in mass of 10% v-d AM
samples A and B is 6.84% (SD 1.67%), whereas 0% v-d samples A and B,
it is 9.95% (SD 1.03%) (p = .157). The means of the slopes of the final 10%
of the drying curves, in % mass per minute, are significantly steeper for
10% v-d AM samples A and B (-2.33E-03, SD 9.69E-05) than for 0% v-d AM
samples A and B (-4.67E-04, SD 6.12E-05) (p = .002). Subsequent statistical
analyses concern samples A and B.
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Figure 3.7: Drying curves of 0% and 10% v-d AM
Drying curves of three pairs of 0% and 10% v-d AM samples are shown. Samples A and B
were prepared by drying for 2h (main phase) and 1 h (final phase). Samples C were prepared
by drying for 1h and 30 mins. The 10 % C sample was washed in PBS prior to drying. The
0% C sample was left exposed to air for 7 days prior to DVS. DVS, dynamic vapour sorption.
Table 3.1: Drying curve parameters
V-d AM % mass loss Final 10% slope
0% A 10.68 -5.09E-04
0% B 9.22 -4.23E-04
0% C 16.72 -7.01E-04
10% A 5.58 -2.26E-03
10% B 8.02 -2.40E-03
10% C 13.76 -2.51E-04
The means of the slopes of the final 10% of the drying curves were measured in % mass per
minute.
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Table 3.2: Water vapour sorption of v-d AM
Target RH
AM Data (SD) 10% 60% 70% 80% 95%
0% v-d AM
% dry mass 104.43 116.88 126.29 169.58 243.48
SD 0.35 0.11 1.45 2.39 3.12
Sample RH 12.7 60.8 70.1 78.7 92.7
SD 0 0 0.35 0.14 0.35
10% v-d AM
% dry mass 101.69 111.08 116.93 126.36 161.29
SD 0.76 1.38 1.69 1.14 1.23
Sample RH 12.5 60.1 69.3 78.3 92.1
SD 0.07 0 0.42 0.57 0.49
Values shown were recorded at the ends of the 10%, 60%, 70%, 80% and 95% RH stages.
RH, relative humidity.
3.4.1.2 Water vapour sorption
Following drying, the samples were equilibrated in steps of increasing tar-
get RH for 500 mins each, followed by decreasing steps of equal duration.
The target RH was plotted alongside sample RH (Aw) against time. To il-
lustrate this relationship, one example (sample A, 0% and 10% v-d AM) is
shown in figure 3.8 A. Data shown are means for samples A and B. In 10%
v-d AM, equilibrium between target RH and sample RH occurs during the
60% RH stage, whereas in 0% v-d AM, it occurs at the 70% RH stage (table
3.2). Water vapour sorption kinetic plots were used to assess the changes
in moisture content (% mass; serrated curves) with step changes in sample
RH (figure 3.8 B). The end of the 60% RH stage is indicated with a black ar-
row for orientation. The mean corresponding changes in mass at the ends of
five stages of RH (10%, 60%, 70%, 80% and 95%) are shown with the mean
sample RH in table 3.2 for 0% and 10% v-d AM. By the end of the 80% RH
stage, the percentage change in mass is significantly higher for 0% v-d AM
(169.6%) than for 10% v-d AM (126.4%) (p = .013).
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Figure 3.8: Water vapour sorption
From the DVS data, target RH and sample RH were plotted against time (A). This plot
represents one pair of 0% and 10% v-d AM samples (A). The 10% v-d AM equilibrated at
60% RH, whereas the 0% v-d AM equilibrated at 70% RH. A water vapour sorption plot
demonstrates changes in the % mass of the v-d AM samples (moisture content) with step
changes in sample RH (Aw) (B). A black arrow indicates the end of the 60% RH stage. RH,
relative humidity.
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Table 3.3: Young and Nelson parameters, v-d AM
Sample A parameter B parameter R2
0% 0.24 (SD 0.02) -0.50 (SD 0.11) 92.0%
10% 0.11 (SD 0.01) -0.22 (SD 0.04) 94.6%
p value .013 .075
3.4.1.3 Isotherm plots
Plots of dry basis moisture content versusAw (isothermal sorption-desorption
plots) are shown for 0% and 10% v-d AM (sample A) in figure 3.9. From the
desorption curves, at a dry basis moisture content of 10%, the mean Aw of
0% v-d AM is 0.35 (SD 0), and that of 10% v-d AM is 0.54 (SD 0.01) (p =
0.003) (black arrows). At a dry basis moisture content of 20%, the mean Aw
of 0% v-d AM is 0.61 (SD 0), and that of 10% v-d AM is 0.70 (SD 0.01) (p
= .014) (gray arrows). The mean hysteresis for 0% v-d AM was 22.8% (SD
3.3), whereas for 10% v-d AM it was 2.8% (SD 2.0) (p = .018). At a target
RH of 70%, 10% v-d AM has a moisture content of 19.33% (SD 0.80) on the
desorption curve, whereas 0% v-d AM has a moisture content of 49.01% (SD
1.88) (p = .002).
3.4.1.4 Young and Nelson plots
Young and Nelson plots were generated automatically from the DVS data
for 0% and 10% v-d AM samples, of which one (sample A) is shown below
(figure 3.10). The A and B parameters respectively indicate the magnitude
of combined (monolayer and multilayer) adsorption and absorption. These
parameters are larger for 0% than 10% v-d AM (table 3.3). The R-squared
values of the plots indicate a good fit to the model.
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Figure 3.9: Sorption-desorption isotherms
Sorption-desorption plots of moisture content versus Aw for representative 0% and 10% v-d
AM samples are shown (of two). At a moisture content of 10%, the Aw of 0% v-d AM is 0.35
and the Aw of 10% v-d AM is 0.53 (black arrows), while at a moisture content of 20%, the
Aw of 0% v-d AM is 0.61 and the Aw of 10% v-d AM is 0.71 (gray arrows). There is increased
increased hysteresis in the 0% v-d AM sample. Aw, water activity.
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Figure 3.10: Young and Nelson plots of 0% and 10% v-d AM
Young and Nelson plots were generated for the 0% and 10% v-d AM samples from the DVS
data (one of two shown). There is increased adsorbtion (in both monolayer and multi-layer
systems) and absorption in 0% v-d AM compared to 10% v-d AM.
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Table 3.4: TGA events at 10°C min-1
Trehalose Evaporation Decomposition Gradient Moisture
0% 138.5°C (0.1) 311.7°C (2.1) -0.45%/°C (0.03) 6.9% (0.1)
5% 165.0°C (5.1) 296.1°C (1.9) -0.79%/°C (0.17) 8.2% (1.8)
10% 175.6°C (0.3) 295.1°C (0.7) -1.06%/°C (0.04) 8.9% (1.5)
Each value represents the mean of two measurements (SD).
3.4.2 Thermal analysis
3.4.2.1 Open pan
The baseline correction determined for a representative sample of v-d AM
affected the results negligibly and was therefore omitted from further anal-
yses. The TGA curves of a representative group of three samples (0%, 5%
and 10% v-d AM) are shown in figure 3.11 A. The analysis cut-off was set at
25.2°C to capture the starting temperature of all the curves. The initial loss
in mass, caused by evaporation of water, appears as a linear slope (black
arrow). The rate of decomposition increases at temperatures above ~250°C.
A TGA curve of pure trehalose dihydrate powder demonstrates initial wa-
ter loss upon heating and a steep decomposition curve beginning at ~250°C
(figure 3.11 B).
First derivative curves First derivative curves were plotted from the
TGA curves for duplicate 0%, 5% and 10% v-d AM samples. These are shown
for a representative v-d AM sample in figure 3.12 A. From the derivatives,
the maximal points of flux of these were identified at 138°C (black arrow)
and 313°C (gray arrow) respectively. The derivative curves of 0% and 10%
v-d AM samples are shown in figure 3.12 B. The maximal evaporation and
decomposition points, decomposition gradients and moisture contents were
measured for 0%, 5% and 10% v-d AM samples. Mean results for the two
sets of AM samples are shown in table 3.4. The analysis was performed on
two further sets of AM samples with a cut-off start temperature of 19.5°C
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Figure 3.11: TGA plots of v-d AM and trehalose
TGA curves were obtained for 0%, 5% and 10% v-d AM. A representative set of traces is
shown above (A). There is an initial linear slope (black arrow). Above ~250°C, the curve
shows a steep decline, with different gradients for treated and untreated samples. A TGA
trace of a sample of pure trehalose dihydrate powder (B) is shown for comparison.
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Figure 3.12: First derivatives
The first derivative of the TGA plot for a representative a v-d AM sample is shown (A). It
enables identification of points of maximal flux (black arrow and gray arrow) . TGA was
performed on 0%, 5% and 10% v-d AM samples from two donors. Derivative curves for
a representative set of samples are shown (B), indicating marked differences in the TGA
profiles of treated and untreated AM preparations.
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Table 3.5: TGA events at 5°C min-1
Trehalose Evaporation Decomposition Gradient Moisture
0% 128.4°C (2.1) 301.0°C (0.1) -0.49%/°C (0.1) 10.0% (0.4)
5% 144.6°C (0.6) 289.9°C (1.1) -0.74%/°C (0.2) 10.2% (1.5)
10% 167.8°C (0.3) 288.0°C (0.1) -0.98%/°C (0.2) 10.8% (1.1)
Each value represents the mean of two measurements (SD).
Figure 3.13: Comparison of drying methods
Four different methods were used to dry AM samples, including vacuum-drying, heat-drying
for 24 and 28 hrs and heat-drying with vacuum (Vacutherm) for 48 hrs. TGA curves were
obtained using the open pan method, and moisture content was calculated as the difference
between the mass at the cut-off and the point of maximal moisture loss.
and a slower heating rate of 5°C min-1(table 3.5).
Alternative drying methods TGA curves for four samples dried by dif-
ferent techniques, including Vacutherm® oven, vacuum-drying and heat-
drying for 24 and 48 hrs are shown in figure 3.13. The AMmoisture contents
were as follows: Vacutherm® oven, 4.9%, drying cupboard 48 hrs, 5.2%,
vacuum-dried, 6.8%, drying cupboard 24 hrs, 9.8%.
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Figure 3.14: Closed pan TGA
The TGA curve of a representative v-d AM sample is shown with a baseline-corrected curve.
The baseline correction changes the moisture content from 12.3% to 13.2% in this example,
and was applied to all subsequent analyses. The cut-off temperature was 25.0°C. The ini-
tial slope is sigmoidal (small black arrow). The smoothed first derivative shows an initial
negative peak at 81.6°C (large black arrow), a positive peak at 159.2°C (gray arrow), and a
second negative peak at 310.0°C (white arrowhead).
3.4.2.2 Closed pan
Since the initial sample mass was found to be highly sensitive to tempera-
ture change using the open pan method of TGA, hermetically sealed pans
were used next. TGA was performed on quadruplicate 0%, 5% and 10%
v-d AM samples. Moisture content calculations were found to be signifi-
cantly different when the baseline adjustment for an empty pan was ap-
plied, as shown for a representative v-d AM sample (figure 3.14). Therefore,
a weighted baseline correction was applied to subsequent analyses. The
initial curve is sigmoidal (small black arrow). The first derivative curves
have an initial negative peak at the point of maximal moisture loss (black
arrow). The points of maximal rate of water loss, completion of evaporation
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Table 3.6: Thermal reversal temperatures by closed pan TGA
Trehalose Peak loss Evaporation Decomposition Moisture
0% 80.5°C (0.4) 161.1°C (1.3) 309.4°C (3.4) 12.8% (2.2)
5% 95.5°C (1.1) 166.6°C (0.4) 285.6°C (1.4) 13.2% (3.9)
10% 100.4°C (9.9) 183.4°C (22.1) 279.0°C (3.9) 12.7% (2.3)
Each value represents the mean of four measurements (SD).
and maximal decomposition are shown in table 3.6. A cut-off temperature
of 25.0°C was applied to the curves.
3.4.2.3 Differential scanning calorimetry
Ramp mode DSC was performed in closed pans in on three 0% v-d AM
samples at temperatures between -50°C and 300°C. The curves are shown
in figure 3.15 (top). These show a small step with a midpoint at 5°C (gray
arrow), an endotherm with a peak at 73 - 79°C (black arrow) and a second
peak at 219°C. Ramp mode DSC runs were conducted on two 10% v-d AM
samples. Two DSC runs are shown in figure 3.15 (bottom). The principal
endotherm peaks occur at between 84 and 88°C and at 171°C.
Cyclic DSC Cyclic DSC was performed on 20.4 g of a 10:1 vacuum-dried
trehalose:PBS mixture. The DSC curves for the trehalose-PBS mixture are
shown in figure 3.16. During the initial run, an endotherm occurs between
39°C and 93°C (arrowheads). This does not reappear during the reheat.
Both the initial run and the reheat are characterised by a sigmoidal step in
heat flow. On the reheat curve, the Tg onset occurs at 6.8°C, the inflection
point at 14.9°C and the endpoint at 21.3°C. Cyclic DSC runs were performed
in duplicate on samples of 0%, 5% and 10% v-d AM at temperatures from
-50°C to 180°C. These showed two principal endotherms (figure 3.17). In
10% v-d AM, the two endotherms merge. Values for the onset, peak and
end point (in °C) and normalised enthalpy (in Jg−1) were obtained for both
peaks from automated software. The mean values for each pair of samples
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Figure 3.15: Ramp mode DSC
DSC was performed on triplicate samples of 0% v-d AM (top) and duplicate samples of 10%
v-d AM (bottom). Two main endotherms are seen, the first peaking at 73 - 79°C (black arrow)
and the second peaking at 219°C in 0% v-d AM. A small step was seen at 5°C (gray arrow).
The two endotherms peak at 84 - 88°C (black arrow) and at 171°C in 10% v-d AM.
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Figure 3.16: Cyclic DSC of trehalose:PBS
A DSC run was conducted on a vacuum-dried mixture of trehalose dihydrate and PBS in
a 10:1 ratio (top). The trace shows an endotherm on the initial run (arrowheads). The
sigmoidal curve on both the initial run and the reheat curve indicates a Tg. From the
magnified curve (below), the Tg has an onset at 6.8°C, an inflection point at 14.9°C and
an endpoint at 21.3°C.
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Figure 3.17: Cyclic DSC of 0%, 5% and 10% v-d AM
Cyclic DSC runs were performed on duplicate 0%, 5% and 10% v-d AM samples (left). The
curves show two endotherms, one occurring between 50°C and 80°C (black arrows) and a
second at ~100°C. Reheat curves are shown on the right. Small sigmoidal steps are visible
(white arrows).
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Table 3.7: Enthalpy values of DSC endotherms
V-d AM
Peak Measurement
points
0% 5% 10%
1
Onset (°C) 42.9 48.8 52.5
Peak (°C) 51.6 65.3 75.7
End point (°C) 58.9 74.6 90.7
Integral (Jg−1) 1.9 11.3 ~40.0
2
Onset (°C) 95.2 86.7 -
Peak (°C) 102.3 97.4 -
End point (°C) 112.0 128.9 -
Integral (Jg−1) 13.6 9.2 7.6
were calculated (table 3.7). The normalised enthalpy for the first isotherm
10% v-d AM was estimated from the total value of the two endotherms (47.6
Jg−1). The reheat curves of the DSC runs are shown separately in figure
3.17. The traces show small sigmoidal steps (white arrows). The mean
inflection points for these transitions was calculated as 26.6°C for 0% v-d
AM (SD 0.9), -4.6°C for 5% v-d AM (SD 0.1) and 3.8°C for 10% v-d AM (SD
8.8) (white arrows).
3.4.3 Dynamic mechanical analysis
3.4.3.1 Frequency sweep
Frequency sweep DMA was conducted on single ply v-d AM strips with a
free length of 10 mm and a width of 10 mm. Multiple samples were lost due
to breakage. Measurements were performed in triplicate on 12 different
strips of 0% v-d AM and six strips of 10% v-d AM at room temperature
(24.0 - 24.4°C). The average thicknesses of the 0% v-d AM and 10% v-d AM
samples were 18.67 μm (SD 4.42) and 25.50 μm (SD 7.99) respectively. The
DMA trace for a representative sample of v-d AM is shown in figure 3.18.
At frequencies between 0.1 and 10 Hz, E´, E´´ and tan δ measurements are
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Figure 3.18: Frequency sweep DMA
This DMA plot is from a representative 0% v-d AM strip. It was performed at room tem-
perature on a 10 mm × 10 mm sample, at oscillatory frequencies between 0.1 and 100 Hz.
Triplicate measurements were obtained. The trace shows a modulus E´ value of ~107, E´´ of
~106 and a tan δ of ~0.1 at frequencies between 0.1 and 10 Hz.
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Table 3.8: Moduli of v-d AM
0% v-d AM 10% v-d AM p value
E´ (SD) 1.95 × 107Pa (1.34 × 107) 1.40 × 107Pa (8.37 × 106) .30
E´´ (SD) 1.95 × 106Pa (1.84 × 106) 2.61 × 106Pa (2.40 × 106) .57
Tan δ (SD) 0.12 (0.07) 0.20 (0.07) .06
relatively constant. The average values of E´, E´´ and tan δ measured were
calculated over this frequency range, and are shown in table 3.8. There
was no significant difference between the two preparations.
3.4.3.2 Humidity sweep
Multifrequency humidity sweep DMA runs were performed on triplicate
samples of 0%, 5% and 10% v-d AM. It was not possible to obtain results for
5% and 10% v-d AM because of early rupture of the samples. Five successful
DMA runs were obtained from 0% v-d AM samples of different dimensions
(free lengths of 1 mm and 10 mm), for which two representative traces are
shown below. DMA runs are presented individually to illustrate the salient
points from the experiment.
A humidity sweep trace is shown in figure 3.19 (top). It was performed
on a single strip of 0% v-d AM (1.1 mm × 5.2 mm × 7 μm) at a constant
temperature of 30°C. The RH was ramped up from 20% to 60% over a period
of ~ 45 mins, maintained at 60% for 60 mins and then reduced to 20%.
The modulus E´ is seen to follow an inverse pattern to RH. As RH rises,
E´ falls from 9.4 × 108 to 3.2 × 108 Pa. E´ then rises to 1.0 × 109 Pa as
RH falls below 20%. Simultaneous measurements of static and dynamic
force and static displacement are shown in figure 3.19 (bottom). Automatic
adjustments are made in the static displacement to retrieve the tension on
the sample. Eventually, the loss in static force cannot be fully compensated
by the displacement.
A second humidity trace obtained from a 3-ply strip of 0% v-d AM (9.9
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Figure 3.19: Humidity-sweep DMA
DMAwas carried out on a 1 mm strip of 0% v-d AM at constant temperature (30°C) (1 trace).
Increasing the RH reduced E´ in a reversible way. A trace of static and dynamic force and
static displacement for this sample is shown below.
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Figure 3.20: Humidity sweep DMA (2)
A humidity sweep DMA was performed at room temperature on 0% v-d AM, demonstrating
a Tg at a RH of ~60% (arrow) (A). E´ (at 1 Hz) is plotted against RH between 30 and 80%
(B).
mm × 10.0 mm × 34 μm) is shown in figure 3.20. The ambient tempera-
ture recorded by the instrument was between 26.0 and 28.5°C. The RH was
ramped down from 40% to 30% and then ramped up to 80%. The initial
values of E´ are 4.1 × 108 Pa (1 Hz) and 4.5 × 108 Pa (10 Hz), while those
of E´´ are 4.6 × 107 Pa (1 Hz) and 4.4 × 107 Pa (10 Hz), making tan δ ~0.1.
As RH rises to ~60% (arrow), a Tg begins to occur, evidenced by a drop in
E´ and peaks in the traces of E´´ and tan δ (10 Hz). There is a separation
of the E´´ and tan δ values by frequency, indicating strain-rate dependence.
E´ (1 Hz) has been plotted against RH (figure 3.20 B). These findings are
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representative of the three remaining humidity sweep traces.
3.4.3.3 Temperature sweep
Multifrequency temperature sweep DMA was performed on triplicate sam-
ples of 0%, 5% and 10% v-d AM samples. The samples had varying geome-
tries, with free lengths of 5 mm and 10 mm. Successful traces were obtained
for 6 samples of 0% v-d AM (4 shown), three samples of 5% and one sample
of 10% v-d AM (all shown). In all cases, RH was not controlled.
Untreated v-d AM Two representative temperature sweep DMA traces
of 10 mm strips of 0% v-d AM are shown in figure 3.21. They were each
performed on performed on 3-ply strips of 0% v-d AM. Sample A (9.8 mm
× 10.0 mm × 48 μm) underwent DMA over a temperature range of -56°C
to 80°C. Initial values of E´ and E´´ were 3.5 × 108 Pa and 4.0 × 107 Pa
respectively. The E´ starts to decrease at -17.5°C, followed by a tan δ peak
at -11.5°C, indicating a Tg. The moduli continue to decrease until 18.9°C.
The sample stiffness then increases again between 20°C and 50°C. The tan
δ reaches a second peak at 19.8°C. The tan δ traces are noisy at low stiffness.
The moduli regain a plateau formation at 50°C, with E´ and E´´ values of 1.6
× 108 Pa and 1.8 × 107 Pa respectively. Sample B (9.80 mm × 10.0 mm × 30
μm) underwent DMA between -6.5°C and 120.0°C. The trace demonstrates a
Tg occurring at the start of the run, with a clear reversal occurring between
20°C and 50°C. These traces indicate that the 0% v-d AM samples were in
a rubbery state at room temperature, and they returned to the glassy state
as the temperature climbed.
Three DMA traces were obtained for 5 mm × 5 mm 0% v-d AM strips,
of which two are shown in figure 3.22. Sample A (single ply; 5.0 mm × 4.9
mm × 16 μm) had an initial E´ of 1.6 × 109 Pa, while sample B (single ply;
5.0 mm × 5.1 mm × 18 μm) had an initial E´ of 1.4 × 109 Pa. In contrast
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Figure 3.21: Temperature sweep DMA of 0% v-d AM (1)
Two temperature-sweep DMA traces of three-ply strips of 0% v-d AM are shown. In A, the
temperature is reduced to -50°C and then raised to 80°C while DMA is performed with two
oscillatory frequencies (1 and 10 Hz), In B, the temperature range is between -10°C and
120°C. Both traces indicate a transition from a glassy to a rubbery state, with a reversal
beginning at ~20°C.
122
Figure 3.22: Temperature sweep DMA (2)
Two temperature sweep DMA traces were obtained from single-ply 5 mm × 5 mm 0% v-d AM
strips (A and B). These were both tested between -40 and 110°C. In both traces, the samples
undergo changes in modulus of less than one decade.
123
Figure 3.23: Temperature-sweep DMA of 5% v-d AM
Temperature sweep DMA traces of 5% v-d AM strips are shown. Trace A was obtained from
an 8-ply strip and B was obtained from a single-ply strip. The samples were subjected to
DMA at two oscillatory frequencies (1 and 10 Hz) between -70°C and 50°C (A) and -30°C
and 110°C (B). Non-recoverable slippage occurred in sample A.
to the 10 mm-long samples, these show falls in E´ and E´´ of less than one
decade. In both cases, the tan δ peaks appear to be merged together, and
the tan δ peak in sample B occurs at a higher temperature than previously
seen. These traces indicate that the samples remain glassy, undergoing
attenuated falls in E´ without a complete Tg.
Trehalose-treated v-d AM A successful DMA trace was obtained from
an 8-ply strip of 5% v-d AM (10.0 mm × 10.0 mm × 123 μm) (figure 3.23 A).
The temperature range was between -70°C and 50°C. The initial value of
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Table 3.9: Tg events of 0%, 5% 10% v-d AM
Sample Maximum E´ E´ onset E´
inflection
E´´ peak Tan δ peak
0% v-d AM 8.4 × 108 Pa -8.0°C -2.8°C -5.5°C -1.2°C
5% v-d AM 3.1 × 109Pa -3.9°C 5.0°C -1.7°C 6.7°C
10% v-d AM 4.7 × 109 Pa 7.4°C 17.8°C 10.9°C 14.7°C
E´ was 3.1 × 109Pa. Above temperatures of -25°C, the E´´ and tan δ values
separate by frequency of oscillation, demonstrating strain-rate dependence.
There is likely sample slippage at 21.9°C. A Tg is indicated by an E´ onset at
1 Hz of 0.6°C and a tan δ peak at 23.5°C. A further DMA run was carried out
on a different 5% v-d AM sample (5.0 mm × 5.2 mm × 16 μm) (figure 3.23
B). The initial value of E´ was 2.6 × 109Pa, and a Tg occurs at a temperature
between ~-5°C and 15°C. A further 5% v-d AM trace (5.0 mm × 5.2 mm ×
12 μm) returned an initial E´ of 5.3 × 109 Pa. The temperature range was
between -40°C and 150°C. There was no evidence of a Tg occurring at room
temperature (figure 3.24 A). A successful trace was obtained for a 10% v-d
AM strip (5.0 mm × 5.0 mm × 19 μm) (figure 3.24 B). The initial value of
E´ of 10% v-d AM was 4.7 × 109 Pa, and the Tg temperature occurs between
7.4°C and 14.7°C. Zoomed-in details of representative DMA traces of 0%, 5%
and 10% v-d AM undergoing Tg at room temperature illustrate the effects
of trehalose (figures 3.25 A, B and C). The E´, E´´ and tan δ measurements
of the three samples are compared in table 3.9 showing increased stiffness
and an upward shift in Tg temperature in the three traces.
3.4.4 Surface analysis
3.4.4.1 X-ray diffraction
XRD traces were obtained for duplicate samples of 0% and 10% v-d AM. A
normalised trace of 0% v-d AM is shown in figure 3.26 A, with an empty
holder provided as a background comparison. In figure 3.26 B, representa-
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Figure 3.24: Temperature sweep DMA of 5% and 10% v-d AM
A A temperature sweep test was performed in a 5mm strip of 5% v-d AM at two oscillatory
frequencies (1 and 10 Hz) between -40°C and 150°C . The trace shows no evidence of a
Tg occurring at room temperature. B This DMA trace was obtained for a single-ply strip
of 10% v-d AM at two oscillatory frequencies (1 and 10 Hz) between -30°C and 110°C. It
demonstrates a transition of less than one decade occurring between 7.4°C and 14.7°C.
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Figure 3.25: Moduli and tan δ of 0%, 5% and 10% v-d AM
Details of representative DMA traces of E´ (A) and E´´ (B) and tan δ (C) of 0%, 5% and
10% v-d AM samples show an upwards temperature shift in Tg temperature with increased
trehalose loading.
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Figure 3.26: XRD of v-d AM
A normalised XRD trace of 0% v-d AM is shown with a background trace of the empty stain-
less steel holder (A) The background diffraction from two representative traces of 0% and
10% v-d AM has been subtracted in B. Three prominent peaks present in v-d AM represent
NaCl (arrows).
128
tive XRD traces of 0% and 10% v-d AM are shown with background diffrac-
tion from the sample holder removed and a sampling proportion of 0.5. The
plot represents the sum of amorphous and crystalline elements within the
sample, and demonstrates three prominent peaks, at diffraction angles 31-
32, 45-46 and 56 representing NaCl (black arrows). The proportion of crys-
tallinity in the v-d AM samples is estimated to be <10%. This suggests that
the AM is principally amorphous, with the crystalline peaks being related
to salt. No additional peaks were detected in the 10% v-d AM samples.
3.4.4.2 Infrared spectroscopy
Normalised IR absorbance spectra are shown for 0%, 5% and 10% v-d AM
(figure 3.27, above). They were obtained using a Bio-Rad spectrometer
equipped with a thallium bromo-iodide crystal. The spectrum for trehalose
dihydrate powder is shown for reference. Characteristic peaks for AM and
for trehalose dihydrate are labelled for reference (arrows). The trehalose-
treated samples show a broad and intense band between 3000 and 3600
cm-1, labelled O H stretching. A detail of the spectra of 10% v-d AM and
trehalose dihydrate powder is shown in figure 3.27 (below). The trehalose
dihydrate spectrum contains peaks at 994 and 954 cm-1. These are shifted
downwards to 986 and 943 cm-1in the 10% v-d AM sample. ATR-FTIR
was performed on six 10% v-d AM samples and untreated controls using a
Bruker spectrometer with a diamond crystal probe. A representative sam-
ple is shown in figure 3.28 A. Four of the samples had trehalose fingerprint
peaks at 994 and 956 cm-1, whereas two had peaks at 991 and 941 cm-1
(figure 3.28 B).
3.4.4.3 Mass spectrometry
Tof-SIMS was performed with PCA to identify major chemical differences
between duplicate samples of 0%, 5% and 10% v-d AM (both sides). Ex-
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Figure 3.27: FTIR absorbance spectra
Normalised ATR-FTIR spectra are obtained for trehalose dihydrate and 0%, 5% and 10%
v-d AM samples. There is a broad band of O H stretching between 3000 and 3600 cm-1in
the 5% and 10% traces. In the fingerprint region of trehalose (detail below), a wavenumber
shift is shown, from 994 and 954 cm−1 in trehalose dihydrate powder to 986 and 943 cm−1
in 10% v-d AM.
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Figure 3.28: FTIR of v-d AM
ATR-FTIR was conducted on six paired samples of 0% and 10% v-d AM using the Bruker
spectrometer. The traces were normalised by an automated non-quantitative vector method.
Representative traces of the spectra for one pair are shown in A. Traces representing the six
10% v-d AM samples are shown in B. Peaks appear at 991 and 941 cm−1 in two samples
and at 994 and 956 cm−1 in four samples.
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Table 3.10: Chemical species identified by PCA
Loading (+ve) m/z Species Loading (-ve) m/z Species
6.35E-01 80.9519 Na2Cl+ -2.79E-01 34.9702 Cl-
3.49E-01 22.9913 Na+ -2.08E-01 92.9286 NaCl2-
2.45E-01 82.949 Na237Cl+ -1.54E-01 86.109 C6H14+
2.37E-01 138.9115 Na3Cl2 + -1.36E-01 94.9256 NaCl37Cl-
2.16E-01 62.9855 PNOH2+ -1.33E-01 36.9669 37Cl-
1.48E-01 140.9097 KNaPO3+ -1.01E-01 58.0696 C3H8N+
1.15E-01 38.9675 K+ -8.27E-02 150.8841 Na2Cl3-
8.58E-02 96.9271 Ca2OH+ -7.89E-02 152.8813 Ca3O2H-
7.85E-02 96.97 PH2O4- -5.45E-02 184.1101 C14H16+
5.23E-02 62.964 PO2- -5.25E-02 43.0574 C3H 7+
cluding positive and negative hydrogen species, there were in total 2938
peaks detected by ToF-SIMS. The eigenvalues for PC1 to PC4 accounted for
98.17% of total variance captured. These four PCS were used for further
analysis. The Hotelling T2 statistic for the scores was 10.08 for each AM
preparation, suggesting equal variance. Scores on PC1 are plotted against
scores on PC2 (figure 3.29 A), highlighting two samples showing maximal
variation in comparison to the remaining samples. These are the b side of
0% v-d AM and the a side of 10% v-d AM. A plot comparing PC3 to PC4
showed less marked variation between the samples, and is not shown. A
loadings plot is shown for PC1 (figure 3.29 B), which accounts for 62.82%
of the variance. The individual species farthest away from the means clus-
ter were identified by their m/z ratio. The 10 most variable positive and 10
most negative loadings are listed in table 3.10. The main differences include
combinations of ionic salt species, such as Na+ and Cl-, but also aliphatic im-
monium ions (e.g. C3H8N+, m/z 58), carbenium ions (e.g. C3H7+, m/z 43) and
saturated hydrocarbon chains (e.g. C6H12+). Many of these species are also
identified as variable by PC2, PC3 and PC4 (not shown). Species not iden-
tified by PC1, but identified by PC2, PC3 or PC4 include CN- and CNO-,
which are present in all amino acids. There were no identifiable amino acid
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Figure 3.29: Scores and loadings plots
ToF-SIMS/PCA was performed in duplicate on both sides of 0%, 5% and 10% v-d AM. The
PC1 and PC2 scores are plotted for the 12 v-d AM samples (A). This indicates that the b
side of 0% v-d AM and the a side of 10% v-d AM can be discriminated from the remaining
samples by both PC1 and PC2. A loadings plot is shown highlighting the fragment ions
with the largest variation across AM samples (B). A small number of ions were identified by
the m/z ratio as positive or negative loadings.
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fragments ions in any of the PCs. A plot showing the spectral peak densities
by AM preparation is shown in figure 3.30. Most of the variation is found in
a small number of positive species on one side of 10% v-d AM, and in a small
number of negative species on one side of 0% v-d AM. This indicates that the
variation found is not a consequence of the trehalose treatment, but is more
likely to reflect the normal range of minor variation between samples.
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Figure 3.30: Chemical species
Chemical species were identified from the positive loadings (A) and negative loadings (B).
The peak densities of the main chemical species identified were elevated on one side of 10%
v-d AM. The main chemical species identified as variable negative loadings register high
peak densities on one side of 0% v-d AM. No amino acids are identifiable.
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Table 3.11: Summary of findings
Investigation Main finding
DVS Provides correlation between Aw and moisture content
TGA End moisture of v-d AM between 10 and 18% (closed pan)
DSC Enthalpy of sorption/desorption increased by trehalose
DMA V-d AM in glassy phase at room temperature at RH < 60%
XRD Amorphous traces shown of 0% and 10% v-d AM samples
FTIR Three trehalose polymorphs identified
Tof-SIMS No amino acids identified
3.5 Discussion
The relationships between AM, trehalose, temperature and moisture were
investigated by moisture sorption, thermal, dynamic mechanical and sur-
face analytical techniques. This work constitutes a framework for optimis-
ing v-d AM and for quality assurance by linking end moisture content (ob-
tained by TGA) to Aw (DVS) and to Tg (DMA, DSC) of the product. In addi-
tion, it provides a platform for investigating the excipient phase (XRD, ATR-
FTIR). While Tof-SIMS/PCA failed to yield meaningful data, the technique
may be optimised for future work. These are essential lines of investigation
in optimising the production, storage and clinical use of v-d AM, since if the
material is stored above the Tg temperature, or its Aw is too high, its shelf
life will be shortened and its quality compromised, whereas if the material
is too rigid, it may crumble. A summary of findings table is provided (table
3.11).
3.5.1 Moisture sorption analysis
Moisture content is of critical importance because of its correlation with
Aw. The DVS drying curves (figure 3.7) indicated that vacuum-drying the
samples for a total of 3 hrs (A and B) produced lower equilibrium moisture
contents than drying the samples for half that time (C). Samples A and B
were analysed together. The A and B curves demonstrate that the moisture
sorption characteristics of v-d AM are altered by the addition of trehalose.
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At the end of drying, the percentage loss in mass in the 0% v-d AM samples
(9.95%) was higher than that of 10% v-d AM samples (6.84%). However, the
10% v-d AM final drying slopes were significantly steeper, indicating that
the 10% v-d AM samples was not fully equilibrated by the end of 500 mins.
This suggests that moisture is retained by the trehalose-treated samples.
Samples C were less dry, suggesting either insufficient drying times or
excessive exposure to ambient air. As seen in the water vapour sorption ki-
netic plots, AM is highly hygroscopic (figure 3.8). Therefore, once dried, it
may rapidly equilibrate with the atmosphere, either gaining or losing mois-
ture. In addition, the effects of trehalose in the 10% v-d AM C sample, which
had a final wash before vacuum-drying, were partially lost, as evidenced by
the flatter drying curve.
The remaining discussion concerns samples A and B. The water vapour
sorption kinetic plots (figure 3.8), demonstrated a significantly lower change
in per cent dry mass in the trehalose-treated samples, suggesting that more
energy is needed to sorb and to desorb moisture. In the untreated v-d AM,
there was a steep rise in the change in mass at ~70% RH. This change
occurred at around 80% RH in the trehalose-treated samples, and was less
marked. Thus, treatment of v-d AM with trehalose appears to make it less
hygroscopic than its untreated counterpart. One explanation for this could
be that the trehalose is in a non-protective crystalline phase, since this does
not retain sorbed water (Surana et al., 2004b). An alternative explanation
is that the trehalose is in the dihydrate crystal form and is saturated with
water. At temperatures below 70°C, water is bound to trehalose dihydrate
in an ice-like crystalline state (Akao et al., 1998). Above this temperature,
the bound water undergoes a thermal transition to a liquid-like state and
can evaporate. In contrast, water is not as strongly bound to anhydrous,
amorphous and glassy trehalose, which can easily sorb and desorb water
(Surana et al., 2004a; Hunter et al., 2010).
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The question of Aw, and therefore end moisture content, of v-d AM has
not been addressed in the literature. Although fungal growth is possible at
and below a Aw of 0.65, depending on environmental factors, this level of
Aw is safe for many foodstuffs (Abdullah et al., 2000), and may be a suit-
able upper limit for the Aw of v-d AM. The sorption-desorption plots (figure
3.9) can be used to determine the upper safety limit of equilibrium moisture
content, depending on the desired stringency level. With an equilibrium
moisture content of 20%, the Aw of the 10% v-d samples was 0.70, whereas
that of the 0% samples was 0.61. Applying a safety limit of Aw of 0.65 would
therefore eliminate the treated samples. The drying curves returned end
moisture contents of 9.95% for 0% v-d AM and 6.84 for 10% v-d AM, equiv-
alent to Aw values of ~0.35. However, the slopes of the drying curves were
significantly steeper in the trehalose-treated samples. This indicates that
they were not at equilibrium as a result of bound water. Therefore, the true
Aw value of 10% v-d AM may be even higher than 0.35.
According to Sitaula and Bhowmick (2006), the Awof a trehalose:PBS
mixture should be less than 0.23 to remain in the glassy phase. From the
sorption-desorption plots, for 10% v-d AM, this would require a moisture
content of below 5%. This may be difficult to achieve, and may even cause
brittleness, which is a feature of amorphous glasses that may become more
evident with ageing of the product (Surana et al., 2004a). A level of Aw of
0.5, as proposed by Costantino et al. (1998b), can be achieved in 10% v-d
AM with a moisture content of ~10%, and may therefore be a more real-
istic compromise. The sorption-desorption isotherms demonstrate that the
0% v-d AM samples have significantly more hysteresis than the 10% sam-
ples, indicating that the 10% v-d AM samples are more stable with respect
to changes in humidity. The effects of this in terms of the quality of the
samples are unclear.
Date from the desorption isotherm can be fit to a two-parameter mathe-
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matical model known as the Brunauer-Emmett-Teller (BET) equation (Zhang
and Zografi, 2000). Sitaula and Bhowmick (2006) quantified the desorption
data of trehalose-PBS mixtures using the BET equation. The model indi-
cated that increasing the concentration of PBS shifted the modelled desorp-
tion curve from sigmoidal to hyperbolic. A sigmoidal isotherm is protective
at low Aw values since, for a given moisture content, Aw is lower than in
a hyperbolic isotherm. The researchers were able to optimise the concen-
tration of PBS according to the curve shape. While the current study data
was not fit to model curves, the actual desorption isotherms of 0% and 10%
v-d AM did not differ substantially in shape, suggesting a modest, if any,
protective influence from the added trehalose. The Young and Nelson pa-
rameters indicated increased multilayer adsorption (caused by water-water
hydrogen bonds) and absorption in the 0% v-d AM compared to 10% v-d AM
(figure 3.10). Trehalose-water hydrogen bonding at the surface monolayer
of treated v-d AM samples may occur in preference to multilayer adsorption
and absorption. This may be analogous to other systems, such as acrylic-
carbohydrate copolymers (Bravo-Osuna et al., 2005), in which the addition
of acrylics to starch derivatives modifies their hygroscopicity and their wa-
ter distribution, protecting them against the effects of plasticisation at high
RH.
3.5.2 Thermal analysis
End moisture content measurements were carried out by TGA. In open pan
TGA, a linear slope at the beginning of heating indicated that the samples
were highly sensitive to temperature variation (figure 3.11). Using the open
method with a cut-off of 19.5°C and a heating rate of 5°C min−1, the mois-
ture content varied between 8.7 and 11.9%, whereas at a heating rate of
10°C min−1 and a cut-off of 25.2°C, the moisture content varied between
6.9 and 10.4%. This suggested that end moisture content was influenced by
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the cut-off temperature. The closed pan method produced sigmoidal slopes
(figure 3.14), making it more robust to minor variations in temperature. As
measured by the closed pan method, the tissue moisture content ranged
from 10.0% to 17.7% of total mass. Faster heating rates can improve the
sensitivity of DSC by making the transition steps larger, which may partly
explain why the results vary across methods. Since room temperature is not
standardised, a representative temperature, e.g., 21°C, would be useful for
moisture content analysis of AM. Other reasons for the variability could in-
clude variations in the preparation protocol, retention of moisture in the AM
folds and water absorption from the atmosphere before packaging or after
opening. The values of end moisture content obtained by TGA are substan-
tially higher than those obtained from the DVS, which does not apply heat.
From the sorption-desorption isotherms it can be seen that even moisture
contents at the high end of this range are associated with an acceptable Aw.
Nonetheless, the protocol for drying AM may need further optimisation to
lower the Aw. Options include modifying the parameters of vacuum-drying
by using higher vacuum and longer drying times. A more costly alternative
may include using temperature-control shelves to lyophilise the samples.
Heating the samples is not considered an option, as it is judged to be harm-
ful to the material. In addition, a comparison of drying methods showed that
vacuum-drying was more effective at removing moisture than heat-drying
for 24 and 48 hrs, and only slightly less effective than drying in a vacutherm
oven for 48 hrs (figure 3.13).
The increase in energy required for moisture desorption in trehalose-
treated samples, indicated by the DVS, is confirmed by TGA. First deriva-
tives of the closed pan TGA curves allowed identification of the maximal rate
of moisture loss as 80.5°C (0% v-d AM), 95.5°C (5% v-d AM) and 100.4°C
(10% v-d AM). The addition of trehalose increases the enthalpy of mois-
ture loss from AM. The TGA experiments suggested that moisture content
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increases with increasing concentration of trehalose. This again suggests
that the trehalose is in the dihydrate crystal form, bound to water (Akao et
al., 2001). The DVS drying curves are consistent with this, as the trehalose-
treated AM was not in equilibrium by the end of 500 mins, indicating bound
water.
The TGA curves obtained were similar to the those of artificially cross-
linked AM-derived collagen reported by Kumar et al. (2003), who described
water loss as occurring between 60°C and 90°C and decomposition between
270°C and 330°C. AM undergoes changes similar to pure extracted collagen,
suggesting that the collagen profile predominates in thermo-analytical test-
ing. TGA and DSC can be performed simultaneously, enabling endotherms
to be matched to thermogravimetric events conducted under the same con-
ditions. This can give a clearer understanding of the thermal analysis, and
is recommended for further AM work.
In ramp mode DSC (figure 3.15), the temperature of first principal en-
dotherm occurred at ~75°C in 0% v-d AM. There was a second endotherm
at 219°C, representing the melting of collagen (Kumar et al., 2003). In 10%
v-d AM, the moisture loss endotherm occurred at 86°C, whereas a second
endotherm occurred at 171°C. The significance of the variance in the sec-
ond endotherm is unknown, but it could represent an earlier decomposition
event. As the melting temperature of the anhydrate trehalose crystal is
215°C (Akao et al., 2001), this is unlikely to be the cause. Peak decompo-
sition of treated samples was shown by closed pan TGA to occur at ~30°C
lower than untreated samples (from ~279.0°C to 309.4°C). These findings
suggest that the decomposition of AM is accelerated by the addition of tre-
halose.
The cyclic DSC runs showed distinct endotherms for 0% v-d AM peaking
at 51.6°C and 102.3°C (figure 3.17). The first peak occurred at higher tem-
peratures in the 5% v-d AM samples (65.3°C) and the 10% v-d AM samples
141
(75.7°C), again reflecting the water binding effect of trehalose. The mean
enthalpy value of the first endotherm was increased by the addition of tre-
halose from 1.9 Jg−1 in 0%, to 11.3 Jg−1 in 5% and 40.0 Jg−1 in 10% v-d AM,
which confirms the water binding effect of trehalose. The second endotherm
at ~100°C identified in the current study may represent protein denatura-
tion. The cyclic DSC plot of the vacuum-dried trehalose:PBS mixture (3.16)
indicated that the trehalose was not in a glassy state at room tempera-
ture, with an inflection point occurring at 14.9°C. Sitaula and Bhowmick
(2006) found that an increase in the Aw of a trehalose/PBS mixture from
0.02 to 0.11 shifted the Tg downwards by around 50°C to ~40°C, which sug-
gests that that the Aw of trehalose/PBS in the current study is considerably
higher. The isotherms of the 10% v-d AM samples indicate Aw values of
~0.35, which would not produce a glass at room temperature.
3.5.3 Dynamic mechanical analysis
One of the main achievements of using DMA testing was to demonstrate the
transition of v-d AM from a glassy to a rubbery state. The starting modu-
lus values, of the order of 109 Pa, are typical of glassy materials (Patist and
Zoerb, 2005). This has not been shown before in dried AM, and is useful
in interpreting the mechanical behaviour of the material. The frequency
sweep tests did not return modulus values that were suggestive of a glassy
material (~107 Pa), which probably reflects suboptimal test conditions as
a result of failure to apply automatic tension mode. This was applied in
the subsequent tests. The humidity sweep DMA tests demonstrated that
v-d AM could be glassy at room temperature, and that rising levels of RH
could precipitate a Tg (figure 3.20). This is a demonstration of the plasti-
cising effect of moisture on v-d AM: as the Tg temperature is brought to
ambient temperature by the rising RH, a transition occurs. In this regard,
v-d AM is similar to synthetic hydrophilic polymers that sorb water, such
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as polypropylene/ethylene alcohol vinyl (PP/EVOH) (Lasagabaster et al.,
2006), and hydrogels used in the pharmaceutical industry, such as poly-
hydroxy ethyl methacrylate (pHEMA) (Roorda et al., 1988).
Temperature sweep tests demonstrated a variety of outcomes. For some
samples, there was a glassy state at low temperatures and a transition oc-
curring over two decades, starting at temperatures as low as ~-20°C (table
3.21), whereas others showed minimal, or even no relaxation (table 3.22 and
table 3.24 A respectively). The explanation for this discrepancy is likely to
reflect differences in RH. The transition to a rubbery state starting at ~-
20°C in some samples of 0% v-d AM could be a consequence of water ab-
sorption from the thawing of ice on the sample surface. Since RH was un-
controlled, moisture may have condensed on the sample, becoming frozen
during the cooling phase of the experiment. The presence of salts on the
sample surface may have contributed to the ice thawing at temperatures
approaching -21.2°C, the eutectic point of saline water. The fact that this
was not observed consistently may be an indication of different ambient
RH.
The reversibility in the transition is further evidence of the plasticising
effect of water. The reversal from a rubbery to a more rigid state was seen in
conditions of decreasing RH (table 3.19) and increasing temperature, both
cases suggesting an effect of drying. This is consistent with the observation
from open pan TGA traces that v-d AM loses moisture rapidly over small
rises in temperature. Another possibility is that the AM undergoes shrink-
age, although this typically occurs at temperatures of above ~50°C (Ma et
al., 2010).
In addition, the DVS, DSC and TGA findings all point to increased en-
thalpy of water sorption in trehalose-treated v-d AM. Therefore, trehalose
would be expected to mitigate the effects of RH, increasing the Tg temper-
ature by preventing plasticisation. This effect is indeed observed in a com-
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parison of three representative DMA runs of 0%, 5% and 10% v-d AM (table
3.25). In this comparison, the temperature of three thermodynamic events
associated with Tg is raised by ~30°C with increasing concentrations of tre-
halose.
Since the RH in the temperature sweep tests was unknown, further tem-
perature sweep tests at constant RH are required to characterise the prop-
erties of v-d AM in greater detail. In DMA, the v-d AM behaved in a manner
highly reminiscent of an amorphous or semi-crystalline polymer (Duncan,
2008). However, in these, the effects of plasticisation are not usually so
evident. Hence, it is possible to perform DMA on a polymer in ambient hu-
midity and achieve highly consistent results. That this proved difficult in
v-d AM is an index of its exceptional sensitivity to the effects of moisture.
Thus, it was not possible to isolate the relaxation, or Tg , of collagen, ex-
pected at 40°C according to Li (2000), because of the plasticising effects of
water molecules (Ntim et al., 2006). In reality, there is no single Tg tem-
perature for any material. In practice, the viscoelastic behaviour of v-d AM
could be defined over a range of RH values.
DMA proved to be a difficult technique, with a high rate of tissue break-
age. This could be due to many factors, including sample size and trehalose
treatment. The best results were obtained on 5 mm × 5 mm samples with
an additional static force of 0.2 N or higher. The trehalose was felt to cause
more brittleness, leading to increased sample loss from crumbling. This is
evidenced by a failure to obtain humidity DMA traces on treated samples,
and has implications for the quality of the membrane. Despite this, evidence
for a glassy state of trehalose on v-d AM was unclear, with the possibility
remaining that it was amorphous or crystalline.
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3.5.4 Surface analysis
Questions regarding the conformational state of trehalose were addressed
by surface analytical techniques. XRD traces obtained for 0% v-d AM and
one for 10% v-d AM suggested a predominantly amorphous content, while
crystalline peaks matching the profile for NaCl stood out. The lack of any
crystalline component in the XRD trace other than the NaCl crystal peaks
suggests a masking effect of the abundant amorphous constituents of AM.
Even peaks for KCl, another major component of PBS, were not found. In
the 10% v-d AM sample, the trehalose dihydrate XRD profile, present in
freeze-dried solutions (Santagapita and Buera, 2008), could not be detected.
The XRD profiles of anhydrous and other crystalline forms of trehalose, as
reported by Nagase et al. (2002), were searched for unsuccessfully. XRD
traces of type I and type III collagen, which can be obtained from purified
protein (Cameron et al., 2002), were also absent.
Three different forms of trehalose were identified in this study by ATR-
FTIR (Figures 3.27 and 3.28). These had characteristic spectral peaks at
986 and 943 cm-1, 991 and 941 cm-1 and 994 and 956 cm-1, representing
symmetric-asymmetric stretching of the glycosidic bond in different tre-
halose polymorphs (Akao et al., 2001). Respectively, the first two of these
are the anhydrate crystal and a form obtained by freeze-drying aqueous so-
lutions of trehalose. In the anhydrate crystal form, trehalose molecules are
densely packed and water cannot penetrate easily, whereas the freeze-dried
form may be similar to the protective anhydrous form that preferentially
bind water to produce the dihydrate molecule. A third polymorph, with
peaks at 994 and 956 cm-1, has not been identified. It may be similar to
the trehalose dihydrate crystal which can have peaks both at 994 and 954
cm-1 and 998 and 956 cm. The amorphous form (983 and 931 cm-1), without
which a glass cannot be formed, was not detected. However, the trehalose in
the 10% v-d samples does not appear to be in a crystalline form. This gives
145
characteristic sharp peaks at 3500 cm-1and in the C H stretching region be-
tween 3000 and 2800 cm-1 (Wolkers et al., 2004), which are missing in the
treated samples. It suggests that the trehalose is simultaneously present as
a mixture of amorphous and crystalline forms. Further drying may produce
detectable levels of the amorphous form. Since the physical properties of
amorphous trehalose change as a result of sample preparation (Surana et
al., 2004b), exposure to moisture Akao et al. (2001) and aging (Surana et
al., 2004a), ATR-FTIR will be a useful guide in characterising the different
states of treated v-d AM produced under different conditions in future work.
In the absence of evidence of glassy trehalose, it is not clear from these find-
ings whether the trehalose has any protective function. In pharmaceutical
systems, crystalline excipients cause instability of the amorphous ingredi-
ents (Costantino et al., 1998a). This suggests that v-d AM may be more
stable by having no stabilising excipient than by having a crystalline sugar.
This O H stretching band located between 3000 and 3600 cm-1 in the
trehalose spectrum, as seen in the treated v-d AM samples, indicates a wide
range and orientation of hydrogen bonds (Wolkers et al., 2004). Sitaula and
Bhowmick (2006) reported that excessively high levels of PBS diminished
the hydrogen bonding capacity of trehalose, producing an upward shift in
the trehalose C H stretching band and a decrease in the absorbance and
width of the O H stretching band. The peak intensities of the O H bands of
the trehalose-treated samples are increased with respect to the untreated
samples, indicating abundant hydrogen bonding and appropriate levels of
PBS.
The ToF-SIMS analysis revealed no significant differences between sam-
ples. The sodium ions are known to exert a matrix effect on the SIMS frag-
mentation process, which could have affected the ionisation of the analytes,
resulting in their suppression (Wagner and Castner, 2001). Trehalose is
also known to suppress ionisation. Indeed, Xia et al. (2002) stipulated that
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a w/v concentration of higher than 0.5% trehalose should not be used for
protein detection. However, since the untreated AM was similarly charac-
terised, it seems most likely that the high concentration of sodiummay have
prevented the Tof-SIMS from identifying amino acid fragments. The differ-
ences found between the samples are likely to reflect sample heterogeneity
rather than a protective effect of the trehalose treatment.
3.6 Conclusion
This work is a sentinel study of the moisture, thermal, dynamic mechanical
and surface analysis of v-d AM, comprising a new approach to the under-
standing of this biomaterial. These analyses provided an interconnected
framework for optimising the dry preservation of v-d AM. A thorough un-
derstanding of the effects of moisture and excipients on the material prop-
erties of AM was achieved once an overview of the different investigations
became available. The concepts of Aw and Tg, rarely discussed in clinical
milieux, were particularly significant in this regard. In the next chapter, I
investigate the material properties of rehydrated v-d AM as an alternative
to f-t AM.
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Chapter 4
PHYSICAL CHARACTERISATION OF AM
4.1 Introduction
As demonstrated in the last chapter, the physical properties of v-d AM de-
pend on moisture content and temperature. For surgical application, v-d
AM can be reconstituted with water or kept dry, depending on the precise
clinical indication. A dried AM patch can be glued inside an area of denuded
cornea, while, as a hydrated patch, AM can drape over the corneal surface
without impeding blinking. From a surgical perspective, AM needs to be
handled easily without tearing, and to last long enough on the ocular surface
to have a clinical effect before undergoing enzymatic degradation. Thus, the
quality attributes that make AM a useful and versatile material in oph-
thalmic surgery include its biocompatibility, pliability, strength and resis-
tance to degradation. It should also be transparent and permeable. Fully
rehydrated v-d AM should be comparable in these qualities to the current
standard, frozen AM, if it is to gain popularity among surgeons. The char-
acterisation of the material properties of v-d AM is therefore an important
aspect of this research. I conducted imaging studies and mechanical prop-
erty tests to characterise differences between the preparations. Tools for
imaging AM included optical, electron and atomic force microscopy (AFM).
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The mechanical properties of the preparations were explored with uniaxial
tensile tests and non-destructive tests such as nanoindentation and acous-
tic wave impedance. I used a mathematical model to define and predict the
mechanical properties of the tissue, which I then attempted to modify by
cross-linking the collagenous matrix.
4.2 Literature review
4.2.1 Physical properties of natural AM
The measurable properties of the foetal membranes near full term, includ-
ing mechanical properties, have been extensively studied in connection with
their premature rupture (Parry and Strauss, 1998). AM provides the ma-
jority of the tensile strength of the intact chorioamniotic membrane, and
is therefore of particular interest (Oyen et al., 2006). As a viscoelastic
material, AM exhibits characteristic properties, including a strain rate-
dependent stress response, relaxation at a fixed displacement and creep at
a fixed load (Lavery and Miller, 1977). These responses exhibit regional
variability, reflecting structural heterogeneity within the membrane and a
broad property range (Joyce et al., 2009). There is regional variation in
the structural composition of AM, which is thickest near the placenta and
thinnest near the rupture site (Artal et al., 1976). A zone of ‘altered mor-
phology’ can be found overlying the cervix, both in spontaneous vaginal de-
liveries (Malak and Bell, 1994) and in elective caesarean sections in the
absence of labour (McLaren et al., 1999). At this zone, biochemical changes
give rise to localised thinning and mechanical weakening of AM in anticipa-
tion of rupture (El Khwad et al., 2005, 2006). This has been correlated with
MMP activation, collagen remodelling and cell apoptosis, supporting the
concept of a programmed natural dissolution of the membrane around the
time of birth (Moore et al., 2006). The maintenance of mechanical strength
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in AM involves a balance between collagen production on one hand and en-
zymatic degradation, mediated primarily by the MMPs, on the other (Parry
and Strauss, 1998). At around the time of rupture the balance shifts deci-
sively in favour of collagenolysis. It is thought that MMPs play a central role
in the premature rupture of the membranes (PROM), a significant cause
of perinatal mortality that is associated with infection (Parry and Strauss,
1998).
4.2.1.1 Structural components
Collagens and non-collagenous proteins make up the structural components
of the BM, the compact layer and the fibroblast layer. Besides numerous
collagens and elastin, AM contains numerous proteoglycans, glycoproteins
and proteins as part of the structural network (see table 4.1). Large proteo-
glycans, such as osteoglycin, are amongst the most abundant stromal pro-
teins (Baharvand et al., 2007). Glycoproteins such as fibronectin, present
throughout the AM stroma, are thought to have a significant strengthening
function (Bryant-Greenwood, 1998). Small leucine rich proteoglycans such
as decorin, mimecan and biglycan interact with collagen networks, increas-
ing the overall mechanical strength (Meinert et al., 2001).
The BM consists largely of collagens III and IV (Malak et al., 1993), with
smaller quantities of type V (Modesti et al., 1989), secreted by the AEC.
Type V and VI collagens form filamentous connections between the BM and
the ECM (Malak et al., 1993). The BM supports the assembly of a network
containing laminin, entactin and heparan sulphate (Endo et al., 2004). The
compact layer and the fibroblast layer consist of stromal interstitial type I
and type III collagens (Aplin et al., 1985). The stroma consists of approx-
imately 10% randomly-arranged types I and III collagen and 2% elastin
(wet weight) (Jabareen et al., 2009). Type I collagen forms parallel bun-
dles that provide mechanical integrity (Malak et al., 1993). Together with
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Table 4.1: Non-collagenous AM matrix proteins
Constituent Role Localisation Reference
Laminin-5 Embryonic cell
organisation
BM Koizumi et al.
(2007)
Laminin-1 Embryonic cell
organisation
BM Dietrich et al.
(2005)
Entactin Cell adhesion,
collagen interaction
BM Dietrich et al.
(2005)
Nidogen-2 ECM interactions BM Dietrich et al.
(2005)
Fibronectin Cell adhesion,
migration
BM, stroma Linnala et al.
(1993)
Heparan sulphate
proteoglycan
Angiogenesis BM Dietrich et al.
(2005)
Lumican Cell migration Stroma Baharvand et al.
(2007)
Integrin α6 Embryogenesis AEC Koizumi et al.
(2007)
Transglutaminase 2 Protein cross-linking Cytoplasm Baharvand et al.
(2007)
Mimecan Collagen interactions Stroma Hopkinson et al.
(2006a)
Decorin Collagen interactions Stroma Baharvand et al.
(2007)
Integrin β4 Laminin receptor BM Koizumi et al.
(2007)
Tenascin-C Epithelial-
mesenchymal
interactions
Stroma Dietrich et al.
(2005)
Biglycan Collagen interactions Stroma Meinert et al.
(2001)
Matrilin-4 Filamentous network
formation
Stroma Dietrich et al.
(2005)
BM, basement membrane; ECM, extracellular matrix.
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smaller amounts of types V, VI and VII collagen, they are synthesized pre-
dominantly by mesenchymal cells (Casey and MacDonald, 1996). In a small
angle light scattering study of the collagen bundles, no preferred fibre ori-
entation was detected in the horizontal plane, although there were small
regions of homogeneous alignment (Joyce et al., 2009). X-ray diffraction
and electron microscopy studies have shown that collagen fibrils are more
loosely spaced and less compact close to the rupture site (Connon et al.,
2007).
Besides their possible roles in strengthening the AM, many of the pro-
teins have functions in promoting healing. For example, the laminins, all of
which are secreted by AEC with the exception of α1 and α4 (Takashima et
al., 2008) are implicated in cell differentiation (Cheng et al., 2009). Human
lumican, a glycoprotein, was found to promote epithelial healing in experi-
ments on lumican-knockout mice (Yeh et al., 2005). Proteoglycans and glyco-
proteins found in the AM stroma, including perlecan, agrin, tenascin C and
nidogen-2 are also found in the human limbal epithelium, which may favour
the role of AM as a substrate for epithelial expansion (Dietrich-Ntoukas et
al., 2012). Laminins and tenascin C act in cooperation to promote adhesion
and spreading of corneal epithelial cells (Katz et al., 2006).
4.2.1.2 Therapeutic preparations
The structural components of therapeutic preparations of AM are similar to
those of the natural tissue. Frozen and lyophilised AM both contain intra-
cytoplasmic vacuoles, a sign of devitalisation (Rodríguez-Ares et al., 2009).
Ultrastructural EM studies have demonstrated few differences between the
two preparations (Libera et al., 2008). Collagen types I, III, IV and V and
fibronectin are all found throughout lyophilised AM, and collagen Type VII
and laminin 5 are retained in the BM (Nakamura et al., 2004, 2008). These
features are morphologically similar to those of f-t AM, although lyophilised
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AM is more compact. While its overall structure may be retained, v-d AM is
significantly thinner than f-t AM (von Versen-Höynck et al., 2004).
4.2.2 Mechanical characterisation
4.2.2.1 Uniaxial testing
Mechanical testing of AM has included three different approaches: uniaxial
testing, biaxial burst and biaxial puncture (Calvin and Oyen, 2007). Uni-
axial tests of AM can be used for force-distance and stress-strain analyses.
Force-distance analyses generate information on the force needed to produce
rupture (ultimate tensile strength, UTS, measured in Newtons), elongation
(ΔL), a measure of reversible (elastic) and irreversible (plastic) deformation
of AM, and the work required to cause rupture (Artal et al., 1976). Failure
strain (εf ) can be calculated from ΔL. Stress-strain calculations can be pro-
duced once geometrical information on the tissue being tested is known (ini-
tial length and cross-sectional area). These include nominal failure stress at
failure (σvNf ), Young’s modulus of elasticity (E) and toughness (T), measured
as the area under the stress-strain curve. Force-distance and stress-strain
measurements can be applied to uniaxial deformation more easily than to
the more complex tests of burst and puncture strength (Joyce et al., 2009).
Unlike burst and puncture tests, they do not mimic physiological conditions,
but give useful information about membrane strength (Moore et al., 2006;
Joyce et al., 2009). Thus, uniaxial tests constitute a practical approach of
assessing the ‘robustness’ of AM as a biomaterial and provide an index of
its surgical worth. Nakamura et al. (2004) reported no difference between
lyophilised AM samples and wet-preserved controls, although the sample
size was very small (n = 6).
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4.2.2.2 Stress-strain analysis
Stress-strain analyses of AM are constrained by the requirement to obtain
the geometric dimensions, as the thickness of AM samples is difficult to
measure accurately and is non-uniform. The main methods of measure-
ment can deform the tissue. These include micrometry (von Versen-Höynck
et al., 2004) and optical microscopy (Connon et al., 2010; Jabareen et al.,
2009). Micrometry can be performed directly with a screw-gauge microme-
ter (von Versen-Höynck et al., 2004), or by sandwiching the tissue between
two Plexiglass plates, a method described by Lavery andMiller (1979). Opti-
cal microscopy is suggested by Jabareen et al. (2009) to be the most accurate
method of AM measurement. They recorded a mean thickness of AM of 111
± 78 μm, which is approximately twice that recorded by previous studies
(Oxlund et al., 1990; Prévost, 2006). Alternative methods have included the
use of confocal laser (Nakamura et al., 2008). AM thickness is variable, de-
creasing from approximately 100 μm in areas proximal to the placenta to
approximately 65 μm in areas distal to it (Connon et al., 2010). In addition,
it is highly dependent on hydration. Measuring approximately 20 - 30 μm in
thickness, dried AM is significantly thinner than both fresh AM (Nakamura
et al., 2008) and f-t AM (Chuck et al., 2004; von Versen-Höynck et al., 2004).
In the absence of thickness measurements, some authors have restricted
the analysis to force-distance, avoiding stress-strain calculations altogether
(Fujisato et al., 1999; Nakamura et al., 2004). Joyce et al. (2009) used
membrane tension as an alternative stress measure, expressed as force/unit
length, to avoid difficult and inaccurate thickness measurements. Oyen et
al. (2004) conducted a stress-strain analysis by assuming the thickness of
AM to be uniform, whereas Chuck et al. (2004) and von Versen-Hoeynck et
al. (2008) reported stress-strain data for therapeutic preparations of both
dried and f-t AM with measured thickness.
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Figure 4.1: Phases of stress-strain behaviour in soft tissue
The stress-strain behaviour of soft tissues is represented diagrammatically. Following the
initial stretching of elastin fibres, collagen fibres become sequentially straightened, causing
the gradient (modulus) to increase at higher strain.
4.2.2.3 Stress-strain characteristics
Biological soft tissues have similar characteristics that include viscoelas-
ticity and non-linear stress-strain behaviour (Fung, 1984). In many soft
tissues, this is characterised by a slow initial rise as elastin fibres are re-
cruited (elastin phase) (Korossis et al., 2002). In AM, the initial ~10% strain
is accompanied by very little stress (Oyen et al., 2004). The initial phase is
followed by an upwardly concave transitional phase in which crimped type
I collagen fibres begin to straighten sequentially (Joyce et al., 2009). There
is then a steep rise in which limited collagen elongation occurs (collagen
phase). The phases are represented by a diagram (figure 4.1). The gradient
of the the elastin phase is known as the low-strain modulus E1, while in the
collagen phase it is called the high-strain modulus, E2 (Fung, 1993). Stress-
strain curves with two different moduli have been described as having bi-
linear behaviour (Fung, 1993). In AM, there are direct correlations between
the elastin content and E1, and between the soluble collagen content and E2
(Jabareen et al., 2009). The collagen phase is concave, rather than linear,
as the modulus increases with strain (Oyen et al., 2004). The modulus of
AM has been termed pseudolinear, and can be measured as the gradient
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of a tangent of the stress-strain curve. In contrast, Young’s modulus (E) is
usually reserved for linear (i.e., Hookean) behaviour. The pseudolinear high
strain modulus increases with with greater peak force, and therefore does
not adequately describe the stress-strain response (Oyen et al., 2004). Re-
searchers have reported a range of pseudolinear modulus values for natural
AM, from 1.62 MPa (Benson-Martin et al., 2006), 19.0 MPa (Oxlund et al.,
1990) and up to 29.5 MPa (Oyen et al., 2004), although the test conditions
and sample sizes varied.
4.2.2.4 Mathematical modelling of AM behaviour
Since a single pseudolinear modulus does not adequately describe the elas-
tic response of AM, researchers have described its non-linear behaviour in
mathematical terms (Oyen et al., 2004; Jabareen et al., 2009). Whereas
Oyen et al. (2004) proposed a quadratic constitutive equation to explain
the non-linear stress-strain behaviour of AM, Jabareen et al. (2009) went
further, describing the behaviour of AM with a two-parameter constitutive
model. Constitutive models are highly useful methods of describing the com-
plex behaviour of soft tissues in response to external loading (Fung, 1993).
They can be used to predict behaviour and to compare tissue characteris-
tics, and can lead to an improved understanding of biological systems. Ru-
bin and Bodner (2002) proposed constitutive mathematical equations to de-
scribe the viscoelastic behaviour of facial skin. The Rubin-Bodner equations
were based on an assumption of the composite nature of skin, consisting of
an elastic component and a viscous (dissipative) component. They desig-
nated two parameters: q, a material constant having the units of stress,
and µ0, a dimensionless constant accounting for non-linearity of the moduli
(Rubin and Bodner, 2002). Using these parameters, Jabareen et al. (2009)
proposed a model to describe the mechanical behaviour of AM, assuming it
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to be an incompressible material:
σvN =
E1
3
exp((qE1/3μ0)(α1−3))((εΝ + 1)− 1
(εΝ + 1)2
) (4.1)
α1 = (ε
Ν + 1)2 +
2
(εΝ + 1)
(4.2)
The values of the low-strain modulus, E1, and the nominal strain, εΝ, were
derived from the data. The values of q and µ0 were determined simultane-
ously by searching for the best possible fit of the experimental stress–strain
curve data to the model. This enabled differences between membranes to
be quantified. For example, a high correlation was found between elastin
content (determined biochemically), E1 and the ratio qμ0 .
4.2.3 Accelerated degradation
In cases of acute inflammation, as after acute burns, AM undergoes necrol-
ysis on the ocular surface, leading to treatment failure (Ma et al., 2002).
Even in the absence of inflammation, the tissue is degraded by endogenous
enzymes after a few days (Spoerl et al., 2004). The effects of enzymatic
degradation on tissue can be assessed by accelerated degradation assays, a
useful tool in the characterisation of biological products (Matejtschuk and
Phillips, 2007). In vitro degradation assays on therapeutic AM have in-
cluded qualitative imaging studies (Chau et al., 2012) and quantitative as-
says (Fujisato et al., 1999; Ma et al., 2010). In these studies, degradation
assays were used to analyse the effects of chemical cross-linking on AM. It
is not known whether dried AM preparations undergo faster degradation
than fresh or f-t counterparts. The clinical application of cross-linked dried
AM illustrates this concern (Kitagawa et al., 2011).
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4.2.4 Non-destructive tests
While the uniaxial test can provide a useful measure of the gross material
properties of AM, it destroys the samples being tested. Non-destructive
tests are available that can provide subtle characterisation of the different
preparations of AM. These include high frequency rheology, AFM and DMA
(discussed in a Chapter 3).
4.2.4.1 High frequency rheology
High frequency rheology measurements give information on the high fre-
quency shear modulus (G∗) of complex fluids and polymers (Raimbault et
al., 2010). The shear storage modulus (G′) and the loss modulus (G′′) re-
spectively measure the elastic and viscous components. These can be mea-
sured by acoustic wave biosensors, instruments that are sensitive enough
to detect proteins, DNA, bacteria and lipid bilayers (see review by Länge et
al., 2008). Different instruments are available, some of which are able to
sense shear horizontally polarised surface acoustic waves (SH-SAW) prop-
agated between two interdigital transducers on a piezoelectric substrate.
One of these is known as the Love wave device, which has transducers
coated with a guiding layer of silicon dioxide on an ST-cut quartz substrate
(Kovacs et al., 1994). ST-cut quartz is a particular cut that enables inter-
digital transducers to generate a wave in the silicon guiding layer. Loading
a sample onto the guiding layer between the transducers changes the sur-
face impedance and shifts the propagation constant of the acoustic wave,
result in its attenuation and a downshift in its centre frequency. From
measurement of the received signal amplitude and centre frequency, and
through comparison with the reference signal, the wave attenuation, centre
frequency shift and hence propagation constant can be determined. Small
changes in viscosity can be detected this way (Jakoby and Vellekoop, 1998).
In a study comparing chemically cross-linked AM to controls, a significantly
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higher G′ in AM treated with transglutaminase (TG) was interpreted as an
indication of increased mechanical strength (Chau et al., 2012).
4.2.4.2 Atomic force microscopy
AFM is an ultra-high resolution technique widely used in the life sciences
for imaging and surface analysis (see review by Parot et al., 2007). It can
provide a wealth of information about the mechanical properties of a mate-
rial, providing the correct techniques and interpretation are applied (Oyen
and Cook, 2009). The instrumentation requires less sample preparation
than other materials testing methods, such as uniaxial tests or dynamic
mechanical analysis, but interpreting the results requires care.
The technique relies on a nanostylus (tip) attached to a microcantilever
that is used to scan an immobilised sample, such as a film of tissue. The
cantilever is connected to a piezoelectric transducer (‘piezo’), in which volt-
age induces movement. A laser beam connected to a photo sensor registers
the cantilever movements, which are fed back to the piezo, enabling the tip
pressure to be applied at constant force. For soft biological samples, the pre-
ferred method of surface imaging is by oscillating a crystal silicone cone tip
over the surface (Parot et al., 2007). This does not result in actual contact
between the tip and the surface (non-contact mode) . Van der Waals forces at
the surface decrease the resonance frequency of the cantilever. The vertical
(z) position of the piezo changes in response to the oscillation amplitude of
the cantilever as it approaches the tissue, maintaining a constant average
distance between the tip and the sample. The movement of the tip over the
surface can be recorded as a topographical image resolved from the nano-
metric scale to a few microns. An alternative to the non-contact mode has
been developed in which the tip comes into intermittent contact with the
sample without damaging it (‘tapping’) (Zhong et al., 1993).
Nanoindentation is a related technique used to investigate the differ-
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Figure 4.2: Force-displacement nanoindentation plot
An example of a force-distance curve obtained from nanoindentation of v-d AM is shown.
From right to left, the cantilever is approaching the sample. Attractive forces overcome the
cantilever stiffness to pull the tip towards the sample surface. The force increases until a
peak force is reached. The probe then starts to withdraw. Adhesive forces cause a downward
dip, until the cantilever is freed.
ent modes of mechanical deformation in biomaterials: elastic, plastic, vis-
cous and fracture (Oyen and Cook, 2009). In static force spectroscopy mode,
AFM permits direct force measurements of tip-sample interactions. The tip
is extended towards the sample and retracted, while the cantilever deflec-
tion signal is measured in volts. The signal can be calibrated to give force
measurements. Each force measurement results in a force curve showing
the cantilever deflection recorded as the tip vertically approaches and then
retracts from the sample surface. The hardness of the sample, as well as ad-
hesive forces between the tip and the sample and energy dissipation, can be
estimated from a force plot generated for every extension-retraction cycle.
A spherical tip can be used in place of a conical tip for this purpose.
An example of a force curve on an AM sample is shown below (figure 4.2).
The trace should be followed from right to left, as the cantilever approaches
the sample. There is an upward slope at the point of deflection as the ex-
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tending cantilever comes into contact with the surface. As the sample is
viscoelastic, the slope of the retracting curve indicates hysteresis, i.e., there
is dissipation of the energy delivered during indentation. The downward
dip during retraction is caused by adhesion forces between the tissue and
the sample.
A variety of mathematical models exist for the different material re-
sponse types of the samples being tested (Oyen and Cook, 2009). The re-
sponses include combinations of elastic, brittle, plastic and viscous. For non-
linear data, the data are commonly analysed with automated software and
solved by a mathematical algorithm known as the Oliver-Pharr analysis,
which differentiates the retractile slope at maximum displacement (Oliver
and Pharr, 1992). The sample surface hardness and Young’s modulus (in Pa)
are calculated from the slope data. The Derjaguin-Müller-Toporov (DMT)
model (Derjaguin et al., 1975) is fitted using data from the contact part
of the force curves. It can be used to generate data on adhesion, energy
dissipation and plasticity. Tip-sample adhesion can be measured from the
maximum negative deflection force of the cantilever while retracting from
the surface. The energy dissipation (in J) is the force integration during a
full extending-retracting cycle. This can be measured as the area between
the extending and retracting curves. Plasticity is calculated as a ratio, and
therefore takes no unit.
AFM has been used to study the surface of air-dried denuded and in-
tact AM (Cooper et al., 2005). The presence of an intact layer of glycocalyx
prevented the topographical mapping of the microvillous surface of the ep-
ithelium. In denuded tissue, the uppermost layer of the basal lamina was
determined to be smooth, suggesting its integrity following removal of ep-
ithelium. In a study of therapeutic freeze-dried AM, AFM was used to docu-
ment damage to collagen fibres by γ-irradiation (Deocaris and Abad, 2005).
Lim et al. (2010) used AFM to depict variations in the height and hardness
161
(CH2)3
(H2C)2
(CH2)4
CHOH
CHO
NH2
CHO
(H2C)2
CHOH
CH2
NH2
(CH2)3
(H2C)2
(CH2)4
CO
HC
NH
H2C
(H2C)2
CHOH
H2C
N
O2-
Hydroxylysine
Aldehyde
LysineAldehyde
Divalent cross-links
Collagen fibril
Figure 4.3: Cross-linking mechanism
In fibrillar collagens, divalent covalent cross-links can occur between telopeptide aldehydes,
formed by the actions of lysyl oxidase, and helical lysine and hydroxylysine residues. Triva-
lent cross-links can also occur (adapted from Eyre et al., 2008). Free radicals, generated by
ultraviolet irradiation of riboflavin, can generate cross-linking reactions.
of the basal lamina of decellularised AM.
4.2.5 Cross-linking of AM
Collagen molecules consist of three helical peptides containing polar amino
acid side chains that can form intermolecular cross-links (Bailey et al., 1964).
In fibrillar collagens, covalent cross-linking occurs between amine groups
( NH2) of helical lysine and hydroxylysine residues and carboxyl groups
( CHO) of telopeptide aldehydes, produced enzymatically by lysysl oxidase
(Eyre et al., 2008) (figure 4.3). Both divalent and trivalent cross-links can
occur between collagen fibrils, which are typically found in load-bearing tis-
sues. Artificial cross-linking may be induced by different methods including
using ultraviolet light with and without sensitisers and aldehyde reactions
(Spoerl et al., 1998). Photo-sensitisation produces free radicals, which break
the hydrocarbon chains in aldehydes (Goodeve and Kitchener, 1938), allow-
ing them to covalently bind amine groups. Cross-linking in collagen may
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also be induced by nonenzymatic glycation, which occurs as a result of age-
ing and diabetes. Natural and artificial cross-linking of tissues is thought to
have many benefits, including increased resistance to proteolytic breakdown
and absorption as well as improved mechanical strength, thermal stability
and biocompatibility (Spoerl et al., 1998; Lee et al., 2001).
Photo-cross-linking of collagen gels by visible light irradiation in the
presence of a photoinitiator was found to improve the mechanical properties
of collagen, while maintaining the triple helical structure (Brinkman et al.,
2003). In recent years, much attention has been given to artificial induce-
ment of cross-linking of human corneal collagens as a means of increasing
its mechanical strength and resistance to enzymatic digestion in the treat-
ment of keratoconus and bacterial keratitis (Spoerl et al., 2004; Wollensak
et al., 2003). Currently, UVA/riboflavin is widely used in ophthalmology to
treat pathological thinning of the cornea by cross-linking (Wollensak et al.,
2003)
Comprising large amounts of type I collagen, AM can also undergo arti-
ficial cross-linking, the putative benefits of which could include increased
toughness and resistance to degradation. Fujisato et al. (1999) first at-
tempted to cross-link AM, both by irradiation (γ-irradiation or electron beam)
and chemically (with glutaraldehyde). They conducted stress-strain mea-
surements on the cross-linked AM. Irradiation weakened the AM, consis-
tent with the observation that it causes scission of the covalent bonds in
collagen, leading to disorganisation (Grant et al., 1973) and increased sus-
ceptibility to trypsin digestion Liu et al. (1989). Subsequently, Spoerl et al.
(2004) developed the technique of cross-linking AM with 0.1% glutaralde-
hyde further. In force-elongation experiments on AM strips, the force of the
cross-linked AM was significantly increased. Furthermore, the cross-linked
AM was significantly more resistant to digestion in a solution of 0.1% col-
lagenase. Hyperdry AM cross-linked with 0.1% glutaraldehyde is currently
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used clinically in some centres, for example in the treatment of corneal per-
forations (Kitagawa et al., 2011). However, glutaraldehyde may cause cal-
cification on the ocular surface (Wilshaw et al., 2008), prompting a search
for alternative methods. Kumar et al. (2003) used chitosan to cross-link
AM-derived collagen scaffolds, finding increased thermodynamic stability
in the cross-linked tissue. Recent developments include the treatment of
whole AM with EDC, which is non-toxic (Ma et al., 2010), and with mi-
crobial TG (Chau et al., 2012). Collagen hydrogels have been successfully
cross-linked with 0.1% riboflavin and UVA irradiation (frequency 370 nm)
(Ahearne et al., 2008), suggesting that it might also be a useful technique
for cross-linking AM.
4.2.5.1 Assessment of cross-linking
A number of methods are available to determine the effects and extent of
cross-linking of AM. Measurements of the effects of cross-linking include
stress-strain measurements and assays of enzymatic digestion Spoerl et al.
(2004). In polymers, stiffness increases in direct proportion with the number
of cross-links. In the rabbit cornea, cross-linking changes the diameter and
interfibrillar distance (IFD) of the collagen fibres (Wollensak et al., 2004).
One elaborate method of analysing cross-links in tissue combines ion-trap
mass spectrometry (MS) with peptide-specific antibodies against specific col-
lagen cross-linking domains (Eyre et al., 2008). Most techniques are more
accessible, but less specific. In a study of corneal collagen cross-linking,
Wollensak and Redl (2008) used gel electrophoretic methods to confirm the
presence of a very high molecular weight protein, which they assumed to
be a cross-linked polymer of Type I collagen. Mature human AM collagen
molecules are trimeric, containing two α1 chains of 139 kDa and an α2chain
of 129 kDa. Monomeric (α), dimeric (β) and trimeric (γ) bands can be re-
solved by gel electrophoresis of AM-derived collagen (Spira et al., 1994).
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While it is unclear whether cross-linking of AM collagen can modify the gel
electrophoretic pattern, it is known to result in the uptake of amino side-
chains (Ma et al., 2010). Colorimetric assays, such as the ninhydrin assay,
can determine the proportion of free amino groups as an inverse marker of
cross-linking.
4.3 Materials and methods
4.3.1 Imaging studies
4.3.1.1 Transparency assay
A transparency assay was modified from the methods used by Ma et al.
(2010) and Chau et al. (2012). Samples of 0%, 5% and 10% v-d AMwere pho-
tographed with a compact digital camera (Praktika DCZ, Pentacon, Dres-
den, Germany) against printed material and against a dark, granulated
background.
4.3.1.2 Electron microscopy
AM samples were cut to the required size after discussion with the mi-
croscopy staff at the Department of Histopathology, who supplied the fix-
atives. Samples of fresh, f-t and v-d AM were submitted for for further
processing as described below. For imaging studies of the intact AM, SEM
and TEM photographs were taken of fresh, f-t and v-d AM. For imaging of
the BM, the epithelium was first removed by the thermolysin method as
described previously.
The AM was fixed and processed before proceeding to SEM or TEM.
First, 0.5 mL of stock 25% glutaraldehyde solution, stored at 4°C, was mixed
with 4.5 mL of sodium cacodylate buffer. Tissue samples, 1 cm × 1 cm, were
dropped into the 2.5% glutaraldehyde:cacodylate solution and stored at 4°C
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for 24 hr prior to further processing.
4.3.1.3 Sample processing1
The samples were washed in 0.1M sodium cacodylate buffer and then post-
fixed in 1% osmium tetroxide for 2 hr. They were then washed in distilled
water and dehydrated in a series of ascending grades of alcohol to three
changes of absolute alcohol. For SEM, the samples were dried to a critical
point drying with a Tousimis® (Virginia, USA) Samdri®-PVT-3 dryer. The
samples were mounted onto aluminium stubs and sputter-coated with gold
(Balzer Union SCD030 sputter coater, Leica, Wetzlar, Germany). For TEM,
fixed samples were washed × 2 in 100% acetone before being embedded in
an epoxy resin (TAAB Laboratories Equipment Limited, Berkshire, UK).
Polymerisation was achieved by heating to 65°C for 16 hr. The polymerised
blocks were cut into 0.5 μm sections on a Reichert Ultracut E microtome.
Following staining with 1% toluidine blue in 1% borax, they were examined
by light microscopy. Areas selected for ultramicrotomy were sectioned to
80 nm. The ultramicrotome sections were mounted on copper grids and
stained with saturated uranyl acetate in 50% ethanol. This was followed by
Reynolds lead citrate staining.
4.3.1.4 Scanning electron microscopy
A JEOL JSM840A scanning electron microscope (JEOL UK Ltd., Welwyn
Garden City) and iScan™ software were used to produce digital images of
the samples. The JEOL 840 Instructions booklet were referred to for de-
tailed instructions on photography. The specimen was obtained fixed to a
brass carrier (stub). Sample stubs were fastened in the brass insert holder
with small set screws, so that the specimen was in the same plane as the
rims of the holder. The holder was mounted in a brass carrier and fixed
1Sample processing for SEM and TEM was carried out by Mr Trevor Gray of the De-
partment of Histopathology.
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with the set screw. The specimen carrier was screwed onto an exchange rod
with a plexiglass block. The carrier and rod assembly were placed in posi-
tion in the exchange chamber. The plexiglass block was held flat against the
chamber seal and a red vacuum operation button was pressed once. When
vacuum was achieved, the red light went out (~55 secs). At this point, the
specimen exchange chamber isolating valve was opened. The specimen was
inserted onto a dovetailed stage. The exchange rod was unscrewed and care-
fully withdrawn. The specimen chamber isolating valve was closed. The red
vacuum operation button was pressed to release the vacuum and dislodge
the exchange rod. The current meter was lit with contrast and brightness
turned fully counterclockwise. The specimen working distance was adjusted
to 10-12 mm. The detector (Secondary Electron Imaging) and accelerating
voltage switches were turned on. Coarse focus was adjusted to bring the
specimen into view. The current meter was lit, and the probe current was
set at 10-10 Amps. Brightness was gradually increased until a line was vis-
ible on the cathode ray tube. The filament knob was slowly turned clock-
wise and the line scan profile was sharpened with fine focus, keeping the
beam current was kept at < 100 μA. A small round feature was selected for
viewing. The X and Y stigmators were rotated to achieve maximum clarity.
This was repeated several times until there was no blurring. The Digital
Scan Generator was turned on and the iScan™ software was launched. Im-
age brightness and contrast were adjusted to obtain an adequate dynamic
range, which varied with scan time. Micrographs were taken of the ep-
ithelial surface and the loose collagenous layer on the underside at various
magnifications (from × 1000 to × 20 000). Defects in the AM samples were
examined for imaging of the compact collagenous and BM layers. En face,
oblique and cross-sectional images of the AM specimens were sought. The
image was captured after the scan, and photographs were saved as .tif files.
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4.3.1.5 Degradation assay
An accelerated degradation assay was performed to compare fresh, f-t and
v-d AM. This was carried out in duplicate. Samples of the different prepara-
tions were punched out of the tissue with a 6 mm skin biopsy punch (Glax-
oSimthKline GmbH & Co., Bad Oldesloe, Germany) and placed into 8 mm
wells in multiwell culture plates (Sigma-Aldrich, UK) in 100 μL of medium.
The test medium consisted of DMEM and keratocyte supernatant culture
medium2 in a 2:1 ratio with 0.01 mg/mL of lyophilised collagenase extracted
from Clostridium Histolyticum (Cat. No. 17018-029, Gibco®, UK). This col-
lagenase is specific for the neutral amino acid-glycine bonds in collagen and
can degrade triple helical collagen. 0.1 mg of collagenase (25 U) were added
to 10 mL of medium. The control medium consisted of DMEM. The AM
samples were incubated in 5% CO2 at 37°C for 72 hrs and then frozen at
-80°C. Next, they were freeze-dried overnight. The lyophilised tissues were
processed for SEM without fixative, and photographed for comparison. The
degradation assay was a basic qualitative test of the different preparations,
and no outcome measure was decided beforehand.
4.3.1.6 Transmission electron microscopy
A JEOL JEM1010 transmission electron microscope (JEOL UK Ltd.) was
used to view the sections. Digital images were captured with a SISMegaView
III charge-coupled device camera (Olympus Soft Imaging Solutions, Lake-
wood, CO, USA) system. The specimen holder was by pulled out and turned
counterclockwise. It was pulled slowly against the vacuum. The specimen
clamps on the specimen holder were opened with forceps. The copper grids
containing the specimens were placed between the clamps. The specimen
holder was then pushed in for the green vacuum light to go on. After the
light went off (~40 secs), the holder was turned clockwise and gently eased
2Courtesy of Dr Khurram Hashmani.
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with the vacuum into position. The beam current was switched on with the
high tension button (to about 80 kV), and brightness and contrast were ad-
justed. The image was focused by bringing a small focus screen into view
and using a wobbler image shift system for coarse and fine focus. The illumi-
nation was centred by bringing the illumination to a small spot and using X
and Y shift. The microscope and camera were linked, and the software was
launched. Magnification was set to × 10 000 and a continuous image of a
selected sample area was obtained. Focus was adjusted with the microscope
focus knobs. The ‘Start Acquire’ button was pressed to record images, which
were saved as .tif files.
4.3.1.7 Atomic force microscopy3
A Digital Instruments Nanoscope IIIa D3000™ scanning probe microscope
(Bruker AXS Corporation, Santa Barbara, CA) was used to compare the to-
pography of stromal and epithelial surfaces of AM samples, with and with-
out trehalose pre-treatment. A piece of double-sided adhesive tape was
placed onto a 1.5 cm diameter steel disk. A square of v-d AM of approx-
imately 1.0 cm × 1.0 cm was placed gently on top of the double-sided ad-
hesive tape, taking care to lay the sample flat with a minimum of folds or
creases. Another square from the same sample of amnion was inverted and
similarly laid onto another steel disc with double-sided tape to present the
opposite face of the same membrane. The disc was then attached magnet-
ically to a sample stage of the microscope. The samples were imaged in
air using the Tapping Mode™. Images were acquired with a silicone probe
(RTESP; Veeco Digital Instruments, Santa Barbara, CA) of inverse pyrami-
dal shape (effective sphere radius 2 nm and effective half-cone angle 19°)
at the resonant frequency of the AFM cantilever of approximately 300 kHz.
The cantilever spring constant had a nominal value of 30 Nm-1, provided by
3This work was carried out in collaboration with Dr Chen Xinyong of the School of Phar-
macy at the University of Nottingham.
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the manufacturer. Flat areas of tissue, 10 μm by 10 μm, were selected for
scanning. Each sample was scanned in triplicate. The scan rate was 1 Hz,
and images were acquired across 512 × 512 points.
4.3.2 Optical microscopy
Optical microscopy was performed on four samples each of f-t AM and v-d
AM for thickness measurements. In addition, samples were stained with
haematoxylin and eosin for visual comparison.
4.3.2.1 Embedding of AM samples
Aluminium foil cups, 1 cm in diameter and 3 cm deep, were fashioned and
filled with optimal cutting temperature (OCT) embedding medium (Jung
Tissue Freezing Medium, Sigma-Aldrich, Missouri, USA). The cups were
lowered into 100 mL beakers containing 5 mL of isopentane, overlying a
liquid N2 bath, for a few seconds until the OCT began to harden. Strips of
AM of approximately 10× 30mmwere laid flat onto a sticky plastic backing,
or wrapped around a frozen OCT core, to ensure correct orientation of the
tissue, and placed into the cups. These were vapour-frozen in a beaker that
until the strips solidified completely. They were stored at -80°C.
4.3.2.2 Slide preparation
SuperFrost slides (LSL, Rochdale, UK) were placed in racks and washed
in 100% acetone for 1 min. They were then placed in 300 mL acetone con-
taining 2% 3-aminopropyltriethoxysilane (APES, Sigma-Aldrich), washed in
distilled water and left to dry in a fume-hood overnight, before being stored
in their original packaging in a dark environment.
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4.3.2.3 Cryostat sectioning
The Leica CM1900 Rapid Sectioning Cryostat was switched on with a tem-
perature setting of -25°C and cleaned with 100% ethanol. The cryostat
heads were cleaned with acetone. The solid media pellets were mounted
onto the cryostat sectioning chuck using OCT as glue. The cryostat sec-
tion thickness was set at 6 μm. Samples were advanced and sectioned onto
APES-coated slides for staining or thickness measurements.
4.3.2.4 Thickness measurement
Mounted AM strips were viewed under a Leica DB4000B light microscope
equipped with digital capture. Samples were photographed, and areas of
AM that were free of folds were selected for measurement. Analysis was
performed with Openlab software (PerkinElmer, USA). Measurements were
made by placing the cursor on BM and dragging it to the stromal edge. The
computer software returned distance values for the linear measurements.
Three to nine measurements were made for each strip, and the mean thick-
nesses of f-t and v-d AM were compared.
4.3.2.5 Haematoxylin and Eosin staining
Slides with tissue sections were placed in trays and immersed in 3% v/v
acetic alcohol before being washed in Tris-buffered saline (TBS), pH 7.6, for
1 min. They were then stained in haematoxylin for 1 - 2 mins in the fume
hood and washed in gently running tap water until they lost their purple
colour. They were then immersed in Scott’s Tap water for 1 min, washed
in distilled water and placed in eosin Y for 1 min for the sections to retain
pink colour. The slides were washed under tap water. A drop of warmed
Glycergel® mounting medium (Dako Ltd., Ely, UK) was gently placed on the
tissue section, and a coverslip placed over the slides, which were allowed to
dry.
171
4.3.3 Uniaxial testing
Fresh, f-t and 0% v-d AM samples from a total of 19 donors were subjected
to uniaxial testing. Samples were obtained from one, two or all three prepa-
ration methods for each donor. Between one and ten samples were tested
for each preparation method. Samples of AM were tested using the Heavy
Duty Texture Analyser (TA.HDplus) from Stable Micro Systems Ltd. (Sur-
rey, UK). The samples were tested after obtaining fresh AM, after 30 mins
thawing of frozen AM or after reconstitution of dried AM in water. All v-d
samples were rehydrated for 5 mins in DI H2O just before the uniaxial tests.
A 10 mm by 30 mm template was drawn onto the surface of a 9 cm di-
ameter PTFE disc with indelible ink (figure 4.4 A). A 90 mm Petri dish
lid (Sterilin, UK) was placed on the PTFE base to provide a hard, dispos-
able surface for cutting AM samples. A layer of Parafilm® was stretched
over the Petri dish as a scaffold for the AM. Each AM sample was laid out
directly onto the Parafilm®. Next, the AM could be cut directly over the vis-
ible template drawing to the specified dimensions. A No. 22 Carbon Steel
Swann-Morton scalpel blade was used to cut 10 mm by 30 mm AM strips by
rolling (not dragging) the curved edge of the blade to avoid feathering of the
edges (figure 4.4 B). Digital micrometry was performed with a low-force dig-
ital micrometer with resolution of 1 μm (Mitutoyo UK Ltd., Coventry, UK).
Next, the AM strips were placed onto slightly larger split cards of similar
dimensions (cut from microplate sealer tape), and the Parafilm® was peeled
off. The horizontal split, two thirds the way down the card, served to allow
mounting of the sample (figure 4.4 C). The AM was gently unfolded with
forceps on the card for correct alignment and to eliminate any folds, tak-
ing care not to introduce holes. The AM-split card bilayer strips were then
mounted at 90° between the gnarled mini-tensile grips (Stable Micro Sys-
tems). The top grip was finger-tightened first, clamping 5 mm of AM-card
with the split downwards (figure 4.4 D). Next, the bottom grip was tightened
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Figure 4.4: Uniaxial testing of AM strips
AM strips were cut to a 10 mm × 30 mm template (A) with Parafilm® backing (B). This
enabled the AM strip to be mounted onto split card (C), which was then clamped between
mini-grips (D) for uniaxial testing.
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with the bottom 5 mm of AM-card in place.
The TA.HDplus was calibrated before every batch of tests. A load cell of
5 kg was used. The vertical height difference between the grips was stan-
dardised in order to achieve an exposed product height of 20 mm. The tests
were run at 100 mm min−1, which gives a strain rate, defined as the rate
of change of length divided by the original length, of 0.083 s−1. The test
was run for a set distance of 20 mm. Force-distance curves were generated
with these parameters. The inclusion of a cross-sectional area permitted
stress-strain curves to be generated. The traces were processed using an
integrated 32-bit Exponent software package, which permitted the data to
be exported in Microsoft Excel files. A total of 208 traces were obtained for
95 fresh AM, 55 f-t and 58 v-d AM samples.
4.3.3.1 Data synthesis
Uniaxial tests were performed on 208 samples of fresh (n = 95), f-t (n = 55)
and v-d (n = 58) AM from a total of 19 donors. The range of traces obtained
per donor ranged from 1 to 28. Data from four donors was obtained across
all three preparation methods, data from three donors was obtained across
three methods and data from 12 donors was obtained for just one method.
The uniaxial tests gave data on UTS (in N) and the change in length, ΔL
(mm), for force-distance analysis. The values of nominal stress at failure
(σvNf ) and true stress at failure (σv
T
f ) (in MPa) were obtained once the cross-
sectional area (mm2) was known. The strain at failure, εf , was calculated
from ΔL and expressed as a percentage. These data permitted conversion
of the force-distance curves into stress-strain curves. A pseudolinear mod-
ulus, E1, was calculated as the tangent of the stress-strain curves between
0.495 and 5 % strain (in MPa). A second pseudolinear modulus, E2, was
calculated as the tangent of the stress-strain curves between 90 and 100%
strain. Toughness (T), measured in Joules (J) per mm3, was obtained by
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Figure 4.5: Uniaxial test data filtration
Stress-strain curves obtained from uniaxial tests were filtered by visual inspection (two ex-
amples of 208 shown). Stress measurements were plotted on the X axis in MPa. Strain is
plotted as a decimal fraction on the Y axis. is The thick line represents experimental data.
The thin line represents a modelled curve. The experimental curve in A is smooth and was
retained for further analysis. The curve in B was classified as non-smooth and was elimi-
nated from the analysis.
integrating the area under the stress-strain curves.
4.3.3.2 Data filtering
For all stress-strain curves, the data points between 0% and 0.495% strain
were deleted to eliminate noise caused at the start of the test. Data filtering
was conducted by screening each stress-strain curve by visual inspection
and by eliminating all non-smooth curves from the analysis. Examples of
smooth and non-smooth curves obtained from experimental data are shown
below (figure 4.5, thick lines). The experimental curves are shown alongside
mathematically modelled curves of the data (thin lines; see below). Soli-
tary and minor infractions in curve smoothness were tolerated. The curves
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were filtered with no reference to the preparation method. The proportion
of traces that were eliminated and the RR of a trace being non-smooth were
calculated for each preparation category as an index of the quality of the
samples.
4.3.3.3 Mathematical modelling
A mathematical model (Equation 4.4) was used to describe the mechani-
cal behaviour of the AM samples. The parameters G′ and d were derived
from the experimental data by specialist mathematical computer software
(MATLAB, MathWorks, Ma, USA).
Equation 4.1 was adapted by introducing a new parameter d:
d =
qE1
3μ0
(4.3)
Since ε = λ1 − 1 and E = 3G,
σvN = G′exp
d(λ21+
2
λ1
−3)
(λ1 − 1
λ21
) (4.4)
As it is applied to the exponential, d is dimensionless. Since σvT = λ1σvN
, experimental data for σvTf and λ1 at failure were used to generate the val-
ues of G′ and d by equation 4.4 for each set of stress-strain data of AM
undergoing uniaxial deformation. The filtered stress-strain data from the
uniaxial tests were obtained in Microsoft Excel spreadsheets and processed
using MATLAB 4. This was programmed to optimise the closest possible fit
to the experimental curves by using Equation 4.4, simultaneously generat-
ing values of G′ and d. To illustrate the effects of change in the values of
d and G′, simulated curves have been plotted of σvN against λ1 (figure 4.6).
Increasing the value of d while G′ is kept constant does not affect the gra-
4This work was carried out in collaboration with Dr Davide De Focatiis, of the School of
Chemistry in the University of Nottingham.
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Figure 4.6: Nominal stress versus stretch ratio
A mathematical model was proposed to describe the stress-strain characteristics of AM
(Equation 4.4). The value of the storage modulus G´ was calculated by using data between
0.495 and 100% strain. Together with a dimensionless parameter d, this was used to model
the tissue behaviour. A Curves illustrating the effects of changing the value of d are shown.
G′ is constant (1.5e+6 Pa). As d increases, the initial gradient is unchanged. At higher
strains, the gradient increases, except in the special case of d = 0. B The effects of changing
the value of G′ at constant d are shown (d = 10). As G′ increases, the initial gradient in-
creases. At higher strains, the gradient approaches constancy. σvN , nominal stress (MPa); λ1,
ratio of final length to original length.
177
dient at low strain, yet it causes the pre-terminal gradient (equivalent to a
high strain modulus) to increase. At a value of d = 0, the curve represents
the case of Gaussian elasticity. Conversely, increasing G′ with a constant
d increases the initial gradient (equivalent to a low strain modulus), while
the pre-terminal gradient remains constant.
Three separate fittings were made using the mathematical model and
the experimental data. For the first fitting, a value of G′ were obtained by
using the experimental data from the whole curve between 0.495 and 100%
strain. G′ and d were obtained simultaneously by searching for the pair of
values that minimise the error over the whole curve. The error is defined as
the square root of the sum of the difference between the measured stresses
and the stresses computed from the model. This was calculated using the
equation
RMS =
1
n
√√√√ n∑
i=1
(σvNi,model − σvNi,experimental)2 (4.5)
where n is the number of data points and i represents each data point. The
errors were normalised to the number of data points, n. Two examples of
model curves of σvN versus λ1 plotted alongside experimental data from two
uniaxial tensile tests are shown in figures 4.7 A and B. The model and ex-
perimental curves in figure 4.7 A demonstrate a close fit, with a RMS of 7.49
kPa, while figure 4.7 B demonstrates a poor fit, with a corresponding RMS
of 11.90 kPa.
For the second fitting, the value of G′ (designated G′2) was determined
from the initial gradient between strain levels of 0.495% and 5%. A new
value of d (designated d2) was then obtained by searching for the value which
minimises the error, based on the initial modulus. All the modelled curves
were plotted alongside the experimental curves. The closeness of the opti-
mised fit was indicated by the RMS error (RMS2).
For the third fitting, a third parameter was introduced. To compensate
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Figure 4.7: Experimental and model curves
Amathematical model was used to describe the stress-strain characteristics of AM (Equation
4.4). In the fitting shown, the storage modulus G´ was obtained between 0.495 and 100%
strain. The closeness of fit of the model is described by the root mean squared of the error
(RMS). A close fit of model and experimental curves is shown (A, RMS = 7.49 kPa). The
model and experimental curves in B demonstrate a less close fit (RMS = 11.90 kPa). σvN ,
nominal stress (MPa); λ1, ratio of final length to original length.
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for the amount of slack or tension in each sample at the start of testing, λ1
was adjusted by varying the starting point. Thus, the model simultaneously
searched for a triplet of values that minimise the error (RMS3) over the
whole curve: G′3, d3 and λ1.
4.3.3.4 Statistical analysis
The effects of method of AM preparation and AM donor on the dependent
variables were assessed. All statistical analysis was carried out using sta-
tistical software (SPSS®, version 20, IBM Corporation, New York, USA).
Detailed instructions for using SPSS® (Pallant, 2007) were followed. Where
possible, normally distributed data were analysed by parametric tests, in-
cluding general linear models such as univariate and multivariate analyses
of variance (ANOVA). Univariate tests of normality were used to explore
the distribution of the data for each dependent variable. Normality was as-
sessed by comparing the 5% trimmed mean to the actual mean, by checking
the kurtosis and skewness values (< 1) and the Kolmogorov-Smirnov statis-
tic (> .05) and by assessing normal Q-Q and detrended normal Q-Q plots
and histograms. Outliers were identified by boxplot analyses. Data values
of more than three times the SD were considered to be extreme outliers.
Main effects of independent variables were only interpreted if no significant
interaction effects were identified.
Multivariate analysis of normality of distribution were conducted by lin-
ear regression. Scatter plot matrices were generated to check for linearity.
Further tests were carried out to assess the assumption of homogeneity of
variance-covariance matrices (Box’s Test) and the assumption of equality
of variance (Levene’s Test). The presence of outliers was assessed by gen-
erating Mahalanobis distances and checking them against critical values.
Tests of correlation between dependent variables (Pearson correlation coeffi-
cient, r) were performed, using Cohen’s guidelines to classify the strength of
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the correlation (Pallant, 2007). Post-hoc comparisons were made using the
Tukey Honestly Significant Difference (HSD) test. Non-Gaussian data were
transformed either by removing a small number of outliers or by logarithmic
conversion of the data. If the data could not be transformed, non-parametric
tests were carried out. For non-parametric testing of independent samples,
the Kruskal-Wallis test was used. Post-hoc tests (Mann Whitney U test)
were conducted to confirm or reject statistically significant findings. To in-
terpret the strength of the different effect sizes, Cohen’s guidelines were
used: .01 was considered small, .06, medium and .138, large (Cohen, 1988).
4.3.4 Non-destructive tests
4.3.4.1 Acoustic impedance5
A Love wave surface acoustic device was used to probe the mechanical prop-
erties of AM through determination of the sample shear storage modulus
(G′) and the loss modulus (G′′). Four different membrane compositions were
studied: fresh AM, f-t AM, rehydrated v-d and thermolysin-denuded, with
three separate sections of the membrane being studied in each case and the
measurements. Samples of the AM preparations, about 2-3 mm in length,
were placed across a sensor with two delay lines, one of which acted as a
reference signal. Waves were transmitted across transducers separated by
a path 6 mm in length at an operating frequency of 118 MHz. A control unit
provided power to the device and an oscilloscope was used to detect the re-
ceived signals. First, a measurement of the received signal with the device
unloaded was made as a reference. Next a small square of the membrane
was placed on the device covering the path between the two transducers.
The received signal was then measured. The received signals were digitised
and analysed using MATLAB software (The MathWorks Ltd., Cambridge,
5This work was carried out in co-operation with Dr Melissa Mathers of the Centre for
Biomolecular Sciences in the University of Nottingham.
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UK). From a determination of the change in the propagation constant (γ),
material properties were calculated from the following equation for G′ and
G′′:
∆γ
β
=
∆α
β
+ i
∆β
β
= S
√
(G′ + iG′) ρ
(
1− G
′ + iG′′
ρν2
)
(4.6)
where α is attenuation, β is the unperturbed wavenumber, s is the device
sensitivity, ρ is the sample density and υ is the Love wave phase velocity.
The measurements were carried out in quadruplicate, although not all mea-
surements were successful. The means and SD were obtained and plotted
for each AM category.
4.3.4.2 Nanoindentation
Nanoindentation was performed to compare the surface properties of 0%
and 10% v-d AM. Samples were mounted on steel discs in the Digital Instru-
ments Nanoscope IIIa D3000™as described previously for AFM scanning.
Force measurements were conducted in static force spectroscopymode. Mea-
surements on one AM were conducted using bare tips with an effective
spherical radius of 2 and 15 nm. A second AM was tested using tips at-
tached with glass spheres of radius of 5 and 15 μm. The surface of both
aspects of the membrane were examined. Between 24 and 127 force mea-
surements were performed on each area. Data was obtained on force and
relative displacement. An Oliver-Pharr analysis was also conducted to as-
sess the modulus of the retraction curve and contact hardness.6 Information
on plasticity, adhesion and dissipation was acquired from the DMT model.
4.3.5 Cross-linking study
Fresh AM samples were treated with ultraviolet A (UVA)/riboflavin to cross-
link the collagen matrix. The extent of cross-linking was analysed by gel
electrophoresis, MS and western blotting of the purified collagen, tensile
6Conducted with the help of Professor Chen Xinyong.
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testing and mathematical modelling, IFD measurement in TEM images and
the ninhydrin assay.
4.3.5.1 Ultraviolet irradiation
AM was harvested and prepared in the usual way and treated with ther-
molysin (12.5 mg in 100 mL PBS) in the usual way. 0.1% riboflavin-5-
phosphate solution (Sigma-Aldrich, St. Louis, MO, USA) was prepared us-
ing deionised (DI) H20 (100 mg in 100 mL). AM was soaked for 30 mins
in 25 mL of riboflavin solution in Petri dish lids. Next, six long UVA flu-
orescent tubes with a peak wavelength of 365 nm were used as a source
of unfocused UVA irradiation (Fluo-Link TFL-312, Vilber Lourmat, Marne
la Vallée, France) placed 4 cm above the AM in Petri dishes for 30 mins.
Irradiance was approximately 16 mW/cm2.
4.3.6 Analysis of cross-linking
4.3.6.1 Extraction of type I collagen
The method used is a modification of the one described by Spoerl et al.
(2004). Irradiated and non-irradiated AM samples were ground in liquid
N2 and the extracts were placed in 50 mL 0.1 M Na acetate on a rocker
overnight at 4°C to dissolve proteoglycans. The suspension was centrifuged
at 4°C for 30 mins at 4000 × g, and the pellet re-suspended in 35 mL of
0.5 M acetic acid containing 2 mg pepsin per mL. This was left overnight
at 4°C to digest the N- and C- telopeptides containing natural cross-links.
After centrifugation at 4°C at 4000 × g, the supernatant was neutralised to
pH 7.0 – 8.0 with NaOH at room temperature. The new pellet, containing
insoluble collagen, was discarded. The supernatant was dialysed overnight
(Spectra/Por® 6 Dialysis Membrane, Spectrum Laboratories Inc., CA, USA)
against 15 L of 2.5 M NaCl in 0.5 M acetic acid to precipitate the solu-
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bilised type I collagen. This was then centrifuged for 30 mins at 4°C and
re-suspended in 0.5 mL 0.1 M acetic acid. The new suspension was dialysed
overnight against 15 L 0.1 M acetic acid to remove residual salt.
4.3.6.2 Protein purification
The 2-D Clean-Up kit (Amersham Biosciences) was used to purify proteins
for electrophoresis. A volume of 100 μL of sample was placed in a 1.5 mL
Eppendorf tube. 300 μL of precipitant was added, and the mixture vortexed
briefly and incubated on ice for 15 mins. Next, a co-precipitant was added,
the mixture vortexed and centrifuged for 5 mins at 4°C at 15 000 × g. The
supernatant was discarded and 40 μL of co-precipitant placed on the pellet,
on ice for 5 mins. After centrifugation, the pellet was re-suspended in 25
μL DI H20. One mL of wash buffer pre-chilled at -20°C for 1 hr, and 5 μL
wash additive, were added. The mixture was vortexed extensively between
incubation periods at -20°C. After 5 mins centrifugation, the supernatant
was discarded.
4.3.6.3 Protein quantification
The 2D Quant kit (GE Healthcare Life Sciences, Amersham, UK) was the
preferred means of measuring the quantity of protein in solution. The
manufacturer’s instructions were followed. Briefly, a standard curve was
prepared using incremental quantities of 2 mg/mL bovine serum albumin
(BSA) in 1.5 mL Eppendorf tubes. A volume of 1 - 50 μL of each sample to be
assayed was pipetted into separate Eppendorfs (depending on the expected
protein concentration). A volume of 500 μL of precipitant was added to the
tubes, which were vortexed briefly. A volume of 500 μL of co-precipitant was
added, and the tubes inverted before centrifugation at 10 000 × g for 5 mins.
The supernatants were removed completely using a micropipette. A volume
of 500 μl of 20% copper solution in DI H20 was added to the pellets, followed
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by 1 mL of working colour reagent. The samples were incubated for 15 -
20 mins. Absorbance was read at 490 nm, and compared to the BSA stan-
dard curve using Softmax® software (MDS Analytical technologies, Toronto,
Canada). Protein quantification was carried out as described, and samples
were concentrated if necessary using spin columns with a 3 kDa molecular
weight cut-off (MWCO) to achieve protein concentrations of 1 - 2 μg/μL.
4.3.6.4 Gel electrophoresis
The pellet was re-suspended in 15 uL of sample buffer made up of 20 parts 1
× lithium dodecyl sulfate (LDS) to 1 part dithiothreitol (DTT). Samples were
heated to 70°C for 10 mins before being loaded onto a 3-8% Tris-Acetate gel
(NuPAGE® Novex®, Invitrogen). Buffer chambers were loaded with Tris-
Acetate SDS Running Buffer (NuPAGE®) and 500 μL antioxidant loaded
in the upper chamber. The HiMark™ Unstained Standard (Novex®, Invit-
rogen), consisting of nine proteins, was used as a high molecular weight
marker. Samples were run for 60 mins at 150V. Gels were then washed
three times in DI H2O and stained for 3 hrs in SimplyBlue™ SafeStain
Coomassie® G-250 stain. De-staining was carried out in DI H20 overnight,
prior to scanning.
4.3.7 Mass spectrometry
The bands were removed from the gels with a Swann-Norton No. 22 blade
and placed in 1.5 mL Eppendorf tubes in DI H20. A strict no-touch technique
was used to avoid contaminating the bands with keratin. The tubes were
sent to the School of Biosciences at the University of Nottingham for mass
spectrometry. 7
The gel bands were cut into smaller pieces and placed into a 96-well
microtitre plate for destaining, reduction and alkylation on a MassPREP
7Courtesy of Dr Susan Liddell.
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robotic liquid handling station (Waters Corporation, Milford, MA, USA).
The bands were incubated in 100 μL of de-stain solution (50 mM ammonium
bicarbonate, 50% acetonitrile) for 10 mins × 3 at 40°C. Following removal of
the final aliquot, the samples were dehydrated by incubation at 40°C in 50
μL of acetonitrile for 5 mins. The acetonitrile was removed and evaporation
allowed to proceed for 10 mins. The samples were reduced by incubation
in 50 μL of reducing solution containing 10 mM DTT and 100 mM ammo-
nium bicarbonate for 30 mins at 40°C. Following removal of the reducing
solution, the samples were incubated in 50 μL of alkylation solution (55 mM
iodoacetamide, 100 mM ammonium bicarbonate) for 20 mins at 40°C. The
gel pieces were then washed at 40°C in 50 μL of 100 mM ammonium bi-
carbonate for 10 mins and 50 μL of acetonitrile for 5 mins. They were then
dehydrated by double 40°C washes in 50 μL of acetonitrile for 5 mins and al-
lowed to evaporate for 5 mins. The microtitre plate containing the gel slices
was cooled to 6°C for 10 mins before addition of 30 μL per well of trypsin
gold (Promega), diluted to 10 ng μL−1 in 50 mM ammonium bicarbonate.
The plate was incubated at 6°C for a further 20 mins to permit trypsin to
infiltrate the gel plugs with minimal protein autocatalysis. A further incu-
bation proceeded for 4 hrs at 37°C. The samples were stored at 4°C until
MS analysis.
The extracted peptides were delivered via a nanoscale LC system to a
Q-ToF™ 2 mass spectrometer (Waters®). The peptides were separated us-
ing a 15 cm PepMap C18 reversed phase column with an inner diameter of
75 μm (LC Packings, Sunnyvale, CA) on a CapLC system (Waters®). This
was attached to a Q-ToF™ 2 mass spectrometer equipped with a nanolock-
spray source and operated with MassLynx Version 4.0 acquisition software.
Selected peptides were automatically analysed by electrospray ionisation
MS/MS. Tandem MS data were acquired using a data-dependent switch-
ing between MS and MS/MS scanning, based upon ion intensity, mass and
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Table 4.2: Mascot Peptide Summary Report data
Mascot variable Explanation
Protein Score Combined scores of observed mass spectra matched to amino acid sequences
Protein sequence coverage Percentage of database protein sequence covered by matching peptides
Matches Number of MS/MS spectra matched to the protein
charge state. Charge state recognition was used to select doubly, triply and
quadruply charged precursor peptide ions for fragmentation. Up to four pre-
cursor masses at a time were chosen for tandem MS acquisition. Collision
energy was automatically adjusted between 15 and 55 eV, based on charge
and mass of each precursor. ProteinLynx Global SERVER version 2.0 was
used to process the uninterpreted MS data into peak list (.pkl) files.
Each MS/MS spectrum was searched (‘queried’) against known human
sequences in the SwissProt and/or National Center for Biotechnology In-
formation (NCBI) non-redundant databases in Mascot MS/MS Ion Search
mode (www.matrixscience.com) (Perkins et al., 1999). Carbamidomethyla-
tion of cysteine and oxidation of methionine and proline were set as variable
modifications. Two missed trypsin cleavages were allowed. Default search
values were entered, with the exceptions of file type (Micromass pkl) and
instrument type (ESI-Q-ToF™ 2). The nomenclature used was assigned by
the Human Genome Organisation (HUGO) Gene Nomenclature Committee.
Protein identifications were accepted only if the probability-based Molecu-
lar Weight Search (MOWSE) scores were above a threshold of p < .05. The
percent coverage, or approximate relative abundance level of each peptide
was recorded in a Peptide Summary Report. An explanation of the data
from the report is summarised below (table 4.2).
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4.3.8 Western blotting
4.3.8.1 Preparation of samples
The purified collagen extracts from cross-linked AM and control samples
were subjected to western blotting under reducing conditions. This was per-
formed on three AM samples. A loading buffer was prepared by mixing 4
× NuPage® LDS sample buffer (5 parts), 1.0 M DTT (1 part, made up by
adding 0.154 g stock powder to 1 mL DI H2O) and 14 parts DI H2O. The
loading buffer was added to the protein extract to obtain a protein concen-
tration of approximately 1.0 μg/μL. The samples were denatured by heating
to 95°C for 4 mins in a thermal cycler (Thermo Hybaid PCR Express Ther-
mal Cycler, Hybaid, Hampshire, UK), and vortexed prior to loading.
4.3.8.2 Protein electrophoresis
A running buffer was prepared by diluting 20× concentrated 2-(N-morpholino)
ethanesulfonic acid (MES)/sodium dodecyl sulfate (SDS) buffer with DI H2O.
The gels used were NuPAGE® 3-8% Tris-Acetate 1.0 mm 10-well Novex gels
(Cat. No. WG1601A, Invitrogen, Paisley, UK), recommended for high molec-
ular weight proteins. The white strip and the plastic comb were removed
from the gel packaging, and the gels washed in DI H2O. One gel was loaded
into the Novex II module tank, which was was filled with running buffer to
completely cover the wells. Next, 500 μL of NuPage® antioxidant was added
to the central tank. The tank was then inserted onto the Novex PowerEase®
500 Power Supply for electrophoresis. Long tip dispensers were used to load
10 μg of protein to each well. A stained HiMark™ molecular weight marker
(Invitrogen) was loaded into the first well. Electrophoresis was carried out
for 35 mins at 200 mV.
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4.3.8.3 Protein transfer
A transfer buffer was made up by adding 200 mL methanol to 750 mL DI
H2O and 50 mL of NuPage® Transfer Buffer (20 ×). Immobilon polyvinyli-
dene fluoride (PVDF) membranes (Millipore, Massachussets, USA) were
soaked in methanol and then transferred to a tray containing sponges and
blotting papers soaked in transfer buffer. The gel was retrieved from the
casing. The blotting apparatus was assembled by sandwiching the mem-
brane and the gel between sheets of blotting paper and sponges, keeping
the combination as wet as possible with transfer buffer. The blotting appa-
ratus was loaded into the tank and topped up. The running time was 1 hr at
30 V. The membrane was washed and transferred to a tray containing TBS-
TM blocking buffer (5% non-fat dry milk in TBS containing 0.1% Tween 20)
for 1 hr on a rocker.
4.3.8.4 Incubation with primary antibody
A rabbit anti-human antibody (Ab34710, Abcam®, Cambridge, UK) was
used as a primary antibody against the type I collagen at a concentration
of 1:5000. The membranes were then transferred into trays containing 10
mL of primary antibody in TBS-TM. The trays were left on a rocker at room
temperature for 4 hrs.
4.3.8.5 Detection of protein bands
The membranes were washed in TBS containing 0.1% Tween 20 (TBST) for
15 mins, followed by three quick washes. An alkaline phosphatase (AP)-
conjugated donkey anti-rabbit secondary antibody (Cat. No. 31345, Pierce,
Rockford, IL, USA) was added for 1 hr (1:20 000 dilution in antibody buffer),
followed by a 15 min wash and three washes for 5 mins each in TBST. A
substrate solution of 5-Bromo-4-chloro-3-indolyl phosphate/Nitro blue tetra-
zolium chloride (BCIP/NBT purple liquid substrate, Sigma) was added for 5
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- 10 mins until the protein bands began to appear. The reaction was stopped
by washing the blots in DI H2O before air-drying.
4.3.9 Analysis of cross-linking by other methods
4.3.9.1 Interfibrillar measurement
A software macro was developed to measure the spaces between the colla-
gen fibres visible on TEM sections at a magnification of 50 000. The macro
automatically optimised brightness and contrast and placed markings sep-
arating the dark fibres from the light spaces, providing over 1000 measure-
ments per sample. Six AMs were divided into two sections. One section was
treated with 0.1% riboflavin-5-phosphate and 30 mins exposure to UVA (at
16 mW/cm2). The other section was kept in PBS solution. Sections were
prepared for TEM. Three specimens were selected from each section to give
a range of collagen densities. Each specimen was visualised with a magni-
fication of × 50 000. The compact layer was identified as the area beneath
the BM. The image was rotated for the BM margin to be aligned with the
vertical axis. The BM was positioned immediately to the left or right of the
frame in order to capture the sub-BM compact layer. An area of 100 μm2 was
photographed. The software macro was launched to measure the IFD across
approximately 30 intercepts, returning a mean and standard deviation for
each image. Three different areas of each AM specimen were photographed.
In total, this produced nine results from several thousand measurements
for each AM section, giving an estimate of the collagen density. A two-way
ANOVA was performed to compare the treated and untreated AM sections
across the six different donors.
190
4.3.9.2 Uniaxial tensile tests
Uniaxial tensile tests were performed on strips of riboflavin/UVA-treated
AM and untreated controls from five AMs (n = 80) as described above (Sub-
section 4.3.3). The data was filtered and fit to the mathematical model
described previously. Statistical analysis was performed on force-distance,
stress-strain and model data to compare the effects of treatment on AM
samples.
4.3.9.3 Ninhydrin assay
Five samples of v-d AM were soaked in 0.01% riboflavin for 30 mins, and
exposed to UVA for 5, 7.5, 10, 12.5 and 30 mins. Two further samples were
immersed in 0.1% and 1% glutaraldehyde as positive controls. Each test
sample was heated in 2% ninhydrin solution for 20 mins at 95°C. The solu-
tion was allowed to cool, and the optical absorbance was measured with a
UV-visible spectrophotometer at 570 nm. The amount of free amino groups
in AM before (Cb) and after (Ca) cross-linking is proportional to the optical
absorbance. The extent of cross-linking was measured as a cross-linking
index as follows:
((Cb − Ca) /Cb)× 100 (4.7)
4.4 Results
4.4.1 Transparency assay
Representative samples of 0% and 10% v-d AM, 5 cm in diameter, are shown
in figure 4.8 A and B. Against print, 0% v-d AM appears more opaque than
10% v-d AM. Against a dark background, a white residue is visible on the
0% v-d AM sample. This fades as the concentration of trehalose increases.
There are several folds visible in the dried tissue; these impede the clarity
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Figure 4.8: Transparency assay
A transparency assay was performed on 0% (A) and 10% v-d AM (B) by digitally pho-
tographing samples overlying print (above). Further samples (0%, 5% and 10% v-d AM)
were photographed against a dark, granulated background (bottom strip) (representative
samples shown).
and the uniformity of the product.
4.4.2 Scanning electron microscopy
Multiple SEM images were taken of intact and denuded fresh AM and 0%
and 10% v-d AM from three donors, and images selected for their quality.
Representative images are shown of epithelial, BM and collagenous layers.
Selected SEM images of denuded v-d AM from are also shown to illustrate
important features. En face images of intact fresh AM and 0% v-d AM are
shown in figure 4.9 (A-F, × 1000). Microvilli form a carpet on the AEC in
fresh tissue (A). The polygonal shapes represent the cell borders. There
are furrows between the devitalised cells, indicating depth. In the v-d AM
sample (B), the microvillous layer is sparse. The polygonal shapes are still
discernible, but there is no depth between the cells, suggesting tissue col-
lapse. At higher magnification (× 4000), it can be seen that the microvilli
in fresh AM (C) retain their shape and density. A few individual microvilli
are still discernible on v-d AM (D). However, the majority of microvilli have
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Figure 4.9: SEM of fresh and v-d AM epithelium
In fresh AM (A), AEC appear full in contrast to the compacted cells in v-d AM (B) (× 1000);
The polygonal shape of fresh AEC (C) is maintained, whereas it is distorted in v-d AM (D),
(× 4000); Microvilli appear integral in fresh AM (E) and sparse in v-d AM (F), (× 20 000).
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Figure 4.10: SEM of collagenous layers
SEM of reticular layer in fresh AM (A) and v-d AM (B) (× 20 000); The compact collagenous
layers in fresh AM (C) and v-d AM (B). The epithelium is visible at the right of the images (E)
(× 4000); Epithelial (Ep), basement membrane (BM) and compact collagenous (Co) layers in
fresh AM (E, × 10 000); BM of denuded v-d AM (F, × 3500). The compact layer is exposed
by localised damage.
become effaced, and the resultant density is much lower. This is confirmed
at higher magnification (× 20 000). The microvilli in v-d AM appear at-
tenuated (F), and in some areas are no longer recognisable as microvilli,
indicating damage to the cell membrane. The microvillous layer in fresh
membrane (E) is intact. Images of the compact and loose collagen layers
were obtained by focusing onto defects in the v-d AM and onto the under-
side respectively (Figures 4.10 A-F). The compaction seen on the epithelial
side of v-d AM is also seen in the loose collagen layers (B), compared to fresh
AM (A) (× 20 000). However, it is less evident in the compact collagenous
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Figure 4.11: SEM images of 10% v-d AM
Epithelial surface, 10% v-d AM, showing preserved microvilli and polygonal shapes (A, ×
1000; B, × 4000); Collagenous layers, 10% v-d AM, showing lamellae and compaction (C, ×
4000; D, × 10 000). Ep, epithelium.
layer, in which the collagen fibres are already densely interpositioned (C,
D) (× 4000). The collagen fibres appear to be distributed in lamellae. The
BM is seldom seen in intact AM. In figure 4.10 E, a the BM is shown sep-
arating the epithelium from the compact collagenous layer. figure 4.10 F
the BM appears smooth. The compact collagenous layer is seen immedi-
ately underlying the BM. On the epithelial surface of 10% v-d AM, the deep
furrows between the cells seen in fresh AM are absent, yet the polygonal
shapes appear well-maintained (figure 4.11 A). There is scattered cellular
debris on the surface. The microvillous layer (B) is well-preserved in com-
parison to the untreated samples (4.11 B). The collagen layers demonstrate
the compaction and lamellar distribution seen previously (figure 4.11 C and
D).
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Figure 4.12: Accelerated degradation assay
Accelerated degradation assays were performed to compare fresh, f-t and v-d AM. Samples
were incubated in 1% collagenase solution for 72 hrs and lyophilised for SEM. SEM im-
ages of fresh (B), f-t (D) and v-d AM (F) (× 1000) treated with collagenase are shown with
untreated controls (A, C and E). One of two representative samples are shown.
4.4.2.1 Degradation assay
Accelerated degradation assays were conducted in duplicate on fresh, f-t
and v-d AM. These were lyophilised in their respective media as a method
of fixation. Representative SEM images from one sample (of two) are shown
in figure 4.12. There is a meshwork of whorls forming a pattern on the
stromal side of the tissue (A, C and E) which could be due to the deposi-
tion of DMEM solutes during freeze-drying. The untreated v-d AM sample
(E) differs from the fresh and f-t controls (A and C) in having a compacted
appearance, although whorls are still visible. As the meshwork was consis-
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Figure 4.13: Cross-section of v-d AM
One SEM image of v-d AM in cross-section is shown (× 1000). This sample is approximately
20 μm in thickness. SL, spongy layer; C, collagenous stroma, E, epithelium.
tent and pronounced, covering virtually the entire stromal surface, this was
used as a reference to compare to the treated samples (B, D and F). It can
be seen that the collagenase-treated tissue is in an advanced state of decay
compared to the controls, with the formation of large lacunae through the
entire thickness of the membrane and the loss of recognisable features. The
three preparations are in broadly similar states of decay. A further image
from the degradation assay corresponds to a control sample and is included
as an illustration of compaction of v-d AM (figure 4.13).
4.4.3 Transmission electron microscopy
Multiple TEM images were taken of intact fresh AM and 0% v-d AM from
three donors, of which representative images were selected and are shown.
Images of fresh AEC (A and C, × 50 000) and v-d AEC (B, × 80 000; D, ×
25 000) are shown in figure 4.14. In fresh AM, villous folds were seen to
form distinct fingerlike projections in the channels between the AEC (A).
Hemidesmosomes are visible in v-d AM (B), while desmosomes or villous
folds were less distinct. The cell nucleoplasm in fresh AM is dense and var-
iegated, suggesting that the nucleus membrane is intact (C). The microvilli
are erect and numerous, and the cytoplasm is organised and contains dis-
197
Figure 4.14: TEM images of fresh and v-d AEC
AEC of fresh (A and C, × 50 000) and v-d AM are shown (B, × 80 000; D, × 25 000). V-d
AEC appear devitalised and flattened, with a loss of distinct features in the cell cytoplasm,
membrane and nucleus. Mv, microvilli; BM, basement membrane; VF, villous folds; Ds,
desmosome; hDs, hemidesmosome; I, type I collagen transverse fibre; III, Type III collagen
transverse fibre; N, nucleoplasm; V, vacuole.
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Figure 4.15: TEM of denuded v-d AM
This TEM image shows the BM and stromal aspects of denuded v-d AM (× 25 000). A
fine meshwork visible close to the BM is suggestive of type III collagen. Transverse and
longitudinal type I collagen is visible throughout, with occasional keratocytes seen in the
loose layer. BM, basement membrane; III, Type III collagen fibres; K, keratocyte.
cernible features. The AEC of v-d AM are devitalised, evidenced by the flat-
tened appearance of the cells and microvilli (D). The signs of devitalisation
include condensed nucleoli, an optically clear and uniform nucleoplasm and
large intracellular vacuoles. There is an absence of detail in the intracel-
lular environment, which appears dense and disorganised. A fine network
of collagens, most likely type III, is visible close to the BM in figure 4.14 B,
where it is interspersed among type I fibres. Figures 4.15 A and B shows
the bulk of the stroma to be made up of small amounts of type III and abun-
dant thick fibres of type I collagens, visible as longitudinal and transverse
structures (round in cross-section) (× 25 000). On the loose collagenous side
of v-d AM, occasional keratocytes may be seen. At a magnification of × 50
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Figure 4.16: IFD measurements
Compact zone collagen fibres with markings for IFD measurements are shown. The images
are representative of fresh AM (A) and v-d AM (B) (× 50 000). The zones selected are
adjacent to BM, the direction of which is indicated by the white arrows.
000, a TEM image of fresh and v-d AM stroma adjacent to the BM (indi-
cated by white arrows) shows an abundance of collagen fibres appearing
as pairs or clusters of lines (figure 4.16). Scale markings have been placed
by the camera software, and enlarged figures have been added for clarity.
Measurement of the IFD was obtained from such images.
4.4.4 Atomic force microscopy
Triplicate AFM images were taken of three samples of 0% and 10%. Rep-
resentative images are shown. Crystalline structures are visible on the ep-
ithelial and stromal aspects of 0% v-d AM (white arrows, A, C) (figure 4.17).
These are not visible in 10% v-d AM (B, D). Microvilli are visible on the ep-
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Figure 4.17: AFM images of v-d AM
Atomic force microscopy images of stromal and epithelial aspects of 0% and 10% v-d AM
are shown. The untreated AM (A, C) is characterised by abundant crystalline structures,
possibly salts, obscuring the tissue details (white arrows). AFM images of the treated AM
may indicate microvilli (black arrow, B) and stromal collagens (D) (z scale not shown).
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Figure 4.18: Optical microscopy ( × 40)
Optical microscopy images of representative samples of v-d AM (B) and f-t AM (A) suggest
compaction of the dried sample (1 pair of three shown). Thickness measurements of AM
sections showed no significant difference between v-d AM and f-t AM samples.
ithelial aspect of the 10% v-d AM (black arrow). The stromal collagen fibres
are clearly discernible in D, but they are partially obscured by salt crystals
on the membrane in C.
4.4.5 Optical microscopy
4.4.5.1 Optical microscopy
A comparison of f-t and v-d AM samples was made by optical microscopy
(representative samples shown in figure 4.18 A and B). The epithelial and
collagenous layers in the v-d tissue (B) appear flattened in comparison with
f-t AM (A). Random thickness measurements were obtained from samples of
unstained and unfixed AM preparations (figure 4.18 C). F-t and v-d samples
were obtained from a total of four AMs. Three sections were processed for
each sample, and a minimum of three measurements were obtained from
each section (n = 134). The mean thickness of f-t AM was 23.9 μm (SD 9.0;
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n = 38), and for reconstituted v-d AM it was 25.9 μm (SD 6.8, n = 96), in-
dicating high variability and no significant difference in thickness between
the two preparations (t test; p = .22).
4.4.6 Uniaxial testing
4.4.6.1 AM micrometry
Thickness measurements were conducted on 185 samples (80 fresh, 47 f-
t and 58 v-d) from 14 donors. Univariate tests of normality showed that
thickness measurements were not distributed normally, indicated by pos-
itive skewness and kurtosis, a Kolmogorov-Smirnov statistic of .002 and
three outliers. Therefore, a Kruskal-Wallis test was used to compare the
effect of preparation method on thickness. It revealed a statistically signif-
icant difference in thickness across the three preparation methods, χ2 (2, n
= 208) = 57.43, p < .001. The median values were: fresh AM, 49 μm (range
31 to 86, n = 80), f-t AM 41 μm (range 31 to 58, n = 47) and v-d AM 28 μm
(range 17 to 55, n = 58). Post-hoc Mann Whitney U tests revealed a signifi-
cant difference between fresh and v-d AM, U = 688.5, z = -7.04, p < .001 with
a large effect size (r = .60), between fresh and f-t AM, U = 1190, z = -3.45, p
= .001 with a medium effect size (r = .31) and between f-t and v-d AM, U =
622.5, z = -4.78, p < .001 with a large effect size (r = .47).
4.4.6.2 Data filtration
Seventy traces that were categorised as non-smooth by masked visual in-
spection (22 fresh, 17 f-t and 31 v-d) were removed from the analysis. Five
traces with an initial E that had a negative value (4 fresh, 1 v-d) were also
removed. From the original data set of 208 traces, 75 in total were elimi-
nated. The proportions of traces eliminated represent 27.4% of fresh AM,
30.1% of f-t AM and 55.2% of v-d AM samples. The RR of a trace of a v-d
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sample being eliminated was 2.02 (95% CI 1.35 to 3.01, p < .001) in compari-
son to a fresh sample, and 1.75 (95% CI 1.11 to 2.79, p = .016) in comparison
to a f-t sample. In contrast, the RR of a f-t sample was not statistically sig-
nificant in comparison to a fresh sample. Following the elimination of these
traces, 133 traces from 17 donors remained for analysis (69 fresh, 38 f-t and
26 v-d AM). Force-distance and stress-strain analyses and mathematical
modelling were performed on these data.
4.4.6.3 Force-distance analysis
Univariate tests of normality were conducted on 133 traces from 17 donors,
using UTS and ΔL as dependent variables (‘pooled data’). These tests de-
tected positive skewness and kurtosis, clustering of the detrended normal
Q-Q plots and multiple outliers, all suggestive of non-Gaussian distribution.
Kruskal-Wallis tests were used to compare UTS and ΔL across three prepa-
ration methods. There were no statistically significant differences in UTS,
χ2 (2, n = 133) = 3.48, p = .176, and ΔL, χ2 (2, n = 133) = 5.11, p = .078.
The median and mean scores in UTS and ΔL are shown in table 4.3. An
inspection of the UTS scores shows that fresh AM samples had the highest
score (Md = 2.09 N), f-t AM had an intermediate score (Md = 1.95 N) and
v-d AM had the lowest score (Md = 1.58 N). The median scores in ΔL shows
that fresh AM samples had the lowest score (Md = 7.30 mm), f-t AM had an
intermediate score (Md = 7.53 mm) and v-d AM had the highest score (Md
= 7.96 mm). A further Kruskal-Wallis test was performed to compare UTS
and ΔL across 17 donors. There were statistically significant differences
across the donor groups in UTS, χ2 (16, n = 133) = 54.34, p < .001, and ΔL,
χ2 (16, n = 133) = 38.18, p = .001, indicating inter-donor variability.
In order to minimise the statistical effects of variability between donors,
UTS and ΔL were compared between groups of AM samples matched by
donor for at least two preparation methods (‘matched data’). This resulted
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Table 4.3: UTS and ΔL of AM
AM Fresh (69) F-t (38) V-d (26)
Total (133) Md UTS/ΔL (n)
1 (2) - 1.71/10.26 (2) -
2 (2) - - 1.40/7.76 (2)
3 (5) - - 1.70/9.68 (5)
4 (15) 1.70/8.43 (2) 2.56/6.61 (8) 1.28/7.48 (5)
5 (10) 2.59/9.48 (3) 1.87/7.88 (7) -
6 (4) 2.09/8.86 (2) - -
7 (1) - 1.94/5.80 (1) -
8 (18) 2.63/8.40 (8) 3.04/9.66 (4) 3.09/7.40 (6)
9 (1) - - 1.50/9.03 (1)
10 (14) 1.69/6.19 (6) 1.39/5.85 (7) 1.20/9.98 (1)
11 (10) 2.05/8.24 (7) - 1.59/9.60 (3)
12 (21) 2.20/8.08 (9) 1.50/8.61 (9) 1.32/7.51 (3)
13 (6) 2.40/7.14 (6) - -
14 (6) 2.22/6.85 (6) - -
15 (6) 2.33/6.82 (6) - -
16 (5) 1.81/6.32 (5) - -
17 (7) 1.69/6.95 (7) - -
Md UTS/N
(range)
2.09 (0.82 - 4.29) 1.95 (1.00 - 4.32) 1.58 (0.93 - 3.91)
M UTS/N (SD) 2.10 (0.67 ) 2.11 (0.82) 1.87 (0.82)
Md ΔL/mm
(range)
7.30 (3.77 - 10.48) 7.53 (4.96 - 12.61) 7.96 (5.75 - 12.24)
M ΔL/mm (SD) 7.42 (1.40) 7.83 (2.00) 8.31 (1.61)
UTS, ultimate tensile strength (N); ΔL, change in length (mm); n, number of samples
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in a total of 88 traces (35 fresh, 35 f-t and 18 v-d) from six donors (6 fresh, 5 f-
t and 5 v-d). Univariate and multivariate tests of normality were conducted.
Despite a degree of positive skewness (.639) in UTS and a Kolmogorov-
Smirnov statistic of .039, the univariate analysis indicated that the matched
data were distributed normally. There was one outlier in the ΔL data which
could safely be retained in the analysis. In the multivariate analysis, the
maximum Mahalanobis distance was below the critical value, indicating an
absence of multivariate outliers. The assumption of linearity was satisfied,
and there was a small correlation between UTS and ΔL (r = .07). A two-way
MANOVA was conducted using donor and preparation method as categor-
ical variables. The data did not violate the assumption of homogeneity of
variance-covariance matrices (Box’s test .525) or equality of variance (Lev-
ene’s test: UTS, .534, ΔL, .606). A Bonferroni adjustment was applied to
account for two variables, giving a new alpha level of .025. There was a sta-
tistically significant difference in the combined dependent variables across
donors, F (10, 144) = 3.79, p < .001, Pillai’s trace .42, partial eta squared =
.21 (large effect size), but not across preparation categories F (4, 144) = .95,
p = .436, Pillai’s trace .05, partial eta squared = .03. The estimated marginal
means indicated a mean UTS score of v-d AM of 1.79 N, SE = .19), which
was lower than the scores of both fresh AM (M = 2.14 N, SE = .12) and f-t
AM (M = 2.19 N, SE = .15). The estimated marginal mean ΔL score of v-d
AM (M = 8.45 mm, SE = .46) was higher than the scores of both fresh AM
(M = 7.86 mm, SE = .31) and f-t AM (M = 7.86 mm, SE = .28). The matched
data demonstrated the same effects of preparation method and donor on
UTS and ΔL as the pooled data.
4.4.6.4 Stress-strain analysis
The pooled data set (n = 133) was used for stress-strain analysis. Five fresh
and two f-t AM samples did not have thickness measurements. These were
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Table 4.4: Stress-strain measurements by AM category
AM E1 (MPa) σvNf (MPa) σv
T
f
(MPa) εf (%) Area
(mm2)
E2 (MPa) T
(J/mm3)
Fresh (69) 0.45 4.09 5.64 36.5 0.50 24.05 0.45
F-t (38) 0.62 4.97 6.45 37.6 0.43 27.71 0.49
V-d (26) 1.01 5.28 7.52 39.8 0.34 29.90 0.61
χ2 .87 9.23 10.52 5.11 31.74 7.52 10.37
p .65 .010 .005 .078 < .001 .023 .006
Median values of dependent variables shown. σvNf , nominal failure stress; σv
T
f , true failure
stress; εf , failure strain; T, toughness; MPa, megaPascals; J, joules; E1, initial modulus; E2,
final modulus.
given nominal thickness values of 40 μm. Univariate tests of normality were
performed for seven dependent variables: cross-sectional area, E1, σvNf , σv
T
f ,
εf , E2 and toughness. Of these, only εf was distributed normally. Therefore,
non-parametric testing was performed throughout. Kruskal Wallis tests
were used to compare each of these dependent variables across preparation
categories (table 4.4). These revealed statistically significant differences in
area, σvNf , σv
T
f , toughness and E2, but not in εf or E1. An examination of the
median scores reveals values of σvNf , σv
T
f , E1, E2 and toughness that are lowest
for fresh AM, intermediate for f-t AM and highest for v-d AM. The trend for
cross-sectional area is in the opposite direction. A post-hoc Mann Whitney
U test was performed to compare the toughness of v-d AM with fresh AM. It
revealed a significant difference, U = 520, z = -3.15, p = .002, r = .3 (medium
effect size). The relationship between area and toughness was investigated
using Pearson product-moment coefficient. A medium negative correlation
was found, r = -.30, n = 88, p = .004. Similar correlations were observed
between area and σvNf (r = -.33, p = .002) and between area and σv
T
f (r = -.32, p
= .002).
To illustrate the effects of thickness measurement on the dependent vari-
ables, a new measurement of σvNf was calculated based on a uniform thick-
ness of 50 μm for all three preparations. A Kruskal Wallis test demonstrated
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Table 4.5: Modelling data by AM category
AM d G′
(MPa)
RMS
(kPa)
d2 G
′
2
(MPa)
RMS2
(kPa)
d3 G
′
3
(MPa)
RMS3
(kPa)
Fresh
(69)
4.16 1.24 6.18 10.91 0.15 21.87 4.36 1.31 6.45
F-t (38) 4.45 1.50 6.95 10.49 0.21 23.44 4.77 1.45 6.64
V-d (26) 3.86 1.18 6.46 8.48 0.34 21.56 3.86 1.18 6.46
χ2 2.41 .66 3.19 8.33 .88 1.98 4.18 .23 .30
p .30 .30 .20 .016 .65 .37 .12 .89 .86
Median values of dependent variables shown. Comparisons made by Kruskal Wallis testing.
RMS, root mean square of the error; d, G´, model parameters.
a statistically significant difference between the values, χ2 (2, n = 133) =
7.88, p = .019. An inspection of the median values shows σvNf to be highest
for fresh AM (4.19 MPa), intermediate for f-t AM (3.91 MPa) and lowest for
v-d AM (3.16 MPa).
4.4.6.5 Model fitting
For the first curve fitting, model parameters G′ and d were derived simulta-
neously from the experimental data of the entire stress-strain curves, gen-
erating model curves. The difference between the experimental and model
curves was expressed as a RMS error. Since the data were non-Gaussian,
Kruskal Wallis tests were conducted to assess the effects of preparation
method on d, G′ and RMS. There was no statistically significant difference in
RMS across the three preparation methods. The median values are shown
in table 4.5.
A second fitting was performed using a value ofG′2 obtained from the gra-
dient between 0.495 and 5% strain. This was used to generate model curves
with new values for d (d2), and with a new RMS error (RMS2). Kruskal
Wallis tests were performed to compare the effects of different preparation
methods on G′2, d2 and RMS2 (table 4.5). A significant difference was found
in d2 of the different preparations (χ2(2, 133) = 8.33, p = .016). Post-hoc
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Mann-Whitney U tests were conducted, comparing v-d AM to the other two
preparations. A Bonferroni adjustment was made, reducing the alpha level
to .025. The value of d2 was significantly lower for v-d AM than fresh AM, U
= 566, z = -2.76, p = .006, r = .24 (medium effect size) and f-t AM, U = 321, z
= -2.37, p = .018, r = .21.
A third fitting was performed by applying an adjustment to the starting
point to compensate for slackness or tension in each sample, generating new
values G′3, d3 and RMS3. An inspection of the median values show that this
adjustment increases the difference in the value of d for v-d AM compared
to the other preparations, although this is not statistically significant (p =
.12).
4.4.7 Non-destructive tests
4.4.7.1 Acoustic wave impedance
The results displayed are the mean values of quadruplicate measurements
taken for three different AM samples in each of four preparation groups
(figure 4.19). Error bars represent standard deviations. The values of both
G′ and G′′ vary between 0 and 20 MPa across the preparation methods.
4.4.7.2 Nanoindentation
Nanoindentation was performed on 0% and 10% v-d AM samples using bare
cone tips with radii of 2 nm (cone 1) and 15 nm (cone 2) and spherical beads
with radii of 5 μm (sphere 1) and 15 μm (sphere 2). Mean values and SDs
of selected variables are shown in table 4.6. Using cone 1, significant dif-
ferences were found in E and hardness between the stromal aspects of 10%
v-d AM and 0% v-d AM (p < .0001). Cone 2 yielded a significant difference
in hardness between stromal 10% and 0% v-d AM (p = .0001). However,
variability was high, as evidenced by the high SD. Tests with sphere 1 and
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Table 4.6: Modulus, contact hardness and plasticity
Tip Trehalose Aspect n E/GPa (SD) Hardness/GPa
(SD)
Cone 1
0% Stroma 96 0.99 (0.68) 6.02 (6.35)
Epithelium 72 7.90 (13.97) 21.41 (76.40)
10% Stroma 72 48.66 (34.86) 56.68 (46.87)
Epithelium 72 28.19 (32.79) 40.18 (54.86)
Cone 2
0% Stroma 192 0.73 (0.89) 2.33 (37.58)
Epithelium 72 2.93 (7.42) 8.22 (87.02)
10% Stroma 24 4.94 (5.81) 59.03
(153.25)
Epithelium 96 1.82 (2.05) 2.33 (7.97)
Tip Trehalose Aspect n E/GPa (SD) Plasticity
(SD)
Sphere 1
0% a 28 0.27 (0.20) 0.21 (0.13)
b 64 0.10 (0.02) 0.23 (0.24)
10% a 63 0.88 (0.38) 0.17 (0.07)
b 63 0.44 (0.21) 0.23 ( 0.10)
Sphere 2
0% a 127 0.03 (0.03) 0.23 ( 0.08)
b 127 0.02 (0.01) 0.29 ( 0.07)
10% a 127 0.15 (0.05) 0.19 ( 0.07)
b 127 0.17 (0.15) 0.18 ( 0.13)
Cone 1, radius 2 nm; Cone 2, radius 15 nm; Sphere 1, radius 5 μm; Sphere 2, radius 15 μm.
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Figure 4.19: Acoustic impedance tests
The shear storage modulus (G′) and loss modulus (G′′) of four different AM preparations
was measured by surface acoustic wave impedance. FRAM, fresh amniotic membrane; TT,
thermolysin-denuded FTAM.
sphere 2 revealed no significant differences between the preparations.
4.4.8 Cross-linking
4.4.8.1 Gel electrophoresis
Collagen extract from samples treated with 0.1% riboflavin-5-phosphate
and 30 mins exposure to UVA (at 16 mW/cm2) was obtained from three AMs
(A, B and C) and subjected to gel electrophoresis (figure 4.20, left) after pro-
tein purification. Controls were run in the lanes to the right of the samples.
An unstained HiMark™ marker was also run (shown with values). Each
lane contained 10 μg of protein. The control lanes contain strong bands lo-
cated at approximately 450, 240, 160 and 130 kDa. The test sample lanes
(1, 2 and 3) are empty, with only a few faint bands. The strong bands in the
control samples were initially presumed to represent the full type I collagen
trimer, γ, the β dimer and the α monomer chains (boxed).
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Figure 4.20: AM collagen extract
A gel (left) is shown with a western blot. AM samples treated with riboflavin-A and ultra-
violet irradiation were loaded into lanes 1, 2 and 3. Untreated AM controls are shown in
adjacent lanes. In the gel, strong bands highlighted by boxes were thought to represent the
the γ, β and α chains of type I collagen. For the blot, an anti-type I collagen antibody was
used. This shows the presence of three strong bands, marked γ, β and α.
4.4.8.2 Western blotting
A western blot was carried out under denaturing and reducing conditions
on the AM samples treated with riboflavin/UVA and controls to confirm the
presence of type I collagen (figure 4.20, right). A stained HiMark™ marker
was run alongside the samples (left). Three bands stand out at approxi-
mately 450 kDa, 200 kDa and 110 kDa, initially thought to be the γ, β and
α bands. Only one of the α bands is clearly visible.
4.4.8.3 Mass spectrometry
The four principal bands identified by gel electrophoresis were sent for mass
spectrometry (figure 4.21). The 450, 240, 160 and 130 kDa bands localised
by gel electrophoresis were labelled a, b, c and d respectively. Two runs were
performed for bands a and d, whereas bands b and c had one run each. The
highest data yielded returned per run are presented in table 4.7. All four
bands contain the α1 chain of type III collagen. It has the highest Protein
Score, the highest number of matches and the highest percent coverage in
each band, except band c, where it has the second highest score. The scores
in the bands a - d are 233, 528, 149 and 953 respectively. The α1 chain of
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Figure 4.21: Mass spectrometry bands
Four principal bands (a-d) were identified by electrophoresis of purified collagen in fresh, untreated AM (right
lane). Riboflavin/UVA-treated AM is shown in the left lane. The bands were located at 450 kDa (a), 240 kDa (b),
160 kDa (c) and 130 kDa (d). These were sent for mass spectrometry. Rbf, riboflavin.
Table 4.7: Mascot Peptide Summary Report
Band ProteinMr pI Collagen Gene Score Matches Sequences Per cent
coverage
a CO3A1 138479 6.21 Alpha-1
(III)
COL3A1 233 25 14 16
a CO1A1 138857 5.60 Alpha-1 (I) COL1A1 52 3 3 3
b CO3A1 138479 6.21 Alpha-1
(III)
COL3A1 528 29 16 19
b CO1A1 138857 5.60 Alpha-1 (I) COL1A1 22 3 2 3
c CO5A1 183447 4.94 Alpha-1 (V) COL5A1 296 20 8 7
c CO3A1 138479 6.21 Alpha-1
(III)
COL3A1 149 3 3 3
c COBA1 180954 5.06 Alpha-1 (XI) COL11A163 6 3 2
d CO3A1 138479 6.21 Alpha-1
(III)
COL3A1 953 54 20 22
d CO1A1 138857 5.60 Alpha-1 (I) COL1A1 85 4 3 3
d CONA1 51912 6.88 Alpha-1
(XXIII)
COL23A144 6 1 2
d CO5A2 144821 6.07 Alpha-2 (V) COL5A2 57 3 3 2
d CO2A1 141698 6.58 Alpha-1 (II) COL2A1 41 2 2 1
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type I collagen is present in bands a, b and d. The scores for type I collagen
in these bands are 52, 22 and 85. Five other collagens chains are present,
of which the α1 chain of type V collagen has the highest score at 296.
4.4.8.4 Inter-fibrillar measurement
The mean IFD was calculated from three sub-BM zones of three TEM im-
ages from six cross-linked AM samples with untreated controls. The mean
IFD of Riboflavin/UVA-treated AM was 230.2 nm (SD 197.2), whereas for
untreated AM it was 214.3 nm (SD 180.7). A two-way ANOVA returned a
Levene statistic significance level of < .001, indicating unequal variances in
the IFD across the AM donors. There was a statistically significant inter-
action effect between the treatment method and the donor F (5, 124 451)
= 197.8, p < .001, indicating that the main effect could not be interpreted
easily. Nonetheless, there were highly significant effects for treatment and
donor (p < .001). This suggests that the mean IFD is significantly different
between treatment groups and between donors. The magnitude of the effect
for preparation is small (partial Eta squared .001).
4.4.8.5 Uniaxial tests of irradiated AM
Eight riboflavin/UVA-treated samples and eight controls from each of five
AMs underwent uniaxial testing (n = 80). Non-smooth curves were fil-
tered out (three treated and 10 controls), resulting in a total of 37 traces
of riboflavin/UVA-treated samples and 30 controls for analysis. The traces
from the experimental and control groups were compared through an array
of dependent variables including force-distance, stress-strain and modelling
data by conducting Kruskal Wallis tests (table 4.8). Statistically significant
differences were found in a number of dependent variables, including ΔL,
E1, E2, toughness, d, G′, d2 and G′2. An inspection of the median values re-
veals that riboflavin-UVA-treated AM had a higher ΔL and toughness and
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Table 4.8: Uniaxial tests of riboflavin/UVA-treated AM
AM Area
(mm2)
UTS
(N)
ΔL
(mm)
E1
(MPa)
σvN
f
(MPa)
σvT
f
(MPa)
εf (%) E2
(MPa)
T
(J/mm3)
Experimental
(37)
0.44 1.86 9.79 0.37 4.65 7.03 0.49 20.01 0.67
Control (30) 0.45 2.08 6.84 0.88 4.57 6.15 0.34 24.31 0.50
χ2 .01 .70 39.04 17.42 .11 .87 39.04 10.75 4.54
p .91 .40 < .001 < .001 .74 .35 < .001 .001 .03
AM d G′
(MPa)
RMS
(kPa)
d2 G′2
(MPa)
RMS2
(kPa)
d3 G′3
(MPa)
RMS3
(kPa)
Experimental
(37)
2.88 0.96 5.65 7.20 0.12 20.20 2.88 0.57 3.14
Control (30) 4.16 1.75 6.75 11.20 0.29 25.27 4.52 1.78 6.00
χ2 25.82 21.30 4.54 28.05 17.42 3.48 25.82 21.30 4.54
p < .001 < .001 .03 < .001 < .001 .06 < .001 < .001 .03
UTS, ultimate tensile strength; E1, initial modulus; E2, terminal modulus; T, toughness; d
and G, model parameters; RMS, root mean squared of error.
lower E1, E2, d, G′, d2 and G′2 than the control samples. The treated AM had
a lower UTS, although this was not statistically significant.
4.4.8.6 Ninhydrin assay
The cross-linking indices calculated from this assay varied from 1.1% for
AM exposed to UVA for 12.5 mins to -8.1% for AM exposed for 30 mins.
For comparison, the AM treated in 0.1% glutaraldehyde had a cross-linking
index of 28.8%, and for AM treated in 1% glutaraldehyde the index was
151.5%. This indicated that treatment of AM with riboflavin/UVA did not
result in cross-linking at the solution strength and irradiation levels used.
4.5 Discussion
Extensive material testing was performed, demonstrating that v-d AM un-
dergoes qualitative change during drying. This was shown by force-distance
analysis, stress-strain analysis and mathematical modelling. Cross-linking
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was unsuccessful, although a template is suggested for future analyses.
Non-destructive testing was also performed. This showed high variability,
suggesting a need for further refinement.
4.5.1 Physical properties of dried AM
From a clinical perspective, it is useful to know whether the process of dry-
ing the tissue causes a deterioration in its quality, and one of the ways of
assessing this is through materials testing. The tests described, such as ten-
sile tests and accelerated degradation studies, have clinical correlates like
robustness and resistance to enzymatic degradation. This is illustrated by
reports of successful cross-linking of AM by chemical means (Ma et al., 2010;
Kitagawa et al., 2011; Chau et al., 2012). Cross-linking can change the me-
chanical properties of AM by by modifying its structure, thereby improving
its clinical effects. There is no single quality threshold for the fitness for pur-
pose of dried AM. Therefore, tests frequently compare it to cryopreserved or
fresh preparations in order to indicate its clinical usefulness.
The EM studies on v-d AM indicate that the tissue becomes compacted
during the drying process (figures 4.9, 4.13 and 4.14). Both the SEM and
TEM images show a flattened and featureless epithelium and a compact
collagenous network. The v-d AM epithelium was found on both SEM and
TEM to be devitalised, in agreement with previous studies (Rodríguez-Ares
et al., 2009). The compaction of the collagenous network in comparison to
the fresh tissue has also been noted previously (Nakamura et al., 2008).
The collagenous layers contained multiple lamellae that were distributed
in heterogeneous orientations within the planes. Since these lamellae may
provide tensile strength in various directions, this leads one to question to
whether AM collagen is isotropic (i.e., uniform in all directions). A previ-
ous study addressed this issue, and identified regions of high collagen fibre
alignment within AM (Joyce et al., 2009). The authors of this study con-
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ducted biaxial tensile tests in which the response of AM was different in
each axis, indicating anisotropy. Thus, mechanical testing on AM varies
depending on the orientation of the samples.
SEM images were useful in demonstrating the effects of trehalose (figure
4.11). The epithelial surface appears to maintain aspects of the fresh tissue,
such as the microvillous layer and polygonal shape, suggesting improved
preservation. The debris seen on the surface of the cells could represent
freeze-dried forms of trehalose, which are detectable by SEM (Surana et al.,
2004b).
A degradation assay was performed using SEM images to judge the de-
gree of degradation in fresh, f-t and v-d AM (figure 4.12). This was per-
formed differently to the previous SEM by lyophilising the samples as a
method of fixation. It returned broadly similar states of decay across the
three preparations.
AFM imaging showed extensive crystallisation on the surface of the un-
treated AM (figure 4.17), probably as a result of PBS residues, of which NaCl
would be the most abundant. The trehalose-treated samples were clearer,
with structures such as microvilli and collagens more easily visible. This
indicates that trehalose treatment improves optical clarity, as suggested by
the transparency assay (figure 4.8).
Uniaxial tensile tests were performed to compare the effects of freeze-
thawing and vacuum-drying on AM samples from 17 donors. The AM di-
mensions and strain rate (0.083 s−1) used in this study were similar to
other studies (Fujisato et al., 1999; Nakamura et al., 2004). The traces
were filtered to include only smooth curves, and curves with a positive
initial modulus. There was a significantly increased risk of non-smooth
traces of v-d AM samples being eliminated, when compared to fresh and
f-t samples. This suggests a change in the quality of the sample, since
this testing method is highly sensitive to flaws (Oyen et al., 2004). Smooth
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stress-strain curves suggest relative uniformity in the sample, whereas non-
smooth curves, characterised by multiple peaks or atypical patterns, may
indicate disruption of the collagen links. Since water bonds have a role in
maintaining the mechanical strength of collagen (Cameron et al., 2002), this
can be explained as an effect of dehydration. It may also have been caused
by suboptimal alignment during mounting, although this would be expected
to affect all the preparation methods equally.
The force-distance analysis demonstrated that UTS was highest in fresh
samples (Md = 2.09 N) and lowest in v-d samples (Md = 1.58 N). The median
value of UTS in f-t AM samples was intermediate (1.95 N), whereas the
mean value was 2.11 N. Conversely, ΔL was highest for v-d AM (Md = 7.96
mm) and lowest for fresh AM (Md = 7.30 mm). This was shown in data
from AM sourced from different donors and also in AM that was matched by
donor. Despite the interdonor variability in UTS and ΔL, the trends across
preparation methods were consistent. The distribution of data was non-
Gaussian, so non-parametric tests were used in the force-distance analysis.
Although the differences did not reach statistical significance, it suggests
that vacuum-drying has a weakening effect on AM, and may make it more
ductile. The high variability can explain why statistical significance was
not reached across preparation methods. This is highlighted by a power
analysis demonstrating the sample size n that would be required to detect
a clinically important difference, d with a standard deviation, SD (Goodall
et al., 2009). The power analysis assumes a Gaussian distribution. The
mean UTS values were ~2.1 N for fresh and f-t AM and ~1.9 N for v-d AM
(a difference of ~10%), and the SD was ~0.7. In a comparative study of UTS
of fresh AM versus v-d AM, a t test could be used to compare means (X),
where the numerator is the difference in means and the denominator is the
standard error:
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t =
(X1 −X2)
SD
√
n
(4.8)
t must be at least 1.96 to achieve a 5% level of significance (p < .05). For
this, the least significant difference between the means is
LSD = 1.96× SD
√
2
n
(4.9)
For a power analysis, to be 90% certain of detecting d, we must also
satisfy the equation
d = LSD + 1.28
SD
√
2
n
(4.10)
where 1.28 corresponds to the 90th percentile of a normal distribution.
Solving for n, we obtain
n =
2 (1.96 + 1.28)2 SD2
d2
(4.11)
≈ 21
(
SD
d
)2
If we assume the UTS if a strip of fresh AM to be ~2.0 N (see table 4.3)
and a 10% reduction to be clinically significant (0.2 N), then with a SD of
0.7 the number of samples required in each category would be
n ≈ 21
(
0.7
0.2
)2
n ≈ 260
Thus, 520 test samples would have been required to demonstrate a sta-
tistically significant reduction of 10% in UTS between fresh and v-d AM
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preparations. The null hypothesis between fresh and v-d AM could not be
rejected by this force-distance analysis, yet this may be a Type II error due
to an underpowered study. The large property range of AM is a major rea-
son for the variability encountered (Oxlund et al., 1990; Oyen et al., 2004).
In addition, there was a significant difference in the mechanical properties
of AM across different donors, which is in agreement with other studies
(Oxlund et al., 1990; Jabareen et al., 2009). The difference between fresh
and f-t AM appears to be slight, suggesting that the quality of v-d AM is in-
ferior to f-t AM. This is reinforced by the higher rate of flawed stress-strain
traces in v-d AM samples.
The importance of accurate and precise dimension measurements in de-
termining the physical properties of AM is paramount (Oyen et al., 2004;
Jabareen et al., 2009). Digital micrometry is highly subjective and measures
only small areas of the tissue. The tissue can easily be crushed by the in-
strument, potentially underestimating the histologically-derived thickness
of AM by a factor of two (Jabareen et al., 2009). In this study, median thick-
nesses of fresh, f-t and v-d AM were 49 μm, 41 μm and 28 μm respectively,
and statistically significant differences were found across all three prepara-
tion methods. The finding of different thickness of fresh and f-t AM may be
a Type I error, since freeze-thawing is not known to cause tissue collapse.
Conversely, v-d AM is visibly more compact than both fresh and f-t AM.
Optical measurements, such as light microscopy, may be more accurate but
require much more time and planning. In the study presented here, no dif-
ferences were found between f-t and v-d AM in light microscopic studies of
thickness, both preparations returning a value of approximately 25 μm. The
method used for thickness measurements described contrasted with that of
Jabareen et al. (2009), as the AM samples were neither fixed nor stained.
However, it gave a quick indication of sample thickness that could be used to
corroborate measurements made by digital micrometry. A direct comparison
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of the two techniques was not made in this study, but could be the subject of
future work, given the importance of accurate and precise measurement of
geometric dimensions for stress-strain analysis.
A stress-strain analysis of the filtered data indicated that σvNf , σv
T
f , E1,
E2 and toughness were lowest for fresh AM, intermediate for f-t AM and
highest for v-d AM. The differences were statistically significant with the
exception of E1. The values reported here for fresh AM (σvNf , 4.09 MpA; area,
0.50 mm2; E1, 0.45 MPa; E2, 24.1 MPa; T, 0.45 Jmm−3) are in approximate
agreement with other uniaxial studies of natural AM. Oxlund et al. (1990)
measured mean AM thickness to be 47 μm and mean σvNf to be 3.94 MPa,
whereas Oyen et al. (2004) reported a pseudolinear modulus E2 of 23.5 ±
6.9 MPa. Jabareen et al. (2009) reported values of E1 of ~0.02 MPa in AM
that was pre-conditioned by cyclic loading. The strain rate they used was
0.005 s−1, in contrast to a strain rate of 0.083 s−1 used in this study, which
may explain some of the variance. The values for f-t AM were as follows: σvNf ,
4.97 MpA; area, 0.43 mm2; E1, 0.62 MPa; E2, 27.7 MPa and T, 0.49 Jmm−3.
For v-d AM, they were: σvNf , 5.28 MpA; area 0.34 mm
2; E1, 1.01 MPa; E2,
29.79 MPa and T, 0.61 Jmm−3.
The apparent increase in σvNf and toughness in f-t and v-d AM requires
further explanation, since a lower UTS and simultaneously higher σvNf and
toughness in f-t and v-d AM may seem paradoxical. The differences are
likely to reflect the sum of influences of thickness measurement and intrin-
sic structural changes to the processed tissues, which are considered sepa-
rately.
These measurements of σvNf , σv
T
f , E1, E2 and toughness have in common an
inversely proportional relationship to cross-sectional area. In this study, an
inverse correlation was noted between cross-sectional area and σvNf , which is
representative of other thickness-dependent variables. Therefore, the differ-
ences in σvNf and toughness can be explained in part by the significantly dif-
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ferent cross-sectional areas across the three preparation categories. Since
the decrease in thickness in v-d AM is caused by compaction of the colla-
gen fibres, rather than tissue loss, v-d AM is a thinner, denser version of
the fresh tissue. The stress-strain measurements that require geometric di-
mensions to be known do not discriminate between a tissue that is thinned
as a consequence of water loss (i.e., v-d AM) and a thinner homogeneous
material that can resist more tensile force per unit area, recording values
that suggest increased strength. To illustrate this, σvNf was re-calculated as-
suming a uniform AM thickness of 50 μm for all preparations, as previously
reported (Oyen et al., 2004). This resulted in the new σvNf measurements
being highest for fresh AM and lowest for v-d AM. The inverse relationship
between thickness and apparent strength may explain reports of dried AM
preparations (30 μm) having greater apparent strength than thawed AM
(45 μm) (von Versen-Hoeynck et al., 2008). In contrast, Chuck et al. (2004)
found the σvNf of wet AM strips to be comparable to that of rehydrated dried
samples, which were significantly thinner.
While the effects of thickness on apparent strength necessitate accurate
and precise measurements, the intrinsic relationship between thickness and
AM strength varies between samples (Calvin and Oyen, 2007). The effects
of dehydration on the collagenous matrix are likely to be deleterious (Zhang
et al., 2011). Therefore, the intrinsic effects of drying on the mechanical
properties of AM cannot be fully understood by stress-strain measurements.
Despite having increased values of σvNf and toughness, it appears likely from
the force-distance analysis that v-d AM is mechanically weaker than fresh
and f-t AM. Due to intrinsic changes during drying, rehydration may not
fully restore the tissue’s former mechanical strength. Although dehydrat-
ing AM may reduce its mechanical strength, it appears to make it stiffer.
Benson-Martin et al. (2006) have reported mean modulus values ranging
from ~2.8 MPa for thawed AM to 17.3 MPa for partially dried AM, which
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suggests an effect beyond that which can be explained by changes in thick-
ness. In keeping with this observation, a study by Chuck et al. (2004) re-
ported the modulus value of fully dried AM to be 86.1 MPa, whereas the
lowest mean value of rehydrated dried AM was 11.8 MPa. Rehydration re-
versed the increased stiffness despite no increase in the thickness of dried
AM preparations following rehydration. Personal experience suggests that
v-d AM is more friable to handle than other preparations. While this does
not preclude its use as a surgical biomaterial, it suggests a clinical disad-
vantage in comparison to f-t AM.
The constitutive mathematical model used in this analysis is a useful
tool in describing the non-linear mechanical behaviour of AM. The differ-
ences between modelled and experimental data can lead to better consti-
tutive models to explain tissue behaviour. The model incorporated exper-
imental data on σvNf , λ1 and G
′ to generate a new parameter, d. To make
maximum use of the model, three fittings were tried. The first fitting cal-
culated measurements of G′ and d simultaneously over the sample’s entire
strain in order to construct the best possible fit by minimising the RMS.
The second fitting used the value of G′ derived from the initial 5% strain,
generating new values of d. The third fitting was almost identical to the
first, except that it incorporated an adjustment to the starting point to com-
pensate for slackness or tension. The first and third fittings failed to expose
significant differences in the mechanical properties of the different prepara-
tions, although in both cases, d was lower for v-d AM. Since d is associated
with changes at higher strain, this suggests that modelled curves of v-d AM
are less steep than fresh and f-t AM in the model equivalent of the collagen
phase. When the value of G′ was derived from the initial 5% strain, the
difference in d across the preparations acquired statistical significance (p =
.016). This indicates that with the experimental data acquired, the model
exposed differences in the mechanical behaviour of the material that were
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not present in f-t AM. This is advance over previous studies that recorded
the pseudolinear modulus to differentiate between membranes. Using a
similar constitutive model, Jabareen et al. (2009) detected a direct correla-
tion between the soluble collagen content of AM and an increase in stiffness
at higher strain. As an extension of this idea, it is possible that the decrease
in d found in v-d AM may be caused by intrinsic weakness in the tissue.
The physical characteristics described by uniaxial testing are essentially
surrogate quality indicators for surgical usefulness, yet these are undefined.
There is no known UTS or E below which v-d AM is no longer a useful bio-
material. It is assumed that the more robust the tissue, the better. Ulti-
mately, however, the usefulness of v-d AM depends on the specific clinical
indication.
Varying test conditions, such as humidity and temperature, can influ-
ence the hydration, and therefore the mechanical behaviour of collagen
Pashley et al. (2003); Ntim et al. (2006). Since AM is already highly variable,
this has the effect of producing data with high standard deviations. In this
series of experiments, humidity and temperature were not controlled. This
may have contributed to the high variability in the data produced. While
fully hydrated, AM has a silky and elastic feel, but on drying it rapidly be-
comes sticky and friable. Thus, the experimenter has to work quickly to
expertly cut and mount the sample, which rapidly loses water to the atmo-
sphere. The elastic tissue tends to contract when laid out for cutting, so that
a strip often has wider dimensions than intended. Tensile property testing
can be invalidated by the AM sample drying out and by incorrect sizing of
the sample.
Sample slippage and failure at the clamping points can nullify stress and
strain failure calculations (Oyen et al., 2004; Jabareen et al., 2009). This
can occur as a result of feathering of the edges during cutting, angulated
mounting and incorrectly aligned grips. All of these factors were a potential
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source of error that made it difficult to obtain consistent, repeatable results.
The tests were refined over successive stages to give more control of the
sample preparation and mounting steps. There was difficulty in ensuring
that the samples were under the correct amount of tension at the start of
the uniaxial tests. The TA.HDplus instrument has a force resolution of 0.1
g, which suggests that it was suitable for testing AM. However, it was not
possible to adjust the static force to take up residual slack in the sample
before the test run, which might have produced more consistent results.
Accelerated degradation assays of fresh, f-t and v-d AM samples were
performed using microscopic imaging studies to compare the tissue appear-
ances after incubation in 1% collagenase. The samples were fixed for SEM
by lyophilisation, which gave an unusual whorl-like pattern on the stromal
side of the AM. The tissues appeared to be in similar states of decay. The
test is a basic assessment of the differences between preparations, and it
calls for more refined qualitative assays, such as analyses of the change in
weight of AM undergoing degradation (Fujisato et al., 1999; Ma et al., 2010).
Highly variable results were obtained by acoustic impedance testing,
suggesting that the test was not useful in comparing AM samples. How-
ever, the results indicate that while some samples produced credible data,
others failed to do so, recording values of G′ that were close to zero. The
reasons for this are unclear, but may reflect different levels of hydration,
size and positioning or excessive noise on the instrument caused by water.
The test was applied successfully to illustrate the difference between na-
tive AM and AM cross-linked by TG, although the sample size was small
(Chau et al., 2012). This suggests that repeat experimentation is required
to determine the specific causes of the high variability encountered.
High variability was encountered, too, using AFM. Amnion is not homo-
geneous, and indentation of the different components, from epithelial cells
to BM and stromal collagen, produced widely differing results. The tips are
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small enough to sample the different components of the tissue, and therefore
the data they produce do not give an consistent impression of the material
properties. Moreover, the membrane is sufficiently thin for measurement
to be influenced by the surface supporting the tissue. The tendency of the
tissue to form folds and tears could also contribute to the high level of vari-
ability. Although indentation with a bare tip suggested that trehalose pro-
duced increased surface stiffness and hardness, this effect was not consis-
tent across different cone tip sizes. Conversely, indentation with a spherical
bead did not return meaningful data and did not point to any differences
between the AM preparations. One previous study by Lim et al. (2010) used
phase images from AFM to study variations in hardness in AM; however,
this did not return any objective data.
Another reason for the failure to acquire consistent data could be a fail-
ure to employ the correct analytical technique. According to Oyen and Cook
(2009), the commonly used Oliver-Pharr analysis is more suited to plastic-
elastic tissues such as bone. Soft tissue analyses have been characterised
with models of viscous-elastic responses (Mattice et al., 2006). This is also
suitable for elastomers, which have similar moduli to AM. The addition of
trehalose could add glassiness to the AM surface; this would require the
addition of a plastic component to the viscous-elastic model Oyen and Cook
(2009).
4.5.2 Cross-linking
AM has been successfully cross-linked by chemical means (Ma et al., 2010;
Kitagawa et al., 2011; Chau et al., 2012). A non-peer-reviewed study from
the US Military reported successful cross-linking of AM by irradiation with
blue light from a Xenon lamp, a 532 nm laser light and Ultraviolet C (Kochevar,
2010). In each case, the irradiance used was approximately 100 times lower
than that used in the study presented here. In the current study, attempts
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to cross-link AM by riboflavin/UVA were unsuccessful. This suggests either
that the irradiance was too high or that photosensitisation was unneces-
sary. It seems likely that the covalent bonds in the collagen fibres were
breaking down, leading to disorganisation and loss of crystallinity (Grant et
al., 1973). The irradiance could not be adjusted in the instrument used in
this study. Cross-linking of collagen can occur without photosensitisation,
especially in thin tissues (Spoerl et al., 1998). This suggests a possible al-
ternative approach to cross-linking AM collagens by irradiation. The use of
alternative light sources should also be considered.
The methods used to detect the cross-linking are of interest. Using the
method described by Wollensak and Redl (2008), soluble collagens were ex-
tracted from AM. Wollensak and Redl found evidence of cross-linked colla-
gens by this method. The polymerised collagens formed thickened bands
at the top of the gel that resisted electrophoretic movements. The absence
of any bands in the UVA/riboflavin-treated AM lanes in the electrophoretic
gels initially led to the supposition that the cross-linked collagens had pre-
cipitated out of solution. The four bands in the control lanes were thought
to represent the trimeric, dimeric and monomeric collagen type I chains.
However, the MS results indicated that most of the collagen was type III,
rather than type I. The predominant peptide isolated was the α1 chain of
type III collagen. Smaller amounts of the α1 chain of type I collagen were
also present, along with smaller quantities of types V, II, XI and XXIII col-
lagens. Types III and V collagen is present in much smaller amounts in AM
than type I (Bryant-Greenwood, 1998). The type I collagen α2 chain does not
appear, suggesting its loss during solubilisation. The loss of these collagens
in the riboflavin/UVA-treated AM suggests that no cross-linking has taken
place.
TEM images were used to detect differences in collagen fibril packing.
Since Wollensak et al. (2004) found a significant enlargement of the di-
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ameter of corneal collagen fibres after cross-linking, the packing density
of collagen fibrils in AM were assumed to be increased by cross-linking. The
riboflavin/UVA-treated AM had a greater IFD than the non-cross-linked tis-
sue, again suggesting that cross-linking had not taken place. XRD studies
of AM by Connon et al. (2007) showed regional variation in the packing den-
sity, suggesting that these differences could have been due to the location
of AM sampling. The tensile tests further suggested that cross-linking had
not occurred. The mathematical model was employed successfully, return-
ing significant differences between the treated AM and controls in multiple
variables, including ΔL, E1, E2 and d2. These indicated that the treated
AM was less stiff and more ductile than the controls, which is the opposite
of what can be expected by cross-linking. The absence of cross-links which
was confirmed by the ninhydrin assay, which indicated an increase in the
free amine groups of the treated AM. Quick and inexpensive to perform,
this was a very effective method of detecting cross-linking, as evidenced by
the cross-linking index of 151% returned for the 1% glutaraldehyde-treated
AM. Using this technique, Ma et al. (2010) found the maximum value of
cross-linked amino groups in AM collagen molecules to be 45.6%, indicating
successful cross-linking with EDC. The methodology used to determine the
presence or absence of artificially induced cross-links in AM will be helpful
in future studies.
4.6 Conclusion
One of the main drawbacks of vacuum-drying may be its effects on the ma-
terial properties of AM. In this study, I demonstrated that v-d AM has a
lower tensile strength than both fresh and f-t preparations, although the
high level of variation between samples meant that statistical significance
was not reached. Whereas stress-strain tests could not detect this differ-
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ence because of the change in thickness across preparation categories, a
novel mathematical model proved a useful discriminator. While attempts
at cross-linking the membrane proved unsuccessful, the methods used to
assess this can serve as a useful template. The next chapter focuses on
biological aspects of the membrane, including its role in infectious and in-
flammatory processes.
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Chapter 5
BIOLOGICAL ACTIVITY OF THERAPEUTIC AM
5.1 Introduction
The contribution of AM-derived factors to healing at the ocular surface is the
subject of debate between those who favour the concept that therapeutic AM
possesses biological activity, and those who take a pragmatic approach to its
functionality as a physical membrane. While the physical properties of AM
are essential to its therapeutic function, it has sometimes been assumed
that soluble biological factors retained by therapeutic AM are beneficial to
the injured eye. In this chapter, I consider the bioavailability in therapeu-
tic AM of two classes of soluble factors, one that is potentially beneficial
and the other potentially harmful. AMPs belong to a recently described
class of molecules with the ability to kill pathogens. Conversely, MMPs and
their inhibitors are well-known enzymes that have the potential to damage
the ocular surface. I investigated the expression of AMPs in human AEC
by cytometric bead analysis (CBA), western blotting and flow cytometry.
Antimicrobial assays were also performed. I used zymography to demon-
strate the elution of MMPs from therapeutic AM. Protein microarrays were
obtained to show the relative quantities of MMPs and tissue inhibitors of
MMPs (TIMPs). Questions remain as to whether AM is capable of modify-
230
ing the host response in a significant way. To address this, I conducted series
of assays measuring the cytokine profile of stimulated human macrophages
that were co-cultured with AM discs. After the assays, I performed electron
microscopy on the discs to image the stromal adhesion of macrophages.
5.2 Literature review
The biological functions of AM can be viewed as those broadly concerned
with homoeostasis and those related to membrane rupture. Natural AM
produces a wide array of cytokines, growth factors and enzymes that may be
present in therapeutic AM (Dua et al., 2004). The concept of AM as a biolog-
ical dressing can be traced to its use in non-ophthalmic surgical specialties
(Talmi et al., 1990) and to its historical use in ophthalmology (Sorsby and
Symons, 1946). Tseng et al. (2004) have made the case that IL-10, activin
and protease inhibitors present in AM transplants have a role in suppress-
ing ocular surface inflammation. Neurotrophic factors detected in AM in-
clude nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF)
and neurotrophin-3 (NT-3) (Uchida et al., 2000). Tseng et al. (2004) have
suggested that these may contribute to scarless wound healing, as is ob-
served in foetuses before the third trimester. Similarly, AM-derived growth
factors, such as EGF, TGF-α, keratinocyte growth factor (KGF), hepatocyte
growth factor (HGF), TGF-β1 and TGF-β2 were considered to contribute to
epithelial healing (Koizumi et al., 2000). This thinking lies behind the ex-
perimental use of topical amniotic fluid (Castro-Combs et al., 2008) and am-
niotic membrane extract (He et al., 2008) to treat epithelial non-healing and
ocular surface inflammation.
Not all the factors produced fit the narrative of a therapeutic tissue. For
example, AM is well known to produce IL-6 and IL-8, which are inflamma-
tory cytokines (Keelan et al., 1997), whereas IL-10 was not detected in AM
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conditioned media (Hori et al., 2006). In addition, TGF-β is well known for
its propensity to cause surgical scarring (Cordeiro et al., 2003). All TGF-β
isoforms are produced by AM (Koizumi et al., 2000b). Indeed, TGF-β1 is
one of the principal isoforms expressed in corneal wound healing, delaying
epithelialisation and promoting keratocyte proliferation and myofibroblast
transformation (Carrington et al., 2006). Suppression of the TGF signalling
pathway may therefore be a crucial aspect of the success of AMT. To explain
this apparent contradiction, Tseng et al. (2004) suggested that the intra-
cellular pathways that are switched on by AM-derived factors both induce
mitogenesis and suppress TGF-β signalling. Corneal and limbal fibroblasts
cultured on the stromal side of preserved human AM matrix showed re-
duced expression of TGF-β1 and TGF-β2 (Tseng et al., 1999). As well as
suppressing the expression of TGF-β isoforms, AM also appears to suppress
TGF receptors in fibroblasts (Lee et al., 2000). Nonetheless, while the view
that therapeutic AM possesses biological function over and above its me-
chanical properties persists, Baum (2002) has argued that the true value
of AM is its ability to provide mechanical protection against eyelid friction
whilst at the same time allowing oxygen and moisture to reach the epithe-
lium.
Prevention of intra-uterine infection is mediated in part by effector molecules
of the innate immune system that have been described as natural antimicro-
bials, and which include AMPs (King et al., 2007a). AM has been reported
to exert antimicrobial activity through direct contact with bacteria (Talmi
et al., 1991), suggested to be due to soluble tissue factors, such as defensins
(Kjaergaard et al., 2001). The elution of AMPs from therapeutic AM may
protect the ocular surface against pathogens.
The gene regulatory networks of AM undergo a series of changes in the
weeks leading up to parturition (Li et al., 2011). This is precipitated by
maternal and placental hormones and pro-inflammatory cytokines, and in-
232
volves the activation of toll-like receptor (TLR) pathways of the innate im-
mune system (Challis et al., 2009). A central transcription factor appears
to be nuclear factor-kappa B (NF-κB). As a result, a wide array of cytokines,
chemokines and enzymes that elicit downstream biological responses are
transcribed. AEC and mesenchymal cells up-regulate the production of
MMP-9 (Xu et al., 2002) and release prostaglandin E2 (PGE2) (Kumar et
al., 2004), which plays a key role in the initiation of contractions. MMPs are
enzymes that are primarily concerned with breaking down the dense col-
lagenous membrane at the time of birth (Bryant-Greenwood, 1998). While
the potential for therapeutic AM to mediate collagenolysis is not clear, the
elution of MMPs may contribute to disease states, evidenced by the reported
case of corneal melting following AMT (Schechter et al., 2005).
5.2.1 Antimicrobial peptides
Defensins (α- and β-) and cathelicidins are two families of peptides widely
found in bacteria, plants and animals (Wang, 2010). These AMPs have a
wide spectrum of activity from wound-healing to immune cell activation
(Frasca and Lande, 2012), and they potentiate the immune response against
bacteria, yeasts and viruses (Sørensen et al., 2008) and possibly even acan-
thamoeba (Otri et al., 2010). They exert both indirect and direct anti-
bacterial actions (Koczulla and Bals, 2003). α-defensins include a subfam-
ily known as human neutrophil peptides (HNP). Together with human β-
defensins (hBDs), they constitute the human defensins. Produced in epithe-
lia, hBD3 is the most potent of the β-defensins and the one with the broad-
est spectrum of activity (Buhimschi et al., 2004). The only human cathe-
licidin, hCAP-18 is an 18 kDa protein that is cleaved following exocytosis,
releasing a 4 kDa AMP called LL-37 (Sørensen et al., 2001). This peptide
alters bacterial cell membranes and binds intracellular proteins and trans-
membrane receptors (Bucki et al., 2010). It is produced in macrophages,
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neutrophils and epithelia (Sørensen, 2005). Each β-defensin and catheli-
cidin has a unique range of activity against an array of pathogens (Starner
et al., 2005). Besides defensins and cathelicidins, there are a number of
other AMPs with less prominent roles in human immunity, including liver-
expressed antimicrobial peptides (LEAPs) (Henriques et al., 2010), ribonu-
cleases (e.g., RNAse-7) (Spencer et al., 2011) and psoriasin (Garreis et al.,
2011). Besides augmenting the response to microbes, AMPs can directly in-
teract with immune cells such as macrophages to modulate the response to
infection (D’Este et al., 2012).
5.2.1.1 Foetal immunity
Innate immunity in the foetus is a complex system (Levy, 2007), in which
AM plays an important part (Buhimschi et al., 2004). AMPs are consid-
ered to be a first line of neonatal defence against microbial invasion at birth
(Yoshio et al., 2004). They are found both in AM and in the vernix caseosa,
a creamy layer found on neonatal skin that is synthesised by the sebaceous
glands of the foetus. hBD3 mRNA has been detected in cultured AECs by
quantitative PCR by Buhimschi et al. (2004). These researchers also de-
tected hBD3 by immunofluorescence in AEC from normal pregnancies at
baseline, although it was up-regulated under stimulated conditions. AEC
respond to different infectious stimuli through TLRs on their surface, ei-
ther secreting inflammatory mediators or undergoing apoptosis (Gillaux et
al., 2011). The production of hBD3 by the AEC is increased following TLR
stimulation (Szukiewicz et al., 2008), and levels in the amniotic fluid rise
following intrauterine insults like microbial infection and inflammation (Es-
pinoza et al., 2003). hBD1 and 2 have also been detected in AEC, both by
PCR (Stock et al., 2007) and by immunohistochemistry (King et al., 2007b).
Psoriasin has been detected in amniotic fluid and in AEC by PCR (Porre et
al., 2005).
234
Besides peptides, human AECs produce antimicrobial proteins, includ-
ing elafin and secretory leukocyte protease inhibitor (SLPI) (Stock et al.,
2007). The role of AM in the production of a number of relevant AMPs is
unclear. For example, LL-37 has been detected in amniotic fluid and vernix
Yoshio et al. (2003), yet its expression in AEC has not been shown. The
vernix also contains HNPs 1 to 3 (Akinbi et al., 2004) and RNAse-7 (Tollin
et al., 2006). LEAP-1 (hepcidin), but not LEAP-2, has been detected in am-
niotic fluid in the first trimester (Evans et al., 2011).
5.2.1.2 Ocular surface immunity
Since the expression of AMPs on the ocular surface was first documented by
Haynes et al. (1999), these molecules have come to be seen as components of
major importance in the innate immune defence of the ocular surface (Gar-
reis et al., 2010). The expression of a spectrum of corneal epithelium-derived
AMPs is regulated in a co-ordinated response to different pathogens, sug-
gesting an array of antimicrobial activities (Otri et al., 2010, 2012). AMPs
that have been detected on the ocular surface include hBD1, 2 and 3, human
cathelicidin (hCAP-18), LEAP-1 and LEAP-2 (McIntosh et al., 2005), HNP1,
2 and 3 (Ikeda et al., 2005), hBD9 (McDermott, 2004), psoriasin (Garreis et
al., 2011) and RNAse-7 (Mohammed et al., 2011).
The presence of AMPs in therapeutic AM is compelling, since it could
augment the natural antimicrobial activity of the ocular surface. In a rat
model of bacterial keratitis, Barequet et al. (2008) found that corneal ulcers
had lower bacterial counts when AM was used as an adjuvant treatment.
Direct anti-bacterial effects of AM have been demonstrated against strepto-
coccus group A, Staphylococcus aureus, Staphylococcus saprophyticus, Es-
cherichia coli, and Pseudomonas aeruginosa (Kjaergaard et al., 2001). On
the other hand, the antimicrobial properties of AM have been attributed
to a reservoir effect in which antibiotics are stored and released over an ex-
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tended period (Gicquel et al., 2007). AM has been found to retain netilmycin,
releasing it gradually over a period of 3 days (Mencucci et al., 2006). This
slow release effect has also been described for ofloxacin (Resch et al., 2011).
5.2.2 Matrix metalloproteases
MMPs are multi-domain zinc-dependent endopeptidases which exist in ac-
tive and inactive isoforms and are regulated at many levels (Nagase et
al., 2006). There are 23 MMPs in humans, and, while their main func-
tion is to degrade the ECM, they mediate a diverse list of intra- and extra-
cellular biological activities including neovascularisation and inflammation.
They have been categorised as collagenase, gelatinase, stromelysin, ma-
trilysin, membrane-type and other enzymes. Most MMPs are secreted as
pro-enzymes in 1:1 stoichiometric complexes with TIMPs. Neutrophil-derived
MMP-9 is one exception, being released in a free form in mice (Ardi et al.,
2007). The production of most MMPs is tightly controlled, with the excep-
tion of MMP2, which is expressed constitutively by many tissues, secreted
in a complex with TIMP-2 and activated by cell-surface membrane-tethered
MMP (MT1-MMP) (Itoh and Seiki, 2006). TIMP-2 acts as a bridge between
the MMP-2 proenzyme and the MT1-MMP activator. MMP-2 and MMP-9
are gelatinases that are expressed as pro-enzymes and activated by cleav-
age of a pro-peptide domain, which occurs in the extracellular compartment.
5.2.2.1 Collagenolysis in AM
All of the components of the MMP cascade are present in AM (Parry and
Strauss, 1998). During gestation, MMPs operate in equilibrium with TIMPs
to remodel the membranes and accommodate foetal growth (Bryant-Greenwood,
1998). Around the time of labour, MMP activity in the AM becomes a highly-
regulated destructive process that is precipitated by inflammatory cascades
(Menon and Fortunato, 2007). The balance can shift in favour of collagenoly-
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sis as a result of infection and inflammation, with increasing levels of MMP-
2, MMP-3, MMP-8 and MMP-9 in amniotic fluid. In rats, up-regulation of
the interstitial collagenase MMP-1 pro-enzyme occurs immediately prior to
labour (Lei et al., 1996). Simultaneously, type I collagen undergoes degrada-
tion, with the accumulation of characteristic three-quarter-length collagen
peptides in the amniotic fluid.
MMP-2 andMMP-9 are key components of theMMP cycle in AM (Bryant-
Greenwood, 1998). Both MMP-2 and MMP-9 degrade type IV collagen,
found in the BM, whereas only MMP-2 degrades type I collagen, predom-
inantly found in stroma. MMP-9 is barely detectable until term or pre-term
labour (Demir-Weusten et al., 2007). A key proteolytic mediator, it can be in-
duced by inflammatory mediators such as tumour necrosis factor (TNF) and
IL-1β in autocrine and paracrine loops (Arechavaleta-Velasco et al., 2002).
In AM, MMP-9 is is normally secreted in a non-angiogenic complex bound
to TIMP-1 (Fortunato et al., 1997). It becomes activated in the ECM by
the MT1-MMP/MMP-2 complex, a process requiring TIMP-2, as well as by
other MMPs (Toth et al., 2003). MMP-2 acts in synergy with other col-
lagenases to degrade fibrillar type I and III collagens (Parry and Strauss,
1998). MMP-1 and MMP-8 cleave the triple helix of type I collagen, which
is then further degraded by MMP-2. These enzymes also cleave elastin,
laminin, type IV and V collagens and other substrates, playing a central
role in ECM degradation (Nagase et al., 2006). MMPs and TIMPs are com-
partmentalised within the AM layers. MMP-9 is associated predominantly
with the epithelial layer, whereas MMP-2, produced by fibroblasts, accumu-
lates mainly in the stroma (Xu et al., 2002).
5.2.2.2 Ocular surface metalloproteases
In the cornea, MMP-2 is present in normal and wounded epithelium and
in stroma, while MMP-9 is present in the BM and superficial stroma of the
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wounded cornea (Ye and Azar, 1998). Upregulation of corneal MMP-9 has
been implicated in undesirable sequelae of ocular surface burns, namely
failure of re-epithelialisation (Fini et al., 1998) and stromal neovasculari-
sation (Ellenberg et al., 2010). While MMP-2 is involved in long-term re-
modelling of the corneal stroma after injury, MMP-9 degrades the epithelial
BM, an event that precedes corneal ulceration. In animal models, prote-
olytic MMPs have been implicated in corneal melting (Fini et al., 1992).
MMP-2 and MMP-9 are over-expressed in peripheral ulcerative keratitis,
an immune-mediated corneal melting condition that principally affects suf-
ferers of rheumatoid arthritis (Smith et al., 1999). The levels of MMP-8 and
MMP-9 have been found to be significantly higher in corneal tissue with fun-
gal growth than in non-infected corneal tissue, suggesting that they have a
role in tissue destruction (Rohini et al., 2007).
Despite the widespread use of AM in ophthalmic surgery, the elution of
potentially unwanted factors such as MMPs onto the ocular surface has not
been greatly considered in the literature. Conversely, AM-derived TIMPs
have been postulated to exert an anti-inflammatory effect on the surface of
the eye (Hao et al., 2000). In mice with induced herpes simplex keratitis,
AMT caused a rapid improvement in the appearance of the ulcers and a
reduction in stromal inflammation, suggested to be due to suppression of
corneal MMPs by AM-derived TIMPs (Heiligenhaus et al., 2005). Similarly,
a study of alkaline burns in a rabbit model found that AMT suppressed
corneal expression of MMP-2, MMP-9 and MT1-MMP (Takahashi et al.,
2007). Koh et al. (2007) found mRNA of both TIMP-1 and TIMP-2 in the
stromal and epithelial cells of both freeze-thawed and dried preparations of
therapeutic AM, suggesting that MMPs are kept in their inactive forms by
their inhibitors.
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5.2.3 Modulation of inflammation
While therapeutically-applied AM is frequently assumed to dampen inflam-
mation, the opposite outcome is also possible. This is suggested by clinical
reports of uveitis after primary AMT (Srinivasan et al., 2007). Therapeutic
preparations of AM contain non-viable allogeneic cells, which far from re-
taining any immunosuppressive activity are more likely to stimulate inflam-
mation. Fresh AEC express MHC class I molecules, but not class II (Hori et
al., 2006). AM can induce donor-specific delayed hypersensitivity, leading to
its rejection by the sensitised recipient following serial AMTs (Gabler and
Lohmann, 2000). Despite this, a number of studies have pointed to an anti-
inflammatory effect, mediated either by soluble factors or by direct contact
with components of AM.
5.2.3.1 Soluble factors
In a mouse mixed lymphocyte reaction, the proliferative response was found
to be suppressed if f-t AM was in the medium Ueta et al. (2002). This did not
occur if the AM was fixed in 100% ethanol first, suggesting that soluble AM-
derived factors were responsible. The proportion of proliferating responder
cells and cytokine levels in the culture supernatants were both significantly
reduced. As known inhibitory cytokines, such as IL-4, IL-10 and TGF-β1,
could not be detected, the authors attributed the anti-inflammatory effects
to unknown soluble factors. Li et al. (2005) isolated AECs by trypsin diges-
tion of fresh AM and suspended them in culture medium for 48 hours. The
AEC-conditioned medium inhibited neutrophil and macrophage chemotaxis
towardsMIP-2 and induced lymphocyte apoptosis. The AEC expressed tran-
scripts for anti-inflammatory mediators such as TNF, TGF-β, TNF-related
apoptosis-inducing ligand (TRAIL) and macrophage migration inhibitory
factor (MIF). Lymphocyte apoptosis was partially inhibited by Fas ligand
(FasL) antibody, suggesting that AEC-derived FasL was a key anti-inflammatory
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factor. Splenocytes from Balb/c mice stimulated with anti-CD3e antibodies
were cultured in the presence of small pieces of dried, intact AM and de-
nuded AM in the medium (Park et al., 2009). Splenocyte proliferation was
suppressed by both AM preparations, but more by the epithelialised AM,
suggesting that epithelial-derived factors are involved. While fresh AMmay
contain soluble anti-inflammatory factors, these may be lost during AM pro-
cessing (Hopkinson et al., 2006b).
5.2.3.2 Direct contact
Other studies have suggested that immune suppression depends on direct
cellular contact with the AM stromal matrix. Marked suppression of IL-
1α and IL-1β and up-regulation of interleukin-1 receptor antagonist (IL-
1ra) was demonstrated in limbal epithelial cells cultured on the stromal
matrix of AM (Solomon et al., 2001). Temporary AM patches were placed
on rabbit eyes after excimer laser ablation, and viewed by TEM follow-
ing retrieval (Park and Tseng, 2000). Neutrophils in direct contact with
the AM stromal matrix, but not the BM, were noted to have undergone
apoptosis within 24 hours. AM patching was seen to entrap polymorphonu-
clear leukocytes in the stromal matrix following alkaline burns in a rab-
bit model (Kim et al., 2000). On the human ocular surface, neutrophils,
CD14+ monocytes/macrophages and lymphocytes underwent apoptosis fol-
lowing contact with the matriceal aspect of a temporary AM graft removed
after a week (Shimmura et al., 2001). Macrophages are key antigen pre-
senting cells involved in acute and chronic immune responses. Interferon
(IFN) γ-activated murine macrophages seeded onto f-t AM stromal matrix
underwent apoptosis between 24 and 48 hours later, the mechanism involv-
ing NF-κB intracellular signalling pathways (Li et al., 2006b). This effect
was not seen in quiescent cells, or in cells cultured on collagen, plastic or
corneal stroma. The authors speculated that an unknown component of
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AM could act synergistically with IFNγ to elicit apoptosis by suppressing
pathways necessary for macrophage survival. The in vitro activity, viability
and pro-inflammatory cytokine secretion of murine monocytes/macrophage
RAW264.7 cells were subsequently shown to be suppressed by soluble AM
extract containing spongy layer (He et al., 2008). This is supported by the
observation that AM spongy layer induces a non-specific cidal effect on a va-
riety of cell types (Lazutina et al., 2008). In vitro studies have demonstrated
suppression of fibrotic mediators in conjunctival and lung fibroblasts seeded
on the stromal aspect of AM, including IL-8 (Solomon et al., 2005).
5.2.3.3 Suppression of neovascularisation
Corneal neovascularisation is necessary to resupply ischaemic tissue, and
is a highly orchestrated process that co-involves both MMP and inflamma-
tory pathways (Ellenberg et al., 2010). AM-derived factors may also sup-
press neovascularisation. BALB/c mice with induced corneal neovascular-
isation that received topical human AEC supernatant for two weeks had
fewer vessels than a control group receiving topical human IL-1RA, suggest-
ing a synergistic anti-inflammatory effect of combined factors derived from
AM (Kamiya et al., 2005). AEC-conditioned medium applied topically to
the inflamed eyes of BALB/c mice appeared to suppress suture-induced neo-
vascularisation Hori et al. (2006), whereas, in a rat model, induced corneal
neovascularisation responded to different concentrations of AM extract in
a dose-dependent fashion (Jiang et al., 2006). AM-derived soluble factors
reported to have anti-angiogenic effects have included PEDF (Shao et al.,
2004), collagen XVIII, thrombospondin-1 (TSP-1), TIMPs -1, -2, -3 and -
4, IL-1ra and IL-10 (Hao et al., 2000). High levels of TIMP-2 found in
AM culture medium were considered to inhibit corneal neovascularisation
induced by bFGF in mice (Ma and Li, 2005). One study noted increased
corneal expression of MMP-2 and MMP-9 following AMT for acute corneal
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Table 5.1: AMP antibodies
Type Target Fluorochrome
Wavelength/
channel
Manufacturer Cat. No. Origin Clonality
Unconjugated Psoriasin Abcam plc 13680 Mouse Mono
Unconjugated LEAP-2 Phoenix Ltd G-075-40 Rabbit Poly
Unconjugated RNAse-7 Human Protein
Atlas
005690 Rabbit Poly
Unconjugated hBD1 Abcam plc 14425 Mouse Mono
Unconjugated hBD2 Abcam plc 66072 Mouse Mono
Unconjugated hBD3 Abcam plc 19270 Rabbit Poly
Unconjugated hBD3 Abcam plc 1128 Rabbit Poly
Unconjugated hBD3 Abcam plc 14422 Mouse Mono
Unconjugated hBD9 Eurogentec Custom Rabbit Poly
Unconjugated hCAP18 Abcam plc 80895 Mouse Mono
Unconjugated LL-37 Abcam plc 64892 Rabbit Poly
Conjugated LL37 PE 575/FL2 Phoenix Ltd G-075-06 Rabbit Poly
Conjugated Vimentin PE 575/FL2 Abcam plc 49918 Mouse Mono
Secondary Mouse IgG APC 647/FL4 Invitrogen A31626 Goat
Secondary Rabbit IgG FITC 488/FL1 Invitrogen A31627 Goat
LEAP, Liver-expressed antimicrobial peptide, RNAse: ribonuclease, hBD: Human beta defensin, PE: Phycoerythrin,
APC: Allophycocyanin, FITC: Fluorescein isothiocyanate
alkali burns in a rabbit model, but, paradoxically, decreased vascularisa-
tion (Rigal-Sastourné et al., 2002). Conversely, AM-derived basic fibrob-
last growth factor (bFGF) may promote neovascularisation (Koizumi et al.,
2000b).
5.3 Materials and methods
AMP expression in fresh AEC was investigated by western blotting, CBA
and flow cytometry. A reference guide for the antibodies used for these tech-
niques is provided in table 5.1.
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Table 5.2: Western blotting of AMPs
WB AM AMP Optimising step
1 2 × extract hBD3
2 5 × extract hBD3 Load increased to 40 μg per well
3 1 × extract hBD3 rhBD3 control
4 1 × extract hBD3 AM fractionated to remove proteins >30 kDa
5 3 × extract hBD3 Overnight incubation in TBSTx; elution by HPLC
6 2 × AEC hBD3 Tricine gel
7 1 × extract hBD1, LL-37 AM fractionated to remove proteins >30 kDa
8 1 × extract hBD1, LL-37 Unfractionated
WB, western blot; AMP, antimicrobial peptide; r, recombinant; fr, fresh; HPLC, High perfor-
mance liquid chromatography
5.3.1 SDS-PAGE/western blotting
A series of western blots were performed using protein extract from whole
AM or from AEC to detect hBD3 (5.1 kDa), LL-37 (4.5 kDa) and hBD1 (4.5
kDa). Optimisation steps included increasing the protein load, modifying
the test conditions and adding positive controls (table 5.2).1
5.3.1.1 Sample preparation
Samples of whole fresh and v-d AM and AECwere extracted in Tris-buffered
saline containing 1% Triton X-100 (TBSTx). The whole AM extracts were
prepared for loading into Bis-Tris gels, whereas the AEC samples were
loaded into both Bis-Tris and Tricine gels. As positive controls, proteins
from mixed placental tissue and tonsil were extracted in the same way as
the whole AM. The mixed placental tissue (chorion and AM) was obtained
during AM processing. Tonsil samples were obtained from elective ton-
sillectomy surgery. Both LL-37 and hBD1 are expressed in non-inflamed
tonsil epithelium (Song et al., 2006; Chae et al., 2001). Recombinant LL-
37 (Hycult® Biotech, Plymouth Meeting, PA, USA) and recombinant hBD3
(ABE1621, Source Bioscience UK Ltd, Nottingham, UK) were obtained as
1This work was done in collaboration with Miss Beth Nancolas.
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specific AMP positive controls. Rabbit polyclonal anti-β actin antibody (Cell
Signaling, 4967) was obtained as a loading control to ascertain even protein
distribution in the lanes.
Whole AM AM samples were weighed and placed in universal contain-
ers containing TBSTx, 1 mL per 200 mg tissue. The samples were then
removed and placed in a mortar pre-cleaned sequentially with TriGene dis-
infectant (MediChem International, Kent, UK), DI H20 and 100% ethanol.
Liquid N2 was poured onto the samples, snap-freezing them to make them
hard and brittle. Once completely frozen, they were tapped into smaller
fragments, and then ground into a powder using a sterile pestle. The fine
powder was then added to Falcon™ tube (BD Biosciences, Oxford, UK) con-
taining TBSTx and mixed briefly. The protein suspension was spun in a
centrifuge (Andreas Hettich GmbH and Co. KG, Tuttlingen, Germany) at
RCF 1780 ×g at 4 °C for 60 mins to remove insoluble material from the AM
extract. The supernatant was decanted into a separate tube. To maximise
protein concentration, the samples were placed in Vivaspin spin columns
(GE Healthcare) with a 3 kDa MWCO and filtrated by centrifuging for sev-
eral hrs at 1780 ×g. The samples in one blot were also fractionated in 30
kDa spin columns to remove large molecular weight proteins. One sample of
AM extract was eluted by high performance liquid chromatography (HPLC)
for purification.2 A sample of AM extract processed by a colleague was ob-
tained as a positive control, as positive staining for hBD3 had been obtained
following overnight incubation of the AM in TBSTx.3
AEC For AEC extract, thermolysin denudation of the AM was performed.
Incubation in thermolysin solution was carried out in the presence of a pro-
tease inhibitor cocktail (Cat. No. P2714, Sigma-Aldrich, UK). The AM sub-
2Courtesy of Dr Chen Peng.
3Courtesy of Dr Manu Mathew.
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strate was removed from the PBS, leaving behind a suspension of whole
AEC. The single cell suspensions were centrifuged briefly at 4°C at 300 ×g,
washed in PBS and placed on ice to minimise protein degradation.
5.3.1.2 Protein quantification
The 2-D Quant kit (GE Healthcare Life Sciences, Amersham, UK) was used
to measure protein concentrations. The manufacturer’s instructions were
followed. A standard curve was prepared using incremental quantities of 2
mg/mL BSA in 1.5 mL Eppendorf tubes. A volume of 1 - 50 μL of each sam-
ple to be assayed was transferred by pipette into an Eppendorf tube (exact
volume depended on the expected protein concentration). A volume of 500
μL of precipitant was added to each tube, which was then vortexed briefly. A
volume of 500 μL of co-precipitant was added, and the tubes were inverted
before centrifuging at 10 000×g for 5 mins. The supernatants were removed
completely using a micropipette. A volume of 500 μL of 20% copper solution
in DI water was added to the pellets, followed by 1 mL of a 1:100 dilution
of working colour reagent. The samples were incubated for 15 - 20 mins.
Absorbance was read at 490 nm, and compared to the BSA standard curve
using Softmax® software (MDS Analytical technologies, Toronto, Canada).
The desired protein concentration was approximately 1.0 - 2.0 μg/μL.
5.3.1.3 Protein extraction
Bis-Tris gels Loading Buffer (2 ×) was prepared by mixing 4 × NuPage®
LDS Sample Buffer (5 parts), 1.0 M DTT (1 part) and DI H2O (4 parts). The
Loading Buffer was added to the AM extracted in TBSTx in a 1:2 ratio.
Tricine gel The AEC pellet was extracted directly into 5 mL Novex® 2 ×
Tricine SDS Sample Buffer containing 0.1 g DTT. For non-reducing condi-
tions, DTT was omitted.
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5.3.1.4 Sample loading
The protein load was typically between 20 and 40 μg per well in a maxi-
mum volume of 28 μL. The protein sample with the lowest concentration
was taken to calculate the baseline volume required. The samples were
denatured by heating to 95°C for 4 mins and vortexed prior to loading.
5.3.1.5 Protein electrophoresis
Bis-Tris gels A litre of running buffer was prepared from the concen-
trated MES/ SDS buffer, using DI H2O. A protease inhibitor (Complete,
Mini, Roche, Mannheim, Germany) was added to the buffer (one tablet per
7 mL). The gels used were NuPage® 12% Bis-Tris 1.0 mm 12-well Novex
gels (Invitrogen, Paisley, UK). The gels were prepared as described previ-
ously and loaded into the Novex II module tank filled with running buffer.
NuPage® antioxidant (0.5 mL) was added to the central tank, which was
inserted onto the Novex PowerEase® 500 Power Supply for electrophoresis.
Long-tip dispensers were used for loading. A volume of 3 μL of Rainbow™
recombinant protein molecular weight marker (GE Healthcare, Amersham,
UK) was loaded into wells adjacent to the samples of interest, which were
loaded from left to right. Electrophoresis was carried out for 35 mins at 200
mV.
Tricine gels An acrylamide gel (Novex® 10-20% Tricine gel, Invitrogen)
was used to resolve the low molecular weight peptides from the AEC ex-
tract. A volume of 3 μL of Rainbow™ ultra-low molecular weight markers
were used (GE Healthcare, Amersham, UK). Electrophoresis was performed
using the Novex® Tricine Running Buffer.
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5.3.1.6 Protein transfer
Transfer buffer was made up by adding 200 mL methanol to 750 mL DI
H2O and 50 mL of NuPage® Transfer Buffer (20 ×). Immobilon PVDF
membranes (Millipore, Massachussets, USA) were soaked in methanol and
then transferred to a tray containing sponges and blotting papers soaked
in transfer buffer. The gels were retrieved from the casing. The blotting
apparatus was assembled as described previously and loaded into the tank.
The running time was 1 hr at 30 V. The Novex® Tris-Glycine transfer buffer
was used for the Tricine gels. At the end of this step, the membranes were
transferred to a tray containing DI water and blocked in TBS-TM blocking
buffer for 1 hr on a rocker.
5.3.1.7 Incubation with primary antibody
Primary antibody was diluted to an appropriate concentration in primary
antibody buffer (TBS-TM). For whole AM extract, rabbit polyclonal anti-
hBD3 (ab1128 and ab19270) and mouse monoclonal anti-hBD3 (ab14422)
were used at a concentration of 1 in 750. Rabbit anti-LL-37 (G-075-06,
Phoenix Pharmaceuticals Ltd) andmouse anti-hBD1 (ab14425, Abcam) were
used at a concentration of 1:500. For AEC extract, two rabbit anti-hBD3
antibodies (ab1128 and ab19270, Abcam) were used at a concentration of
1:500. The membranes were transferred into trays containing 10 mL of pri-
mary antibody in TBS-TM. The trays were kept on a rocker overnight at
4°C, or at room temperature for 4 hrs.
5.3.1.8 Detection of protein bands
The membranes were washed in TBST for 5 mins × 3, washed and incu-
bated in 10 mL of AP-conjugated goat anti-rabbit secondary antibody (Cat.
No. 7054, Cell Signaling Technology, Inc., Beverly, MA) at a dilution of
1:5000 for 1 hr. They were then washed × 1 for 15 mins and × 3 for 5 mins
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in TBST. A volume of 8 mL of substrate solution (BCIP/NBT purple liquid
substrate, Sigma) were added for 5 - 10 mins until protein bands appeared.
The blots were washed and dried before being scanned and labelled using
Adobe® Photoshop® CS4 software.
5.3.1.9 Minigel staining
Gels from western blots were stained in Simply blue™ SafeStain (Invitro-
gen) to highlight the protein bands. The gels were placed in a glass dish
with DI H2O and microwaved × 3 for 1 min. They were then placed in 20
mL Simply blue™ SafeStain for 1 hr, rinsed off in DI H2O for 4 hrs and
dried.
5.3.1.10 Gel drying
Destained gels were washed × 3 for 2 mins in DI H2O (50 mL per mini-
gel) on a rotary shaker. Gel-Dry™ drying solution (35 mL per mini-gel) was
added. The gel was equilibrated in the Gel-Dry™ Drying Solution by shak-
ing the gel for 5 mins in the StainEase® Gel staining tray. One sheet of
cellophane at a time was immersed in the Gel-Dry™ drying solution, mak-
ing sure to cover both sides of the sheet with solution. One side of the
DryEase® Gel drying frame was placed with the corner pin facing up, on
the DryEase® Gel Drying Base. Pre-soaked cellophane was placed over the
base/frame combination, so the cellophane lay over the inner edge of the
frame. The gel was laid on the center of the cellophane sheet making sure
no bubbles were trapped between the gel and the cellophane. The second
sheet of cellophane was laid over the gel so that no bubbles were trapped
between the cellophane and the gel. Any wrinkles in the assembly were
smoothed out with a gloved hand. The remaining frame was aligned so that
its corner pins fit into the appropriate holes on the bottom frame and the
plastic clamps were sealed onto the four edges of the frames. Drying took
248
between 12 and 36 hrs depending on humidity and gel thickness.
5.3.2 Mass spectrometry
Mass spectrometry (MS) was performed on one band identified on western
blotting. The technique is described in Chapter 4 (subsection 4.3.7).
5.3.3 Cytometric Bead Analysis4
CBA is a technique that can be used for detecting protein and measur-
ing protein concentrations. It uses a system of beads of different sizes
coated with different fluorophores. The beads can be conjugated to the
complement-binding portion of antibodies. Thus, beads can be coated with
one type of antibody that is specific for an epitope of interest. The bead-
antibody conjugates can be used to ‘capture’ the relevant protein. A sec-
ond, fluorochrome-labelled antibody is used to detect the protein. The beads
can be discriminated by flow cytometry. This operates by directing a single
wavelength beam of laser light onto a stream of liquid containing the beads
of interest. Each bead both scatters and emits light. The forward scatter re-
flects the bead size, while the wavelength of the emitted light corresponds to
the bead and the detection antibody fluorophores. The resulting signals can
be converted into digital data and recorded as plots. Hence, bead mixtures
can be used to detect and quantify an array of analytes of interest.
A CBA assay was performed on supernatants of fresh, f-t and v-d AM
extracts from two AMs (1 and 2) to detect hCAP18. The antibody cho-
sen for capture was a mouse monoclonal antibody to the pro-region (115-
NQARGSF-121) of hCAP18 (ab80895, Abcam plc, Cambridge, UK). A puri-
fied polyclonal rabbit anti-LL-37 antibody (Catalog No.: G-075-06, Phoenix
Pharmaceuticals, Inc., Belmont, CA) was used as a detection antibody. The
4This work was carried out with the help of Dr Sue Fox, Ms. Jane Limer of BD Bio-
sciences and Mrs Jackie Glenn.
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capture beads were pre-coated with APC.
5.3.3.1 Labelling of detection antibody
The LYNX Rapid Conjugation Kit® (AbD Serotec, North Carolina, USA)
was used to label the detection antibody, G-075-06, with R-phycoerythrin
(RPE). A total of 60 μg of antibody in H2O (0.5 μg/μL) was mixed with 12
μL of Modifier reagent. This mixture was added to 100 μg of the lyophilised
RPE label and incubated at room temperature overnight. Next, 12 μL of
Quencher reagent was added.
5.3.3.2 Bead preparation
A Functional Bead Conjugation Buffer Set (BD Biosciences) was used to
covalently link the capture antibody, ab80895, to the surface of fluorescent
beads. Before starting the procedure, all reagents were brought to room
temperature. The beads were covered with aluminium foil to protect from
light at all times. The samples were free of detergents. Aliquots of 1.0
M DTT in H2O were prepared. The functional beads for conjugation were
vortexed for 30 secs, prior to transfer to a microcentrifuge tube (75 μL of
beads for a 500 test reaction). The beads were sonicated for 1 min. A volume
of 1.9 μL of 1 M DTT was added to the microcentrifuge tube containing the
functional beads and vortexed for 5 secs. The beads were incubated for 1
hr at room temperature and vortexed every 15 mins. A volume of 1 mL of
Coupling Buffer was added and vortexed for 5 secs. The beads were pelleted
by centrifugation at 900 ×g for 3 mins, and the supernatant discarded. This
was repeated × 2. The bead pellet was resuspended with 20 μL of Coupling
Buffer.
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5.3.3.3 Capture antibody modification
A microcentrifuge tube containing 90 μL of the capture antibody (0.5 μg/μL
in H2O) was covered with aluminium foil. A stock solution of 2 mg/mL of the
3-sulfo-N-hydroxysuccinimide ester sodium salt of 4-(N-maleimidomethyl)cyclohexane-
1-carboxylic acid (sulfo-SMCC) was prepared in DI H2O immediately before
use. A volume of 2 μL of sulfo-SMCC was added to the capture antibody so-
lution in the microcentrifuge tube and vortexed for 5 secs. The protein was
incubated in darkness for 1 hr at room temperature and vortexed every 15
mins.
5.3.3.4 Buffer exchange
A Bio-Rad Spin Column (Cat No. 732-6231, Bio-Rad Laboratories, Hemel
Hempstead, UK) was filled with Coupling Buffer and drained × 3. The spin
column was placed in a 12 × 75 mm test tube and centrifuged at 1000 ×g for
2 mins, and the tube was discarded. The spin column was placed in a new
12 × 75 mm test tube. The entire volume of antibody/sulfo-SMCC solution
was added to the spin column and centrifuged at 1000 ×g for 2 mins 15 secs
to transfer the modified protein into the 12 × 75 mm test tube in Coupling
Buffer.
5.3.3.5 Protein Conjugation
The modified capture antibody was transferred from the 12 × 75 mm tube
to the microcentrifuge tube containing the fluorescent beads and microcen-
trifuged for 5 secs. The antibody and beads were incubated for 1 hr at room
temperature in darkness, and vortexed every 15 mins. Aliquots of 2 mg/mL
of N-Ethylmaleimide (NEM) in DMSO were prepared, and 2 μL added to
the microcentrifuge tube containing the functional beads and capture anti-
body. The microcentrifuge tube was vortexed for 5 secs and incubated for 15
mins. A volume of 1 mL of Storage Buffer was added to the microcentrifuge
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tube. The beads were pelleted by centrifugation at 900 ×g for 3 mins and
the supernatant discarded × 3. The bead pellet was then resuspended in
0.5 mL of Storage Buffer. The beads were now at a final concentration of
approximately 6 × 106 beads/mL and ready to be validated.
5.3.3.6 Confirmation of conjugation of beads
Confirmation of conjugation was carried out on a BD LSR II™ flow cytome-
ter. Three 12 × 75 mm test tubes were labelled: (1) diluted functional beads,
(2) negative control, and (3) test sample. The beads were vortexed for 5 secs.
245 μL of Wash Buffer from one Master Buffer Kit used to run the assays
was added to the diluted functional beads tube (1). A 5 μL sample of the
functional beads were added to the diluted functional beads tube (1) and
vortexed for 5 secs. A volume of 50 μL of beads were transferred from the
diluted functional beads tube (1) to the negative control tube (2) and to the
test sample tube (3). A volume of 50 μL of wash buffer was added to the
negative control tube (2). A volume of 50 μL of a rabbit phycoerythrin (PE)
anti-Ig Detector (BD biosciences) was added to the test sample tube (3).
Both the negative and test sample control tubes were vortexed for 5 secs
and incubated for 30 mins in the dark, at room temperature. A volume of 1
mL of Wash Buffer was added to both tubes, which were centrifuged at 1000
× g for 5 mins. Bead pellets for both tubes were re-suspended with 150 μL of
Wash Buffer. The tubes were processed on the BD LSR II™ flow cytometer.
5.3.3.7 Cytometric analysis5
The BD LSR II™flow cytometer was set up by starting the instrument and
the computer, following the 2007 User’s Guide (BD Biosciences). BD FACS-
Diva software was activated on the desktop. The required optical filters for
APC (beads) and PE (antibody) fluorochrome detection were set up. The flu-
5Performed by of Dr Jane Limer of Becton, Dickinson and Company, UK
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idics were checked and primed. The software parameters were set up to read
forward scatter and the fluorochrome intensity. An unstained control tube
was installed onto the sample injection port. The control was processed and
data acquired. This was used to adjust the forward and side scatter voltage
and forward scatter threshold to gate the population of interest. A gate was
applied to the singlet population of beads. The first sample tube was then
inserted onto the sample injection port. Digitised data was recorded via
channels for APC and PE. The mean fluorescence intensity (MFI) of control
and test populations of 1000 beads was measured to ensure correct labelling
of the beads.
5.3.3.8 Protein extraction
Protein extracts from whole f-t and v-d AM samples were obtained by grind-
ing under liquid N2 as previously described (section 5.3.1.1). The super-
natant was obtained from the ground AM. The total concentration of protein
was measured. CBA was performed directly on the AM supernatants.
5.3.3.9 Detection of antigen in samples
Mixed Capture Beads were vortexed for at least 5 secs and 25 μL added to
each assay tube. A volume of 25 μL of sample was added to the assay tubes,
which were mixed gently and incubated for 3 hrs at room temperature away
from direct exposure to light. A volume of 10 μL of the detection antibody
(10% or 20%) was added to each assay tube. The tubes were mixed gently
and incubated for 2 or 4 hrs at room temperature in the dark. A volume of 1
mL of Wash Buffer was added to each assay tube and these were centrifuged
at 4°C for 5 mins at 200 ×g. The supernatant from each assay tube was
discarded. A volume of 300 μL of Wash Buffer was added to each assay
tube and mixed gently before analysis on the BD LSR II™ flow cytometer.
Appropriate BD CBA Flex Setup instrument settings were used. The MFI
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of the test sample was compared to a negative (blank) sample.
5.3.4 Flow cytometry
The technique of flow cytometry can be used to analyse populations of cells.
The principles of this technique have been explained in relation to CBA
(above). For analysing cells, another parameter, side scatter can be mea-
sured to represent the cell’s inner complexity. The cells can be labelled di-
rectly with conjugated primary antibodies, which can be detected by their
fluorophores. These can be directed at the cell surface or the internal cell.
Flow cytometry was performed on permeabilised AEC from five AMs (in-
cluding one optimisation step), by using an array of primary antibodies
against a range of AMPs to document their expression in human AEC. The
AMPs investigated in this way included psoriasin, LEAP-2, RNAse-7, hBD2,
hBD3 and LL-37.
5.3.4.1 Preparation of single cell suspension
A technique for preparing single cell suspensions of human AEC by trypsin-
ising whole AM in culture medium was described by Casey and MacDonald
(1996). Gicquel et al. (2009) obtained total detachment of individual epithe-
lial cells by incubating whole AM pieces in thermolysin for 15 mins at room
temperature, leaving a clean BM. In the current study, AECs were lifted
using the thermolysin method described in subsection 3.3.1.3. The remain-
ing AM tissue was removed to leave a cell suspension. A wash buffer was
prepared by adding 1% sodium azide and 3% BSA to 1 × PBS. The detached
cells were washed in PBS and centrifuged × 2 for 5 mins at 4°C at 200 ×g.
After centrifugation, the cells were fixed by resuspending the pellet in 0.5%
FA in 100 μL of wash buffer. The cells were centrifuged one more time and
resuspended for 15 mins at 4°C in 100 μL of permeabilising reagent consist-
ing of 0.2% Tween 20 in wash buffer. The cells were blocked in 300 μL of
254
1:10 normal goat serum (NGS) for 30 mins, They were then washed in 1 mL
of permeabilising reagent in preparation for flow cytometry.
5.3.4.2 Optimisation of permeabilisation and fixation
Flow cytometry was carried out on the AEC from one AM to assess the ef-
fects of permeabilisation and formaldehyde (FA) fixation of the cells. Cells
were either permeabilised and fixed in 0.5% or 3% FA or non-permeabilised
and fixed in 0.5% FA. The cells were incubated with rabbit polyclonal anti-
hBD3 (ab19270, 1:100) overnight at 4°C and with secondary antibody con-
jugated to Alexa Fluor® fluorescein isothiocyanate (FITC) for 1 hr. Nega-
tive controls were incubated with secondary antibodies conjugated to FITC
without primary antibody.
5.3.4.3 Antibody staining
AEC obtained from four AMs were stained with an array of antibodies in
four separate flow cytometry experiments. Separate samples were prepared
to test for each AMP. For negative controls, samples were incubated with
secondary antibodies conjugated to Alexa Fluor® fluorophores FITC and al-
lophycocyanin (APC) without primary antibody. Vimentin, an intermediate
filament protein, was used as a positive control for PE-conjugated antibod-
ies. The primary antibodies used in each experiment are shown in figure
5.3. The cell pellets were resuspended in 1 mL of permeabilising reagent. A
volume of 30 μL of primary antibody (1:50 - 1:100 in wash buffer) was added
and left to incubate at room temperature for 2 hrs. In one experiment (no.
4), the samples were incubated overnight at 4°C, and the experiment con-
tinued the next day. The cells were then washed in 1 mL of permeabilising
reagent. A volume of 30 μL of secondary antibody (1:1000) was added, in-
cubating at room temperature in the dark for 1 hr. The cells were washed
in 1 mL washing buffer, pelleted and resuspended in 500 μL PBS for flow
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Table 5.3: Primary antibodies, flow cytometry
EXPT 1 EXPT 2 EXPT 3 EXPT 4
Psoriasin (m), 1:50 Psoriasin (m), 1:50 Psoriasin (m), 1:50 Psoriasin (m), 1:50
LEAP-2 (r), 1:100 LEAP-2 (r), 1:100 LEAP-2 (r), 1:100 LEAP-2 (r), 1:100
hBD2 (m), 1:50 hBD2 (m), 1:50 hBD2 (m), 1:50 RNAse-7 (r), 1:100
hBD3 (m), 1:50 hBD3 (m), 1:50 hBD3 (m), 1:50 hBD3 (r), 1:100
RNAse-7 (r), 1:100 RNAse-7 (r), 1:100 hBD3 (r) 1:100 LL-37 (r, PE), 1:50
LL-37 (r), 1:100
Expt, experiment; m, mouse; r, rabbit; PE, phycoerythrin-conjugated
cytometry analysis. Each sample underwent flow cytometry once.
5.3.4.4 Flow cytometry
The flow cytometers used for these experiments were either the BD LSR
II™ flow cytometer or the Beckman-Coulter FC 500 Analyzer (Beckman-
Coulter Inc., Pasadena, CA, USA) equipped with CXP software.6 The FC
500 instrument was prepared using the 2004 Cytomics FC 500 Instructions
for Use. Briefly, the sheath tank was filled with water and the waste tank
emptied. The computer software was activated, and protocols were created
with the parameters to be acquired for each experiment, such as instrument
settings. These were based on pre-ordained protocols. Panels were created
to enable the number of tubes required to be programmed. The fluorescence
channels selected included FL1 (FITC), FL2 (PE) and FL4 (APC). Samples
were loaded onto the carousel with 32 tube positions, which was placed in
the multi-tube carousel loader for automated sampling. Unstained samples
were run initially to check the parameters. Polygonal gates were superim-
posed on the two parameter dot plots to capture representative batches of
cells, avoiding extremes of forward and side scatter. Thus, cells with ab-
normally high or values were excluded as possible cell fragments or swollen
cells. Samples were analysed in sequence, and data was saved in transfer-
6Performed with the assistance of Mrs Nina Lane, Flow Cytometry Technician, Faculty
of Medicine & Health Sciences.
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able .fcs data files.
5.3.4.5 Data analysis
The data files were analysed separately using Weasel software (version
3.0.2) available from the Walter and Eliza Hall Institute of Medical Re-
search at the University of Melbourne, Australia. The logarithm of fluo-
rescence at the appropriate wavelength for each sample was plotted against
forward scatter on a linear scale. Cut-off markers were set for the negative
and positive controls, separating 99.5% of recorded events from the remain-
ing 0.5%. The cut-off markers were then applied to the test samples for
direct comparison with the controls. This returned the percentage of posi-
tive events (antibody bound to cell antigens) for each analyte above baseline
in the cell population of interest (Shapiro, 2003).
5.3.5 Antimicrobial assays7
Antimicrobial activity was determined from the minimum inhibitory con-
centration (MIC). Briefly 50 μL/well of lysogeny broth (LB) medium was
added to a 96-well plate. In column 1, 50 μL of whole AM extract (fresh AM,
f-t AM, denuded AM, v-d AM, 10% v-d AM) at 100 μg/mL was applied in
triplicate. Using a multichannel pipette serial dilutions were made across
the plate leaving column 12 containing medium only to act as a control.
A selection of Gram positive (Staphylococcus epidermidis, Staphylococcus
aureus, and Corynebacterium diphtheria) and Gram negative (Moraxella)
bacterial strains were grown up in LB broth until the optical density at 600
nm reached 0.1. Bacterial cell suspensions were then added to the plate us-
ing a multichannel, at 50 μL/well. Plates were incubated overnight at 37°C
for 24 hrs. Results were assessed visually with the MIC being equivalent to
the last clear well.
7This work was performed by Dr Claire Allen.
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Circular discs of chromatography paper were saturated with concen-
trated AM extract and incubated with LB agar plates seeded with the bac-
terial strains. Antibacterial activity was assessed using the radial diffusion
method. This involved measuring zones of inhibition around the discs sat-
urated with extract. Alternatively, 1 × 1 cm sheets of AM were directly
applied to Petri dishes containing lawns of bacterial strains grown on LB
agar. AM extract and bacteria were incubated for 24 hrs and antimicrobial
activity was assessed visually.
AM sections were saturated in a pre-prepared antibiotic solution for
10 mins. A volume of 10 mL of the following was added to 500 mL of
Endosol; Gentamicin 200 mg/mL, Imipenem 10 mg/mL, Nystatin 125,000
U/mL, Polymyxin B 10 mg/mL and Vancomycin 2.5 mg/mL. Membranes
were then immersed in sterile PBS for different periods of time (10 mins,
20 min, 60 mins, 2, 6, 12, 24 and 48 hrs) before extracting proteins from the
tissue using a liquid N2 bath and a pestle and mortar. Antimicrobial MIC
assays were then performed using the assay described previously.
5.3.6 Protein microarray
As part of the study on the MMP/TIMP cascade in therapeutic AM, the lo-
calisation and concentration of the enzymes and their inhibitors in the dif-
ferent preparations were investigated by a quantitative protein microarray.
The samples were sent to an external provider (Aushon BioSystems Inc.,
Billerica, MA) for chemiluminescent antibody-based microarrays (Search-
Light), which provide quantitative data on selected biomarkers. The follow-
ing MMPs and TIMPs were selected for analysis: MMP-1, MMP-2, MMP-
3, MMP-7, MMP-8, MMP-9, MMP-10 and MMP-13, TIMP-1 and TIMP-
2. The SearchLight results were normalised with reference to the protein
concentrations of the analysed tissues, and levels of analytes expressed as
picograms per milligram of tissue.
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5.3.6.1 Sample preparation
Four AMs were processed for protein microarrays.8 The preparations in-
cluded fresh, de-epithelialised (thermolysin-treated), v-d and f-t AM. The
tissue was sectioned into pieces measuring approximately 10 × 10 cm and
weighing approximately 1 g. The samples were extracted by grinding in liq-
uid N2 and adding the homogenate to 1 mL of TBSTx per 250 mg tissue. The
samples were centrifuged at 20 000 ×g for 15 mins at 4°C to remove insolu-
ble material. Protein quantification was carried out on all supernatants in
duplicate using a 2-D quantification kit (GE Healthcare, UK).
5.3.6.2 Data analysis
Missing data were ignored rather than imputed. All of the analytes had a
least two data values. The median was used for analysis. For ease of anal-
ysis, when analyte levels were below the threshold for detection, they were
given a value of 0 pg/mg. Matched non-parametric tests (Friedman) with
post-hoc analyses (Dunn’s multiple comparison test) were used to compare
the analytes in the different preparations.
5.3.7 Zymography9
To determine whetherMMP-2 andMMP-9 are eluted from therapeutic prepa-
rations of AM, zymography was performed on AM supernatants and ho-
mogenates to investigate the presence of MMP-2 and MMP-9 in fresh and
preserved AM immediately after processing the tissue for clinical use (0 hrs)
and following a period of incubation (24 or 48 hrs).
8This work was carried out in collaboration with Dr Claire Allen.
9This work was carried out with the help of Dr Imran Haq.
259
5.3.7.1 Sample preparation
AM was obtained in the usual way. Sections of fresh tissue, 5 cm × 5 cm
in size, were each placed into separate polypropylene universal sample con-
tainers containing 5 mL RPMI-1640 medium (Sigma-Aldrich). The 500 mL
bottle of culture mediumwas pre-treated with 1mLGentamicin/Amphotericin
B suspension (Cascade Biologics Inc., Eugene, Oregon, USA). Further sec-
tions were vacuum-dried or frozen for a minimum of 3 hrs in 5 mL PBS.
After drying, v-d AM was reconstituted in 5 mL of DI H2O. F-t AM was
thawed for 30 mins in a 37°C water bath.
Matched pairs of each of the fresh, f-t and v-d AM sections were removed
from their respective media and placed in 1 mL RPMI-1640 medium per 200
mg of wet tissue. After 5 mins, a volume of 10 μL of supernatant from one set
of samples was extracted. The containers were then sealed and incubated at
37°C. The storage and wash media of the f-t AM was also sampled to assess
the elution of MMPs. At this time point (baseline, 0h), the matched samples
were homogenised by grinding AM in liquid N2 and suspending the lysate in
1 mL of TBSTx per 200 mg wet weight. The suspension were centrifuged at
12 000 × g to remove particulate matter. At the end of the incubation time
(24 or 48 hrs), the supernatants were sampled again. The samples were
then homogenised as before. In this way, supernatants and homogenates
were obtained at baseline and after 24 or 48 hrs.
A volume of 10 μL of supernatant/homogenate was mixed with 10 μL of
Novex® Tris-Glycine SDS sample buffer (2 ×) (Invitrogen, Carlsbad, Ca,
USA). Each sample was loaded into the zymogram gels in triplicate.
Zymography was carried out on supernatants and homogenates of fresh,
v-d and f-t AM from three AMs at 0h and 24h. F-t storage and wash me-
dia were also sampled. Samples were loaded in triplicate. In this initial
zymography experiment protein concentrations were not standardised.
Zymography was then performed on samples from six AMs (two sepa-
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rate experiments) at 0h and 48h. The initial experiment was modified. To
obtain sufficient quantities of protein, homogenates were used for baseline
measurements. F-t AM storage medium was also analysed. After incu-
bation, there were sufficient quantities of protein in the supernatants, so
homogenates were not necessary. Protein quantification was performed to
standardise the quantities of protein per well. A total of 1.5 μg of protein
was dispensed into each well in the zymograms. The protein concentrations
were normalised across the wells by calculating the volume required from
the sample with the lowest concentration. Remaining samples were diluted
in buffer to the same concentration, so that volumes were equal in every
well.
5.3.7.2 MMP markers
Recombinant human MMP-2 was obtained from R&D Systems Inc. (Cat.
No. 902-MP-010, Minneapolis, MN, USA). A total of 2.5 ng of recombi-
nant human MMP-2 in 20 μL sample buffer were loaded onto each 10%
Zymogram acrylamide/gelatin gel (Invitrogen™). MMP-9 was loaded into
each gel for localisation of the pro-enzyme, not for comparison of concen-
trations. An MMP-9 marker was obtained from a full length construct (Fu-
Gene®, Roche, Indianapolis, IN, USA). The construct was transfected into
an African Green Monkey simian virus-transfected kidney fibroblast cell
line, known as Cos7, using a standard protocol.10 The Cos7 cells were cul-
tured in DMEM (Gibco®) and 10% FCS. The medium was replaced with
serum-free DMEM after 24 hrs. The supernatant, containing MMP-9, was
extracted 24 hrs later, and stored at -80°C.
10MMP-9 markers courtesy of Dr Imran Haq.
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5.3.7.3 Gel electrophoresis
The samples were loaded into wells on a pre-cast 10% Zymogram gel (In-
vitrogen). MMP-2 markers were loaded into each gel, whereas MMP-9 was
loaded once per experiment. Each gel chamber was filled with 500 mL Tris-
Glycine SDS zymogram running buffer (Invitrogen®). Gel electrophoresis
was carried out for 2 hrs at 120 – 140 V. The gels were then soaked in
renaturing buffer for 30 mins × 2 on a rocker, followed by incubation at
37°C in developing buffer overnight. After 24 hrs, the gels were stained
in Coomassie Brilliant Blue R 250, and then destained in a methanol and
acetic acid solution (500 mL H20, 400 mL methanol and 100 mL acetic acid)
for 30 mins. The gels were then ready for ultraviolet transillumination (300
nm) and photography, using image capture software. Each gel was scanned
using a reflected ultraviolet light photographic system with a yellow filter
(Gene Genius Bio Imaging System, Syngene, Cambridge, UK), and images
were captured using Syngene gel documentation and analysis software.
5.3.7.4 Band intensity measurement
The zymography band intensities were normalised to the marker intensity
using ImageJ software.11 The individual bands were circumscribed using
the cursor. The optical densities of the demarcated zymography bands were
obtained numerically from the software and normalised to the MMP-2 stan-
dard to give percentage measurements of relative density. An average read-
ing of the triplicate bands was taken for statistical analysis.
5.3.7.5 Statistical analysis
Statistical analysis was performed using GraphPad Prism software (La Jolla,
CA, USA). Non-parametric tests were performed throughout. The data were
11Software developed by Wayne Rasband at the Research Services Branch, National In-
stitute of Mental Health, Bethesda, Maryland, USA.
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Table 5.4: Culture medium
Reagent Cat. No. Volume Final conc.
RPMI-1640 Sigma R8758 42.5 mL 85%
Human AB serum Sigma H4522 7.5 mL 15%
L-glutamine Sigma G7513 500 μL 2 mM
Penicillin/streptomycin Sigma P4333 500 μL 100 U/mL/100 μg/mL
HEPES Sigma H3375 500 μL 10 mM
pooled to give an overall picture of MMP-2 and MMP-9 expression in pro-
cessed AM. Statistical significance was sought at the level of 5%.
5.3.8 Macrophage assays
Macrophages were cultured from peripheral bloodmononuclear cells (PBMCs)
for inflammation assays with AM.12 PBMCs were obtained from fresh blood
or from buffy coats and cultured in Teflon-coated bottles or ultra-low adher-
ence flasks.
5.3.8.1 Macrophage culture
Before starting, reagents were placed in a water bath to bring them to
37°C. These included Hanks’ Balanced salt Solution (BSS, Sigma H9394),
Histopaque®-1077 (Sigma H8889) and Roswell Park Memorial Institute
medium (RPMI-1640, Sigma R8758). Culture medium was prepared by
mixing RPMI-1640, 15% human AB serum, L glutamine, penicillin, strepto-
mycin, and 4-(2-hydroxyethyl)-1-piperazine ethanesulfonic acid (HEPES, 10
mM) in the proportions shown in table 5.4. Magnetic-Activated Cell Separa-
tion buffer (MACS®, Miltenyi Biotec, Gladbach, Germany) was made up in
500 mL PBS by adding 2.5 g BSA (final concentration 0.5%) and 2 mL of 0.5
M EDTA (Invitrogen, 15575-020; final concentration 2 mM) in Dulbecco’s
PBS. This was sterile-filtered and refrigerated throughout the isolation pro-
12Special thanks are due to Sonali Singh, who showed me the techniques listed below,
and to Dr Luisa Martinez-Pomares, who helped to devise the assays.
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cedure.
5.3.8.2 Extraction of peripheral blood mononuclear cells
Whole blood A volume of 50 mL of freshly extracted whole blood was
pooled from EDTA vacutainer tubes and transferred to a T-75 flasks under
sterile conditions. The blood was diluted with an equal volume of Hanks’
BSS. This mixture was divided into four new 50 mL Falcon tubes each con-
taining 10mL of Histopaque® for 25 mL. The blood and the Histopaque®
formed two distinct layers, created by holding the tube containing Histopaque®
at a 45 degree angle and trickling a few drops of the blood-Hanks’ mixture
along the wall of the tube. By keeping the tip of the pipette just below the
rim of the Falcon tube and trickling in the blood-Hanks’ mixture, disrup-
tion of the Histopaque® interface was minimised. The tubes were carefully
transferred to the centrifuge, again trying as far as possible to prevent ad-
mixture. They were centrifuged at 800 × g at 23°C, with slow accelera-
tion and deceleration for 30 mins. The PBMC was then removed with a
5 mL pipette, trying as far as possible to avoid admixture with RBCs, as
described above. The collected PBMCs were divided into two Falcon tubes.
The PBMCs in both tubes were washed once with 50 mL Hanks’ solution
(350 × g, 23°C) for 7 mins.
Buffy coats Monocytes were isolated from buffy coats obtained from hu-
man blood banks. A volume of 50 mL of blood was poured out into T-75
flasks under sterile conditions in a laminated hood, and made up to a vol-
ume of 140 mL with PBS. 35 mL of this mixture was layered over 15 mL
of Histopaque®-1077 (Sigma-Aldrich) in 50 mL Falcon tubes as described
above. The tubes were centrifuged at 800 × g at 23°C for 30 mins. The
upper plasma layer was removed with a 25 mL pipette. The PBMC rings
were collected using a sterile 5 mL pipette and transferred to two fresh 50
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mL Falcon tubes. The PMCs were washed × 2 with PBS (350 × g, 23°C, ac-
celeration 3, deceleration 3, 5 mins). The supernatants were cloudy due to
platelet contamination; these were discarded and the PBMC pellets washed
twice more with PBS.
5.3.8.3 Cell counting
The supernatant was discarded, and the PBMCs were resuspended in ex-
actly 10 mL of Hanks’ (whole blood) or PBS (buffy coat), mixing pellets from
both Falcon tubes. A 100 μL aliquot was removed for cell counting. For
this, a volume of 100 μL of cell suspension was mixed with 900μL PBS. Of
this, 100 μL was mixed with 100 μL Trypan blue to give a dilution of 1:20.
A haemocytometer and its cover slip were washed in distilled water and
wiped over with alcohol. When dry, the surface of the haemocytometer was
breathed on and the cover slip quickly placed at the centre of the count-
ing chamber. A small amount of the cell suspension/solution to be counted
was taken up in a pipette. The pipette was touched against the side of the
cover slip where it touches the base of a depression in haemocytometer. One
drop was slowly squeezed up to fill one counting chamber with nine squares,
each containing a volume of 0.1 mm3. Cells in five squares of the counting
chamber (the four corners and the centre) were counted under the 40 × ob-
jective of an optical microscope. Cells falling on the bordering triple lines
were counted if they were on the top or on the left lines. The average cell
count per square was calculated by dividing the total by 5. This figure was
multiplied by the dilution factor (20) and by 104 to obtain cell density as the
number of cells per mL. To obtain total cell count, this value was multiplied
by 10.
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5.3.8.4 Labelling of monocytes
The PBMCs were centrifuged (350 × g, 23°C) for 5 mins and the super-
natant aspirated. The pellets were then washed in cold, sterile MACS®
buffer (350 × g, 23°C) for 5 mins and resuspended in 800 μL of the same
buffer per 107 cells. A volume of 200μL of CD14Microbeads (Miltenyi Biotec)
were added per 107 cells, mixed well and incubated at 4°C in the dark for
15 mins. If fewer than 107 PBMCs were counted, 200μL of CD14 beads were
added. It was important to work fast, keeping cells cold, and using pre-
cooled solutions to prevent capping of the antibodies on the cell surface and
non-specific cell labelling. Once the incubation was over, the CD14-labelled
cells were washed once with 20 mL MACS® buffer (350 × g, 5 mins).
5.3.8.5 Magnetic cell separation
Magnetic cell separation columns (Miltenyi Biotec) were set up. Pre-separation
filters were placed in the columns and washed with 3 mL MACS® buffer to
prevent any cell clumps from entering the column and blocking it. The cells
were resuspended in 3 mL MACS® buffer and placed in the columns. The
columns were then washed with 3 mL MACS® buffer 3 times, so that only
CD14+ cells were retained in the columns. These were then flushed out into
15 mL tubes with 10 mL MACS® buffer, and stored at room temperature.
The cells were counted, and then centrifuged (350 × g, 23°C) for 5 mins.
These were resuspended in culture medium to a maximum total density of
2 × 106 cells/mL in 10 mL. A volume of 10 μL of granulocyte-macrophage
colony-stimulating factor (GM-CSF, 10 μg/mL stock solution) was added to
the 10 mL suspensions to give a final concentration of 10 ng/mL.
5.3.8.6 Monocyte culture
A volume of 5 mL of cell suspension were seeded into sterile Teflon bottles
or ultra-low adherence 75 cm3 flasks (Corning®, MA). Teflon bottle caps
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were left slightly unscrewed to allow air exchange, secured with labelled
masking tape and left to incubate at 37°C in 5% CO2. After three days,
the cell survival was verified by Trypan blue staining. A volume of 1.5 mL
of fresh medium containing 10 ng/mL GM-CSF was added to the bottles.
Macrophages were ready for harvesting by day 7.
5.3.8.7 Harvesting of macrophages
After incubation for 7 days, the medium containing the suspendedmacrophages
was recovered and pipetted into a Falcon tube on ice. Adherent macrophages
left in the ultra-low adherence flasks were removed by additional steps. The
inner walls were washed with 5 mL sterile PBS. A volume of 5 mL sterile
non-enzymatic cell dissociation buffer was added to each flask and incu-
bated on ice for 40 mins. At the end of 40 mins, the flasks were checked
under the microscope to confirm that all cells detached from the surface.
The cells appeared round and bright instead of flat and grey. A 5 mL pipette
was used to flush the cells out of the flask and add this solution to the Falcon
tube. This was centrifuged at 350 × g for 5 mins at 4°C. The cell pellet was
washed in RPMI-1640 medium for 5 mins at 4°C, and resuspended in 10 mL
of medium. The cells were counted, centrifuged and resuspended to give a
cell density of 5 × 105 cells/mL. A volume of 1 μL of 10 μg/mL GM-CSF was
added to each mL of medium.
5.3.8.8 Confirmation of phenotype
Flow cytometry was performed on cells from two different buffy coat donors
to confirm their phenotype as activated macrophages. Depending on re-
quirements, a cell suspension containing between 20 000 to 100 000 cells
from the previous step was centrifuged (350 × g, 4°C, 5 mins). The super-
natant medium was discarded. The remaining pellet was washed in PBA
for 5 mins and then centrifuged (350 × g, 4°C, 5 mins). The cells were
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Table 5.5: Markers of activated macrophages
Isotype Label Control No. Markers Antibody No.
IgG1
PE 130-092-212
CD16 130-091-245
Mannose receptor 130-095-220
FITC
130-092-213 CD11b 130-081-201
IgG2a
130-091-837
CD14 130-080-701
CD3 130-080-402
PCy5 130-091-836 HLA-DR 130-095-297
PE, phycoerythrin; FITC, fluoroisothiocyanate; PCy5, Phycoerythrin-coupled cyanin 5.
counted in the haemocytometer, and the remaining pellet was resuspended
to the required cell density. 100 μL aliquots were separated into tubes for
flow cytometry. Next, they were incubated in 100 μL 5% mouse serum for
1 hr at 4°C. This was followed by a further wash in 400 μL PBS. Conju-
gated mouse monoclonal antibodies from Miltenyi Biotec were used. Spe-
cific markers included IgG2a antibodies against HLA-DR, CD14 and CD3
and IgG1 antibodies against CD11b, CD16 and mannose receptor. Isotype
controls included IgG1 labelled with FITC and PE and IgG2A labelled with
FITC and phycoerythrin-coupled cyanin 5 (PCy5). (table 5.5). These were
diluted to 1:10 (5 μL Ab in 45 μL PBA). The cells were then incubated with 5
μL of diluted primary antibodies for 30 mins, with one tube set aside as an
unstained control. After incubation with primary antibody, the cells were
washed and suspended in 400 μL PBS containing 0.5% formaldehyde. Flow
cytometry was carried out on an Altra Flow Cytometer (Beckman Coulter),
and Weasel software was used to interpret the data.
5.3.8.9 Inflammation assays
Inflammation assays were performed by incubating AM discs with the cul-
tured macrophages. The macrophages were stimulated with lipopolysaccha-
ride (LPS) or antigen from Pseudomonas aeruginosa obtained as a French
press lysate (FPL), and the profile of inflammatory cytokines was measured
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Table 5.6: Macrophage assays
Assay MΦ Bottles AM Disc FPL LPS
(mm) (μg/mL) (ng/mL)
1 FB Teflon - - - -
2 BC × 2 Teflon F-t, v-d 3 1, 10 25, 100
3 BC × 2 Teflon Fresh, f-t, v-d 4 1 25
4 BC × 2 Teflon Fresh, f-t, v-d, 10% v-d, TT 6 0.1 10
5 BC × 1 Teflon - - - -
6 BC × 1 ULA F-t, v-d, 10% v-d 6 0.07 100
7 BC × 1 ULA F-t, v-d × 3 8 0.1 10
MΦ, macrophage source; FB, fresh blood; BC, buffy coat; ULA, ultra-low adherence flask;
FPL, French press lysate; LPS, lipopolysaccharide; TT, thermolysin-treated.
after a period of incubation. The assays are outlined as a series of six opti-
mising steps (Assays 1 to 6) and a triplicate experiment (Assay 7) in table
5.6. For the first five assays, Teflon bottles were used, whereas for the final
two, ultra-low adherence flasks were used. AM was prepared in the usual
way. The f-t AM was thawed and washed in 50 mL of a 500 mL PBS solution
of containing 1 mL gentamicin/amphotericin B (Gibco). Dried preparations,
including 0% and 10% v-d AM, were rehydrated separately in 50 mL of the
same solution. Denuded AM was prepared using the thermolysin method
(section 3.3.1.3). Discs of AM (3 to 8 mm in diameter) were punched out
using a skin biopsy punch and placed at the bottom of a 96-well plate work-
ing fast and covering the wells to prevent dehydration of the samples. In
one optimising step (Assay 4), the discs were moistened with 10 μL H2O to
prevent drying. Assay 7 was performed using three different AMs.
5.3.8.10 Preparation of stimulants
LPS from E. coli was obtained from Enzo Life Sciences Ltd. (Exeter, UK).13
The stock concentration was 10 μg/mL. A volume of 5 μL was added to each
well, using the standard formula
13The LPS and PA stock solutions were kindly provided by Dr Sonali Singh.
269
Concentration(A)× volume(A) = concentration(B)× volume(B) (5.1)
where A stands for initial and B stands for final, to obtain the desired
concentration. The concentration used was 10 - 1000 ng/mL. FPL was pre-
pared by passing mid-log phase P. aeruginosa 01 (PA01) cells through a
French press until all the cells had been lysed. The stock concentration
of FPL was 1092.45 μg/mL. The concentration used was 0.07 - 10 μg/mL.
5.3.8.11 Stimulation of macrophages
The macrophages were seeded onto the 96-well plate containing the AM
discs. A 100 μL suspension containing 50 000 donor cells was added to each
well. The cells were left to incubate at 37°C for 2 hrs, after which they
were stimulated with the desired concentration of LPS or FPL. The plate
was placed in the incubator for 24 hrs. After incubation, the plate was cen-
trifuged at 400 × g for 5 mins. The supernatants were extracted and placed
into a second 96-well plate, taking care not to disturb the amnion sample at
the bottom of the wells. The plate with the supernatants was then frozen
at -80°C. The next day, cytometric analysis was performed to quantify the
cytokines produced by the macrophages.
5.3.8.12 Cytometric bead preparation
Human cytokine 6-plex FlowCytomix™ kits (eBiosciences Ltd., Hatfield,
UK) were obtained for TNF, IL-4, IL-6, IL-8, IL-10 and IL-13. A standard
mixture of cytokines was prepared by mixing 3 μL of each of the reconsti-
tuted cytokines and adding an assay buffer to a total volume of 60 μL. Six
serial 1:3 dilutions were prepared to plot a standard curve. The standard
curves covered a range from 0 to 20 000 pg/mL for analytes IL-4, IL-6, IL-10,
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IL-13 and TNF, and from 0 to 10 000 pg/mL for IL-8.
Cytokine antibody-labelled fluorescent beads were prepared. The final
volume of bead mixture required was calculated according to the number
of samples to be tested. A volume of 10 μL of bead mixture was used per
sample. The bead mixture was prepared by vortexing the beads for 5 secs,
mixing equivalent volumes (1/20 of the final volume) of each bead and mak-
ing up the difference to the final volume with reagent dilution buffer (RDB).
The biotin-conjugated antibodies of each cytokine were prepared as a mix-
ture by calculating 1/20 of the final volume of each conjugate. The required
volume was made up to the final volume with RDB. A volume of 20 μL was
required per test.
Flow cytometry tubes were labelled for blanks, standards and samples.
A volume of 10 μL of standard mixture solutions, samples and a blank with
assay buffer only was added to designated tubes. The bead mixture was
vortexed and 10 μL added to all tubes. A volume of 20 μL of biotin-conjugate
was added to all tubes. The tubes were vortexed and incubated at room
temperature for 2 hrs in the dark. Immediately prior to the next step, the
streptavidin-PE was prepared by calculating 0.7 μL per tube and adding a
volume of assay buffer sufficient to dispense a volume of 20 μL streptavidin-
PE/assay buffer mixture per tube. The tubes were washed × 2 with 400 μL
of assay buffer and centrifuged at 350 × g for 5 mins. A volume of 20 μL
of streptavidin-PE was added to each tube, mixed and incubated for 1 hr
in the dark. Two further washes were carried out. The pellets were then
resuspended in 400 μL assay buffer and stored at 4°C for flow cytometry.
5.3.8.13 Flow cytometry
The flow cytometry analysis was carried out on a Beckman Coulter FC500
instrument as described previously. Acquired data was analysed with Flow-
Cytomix Pro 2.2 software. Each sample was measured in duplicate. The
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forward scatter collection angle setting was changed for bead detection. The
concentrations of IL-4, IL-6, IL-8, IL-10, IL-13 and TNF were obtained in
pg/mL by cytometric analysis for Assays 2-4. For Assays 5-7, IL-6, IL-
8 and TNF were measured. Mean values of the duplicate measurements
were taken for analysis. In the case of missing data, single measurements
were used. Statistical analysis of the results was performed using Graph-
Pad Prism® software. Data that surpassed the standard detection limits
by more for each analyte were not analysed statistically, but were described
as trends if possible. For the Assay 7, the supernatants were diluted 1:10
in RPMI 1640 for cytokine analysis. The average values with standard de-
viations for three AMs were calculated for statistical analysis. Negative
controls were performed in duplicate.
5.3.9 Scanning electron microscopy
Following the macrophage assays, samples of the AM discs used were freeze-
dried and subjected to scanning electron microscopy (technique described in
Chapter 4 section 4.3.1).
5.4 Results
5.4.1 Antimicrobial peptide detection
5.4.1.1 Western blotting
Human β-defensin 3 Western blots performed on whole AM extract for
hBD3 are shown in figures 5.1 A-E (left). Whole AM extracts from two AMs
were used in A. Fresh AM was loaded into lanes 1 and 4, v-d AM in lanes 2
and 5, and f-t AM in lanes 3 and 6. The prominent band at ~10 kDa (black
arrow) was sent for identification by MS (section 5.4.1.1). A β actin loading
control and a SimplyBlue™ SafeStain gel are shown in B and C. The west-
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ern blot was repeated using AM extracts from five AMs (lanes 1 to 5) (D).
No low molecular weight bands are visible. A western blot of recombinant
hBD3 was loaded from left to right in halving doses from 250 ng to 7.8 ng
(E), indicating the dose that can be detected by this method. Further west-
ern blots are shown in figure 5.1 A-E (right). Two AM samples underwent
western blotting (lanes 3 and 4) next to recombinant hBD3 in lane 1 (15.6
ng) and lane 2 (7.8 ng) (A). hBD3 was not detected in the samples. The sam-
ples in B were fractionated to remove proteins above 30 kDa. Lanes 1 and 2
contained AM extract. Lanes 3 and 4 contained placental samples. All lanes
were negative for hBD3. A SimplyBlue™ SafeStain containing fractionated
samples in lanes 1 and 2 and unfractionated samples in lanes 3 and 4 is
shown (C). Less protein is present in the fractionated sample, suggesting
that protein loss has occurred. In D, AM extract was loaded in lane 1, AEC
extract in lane 2, AM extract obtained after overnight incubation in TBSTx
in lane 3 and a HPLC-purified sample in lane 4. Bands of 5 kDa proteins
are seen in lane 3 and 4. A western blot of a Tricine gel of samples of AEC
extract is shown in E. Lanes 1 and 3 contain reduced samples, and lanes 2
and 4 were non-reduced. Low molecular weight bands are visible in lanes 1
and 3.
Human β-defensin 1/LL-37 Two western blots to detect hBD1 and LL-37
are shown in figure 5.2 A-F. In A-C, fractionated placental tissue (lane 1) and
tonsil (lane 2) were run alongside AM extract (lane 3). hBD1 (A) and LL-37
(B) are negative. In B, 1 ng of recombinant LL-37 was run in lane 4. The
SimplyBlue™ SafeStain image (C) shows minimal protein. Unfractionated
samples were run in figure 5.2 D-E. The samples are in lane 1, with tonsillar
controls in lane 2. These were negative for hBD1 (D) and LL-37 (E).
Mass spectrometry A ~10 kDa protein band from the gel obtained by
western blot (shown above in figure 5.1 A) was sent for MS. The proteins
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Figure 5.1: Western blots of hBD3
Western blots were performed on whole AM extract to detect hBD3 (left). A Extract from
fresh AM (lanes 1 and 2), v-d AM (3 and 4) and f-t AM (5 and 6). 30 μg of protein was added
to each well under reducing conditions. A rabbit polyclonal antibody to hBD3, ab19270,
was used as a primary antibody. A low molecular weight protein was identified at ~9 kDa
(black arrow). B A β actin loading control was run to ascertain equivalent loading. C
SimplyBlue™ SafeStain was used to demonstrate protein in the gels. D Western blotting
was repeated with 40 μg of extract from 5 donors (and 1 repeat). E Recombinant hBD3 was
loaded in halving doses from 250 ng (lane 1) to 7.8 ng (lane 6). Right: A A western blot with
recombinant hBD3 in lanes 1 (15.6 ng) and 2 (7.8 ng) is shown. AM samples were run in
lanes 3 and 4. B Fractionated AM samples (to remove proteins >30 kDa) were run in lanes
1 and 2. Fractionated whole placental samples were run in lanes 3 and 4. C A gel was run
with fractionated AM extract in lanes 1 and 2 and unfractionated samples in lanes 3 and 4.
This was stained with SimplyBlue™ SafeStain. D Two AM extracts were loaded in lanes 1
and 2 (40 μg per lane). In lane 3, 25 μg of an AM sample that was obtained separately was
loaded; a band is shown at 5 kDa (black arrow). In lane 4, the AM was purified by high
performance liquid chromatography. E 30 μg of extract from each of 2 AM samples were
loaded into a Tricine gel. In lanes 1 and 3, the sample was reduced. In lanes 2 and 4, the
sample was non-reduced.
274
Figure 5.2: Western blots of hBD1 and LL-37
Two western blots were performed to detect hBD1 and LL-37. The first blot (A-C) was per-
formed on fractionated samples. HBD1 (A) and LL-37 (B) are negative. A band representing
recombinant LL-37 (1 ng) is shown in lane 4 (B). The gel was stained with SimplyBlue™
SafeStain, demonstrating protein loss (C). In the second blot (D-E), unfractionated samples
(lane 1) were run alongside tonsil controls (lane 2). These were negative for hBD1 (D) and
LL-37 (E).
identified by MS are members of the S100 family (table 5.7), which are lo-
calised in the cytoplasm and/or nucleus of a wide range of cells, and are
involved in the regulation of a number of cellular processes such as cell cy-
cle progression and differentiation. S100 genes include at least 13 members
located as a cluster on chromosome 1q21.
Table 5.7: Mascot Peptide Summary Report
Protein Mr Protein Score Matches %
coverage
S100A4 11721 Calcium-binding protein A4 131 4 19
S100A11 11733 Calcium-binding protein
A11
59 1 8
S100A10 11064 Chain A, P11, Ligand of
Annexin Ii
56 2 17
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Table 5.8: LL-37 levels in AM
Incubation period 2 hrs 4h
1° ab concentration 10% 20% 10% 20%
MFI Mean Md Mean Md Mean Md Mean Md
Blank 1 240 235 158 159 302 279 107 107
Fresh AM 1 186 172 118 109 184 161 118 118
Fresh AM 2 172 124 126 119 186 170 120 116
F-t AM 1 161 179 117 118 200 217 142 139
F-t AM 2 186 175 132 121 241 229 125 126
V-d AM 1 184 162 120 120 213 204 125 121
V-d AM 2 172 153 119 113 169 174 192 190
Md, median; ab, antibody; MFI, mean fluorescence intensity
5.4.1.2 Cytometric bead analysis
The functional beads that were coated with a mouse monoclonal capture an-
tibody to LL-37, and the negative control, underwent flow cytometry. The
MFI measured by the PE channel was 145 for the control sample and 26
336 for the antibody-coated beads. Measured via the APC channel, the MFI
readings were 2380 for the controls and 2370 for the test sample. This in-
dicated that the covalent linking of the functional beads with the capture
antibody had been successful. The initial concentration of the rabbit poly-
clonal detection antibody was 428 μg/mg. The samples were incubated with
a 10% and 20% concentration of detection antibody for 2 hrs and 4 hrs. Plots
of the MFI (mean and median) of the control and test samples are shown in
figure 5.3. The data are shown in table 5.8. In the samples incubated for
2 hrs (10% and 20% antibody concentration) and 4 hrs (10% concentration),
the blank samples had a higher MFI than the test samples. In the samples
incubated for 4 hrs at 20% antibody concentration, no significant difference
was observed between MFI of the AM supernatants and negative controls.
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Figure 5.3: CBA assay for LL-37
CBA assay of supernatants of fresh, v-d and f-t AM extracts were performed in duplicate.
The samples were incubated with 10% and 20% concentrations of primary antibody for 2
hrs and 4 hrs. The negative control is labelled blank.
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Table 5.9: AMP fluorescence per AM
EXPT 1 EXPT 2 EXPT 3 EXPT 4
Psoriasin (m), -ve Psoriasin (m), 9.0% Psoriasin (m), -ve Psoriasin(m), 61.8%
LEAP-2 (r), 14.7% LEAP-2 (r), 54.3% LEAP-2 (r), -ve LEAP-2 (r), 91.3%
hBD2 (m), -ve hBD2 (m), -ve hBD2 (m), -ve
hBD3 (m), -ve hBD3 (m), 3.8% hBD3 (m), -ve
hBD3 (r) 53.5% hBD3 (r), 84.8%
RNAse-7 (r), 3.7% RNAse-7 (r), 81.4% RNAse-7 (r), 88.1%
LL-37 (r), 37.5% LL-37 (r, PE), 98.6%
M, mouse; r, rabbit; PE, phycoerythrin-conjugated
5.4.1.3 Flow cytometry
Optimisation step A single cell suspension of AEC was stained with rab-
bit polyclonal anti-hBD3 antibody. Positivity was obtained for hBD3 ex-
pression in cells that were either permeabilised and fixed in 3% FA (row A,
96.6%) or permeabilised and fixed in 0.5% FA (row C, 97.9%) (figure 5.4).
Cells that were non-permeabilised and fixed in 0.5% FA exhibited less in-
tense staining (row B, 53.8%).
Antimicrobial peptide detection The dot plots of flow cytometry anal-
yses of permeabilised AEC from four AMs (flow cytometry 1 to 4). Flow
cytometry 1 and 2 are shown in figure 5.5 and 3 and 4 are shown in figure
5.6. The percentages of fluorescent cells compared to the negative control
for each sample are listed in table 5.9, with figures of less than 1% listed as
negative. In flow cytometry 1, rabbit polyclonal antibodies detected LEAP-2
(14.7%) and RNAse-7 (3.7%) in AEC (figure 5.5). Using mouse monoclonal
antibodies, hBD2, hBD3 and psoriasin were not detected. In flow cytome-
try 2 there was positivity for hBD3 (3.8%) and psoriasin (9.0%) using mouse
monoclonal antibodies and LEAP-2 (54.3%) and RNAse-7 (81.4%) using rab-
bit polyclonals. HBD2 (mouse) was negative. In flow cytometry 3, hBD3
(53.5%) and LL-37 (37.5%), both raised in rabbit, were positive (figure 5.6),
whereas LEAP-2 (rabbit) and psoriasin, hBD2 and hBD3 (mouse) were all
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Figure 5.4: Flow cytometry optimisation
Dot plots of AEC are shown in 3 rows and columns. In the left hand column, the cells are
sorted by linear side scatter (SSLin, Y axis) and linear forward scatter (FSLin, X axis). A
central polygonal shape (gate) has been drawn around a population of cells to capture cells
of average size and shape. Cells incubated with rabbit polyclonal anti-hBD3 antibodies are
shown in the dot plots on the right. The antibodies were labelled with fluorescein isothio-
cyanate (FITC), which was detected on the FL1 channel (Y axis). The plots of A and C were
obtained after permeabilising the epithelial cells and fixing them in 3% FA and 0.5% FA
respectively. The cells in row B were not permeabilised. Negative controls are shown in the
central column.
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Figure 5.5: Flow cytometry for AMPs (1)
1 Flow cytometry was conducted on AEC to detect an array of AMPs. Cells were sorted by
linear side scatter and forward scatter and gated. Fluorescence is shown on a logarithmic
scale for APC (channel FL4) and FITC (FL1). Negative controls (no primary antibody) are
labelled as APC and FITC. Positivity was obtained for LEAP-2 (14.7%) and RNAse 7 (3.7%).
2 Positivity was obtained for LEAP-2 (54.3%) and RNAse 7 (81.4%), psoriasin (9.0%) and
hBD3 (3.8%), but not for hBD2. APC, allophycocyanin; FITC, fluorescein isothiocyanate.
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negative. In flow cytometry 4, the AEC were incubated overnight at 4°C
with primary antibody. There was strong positivity for psoriasin (mouse,
61.8%), LEAP-2 (rabbit, 91.3%), hBD3 (rabbit, 84.8%), RNAse-7 (rabbit,
88.1%) and LL-37 (rabbit, 98.6%).
5.4.2 Antimicrobial assays
Concentrated extracts of v-d AM were incubated with Gram positive and
Gram negative bacterial strains in 96-well plates. The MIC for the amnion
extracts could not be determined due to the absence of antimicrobial activity.
Bacterial growth was observed at each concentration of extract and with
each of the bacterial strains tested. In agreement with the MIC tests, no
antibacterial activity was observed in concentrated AM extract or in AM
squares incubated on LB agar. Each of the bacterial strains populated the
outer edges of the chromatography discs saturated with AM extract and
zones of inhibition could not be identified. Only AM samples saturated in
antibiotic solution displayed antimicrobial activity.
5.4.3 Protein microarray
Protein microarrays of four different AM preparations were performed to
compare MMP/TIMP levels and to determine their localisation. These re-
sults are taken from a total of four AMs, normalised by total protein concen-
tration in extraction medium and expressed in pg/mg. Median normalised
levels of MMP/TIMP analytes are shown in table 5.10. MMP-13 was not
detected. The median levels of TIMPs in fresh AM were significantly higher
than levels of MMPs (Kruskal-Wallis, p < 0.001) (figure 5.7). The com-
partmentalisation of MMPs is indicated by the respective concentrations
(figure 5.8). The concentration of MMP-1 was significantly higher in de-
epithelialised than in fresh AM (p < .05). The concentrations of MMP-3 and
TIMP-1 were significantly higher in fresh than in de-epithelialised AM (p
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Figure 5.6: Flow cytometry (2)
3 Flow cytometry dot plots were conducted on AEC to detect AMPs. Positivity was obtained
for LL-37 (rabbit, 37.5%) and hBD3 (rabbit, 53.5%), while LEAP-2, psoriasin, mouse hBD3
and hBD2 were negative. Negative controls are labelled as APC and FITC. Fluorescence
is shown on a logarithmic scale. 4 Positivity was obtained for LEAP-2 (91.3%), RNAse 7
(88.1%), psoriasin (61.8%), hBD3 (84.8%) and rabbit LL-37 (98.6%). A positive vimentin
control was labelled with PE (channel FL2). APC, allophycocyanin; FITC, fluorescein isoth-
iocyanate; PE, phycoerythrin.
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Table 5.10: Median levels of MMPs and TIMPs
AM preparation MMP-
1
MMP-
2
MMP-
3
MMP-
7
MMP-
8
MMP-
9
MMP-
10
TIMP-
1
TIMP-
2
Fresh 215.0 9512.0 287.0 372.0 381.5 1572.5 1026.0 97562.0 32673.0
De-epithelialised 4996.0 12049.5 0 173.5 183.5 1238.5 2020.0 11625.0 23798.0
Freeze-thawed 422.0 12968.5 76.50 754.5 1259.0 1399.5 1520.5 82051.5 25956.5
Vacuum-dried 944.0 13213.0 435.5 669.5 780.0 4277.0 2370.0 136987.0 55299.5
Protein microarrays were carried out on the homogenates of four AM preparations. Levels
of MMPs and TIMPs are expressed as pg of analyte per mg of homogenised tissue.
Figure 5.7: MMPs and TIMPs in fresh AM
MMPs and TIMPs in fresh AM were measured in quadruplicate by protein microarray and
expressed as pg per mg of total protein. Median values are shown, with error bars represent-
ing the ranges.
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Figure 5.8: Protein microarrays of MMPs and TIMPs
Protein microarrays were performed in quadruplicate on four different AM preparations
(fresh, de-epithelialised, v-d and f-t AM), demonstrating the compartmentalisation of MMPs
and TIMPs in AM. MMP-1, MMP-2, MMP-3, MMP-7, MMP-8, MMP-9, MMP-10, TIMP-1
and TIMP-2 were analysed and TIMP-1. The analyte levels are expressed as pg/mg of total
protein.
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Figure 5.9: MMP-2 and MMP-9 zymography markers
Zymographic markers are shown for MMP-2 and MMP-9. Separate bands are seen for the
MMP-2 pro-enzyme (72 kDa), active MMP-2 (64 kDa) and MMP-9 pro-enzyme (92 kDa).
< .05). The concentrations of MMP-2, MMP-9, TIMP-1 and TIMP-2 were
higher in v-d AM than in f-t AM and fresh AM. In all preparations, MMP-2
was significantly higher than all other MMPs (p < .05).
5.4.3.1 Matrix metalloprotease elution
The MMP-2 marker reveals separate bands for the inactive pro-enzyme (72
kDa) and the active enzyme (64 kDa) (figure 5.9). The pro-enzyme of MMP-9
exhibits a distinct band at 92 kDa. A low molecular weight cleavage product
of MMP-2, of no significance, is also visible (unmarked).
Elution at 24h Zymography was performed in two experiments on ho-
mogenates and supernatants of fresh, f-t and v-d AM preparations at base-
line and 24 hrs. Triplicate measurements were taken for each sample of AM
as well as the f-t AM wash medium (‘wash’) and storage medium (‘medium’).
Zymograms from one representative sample are shown in figure 5.10. Protein
levels were not normalised for this experiment. Pro-MMP-2 is present in the
supernatant and homogenate at 0h (gels 1 and 2). The MMP-2 pro-enzyme
is also present in the f-t AM wash and storage media (gels 2 and 3) and
in both the supernatants and homogenates after 24 hrs (gels 3 and 4). No
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Figure 5.10: Zymography of fresh, v-d and f-t AM
Zymography was performed on fresh, f-t and v-d AM supernatants and homogenates at 0h
and 24h. F-t AM storage (‘medium’) and wash media (‘wash’) were also sampled. Protein
levels were not normalised. MMP-2 pro-enzyme bands are seen at baseline (small white
arrow) and after 24 hrs. Faint MMP-9 bands are seen after 24 hrs (large white arrowhead).
This represents one of two replicate experiments.
MMP-9 is detected at baseline. There is faint expression of MMP-9 after 24
hrs in fresh and v-d AM supernatants and homogenates.
Elution at 48h Zymography was performed on a total of six AMs in two
experiments to detect MMP-2 and MMP-9 at baseline and at 48 hrs Each
measurement was made in triplicate. Homogenised samples were taken at
baseline, while supernatants were taken at 48h. Samples were obtained
from samples of AM at 0h and 48h and from f-t AM storage medium at 0h.
A total of 1.5 μg of protein was dispensed into each well. Representative
zymograms for three AMs are shown (figure 5.11). At 0h, there are bands
of MMP-2 pro-enzyme in all preparations. MMP-9 is not present in AM
extracted at baseline. After 48 hrs, MMP-2 pro-enzyme is present in all
preparations. MMP-9 bands were detected in the fresh AM supernatants
(white arrow) and in the supernatant of one f-t AM sample (large white
arrowhead).
Band intensity measurements were pooled for both experiments. The
median intensity values, which do not take a unit, are shown in table 5.11.
One of the zymograms, for fresh AM at 48h, was damaged and did not return
any data. A statistically significant increase in normalised values of MMP-2
pro-enzyme intensity was found between baseline and after 48 hrs for fresh
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Figure 5.11: Elution of MMP-2 and MMP-9
Zymography was performed on fresh, f-t and v-d AM after processing for use (0h), on f-t
AM storage medium at baseline (0h) and after 48 hrs incubation. A total of 1.5 μg was
dispensed into each well. MMP-2 and MMP-9 were analysed in triplicate in homogenates at
0h and supernatants at 48h of three AMs (a, b and c). This represents one of two replicate
experiments. The white arrowhead and white arrow showMMP-9 bands in f-t AM and fresh
AM respectively.
Table 5.11: Intensity values, MMP-2
Zymogram AM
0h 48h
Fresh F-t V-d Fresh F-t V-d
1
a 117.1 86.9 84.0 125.7 176.3 172.3
b 90.7 76.6 119.2 112.7 116.3 78.7
c 73.2 34.2 87.7 126.0 151.3 168.0
2
a 88.9 71.8 94.4 - 91.1 137.0
b 85.8 129.5 79.2 - 125.8 156.7
c 65.0 122.7 69.6 - 106.2 60.6
Median 87.3 81.8 85.9 121.1 125.7 146.9
287
Fr
es
h 
H
 0
 h
V
-d
 H
 0
 h
F-
t H
 0
 h
Fr
es
h 
S
/N
 4
8 
h
V
-d
 S
/N
 4
8 
h
F-
t S
/N
 4
8 
h
0
50
100
150
200
Preparation
B
ri
g
h
tn
e
s
s
Figure 5.12: MMP-2 band intensity
Zymography was performed on a total of six AMs to compare the intensity of MMP-2 and
MMP-9 at baseline and after incubation for 48 hrs. The intensity of the bands was nor-
malised against MMP markers in each zymogram gel. There is an increase in the intensity
of MMP-2 after 48 hrs. Median values are shown with error bars representing range.
and f-t AM (p = 0.024 and 0.047 respectively; Mann Whitney) (figure 5.12).
The increase in intensity between v-d AM at 0h (Md 85.9) and at 48h (Md
146.9) was non-significant.
5.4.4 Macrophage assays
Six optimising steps and one triplicate macrophage assay were performed.
Fresh uncoagulated whole blood samples resulted in an insufficient yield of
macrophages. This technique was abandoned in favour of using buffy coats.
Flow cytometry results from one representative sample of cells cultured by
this method are shown in figure 5.13. The events (cells) were positive for
CD14 (76.7%), HLA-DR (86.8%), mannose receptor (93.3%), CD11b (94.2%)
and CD16 (69.0%), and negative for CD3. This was taken as evidence of
activated macrophages.
In Assay 2, 3-mm f-t and v-d AM discs were incubated with macrophages
from two buffy coats cultured in Teflon bottles. The macrophages were stim-
ulated with 1 - 10 μg/mL of FPL or 25 - 100 ng/mL of LPS. The negative
288
Figure 5.13: Activated macrophage markers
CD14+ cells extracted from buffy coats were cultured for 7 days. After 7 days, the cells
were labelled with IgG1 and IgG2a monoclonal antibodies to CD16, CD14, CD11b, CD3,
HLA-DR and mannose receptor with isotype controls. Flow cytometry was performed (rep-
resentative sample shown).
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Figure 5.14: Macrophage Assay 2
LPS, lipopolysaccharide; FPL, French press lysate (pseudomonas antigen); IL-6, interleukin
6; IL-8, interleukin 8; TNF, tumour necrosis factor, alpha
controls and several of the test samples were irretrievably damaged during
cytokine analysis, and it was not possible to analyse the levels of IL-8 or
IL-10. Following stimulation by LPS and FPL, IL-4, and IL-13 were unde-
tectable. The levels of IL-6 and TNF are shown in figure 5.14. Levels of
FPL-stimulated TNF, and LPS-stimulated TNF in one set of macrophages
(buffy coat 2), were considerably higher than the recommended detection
limit of 20 000 pg/mL covered by the standard curve. The IL-6 responses of
LPS-stimulated macrophages cultured with f-t AM and v-d AM were sim-
ilar, while there was variability between macrophage donors across both
levels of LPS stimulation (100 ng/mL, p = .006; 25 ng/mL, p = .09). The
values are shown in table 5.12.
In Assay 3, 4-mm f-t and v-d AM discs were incubated with macrophages
from two buffy coats. The macrophages were stimulated with 1 μg/mL of
FPL or 25 ng/mL of LPS. The data for Il-6, IL-8, IL-10 and TNF are shown
in table 5.13, and plots of IL-6, IL-8, and TNF levels for each buffy coat are
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Table 5.12: Cytokine levels, Assay 2
Stimulant - LPS (ng/mL) FPL (μg/mL)
Analyte AM 100 25 10 1
Buffy coat 1
IL-6
F-t 0 12296 10985 6591 8064
V-d 0 11569 11264 4840 6792
TNF
F-t 564 16735 12461 38365 36759
V-d 588 17560 16431 49257 42756
Buffy coat 2
IL-6
F-t 200 5402 7238 1759 2064
V-d 0 4545 6349 1605 1765
TNF
F-t 0 54782 52390 529122 272946
V-d 0 85873 71910 620556 745971
LPS, lipopolysaccharide; FPL, French press lysate; IL, interleukin; TNF, tumour necrosis
factor.
shown in figure 5.15.
Levels of TNF produced by LPS- and FPL- stimulated macrophages were
over the recommended detection limit. The levels of IL-8 in unstimulated
macrophages were significantly higher than inmacrophages stimulated with
LPS (p < .0001) and FPL (p < .0001). A trend is suggested from the IL-6
levels of the LPS-stimulated macrophages of buffy coat 1, which are low-
est for the control and highest for f-t AM. Conversely, TNF, which is only
marginally outside the standard, is highest for control AM and lowest for f-t
AM.
In Assay 4, 6-mm AM discs were incubated with macrophages from two
buffy coats. There were five preparations of AM, including fresh, f-t, 0% v-d,
10% v-d and thermolysin-denuded AM (figure 5.14, table 5.16).
Several measurements of IL-6 were beyond the limits of the standard
curve. The levels of IL-8 were higher in unstimulated macrophages were
higher than in macrophages stimulated with LPS and FPL (beyond stan-
dard limits). There were minimal levels of IL-10. The macrophages in-
cubated with no AM (negative control) produced levels of TNF that were
beyond the standard limit. The levels are higher than those produced by
macrophages incubated with AM from each preparation, except for one value
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Table 5.13: Cytokine levels, Assay 3
Buffy coat 1 Buffy coat 2
Stimulant - LPS FPL - LPS FPL
Analyte AM 25 (ng/mL) 1 (μg/mL) 25 (ng/mL) 1 (μg/mL)
IL-6 F-t 74 20307 8518 198 7446 1839
V-d 48 13378 8287 586 7548 1667
Control 51 12161 6927 39 7232 1718
IL-8 F-t 5842 3024 2241 4783 2072 1398
V-d 5187 3300 2327 4482 2194 1417
Control 5492 3111 2383 5014 2160 1456
IL-10 F-t 0 0 31 0 39 928
V-d 0 0 26 0 20 999
Control 0 0 25 0 10 620
TNF F-t 595 19321 42102 55 51583 464653
V-d 510 23382 48219 70 57271 651916
Control 807 27251 55618 49 62151 95681
LPS, lipopolysaccharide; FPL, French press lysate; IL, interleukin; TNF, tumour necrosis
factor.
Figure 5.15: Macrophage Assay 3
LPS, lipopolysaccharide; FPL, French press lysate (pseudomonas antigen); f-t AM, freeze-
thawed amniotic membrane; v-d AM, vacuum-dried amniotic membrane; IL-6, interleukin
6; IL-8, interleukin 8; TNF, tumour necrosis factor, alpha
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Table 5.14: Cytokine levels, Assay 4
Buffy coat 1 Buffy coat 2
Stimulant - LPS FPL - LPS FPL
Analyte AM 10 (ng/mL) 0.01 (μg/mL) 10 (ng/mL) 0.01 (μg/mL)
IL-6 F-t 134 26813 27978 50 39432 68186
V-d 125 27145 23234 61 27912 16521
Control 1 20821 18596 21 39726 31484
Fresh 106 21516 18383 37 36481 19899
Denuded 25 37005 - 88 95626 42834
10% v-d 31 20256 16186 63 27428 15392
IL-8 F-t 11950 6192 5372 16708 7817 5721
V-d 12607 6230 4939 16390 7813 4626
Control 11527 5895 4907 18572 7479 5690
Fresh 10775 4908 5341 16721 6791 4853
Denuded 12984 7011 - 17627 8912 5713
10% v-d 8072 5480 4356 17267 7547 4479
IL-10 F-t 0 54 53 0 2 33
V-d 0 45 74 1 8 61
Control 0 80 46 10 8 11
Fresh 0 0 - 5 5 39
Denuded 0 38 - 0 0 34
10% v-d 0 61 - 0 0 62
TNF F-t 42 7931 3593 119 7249 20867
V-d 51 7296 3150 143 2357 40374
Control 1 27206 29405 138 14977 41577
Fresh 50 6600 5486 124 4543 37872
Denuded 10 7277 - 108 3021 18226
10% v-d 23 4720 12789 78 3436 43367
LPS, lipopolysaccharide; FPL, French press lysate; IL, interleukin; TNF, tumour necrosis
factor.
293
Figure 5.16: Macrophage Assay 4
LPS, lipopolysaccharide; FPL, French press lysate (pseudomonas antigen); TT-AM,
thermolysin-denuded AM; FrAM, fresh AM; V-d AM10%, trehalose-treated AM; IL-6, in-
terleukin 6; IL-8, interleukin 8; TNF, tumour necrosis factor, alpha
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Table 5.15: Cytokine levels, Assay 6
Stimulant - LPS FPL
Analyte AM 100 ng/mL 70 ng/mL
IL-6 F-t 222 36610 26607
V-d 130 38049 -
Control 135 38607 16006
10% v-d 1234 36094 23521
IL-8 F-t 2686 5482 7904
V-d 3690 5478 -
Control 2520 5570 8962
10% v-d 8353 5392 7823
IL-10 F-t 30 12 12
V-d 36 - -
Control 1 16 16
10% v-d 0 36 36
TNF F-t 98 9003 5079
V-d 27 14144 -
Control 0 21633 4014
10% v-d 0 8882 2577
LPS, lipopolysaccharide; FPL, French press lysate; IL, interleukin; TNF, tumour necrosis
factor.
of v-d AM (donor 2).
A fifth assay resulted in a yield of macrophages that was too low to pro-
ceed. This prompted a switch to the ultra-low adherence flasks.
In Assay 6, AM discs of 6 mmwere incubated with macrophages from one
buffy coat cultured in ultra-low adherence flasks. AM preparations included
f-t, v-d and 10% v-d AM. These were stimulated with 100 ng/mL of LPS and
70 ng/mL of FPL. The data are shown in table 5.15 with plots in figure 5.17.
The levels of IL-6 were beyond the standard curve. IL-8 is higher in the
stimulated preparations (non-significant). The level of TNF is higher in the
negative control than in the three AM preparations.
In Assay 7, the format of the experiment was changed to include three
different AMs. F-t, v-d and 10% v-d AM discs of 8 mm were incubated with
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Figure 5.17: Macrophage Assay 6
LPS, lipopolysaccharide; FPL, French press lysate (pseudomonas antigen); V-d AM10%,
trehalose-treated v-d AM; IL-6, interleukin 6; IL-8, interleukin 8; TNF, tumour necrosis
factor, alpha
macrophages from one buffy coat. The supernatants were diluted 1:10 in
RPMI-1640 for cytokine analysis. The data are shown in table 5.16. IL-
8 measurements were beyond the detection limits. Plots are shown of the
mean values of IL-6 and TNF across the three AMs with error bars repre-
senting SD values. (figure 5.18). The mean values of the cytokines (SD) are
shown in table 5.17. In the supernatants of both LPS- and FPL-stimulated
macrophages, IL-6 levels were higher in f-t AM and v-d AM than in nega-
tive controls (non-significant). In LPS-stimulated macrophages, TNF levels
were higher in controls than either f-t AM or v-d AM. There was a significant
difference in TNF levels between LPS-stimulated macrophages incubated
with f-t AM and negative controls (p = .026, paired t test).
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Table 5.16: Cytokine levels, Assay 7
Stimulant - LPS FPL - LPS FPL
Analyte AM 10 ng/mL 100 ng/mL 10 ng/mL 100 ng/mL
AM 1 AM 2
IL-6 F-t 6 21870 13904 0 13714 10016
V-d 125 20900 20300 0 20861 10287
Control 0 16419 6637 6 14631 5793
IL-8 F-t 1041 16406 16408 1101 27677 30302
V-d 2881 25160 14727 3303 13552 16270
Control 2388 15750 31852 2183 28658 36239
TNF F-t 0 4023 5168 0 3266 2707
V-d 0 5001 4020 0 4569 3369
Control 0 6019 3480 0 5224 2924
AM 3
IL-6 F-t 214 21256 7938
V-d 6 15341 9191
Control 3 15525 6215
IL-8 F-t 2444 15892 13464
V-d 1297 25669 11456
Control 2286 22204 34045
TNF F-t 17 2484 1950
V-d 0 3246 2724
Control 0 5622 3202
LPS, lipopolysaccharide; FPL, French press lysate; IL, interleukin; TNF, tumour necrosis
factor.
Table 5.17: Mean cytokine levels, Assay 7
Stimulant LPS FPL
AM IL-6 TNF IL-6 TNF
F-t 18 947 (4542) 3258 (770) 10 619 (3029) 3275 (1682)
V-d 19 034 (3198) 4272 (914) 13 259 (6122) 3371 (648)
Control 15 525 (894) 5622 (398) 6215 (422) 3202 (398)
Mean values are shown (SD) in pg/mL.
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Figure 5.18: Macrophage Assay 7
Macrophages were stimulated with LPS and FPL in co-culture with three different f-t and
v-d AM samples and negative controls. IL-6 and TNF in the supernatants were measured
in pg/mL. Plots of mean values with error bars representing standard deviation are shown.
LPS, lipopolysaccharide; FPL, French press lysate; IL, interleukin; TNF, tumour necrosis
factor.
298
Figure 5.19: Macrophage adherence
Macrophages were co-cultured with AM discs and stimulated with LPS or FPL. The
samples were lyophilised and SEM images taken of both epithelial and stromal aspects.
Macrophages are shown to adhere to spongy layer remnants (black arrows). Representative
images are shown for fresh AM (A and B) and v-d AM (C and D). LPS, lipopolysaccharide;
FPL, French press lysate.
5.4.5 Scanning electron microscopy
SEM images of the epithelial and stromal sides of fresh AM (A and B) and
v-d AM (C and D) are shown in figure 5.19 shows that the macrophages
adhere preferentially to the network of residual spongy layer on the stromal
aspect. Fewer macrophages can be seen on the epithelial aspect of the same
AM samples.
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5.5 Discussion
5.5.1 Antimicrobial activity
The expression of hBD3 in AEC is well-known (Buhimschi et al., 2004; Stock
et al., 2007; King et al., 2007b), and psoriasin has been detected in AEC by
PCR (Porre et al., 2005). The documentation of AM-derived AMPs is impor-
tant, as it suggests a potentially useful therapeutic avenue. In this study,
the detection of AM-derived AMPs by western blotting proved difficult. The
repeated negative findings were obtained despite concentrating the proteins
and using using different antibodies. Fractionation of proteins was also
tried, although protein loss occurred. The western blots were conducted on
whole tissue and AEC extracts. Low molecular weight bands were detected
in one sample extracted in TBSTx overnight and in two reduced samples on
a Tricine gel (figure 5.2). These could represent hBD3. hBD1 and LL-37
were not detected. The technique of western blotting is suitable for detect-
ing AMPs. Strong bands of psoriasin were detected in a western blot of
ocular surface epithelial cells (Garreis et al., 2011), and the presence of α-
defensins in amniotic fluid has been shown by western blotting (Akinbi et
al., 2004). Sørensen et al. (2003) were able to demonstrate the presence of
hCAP-18 in keratinocyte medium on SDS-polyacrylamide gel electrophore-
sis (PAGE) followed by immunoblotting. The most likely explanation for
the inconsistent expression of hBD3 may be that it can only be detected by
western blotting in stimulated AM. HBD3 can be present in in unstimulated
AEC, yet it is upregulated by inflammatory stimuli (Buhimschi et al., 2004).
hBD3 can be upregulated in other tissues. HBD3 and hBD9 were found to
be constitutively expressed on the ocular surface, becoming up-regulated in
bacterial keratitis (Otri et al., 2012). Similarly, 10-fold expression in hBD3
was found in corneal epithelial cells exposed to Acanthamoeba castellanii
(Otri et al., 2010). Sørensen et al. (2003) found no basal expression of hBD3
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in keratinocytes, but were able to demonstrate its presence in keratinocyte
medium following stimulation with TGF-α. Several other AMPs are simi-
larly inducible. Ikeda et al. (2005) found constitutive expression of HNP 1
- 3 and hBD1 on the ocular surface, yet the detection of hBD2 was contin-
gent upon the stage of ocular surface disease. In the same study, RNase-7
was consistently up-regulated, whereas hBD1 was downgraded Otri et al.
(2010).
The failure of the CBA assay to detect hCAP-18/LL-37 in the AM is
not likely to reflect the choice of antibodies. The capture antibody used
(ab80895) is specific to the N-terminal pro-region of the hCAP-18 molecule,
and not the microbicidal C-terminus, LL-37. Since intracellular hCAP-18
remains uncleaved until exocytosis (Sørensen et al., 2001), it may be ex-
pressed in AEC. The detection antibody (G-075-06) also recognises the un-
cleaved molecule (Heilborn et al., 2003). The next stage of the CBA would
have been to quantitate the protein against a known quantity of recombi-
nant LL-37, but in the absence of any detection of the peptide, this stage
was deferred. Although CBA is a more sensitive tool than western blotting,
the failure to detect LL-37 could have been due to insufficient titration of
the detection antibody.
For flow cytometry experiments, single cell suspensions of AECwas gated
in the central portion of the cells sorted by side scatter and linear scatter to
reduce the proportion of non-viable cells, which can give rise to non-specific
staining. Permeabilisation was useful in obtaining increased positivity for
hBD3, suggesting a predominantly intracellular localisation (figure 5.4). An
inspection of the results shows that the rabbit polyclonal antibodies pro-
duced higher rates of positive results than the mouse monoclonals (table
5.9). In the first three flow cytometry experiments after the optimisation
step, only one test out of seven using rabbit polyclonals returned a negative
result. Of the rest, frequent high values were reported for positivity (e.g.,
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81.4% for RNAse-7, 54.3% for LEAP-2, 53.5% for hBD3). In contrast, the
experiments using mouse monoclonals returned negative values in seven
out of nine tests. The two positives were low (9.0% for psoriasin, 3.8% for
hBD3). In the final flow cytometry experiment, the incubation with pri-
mary antibody was overnight at 4°C. Strong positives were returned for all
the antibodies (one mouse, four rabbit). Of these, the mouse antibody had
the least positivity (psoriasin, 61.8%), whereas the four rabbit antibodies
returned positivities of between 84.8% and 98.6%. Therefore, the possibility
of non-specific binding must be considered.
Polyclonal antibodies can recognise a variety of epitopes, and therefore
have an increased propensity for non-specific binding. In addition, the poly-
clonal antibodies used were not validated specifically for intracellular stain-
ing. In the case of psoriasin it is interesting to note that the likelihood of
non-specific binding has been noted in previous studies (Porre et al., 2005).
This is because psoriasin contains a calcium-binding region which is homol-
ogous with that of other members of the S100 family of calcium-binding pro-
teins. Non-specific binding is unpredictable, even for fluorochrome-conjugated
monoclonal antibodies (Keeney et al., 1998). For this reason, non-specific
binding sites are blocked by pre-incubating the cells in serum. In the cur-
rent study, the cells were blocked in NGS. It has been suggested that that
the serum should be the same species as the primary antibodies (Stew-
art and Stewart, 1994), which, in this study, were produced in rabbit and
mouse. In addition to adequate blocking, flow cytometry usually necessi-
tates a negative control. For monoclonal reagents, isotype-matched con-
trols are recommended to generate background fluorescence as a reference
point for optimising the experiment (O’Gorman and Thomas, 1999). There
are alternatives to isotype-matched controls, such as blocking the antibody-
binding portion of the antibody to allow visualisation of the extent of non-
specific binding (Keeney et al., 1998). In the current study, both monoclonal
302
and polyclonal antibodies were used, for which isotype controls may not
have been suitable as they contain more than one IgG subclass. There-
fore, the negative controls consisted of secondary antibody with no primary.
While this may be flawed, since the goat secondaries will have different
non-specific binding sites to the rabbit and mouse primaries, it provided a
gross estimate of background non-specific binding. In order to increase con-
fidence in the positive findings, directly conjugated monoclonal antibodies
with isotype-matched controls are recommended for future testing.
The antimicrobial assays returned an absence of antimicrobial activity
in fresh and therapeutic AM against common Gram positive and Gram neg-
ative pathogens. This is in contrast with the findings of Talmi et al. (1991)
and Kjaergaard et al. (2001). The latter study demonstrated marked inhi-
bition of S. aureus, S. saprophyticus and group A streptococci. The authors
noted that direct contact was not mandatory for the effect, suggesting it
might be due to the presence of defensins. The relevance of detecting AMPs
in fresh AM was lessened by the inability to reproduce these findings. No
definitive evidence was found for AM-derived AMPs by any technique.
5.5.2 The elution of metalloproteases
In protein microarrays, higher levels of TIMPs than MMPs were found in
fresh and processed AM (figure 5.10). As an illustration, the median level
of TIMP-1 in fresh AM was 97 562 pg per mg of tissue extract, which when
compared to 9512 pg of constitutively-expressedMMP-2 gives a ratio of 10:1.
Since TIMP molecules inhibit MMP molecules stoichiometrically (Zucker
and Cao, 2006; Ardi et al., 2009), this suggests that AM-derived TIMPs pre-
vents MMPs from degrading collagens. By far the most abundant MMP was
MMP-2, which was significantly higher than all other MMPs in all prepara-
tions. MMP-9 was second. These were compartmentalised in both epithelial
and stromal layers. While MMP-2 is constitutively expressed, gestational
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timing and individual variation can influence the expression of MMP-9. In-
deed, Fortunato et al. (1997) were only able to detect MMP-9 in membranes
from women with intra-amniotic infections. In an organ culture model, in-
flammatory mediators such as LPS, TNF and IL-1β stimulated the produc-
tion of MMP-9 pro-enzyme from AM (Arechavaleta-Velasco et al., 2002).
Analytes with concentrations higher in de-epithelialised tissue than in
fresh tissue have a stromal compartmentalisation, while the converse sug-
gests an epithelial compartmentalisation. Statistically significant examples
include MMP-1, which was predominantly retained in the stroma, while
MMP-3 and TIMP-1 were compartmentalised in the epithelium. Retention
of the analytes in f-t AM (compared to fresh) may indicate low water solubil-
ity, as the factors would otherwise have been eluted in the storage medium
and washes. This is most evident for MMP-7 and MMP-8 (non-significant).
The higher levels of MMP-2, MMP9, TIMP-1 and TIMP-2 in v-d AM suggest
a higher concentration of protein was present in the v-d AM samples. This
is a concentration effect, since the wet preparations all lose protein during
processing, whereas in v-d AM water soluble proteins are highly concen-
trated.
MMP-2 pro-enzyme was detected in supernatants and homogenates at
baseline and after incubating for 24 hours (figure 5.10) and 48 hours (figure
5.11). Higher concentrations of protein were obtained by homogenising the
samples at baseline, while sufficient protein levels in the supernatant were
available after incubation. MMP-2 pro-enzyme was detected in AM super-
natants after incubation, indicating its elution. The intensity of MMP-2 in
supernatants after incubation for 48 hours was higher than in homogenates
at baseline. Although the protein levels were normalised across the wells,
the technique of zymography is difficult and can lead to variable results.
The increased in MMP-2 intensity after incubation for 48 hrs may have oc-
curred by chance alone. However, an inspection of the zymograms suggests
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that the MMP-2 levels are indeed higher after incubation in all prepara-
tions. As is the case for other soluble molecules (Hopkinson et al., 2006b), f-t
AM loses soluble MMP-2 into the storage and washing media during freez-
ing and preparation for use. MMP-9 expression can occur after incubation
of fresh tissue. It can also be detected in preserved, devitalised tissue after
incubation, suggesting its expression prior to preservation. MMP-9 was not
detected in baseline homogenates.
It is not clear why MMP-2 and MMP-9 were detected in preserved AM
after incubation, since the tissue is devitalised. The possibilities include
that they was not completely extracted at baseline. However, the protein
microarrays indicate that MMP-9 is present in the preserved tissues. An
alternative explanation is that the latent pro-enzymes may be undetectable
by zymography at baseline, undergoing conformational change during incu-
bation to become detectable. An unlikely explanation is that residual living
cells are expressing these enzymes.
The significance of elution of inactive MMP-2 and MMP-9 is unclear. As
they are highly regulated, they may remain largely inactive. Since MMP-
9 is normally bound to TIMP-1 (Goldberg et al., 1992), it is unlikely that it
would affect the ocular surface in the same way as neutrophil-derived MMP-
9, which is TIMP-free (Ardi et al., 2007). However, Arechavaleta-Velasco et
al. (2002) indicate that the pro-enzyme may become activated by MMP-2
and MMP-3, suggesting that MMP-9 activation may occur on the inflamed
ocular surface.
Taken together, these data indicate that MMPs are are a factor to be
considered when applying AM therapeutically, for example in patients with
corneal melting (Hossain, 2012). The clinical effects of these enzymes on the
ocular surface are incompletely understood, reflecting the complex interac-
tion between MMPs and their inhibitors.
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5.5.3 Macrophage suppression
Macrophages that were cultured with GM-CSF were identified by their ex-
pression of a range of markers, including CD14, CD16, mannose receptor,
CD11b and HLA-DR (figure 5.13). These were co-cultured with various
preparations of AM and stimulated with LPS or FPL. This was optimised
over a series of assays. The technique was difficult, and subject to high
levels of variability between the responses of macrophages from different
sources (e.g., Assay 2, figure 5.14), between the methods of culture (i.e.,
Teflon bottles versus ultra-low adherence flasks) and even in cytokine levels
across similar preparations. The latter could be due to variations in tech-
nique, which may have resulted in occasional incidences of missed data and
spurious measurements (e.g., TNF levels in FPL-stimulated macrophages
in Assay 3, table 5.15). In addition, while buffy coats generally gave suf-
ficient yields of PBMCs, their supply was dependent on availability, which
was a limiting factor in this study. Future researchers may consider using
whole-blood leukoreduction filters, which provide a safely and convenient
source of white blood cells from donated blood (Néron et al., 2007). Two
assays did not yield sufficient PBMCs.
Despite the variability, a pattern was observed in Assay 3 (buffy coat
1, figure 5.15) which suggested TNF suppression in the supernatants of
macrophages co-cultured with AM, and, paradoxically, concomitant eleva-
tion of IL-6. IL-8 levels were unchanged. However, the data for TNF were
beyond the standard curves, so could not be used. As these were single
measurements, statistical analysis was not performed. In Assay 4 (buffy
coat 1 and buffy coat 2, figure 5.16), the suppression of LPS-stimulated
macrophage TNF (and also FPL-stimulated macrophages from buffy coat
1) was marked across all preparations of AM. There was high variability
across the IL-6 levels, whereas IL-8 levels remained consistent. Suppres-
sion of TNF was again noted in Assay 6 (LPS-stimulated; figure 5.17). A
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further assay using triplicate AMs demonstrated TNF suppression and IL-
6 elevation in LPS-stimulated macrophages (Assay 7, figure5.18). An ele-
vated IL-6 response by FPL-stimulated macrophages co-cultured with AM
was also seen. Thus, the suppression of TNF and elevation of IL-6 expressed
by macrophages was demonstrated on different occasions using different
buffy coats and different AMs. IL-10 expression was negligible, whereas
IL-8 expression did not show any clear trends. This suggests complex inter-
action effects between the macrophages and AM. There was no evidence of a
difference in the effects across the different preparations of AM was found.
The activation of macrophages is of key importance in acute inflamma-
tion and wound healing (Alber et al., 2012). Depending on their stimu-
lation, macrophages can give rise to pro-inflammatory, anti-inflammatory
or regulatory subtypes. Activation of macrophages triggers an intracellu-
lar signalling cascade leading to NF-kB-mediated production of cytokines,
including IL-1α, IL-6, IL-10, TNF and GM-CSF and chemokines such as
monocyte chemotactic protein-1 (MCP-1), macrophage inflammatory pro-
tein (MIP) -1a and -1b and RANTES (regulated upon activation, normal
T-cell expressed and secreted) (Zhou et al., 2012). Macrophages may also
up-regulate MMP-9 and vascular endothelial growth factor (VEGF), key
promoters of neovascularisation (Li et al., 2012). The NF-κB pathway is
one of the principal intracellular pathways by which LPS, a major com-
ponent of the outer membrane of the cell-wall of Gram negative bacteria,
is able to stimulate a pro-inflammmatory cytokine response (Dos Santos
et al., 2007). While pro-inflammatory macrophages are classically stimu-
lated by IFN-γ and LPS, activation can also be initiated by key regulators
of corneal epithelial healing such as IL-1 (Scheel et al., 2006) and TNF
(Saika, 2007). As CD11b+ macrophages mediate angiogenesis in the in-
flamed cornea (Maruyama et al., 2005), their modulation by AM is highly
relevant. TNF, which is produced primarily by macrophages, is a major pro-
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inflammatory cytokine (Ming et al., 1987). In addition, while IL-6 can have
pro-inflammatory effects, it can also suppress inflammation by inhibiting
TNF production by LPS-stimulated human monocytes (Aderka et al., 1989)
and murine macrophages in vivo (Di Santo et al., 1997), suggesting an auto-
regulatory role. Therefore, the apparent modulation of TNF and IL-6 levels
by AM may be clinically significant.
It is not clear from the SEM images whether the macrophages in the
current study became apoptotic, as implied by previous reports (He et al.,
2008; Li et al., 2006a). However, the possible elevation of IL-6 levels sug-
gests that the cells may remain viable. Clinical reports have indicated that
inflammatory cells, including monocytes, are entrapped by the AM stroma
(Shimmura et al., 2001). However, EM images from the current study show
that the component of AM to which the cells adhere is the spongy layer (fig-
ure 5.19). In this study, the spongy layer was routinely removed, leaving
residual strands behind. It may be that removing the spongy layer also
removes an important anti-inflammatory component of AM.
The specific intracellular pathways of AM-induced immune suppression
are of great interest, and may help determine whether AM can suppress
inflammation over and above topical corticosteroids. Expression of the gene
encoding TNF is suppressed by phosphorylation of NF-κB (Wall et al., 2009).
This pathway has been implicated in macrophage apoptosis induced by AM-
derived factors (He et al., 2008; Li et al., 2006a). The reduced expression of
corneal epithelial IL-1α and IL-1β has also been linked to the suppression of
NF-κB cytokine pathways by matriceal hyaluronans (Solomon et al., 2001).
These nonsulphated glycosaminoglycans are abundant structural compo-
nents of AM, and are predominantly located in the spongy layer (Meinert
et al., 2001). Therefore, the adherence of macrophages to spongy layer rem-
nants implicates hyaluronans. High molecular weight hyaluronans have a
marked anti-inflammatory effect, inhibiting inflammatory cell chemotaxis
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Figure 5.20: Suppression of inflammation by AM
Simplified schema representing the putative mechanisms of suppression of inflammation by
AM. High molecular weight hyaluronans in the spongy layer may suppress TNF-mediated
NF-κB pathways in activated macrophages and neutrophils via the CD44 receptor, as well as
directly suppressing TGF-β and IL-1α production on the ocular surface. This would result
in suppression of neovascularisation (MMP-9), inflammation (TNF) and scarring (TGF).
Macrophage IL-6 may have an auto-regulatory function.
and phagocytosis (Tamoto et al., 1994). They can inhibit NF-κB-induced
inflammatory cytokine up-regulation in macrophages via the CD44 recep-
tor (Neumann et al., 1999). This receptor is known to mediate adhesion
between lymphocytes and the stromal aspect of AM (Higa et al., 2005). In
a study by He et al. (2009), high molecular weight hyaluronans isolated
from AM extract suppressed TGF transcription in corneal stromal cells and
induced macrophage apoptosis. The authors suggest that these hyaluro-
nans constitute the principal active component in AM to cause clinically
observed suppression of scarring and inflammation. These interactions are
summarised in figure 5.20.
These findings suggest that some of the principal biological mediators of
AM may be relatively insoluble structural components of the ECM, rather
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than soluble factors derived from the epithelium, such as IL-10, as previ-
ously suggested (Tseng et al., 2004). This is consistent with the finding
that a proteoglycan present in AM stroma, lumican, can promote epithelial
wound healing in the cornea (Yeh et al., 2005). This has significant im-
plications on AM processing, since it suggests that the epithelium can be
removed with no adverse consequences and that the spongy layer may be
a useful therapeutic adjunct and a valuable component of AM. It also in-
dicates that f-t and v-d AM might retain the anti-inflammatory properties
of the fresh tissue, since, unlike soluble factors, the high molecular weight
hyaluronans may not be easily eluted.
5.6 Conclusion
Questions remain as to whether AM-derived factors such as AMPs and
MMPs can have any activity on the ocular surface and contribute towards
wanted or unwanted effects. However, the interaction of the macrophages
with the spongy layer remnants suggests that suppression occurs as a con-
sequence of direct contact, rather than through soluble factors. This may be
the most significant of the biological properties of therapeutic AM. The two
hypotheses are not mutually exclusive, illustrating the complexity of the tis-
sue as a therapeutic modality. To resolve these questions, in vitromodels or
animal models of eye injury will be important in establishing whether this
laboratory finding has a clinical parallel.
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Chapter 6
CONCLUSION
6.1 Discussion
This study of the use of dried AM in the treatment of acute ocular surface
injuries brings together seemingly unrelated study domains, including evi-
dence based medicine, materials science and biology, and makes a number
of original contributions. These include an investigation of the evidence for
AMT in acute ocular surface burns. In addition, a novel framework was de-
vised for the optimisation of dried AM using methods usually available to
food scientists, pharmacists and polymer engineers. Mechanical tests and a
novel mathematical model indicated that dried AM is weaker than fresh or
frozen preparations. This led to an unsuccessful attempt to strengthen the
tissue by cross-linking the collagen matrix. Finally, a human macrophage
assay was performed in which the suppression of TNF was shown, possibly
as a result of direct contact with the AM spongy layer.
6.1.1 Significance of this study
6.1.1.1 Clinical trials
As a biological treatment, AM is unique, being the only allogeneic tissue
to be transplanted with no expectation of permanence and usually not for
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reasons of organ failure, and often without clear evidence to support its
use. While a systematic review can be effective in highlighting the need for
high-quality RCTs, ocular burns are sufficiently uncommon, in many parts
of the world, to make this a challenging proposition. These injuries are more
common in geographical areas in which medical services are not equipped
to manage them comprehensively (Adepoju et al., 2007), making it even
harder to organise a RCT. The emergence of RCTs from India (Tamhane
et al., 2005; Tandon et al., 2011) is encouraging, combining high rates of
presentation with modern treatment and academic attention. The review
emphasises the need for more RCTs. In turn, this should encourage clear
objectives in AM treatment, with objective criteria for success and failure in
outcome reporting.
6.1.1.2 Optimisation of AM
The tissue moisture sorption, thermal and surface characteristics are highly
relevant to its stability. Since the end moisture content of dried AM is di-
rectly linked to its Aw, these are mandatory parameters in optimisation. In
addition, AM can be in a glassy phase at ambient temperature, depending
on the moisture content. As it is highly hygroscopic, it may rapidly absorb
ambient humidity, indicating a need for drying and sealing to be performed
in a closed system. Trehalose increased the enthalpy of moisture sorption,
stabilising the tissue. On the other hand, the trehalose excipient was not
in a glassy state, prompting a need for further drying. The vitrification
of trehalose/PBS mixtures can be optimised using thermoanalytical meth-
ods such as DVS in conjunction with mathematical models (Sitaula and
Bhowmick, 2006). Since crystallisation of trehalose may harm the stability
of the tissue by releasing water, it is important for it be vitrified (Costantino
et al., 1998a), and the same is likely to apply to any excipient sugar. The
further characterisation of polymorphs will be useful in this regard, as the
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causes of excipient crystallisation on v-d AM are not fully understood.
6.1.1.3 Cross-linking of AM
The cross-linking of dried AM remains an important goal. Extensive me-
chanical testing showed that, while v-d AM may be sufficiently robust for
clinical use, it is weaker than fresh and f-t AM. This was further indicated
by a novel approach using mathematical modelling, which promises to be a
useful technique in characterising different preparations of AM. Although
cross-linking protocols, such as the one described by Ma et al. (2010), have
already been shown to be effective at cross-linking AM, the clinical worth
of dried cross-linked AM is just beginning to emerge Kitagawa et al. (2011).
The effectiveness of alternative chemical means of cross-linking AM, such
as the transglutaminase method (Chau et al., 2012), has not been demon-
strated conclusively.
6.1.1.4 Biological activity of AM
Evidence of AMP expression in therapeutic AM was scant, while separate
testing revealed no evidence of anti-microbial activity. However, the increas-
ingly well-known reservoir effect of AM suggests that it may have genuine
usefulness in treating infections (Gicquel et al., 2007). On the other hand,
the possibility that inactive MMPs may become activated on the ocular sur-
face prompts questions as to whether these enzymes can cause enzymatic
degradation of corneal collagens or facilitate neovascularisation. This might
be investigated by degradation assays using in vitro models of AM treat-
ment on cadaveric human eyes. While the effects of MMPs are unclear, AM-
induced TNF suppression could represent a significant contributor towards
the clinical action of AM. Macrophage assays produced variable results, sug-
gesting a need for further refinement. However, if the anti-inflammatory ac-
tivity of AM is mediated principally by high molecular weight hyaluronans
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in the spongy layer, the retention of epithelial soluble factors such as IL-
10 would become less relevant, and the epithelium could be removed with
no loss of function. It also suggests that purified spongy layer hyaluronans
may have therapeutic potential.
6.1.2 Further work
6.1.2.1 Future RCTs
Although the lack of suitable RCTs of AMT for acute ocular burns precluded
a meta-analysis, it is clear that well-designed RCTs are preferable to un-
controlled case series. Since the injury is relatively rare, a multicentre RCT
can be considered to ensure sufficient numbers of cases. This could be made
easier by introducing an anonymised worldwide web-based registry of ocu-
lar burns, enabling ocular burns and their treatment to be recorded in an
accessible way, and has been proposed in a new grant application recently
submitted by the University of Nottingham. In relatively uncommon and
complex diseases, RCTs can be very difficult. Professor Radhika Tandon, of
the Rajendra Prasad Eye Institute, has suggested that a stepwise sequen-
tial treatment trial with stratified randomisation would be a useful model
to determine best practice.
For more precise classification, the Dua grading system is recommended
for future studies. It is important that the treatment be performed in the
acute phase (by day 7) in order to clearly demarcate the timing of the inter-
vention. Since the timing of AMT is variable, this will improve confidence
in the findings of an RCT by increasing the homogeneity of the patient base.
The length of treatment can also be temporary (e.g., patch removed at 21
days post-injury). This would facilitate a masked assessment of epithelial
recovery and avoid the problem of attempting to measure the rate of epithe-
lial healing through an opaque membrane. Temporary patching may also
reduce the risk of adverse outcomes, such as fungal keratitis, which often
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take several weeks to develop. It is unlikely that an AM patch will continue
to have any effect after this period. The inclusion of patients with a nar-
row grade of burn will increase confidence in the study findings, as it may
help to equalise the baseline characteristics between treatment and control
arms. The grade of burn should be severe enough to warrant treatment, but
not so severe as to carry a high likelihood of secondary procedures or dismal
prognosis. Furthermore, inclusion criteria should specify a single category
of causative agent, since it is possible that burns from different causes will
respond differently to treatment.
Clear outcomemeasures are of great importance in RCTs, and should an-
swer clinically meaningful questions. For example, does AMT in the acute
phase of a grade III alkaline burn result in a higher likelihood of complete
epithelial healing by the end of the early reparative phase, compared to an
untreated control? Many studies compare the daily epithelial healing rate,
which fails to answer this fundamental question. This could be addressed
by assessing epithelial healing at a fixed time point (i.e., day 21 post-injury),
rather than by measuring the epithelial healing rate. A statistically signif-
icant difference in the size of a PED between treated and untreated groups
by day 21 would constitute a clinically meaningful outcome, and would be
simple to measure. In contrast, epithelial healing rates are highly depen-
dent on case-by-case factors, such as timing of presentation and depth of
burn. In addition, they are difficult to measure and subject to observer
biases. The epithelial defect on day 21 could be measured with the AMT
removed to minimise assessor bias.
Similarly, an assessment of visual outcomes should be performed after
a fixed interval, rather than across a range of different time-points, as this
is imprecise and can introduce bias. It is important to specify previously
identified visual loss among study participants, and whether visual acuities
were measured with or without correction. A comparison between the visual
315
outcomes of treatment and control groups can be misleading; a comparison
of the improvement in visual acuity before and after treatment is more help-
ful. Separate studies could address the prevention of symblepharon, helping
to direct treatment with AMT in increasingly specific ways. For example,
in symblepharon prevention studies, AMT would be reserved for cases in
which there was forniceal involvement, which would tend to be more se-
vere. Simple grading systems for pain and neovascularisation are useful.
An assessment of pain relief could include visual analogue pain rating scales
before and after treatment. Convincing evidence of improved comfort alone
could justify treatment of acute burns with AMT, but even this is currently
lacking.
6.1.2.2 Animal model
A protocol for an animal model for AM treatment of chemical eye burns
has been prepared as part of the wider project and is currently proceeding.
The ARRIVE guidelines of the National Centre for the Replacement, Refine-
ment and Reduction of Animals in Research were followed in the protocol
design. A summary is provided below. The primary objective of the study
is to compare the rate of corneal epithelialisation following patching of an
acute chemical injury with either f-t AM or v-d AM. Ethical review permis-
sion has been sought and relevant licences applied for under the Animals
(Scientific Procedures) Act 1986. The study was designed as a randomised
control trial, with random sequence generation of the animals, random al-
location of treatment and masked participants.
To facilitate statistical analysis, and to maximise the yield of informa-
tion, the fellow eye was designated as a control (Murdoch et al., 1998). A
power analysis was performed to determine the number of animals that
would be required. Assuming a level of 10% increased epithelial healing in
the treatment group to be clinically significant and a standard deviation of
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10% in the epithelial healing rate, for a study with 90% power, this returned
the number of eyes for each treatment and control arm as 21, giving the to-
tal number of rabbits as 42. The primary outcome to be assessed is corneal
epithelial healing. This can be calculated as the percentage of recovered
epithelium by subtracting the residual defect size from the original defect
size, returning a continuous variable.
The entire experiment can be performed in the biomedical sciences unit
animal facility laboratory of the University of Nottingham, where female
and male New Zealand white rabbits can be kept anaesthetised for the en-
tire duration of the experiment, and euthanised at the end for eye retrieval.
A method of chemical injury was proposed to cause minimal damage to the
ocular surface of the white rabbit by placing a corneal ring, similar to the
rings used for alcohol delamination in human eyes, on the rabbit ocular
surface. A volume of alkali or acid can be placed inside the ring for a pre-
determined period of time, and then removed with a Weck-cell sponge. The
strength, volume and duration can be determined by prior in vitro testing
of animal eyes. Both eyes will receive medical therapy, including irrigation
with phosphate-free isotonic media (until pH neutrality is achieved), and
antibiotics and steroids four times a day. The surgeon will be masked to
the treatment (f-t or v-d), which can be applied to the rabbit ocular surface
by using a PMMA ring with fibrin glue (Liu et al., 2008). Following AMT,
both eyes can be closed with tape, and the animal monitored until the end
of the experiment. After a specified period, the AM can be removed, the
eyes stained with fluorescein dye and photographed and the digital images
assessed by a masked observer. The size of the epithelial defect can be mea-
sured using computer software to compare the AM-treated injuries to the
untreated controls.
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6.1.2.3 Tissue engineering
The cultivation of oral and corneal stem cell sheets is technically demanding
and there is a lag period between the patient presenting and the sheet being
ready for transplantation (Kinoshita et al., 2004). A readily transplantable
construct of stable, non-immunogenic stem cells could circumvent the limi-
tations encountered with expanded cell sheets. Researchers have used mes-
enchymal stem cell sheets to treat acute ocular surface burns in experimen-
tal animal models (Ye et al., 2006). These cells have anti-inflammatory and
anti-angiogenic properties (Oh et al., 2008), and have the capacity to differ-
entiate into corneal epithelial cells (Gu et al., 2009), making them attractive
propositions for treating acute ocular chemical injuries. As mesenchymal
sheets do not need to be cultivated on AM, the possibility of combining a
multilayered mesenchymal stem cell network supported by a synthetic tis-
sue engineered scaffold is attractive, and constitutes a potential research
avenue. A synthetic construct in place of AM will circumvent the key issues
of supply, variability and risks associated with AM. The artificial constructs
must be biocompatible and robust enough to resist the ocular inflammatory
response, while helping to prevent inflammation and promoting LSC sur-
vival in the early repair phase.
6.2 Conclusion
This thesis contributes original research to the body of knowledge available
to ophthalmic surgeons about the properties and usefulness of AM as a bio-
material. In its dried form, it can constitute a part of the overall treatment
armamentarium for ophthalmologists at the battlefield. While the lack of
conclusive evidence for its use in acute burns highlights the limitations of
AM treatment, it remains useful as a biocompatible material with added
biological functionality. Dried AM can contribute to the treatment of eye in-
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juries sustained on the battlefield only once a full assessment has been car-
ried out by a military ophthalmologist, and where it can be demonstrated
that the benefits of treatment outweigh the potential risks.
Word count: 99 995
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1 CENTRAL search strategy
#1 MeSH descriptor Eye Burns
#2 (eye* or ocular) near/6 (burn*)
#3 (#1 OR #2)
#4 MeSH descriptor Amnion
#5 amniotic near/3 membrane*
#6 AMT
#7 (#4 OR #5 OR #6)
#8 (#3 AND #7)
2 MEDLINE (OVID) search strategy
1. Eye burns/
2. ((eye$ or ocular) adj6 burn$).tw.
3. or/1-2
4. exp Amnion/
5. (amniotic adj3 membrane$).tw.
6. AMT.tw.
7. or/4-6
8. 3 and 7
3 EMBASE (OVID) search strategy
1. Eye burn/
2. Cornea burn/
3. ((eye$ or ocular) adj6 burn$).tw.
4. or/1-3
5. exp Amnion/
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6. (amniotic adj3 membrane$).tw.
7. AMT.tw.
8. or/5-7
9. 4 and 8
4 LILACS search strategy
amniotic and eye or ocular burn$
5 metaRegister of Controlled Trials search strategy
amniotic and ocular burn
6 ClinicalTrials.gov search strategy
amniotic AND ocular burn
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